Epigenetics-targeted drugs: current paradigms and future challenges.

Introduction

From a historical perspective, the term “epigenetics” was first introduced by Conrad Waddington in 1942 to describe heritable changes in gene function that do not involve alterations to the DNA sequence, leading to changes in biological phenotypes. Following nearly a century of rigorous research, a diverse array of epigenetic-modifying enzymes has been identified, and the elucidation of distinct molecular mechanisms has established epigenetics as a robust discipline. 1 Presently, epigenetics is defined as a chromatin state regulatory system comprised of five principal mechanisms: DNA modifications, 2 histone modifications, 3 RNA modifications, 4 chromatin remodeling, 5 and the regulation based on non-coding RNA (ncRNA). 6 These mechanisms independently transmit genetic information from the DNA sequence, enabling the activation or repression of specific genome regions in response to physiological or pathological signals (Fig. 1 ). Fig. 1 Epigenetic mechanisms and key examples of widely studied modifications and their modifying enzymes. a DNA modifications, histone modifications, RNA modifications, chromatin remodeling, and the regulation based on non-coding RNA constitute the core content of epigenetics, being responsible for passing on heritable variations of genetic information independently of the DNA sequence. b Epigenetic modifications are reversible progress catalyzed by functionally complementary modifying enzymes, which provide targets for disease therapeutics

Enzymes that regulate epigenetic modifications are categorized into “writers,” “erasers,” “readers,” and “remodelers” based on their functions. 7 – 9 Writers modify specific bases or amino acids, whereas erasers remove these modifications, exerting reciprocal effects on gene expression. For instance, DNA methyltransferase (DNMT) catalyzes the addition of methyl groups to form 5-methylcytosine (m5C) in DNA bases, 10 whereas the ten-eleven translocation (TET) enzymes initiate DNA demethylation, converting m5C into derivatives, such as 5-hydroxymethylcytosine (5hmC), 5-formylcytosine, and 5-carboxycytosine. 11 Typically, genes expressed at higher levels exhibit lower methylation, whereas genes with lower expression levels tend to be more heavily methylated. 12 Readers are proteins that contain specific motifs to recognize and bind these modifications, such as the methyl-CpG-binding domain (MBD) responsible for recognizing 5mC. 13 These proteins influence chromatin status and recruit or collaborate with other enzymes to regulate gene expression. 13 , 14 Remodelers are crucial in chromatin remodeling, moving or removing nucleosomes at vital regulatory elements like enhancers and promoters to modify chromatin accessibility. 15 Furthermore, as unique epigenetic regulators distinct from epigenetic-modifying enzymes, ncRNAs directly bind to various genomic regions or specific RNA sequences to modulate gene expression. 16 Variations in the given ncRNA may regulate the interactions or functions of its interactor partners, including proteins, RNAs, DNAs, and lipids, thereby influencing various biological cellular processes or pathological phenotypes. 17

The discovery of functionally complementary epigenetic-modifying enzymes has underscored the reversibility of most known epigenetic modifications. This insight supports the development of strategies to modulate gene expression via targeted regulation of these enzymes, providing a strong theoretical basis for creating novel therapeutic approaches from an epigenetic perspective. To date, four categories of epigenetics-targeted drugs have received the Food and Drug Administration (FDA) approval for clinical use, with numerous clinical trials ongoing to refine their applications. A timeline of significant milestones in epigenetic research is depicted in Fig. 2 . Fig. 2 Timeline of major discoveries and advances in epigenetic research. The significant discoveries and advances are depicted in the illustrator and displayed as primarily “Early foundations” (yellow boxes) on the top, “Improving safety and efficacy” (purple boxes) in the middle, and “Breakthroughs in the clinical practice” (pink boxes) at the bottom

Over the past few decades, numerous studies have underscored that abnormalities in the expression and function of epigenetic-regulating enzymes are crucial in the onset and progression of various diseases. Epigenetics-targeted drugs, therefore, have emerged as pivotal topics due to their significant physiological and pathological implications. The development of drug screening models rooted in epigenetic principles is anticipated to substantially expand therapeutic options in clinical settings. Moreover, advancements in epigenetic analysis and molecular modification techniques have accelerated the clinical adoption of these targeted drugs. Despite these developments, there remains a gap in comprehensive reviews that address epigenetic regulations in physiological and disease contexts and detail the latest advancements in drug development targeting these mechanisms. This review aims to fill that void by summarizing the current understanding of epigenetic regulations and clinical trials of targeted drugs, thereby outlining the future application of these promising agents. We begin with an overview of epigenetic mechanisms and their crucial roles in health and disease, followed by an in-depth discussion on the exploration and application of marketed epigenetic drugs. We then provide a systematic account of recent progress in developing potential therapeutic agents targeting various epigenetic enzymes, highlighting emerging research trends. Finally, we present the breakthroughs and challenges in epigenetic drugs, particularly the benefits of combining them with traditional therapies such as radiotherapy, chemotherapy, and targeted therapy, to underscore their potential in translational medicine.

Biological and pathological roles of epigenetics

Epigenetic modifications are a fundamental mechanism regulating gene expression, crucial for various cellular functions. Dysregulated epigenetic regulators, whether overexpressed or underactive, compromise normal functions and contribute to disease onset. Thus, epigenetic modifications hold significant potential for disease treatment and biotechnological applications, driving the development of targeted therapeutic drugs.

Epigenetics and early embryonic development

Epigenetic landscapes undergo substantial changes to ensure the coordinated progression of embryogenesis and subsequent development throughout an individual’s life. 18 Mutations in epigenetic-modifying enzymes, whether heterozygous or hemizygous, are commonly associated with congenital conditions, such as Rubinstein-Taybi syndrome, linked to mutations in the cyclic adenosine monophosphate-responsive element-binding protein (CREB)-binding protein (CBP) and its paralog, E1A-binding protein (P300), 19 immunodeficiency-centromeric instability-facial anomalies syndrome related to DNMT3B mutations, 20 and Kabuki syndrome due to mutations in lysine methyltransferase 2D (KMT2D). 21 DNA methylation reprogramming, a pivotal aspect of epigenetic modification in early embryonic stages, involves genome-wide removal of epigenetic marks through extensive DNA demethylation, followed by remethylation. 22 This process, integral to mammalian development, has only been fully understood with the advent of whole-genome bisulfite sequencing, which allows for single-base resolution analysis of DNA methylation kinetics. 23 , 24 Advances in precise assays for assessing DNA methylation at specific genetic loci have led to significant insights into these epigenomic reprogramming processes. This reprogramming results in global hypomethylation and significant loss of genetic memory, which is foundational for acquiring pluripotency and redetermining cell fate. 25 Following fertilization, methylation patterns evolve progressively, enabling cells to differentiate and contribute to the development of various biological systems. The dynamic regulation of DNA methylation, including reprogramming, is indispensable for mammalian development and differentiation. Another vital mechanism, histone modification, plays a critical role during zygotic genome activation (ZGA), which involves the transition of the zygotic genome from a state of silence to active transcription. 26 Notably, the de novo establishment of histone 3 lysine 14 acetylation (H3K14ac) and histone 3 lysine 9 trimethylation (H3K9me3) following fertilization is crucial for the timely activation of ZGA genes during development. 27 , 28 The SWItch/Sucrose NonFermentable (SWI/SNF) complex also plays a significant role in the precise activation and repression of tissue-specific transcription factors, functioning as a chromatin remodeler that orchestrates the coordinated differentiation of multiple cell lineages during development. 29 , 30 Additionally, the role of RNA modifications in embryo development is increasingly recognized and summarized. 31 , 32 Recent studies indicate that deficiencies in methyltransferase-like proteins (METTLs) and their associated RNA N6-methyladenosine (m6A) levels can induce G1/S cell cycle arrest in hematopoietic stem and progenitor cells in model organisms. 33 Furthermore, aberrant RNA modification patterns are integrated into the regulatory networks of other epigenetic mechanisms, such as histone deubiquitylation and DNA methylation, playing critical roles in nuclear reprogramming. 34 , 35 Recently, preliminary evidence of ncRNAs being engaged in embryo development has been proposed according to the reported variation among ncRNAs contents during different stages of early embryonic development in mouse models. 36 – 38 As an indicator of developmental competence, ncRNA plays an irreplaceable role in the continuous stages of pre-implantation development, embryo implantation, and post-implantation development. 39 Aberrant levels of certain ncRNAs may disturb the transition of fertilized oocytes to pluripotent blastocysts, and may even affect the differentiation of epiblast stem cells. 40 , 41 Notably, ncRNAs may also act as regulatory factors for other epigenetic mechanisms. For example, during mouse ZGA, the negative regulation of Dnmt3a/3b expression by microRNA-29b (miR-29b) helps maintain proper DNA demethylation to establish the imprinting of genes. 42 However, considering that most of the current understanding has only been validated in animal models, much work is still required to explore the role of ncRNAs during embryonic and fetal development in humans.

Epigenetics and aging

Since the late 1990s and early 21st century, researchers have observed that epigenetic changes accompany aging based on data derived from cellular experiments. 43 Initially, it was unclear whether these epigenetic alterations were a cause or a consequence of aging. Recent work by Yang et al. 44 has successfully dissociated epigenetic dysregulation from genetic changes, confirming that the collapse of epigenetic modifications is a potent driver of aging. DNA methylation, a central epigenetic mechanism, regulates both development and aging. Notably, global DNA methylation levels in most regeneratively capable tissues tend to decrease with age. 45 Beyond global changes, studies increasingly report high frequencies of age-related alterations in DNA methylation accumulated in specific cellular regions. These differentially methylated regions associated with aging lead to either the upregulation or repression of downstream genes. For example, age-related hypermethylation within the promoter regions of tumor suppressor and metabolic genes may partially explain the increased susceptibility of the elderly to tumors and various metabolic disorders. 46 Conversely, DNMT inhibitor decitabine can reverse hypermethylation in tumor suppressors, enhancing their expression and inducing a senescence-like phenotype in tumor cell lines. 47 Other mechanisms, such as histone modifications and chromatin remodeling, are also strongly linked to aging. A deficiency in sirtuin 7 (SIRT7) and histone methylation patterns like H3K9me2 and H3K27me3, for example, can activate the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes pathway, a well-recognized aging-associated signaling pathway, thus exacerbating the aging process. 48 , 49 Moreover, the importance of RNA modifications—particularly m6A and m5C—and ncRNA regulation is increasingly studied in aging research. 50 – 52

Epigenetics and cancer

Abnormal epigenetic mechanisms play crucial roles at various stages of tumor development, including initiation, progression, invasion, migration, and the development of chemotherapy resistance (Fig. 3 ). DNA methylation was the first discovered epigenetic mechanism associated with tumors, initially implicated in the hypermethylation of specific gene promoter regions, which drives tumor development by silencing gene transcription. 53 This silencing leads to the dysfunction of critical genes such as tumor suppressor and DNA repair genes, disrupting normal cell proliferation and differentiation and fostering the malignant phenotype of tumor cells. 54 , 55 Moreover, methylation loss at specific sites in tumor cell genomes, particularly in oncogene promoter regions, and extensive demethylation in DNA repeat sequences, undermines chromosome stability, facilitating tumor development. 56 , 57 Changes in histone modifications are also prevalent in tumors. The roles of histone methylation and acetylation in tumor progression have been extensively explored, with numerous reviews summarizing therapeutic strategies targeting these histone modifications or their associated epigenetic-modifying enzymes, underscoring their pathological significance and therapeutic potential. 58 , 59 Noticeably, bromodomain (BD) and extra-terminal (BET) family member proteins, including BRD2, BRD3, BRD4, and BRDT, serving as interpreters of histone acetylation modification, have recently been found to facilitate tumorigenesis when overexpressed. 60 , 61 Upregulated BET proteins can function as oncogenic transcriptional factors in tissue cells, driving a unique transcriptional program and controlling cell phenotype. 62 , 63 Therefore, potent inhibitors targeting BET proteins may be considered potential agents for tumor treatment. Research into metabolic reprogramming and the Warburg effect in tumor cells has recently highlighted histone lactylation’s function in pathological processes. 64 , 65 Histone lactylation, induced by glycolysis, has been studied extensively in various malignancies such as endometrial cancer, pancreatic ductal adenocarcinoma, and glioblastoma, where it plays roles in tumor progression and the suppression of the immune microenvironment. 66 – 68 Additionally, dysregulation in RNA modifications, particularly m6A, is linked to the malignant potential and resistance of tumor cells, 69 , 70 affecting multiple pathways that ensure tumor cell survival, including the maintenance of stemness, 71 the establishment of vascular networks, 72 and the formation of an immunosuppressive tumor microenvironment (TME). 73 Thus, targeting aberrant RNA modifications could effectively disrupt the survival mechanisms of tumor cells, offering new avenues for cancer treatment. 74 Changes in ncRNA families have also been observed in various tumors, first noted in chronic lymphocytic leukemia with chromosome 13q14 deletion, characterized by decreased levels of miR-15 and miR-16. 75 Among these, various ncRNA molecules with antitumor effects have been identified and are commonly suppressed in various tumor diseases, representing promising targets for therapeutic intervention. 76 Furthermore, ncRNAs can participate in the post-translational regulation of other epigenetic-modifying enzymes, integrating into broader epigenetic networks. 77 In addition to functioning as pathogenic triggers in different tumors, ncRNAs present in extracellular vesicles in the TME also hold promise for assessing therapeutic response. 78 – 80 According to clinical data from well-organized observational studies, unique plasma exosomal miRNA profiles are associated with predicting the efficacy of antitumor therapies in various tumor diseases, such as advanced non-small cell lung cancer, 81 colorectal cancer, 82 , 83 and breast cancer. 84 Fig. 3 Epigenetic mechanisms in cancer. Epigenetic alterations in cancer cells affect various cellular responses, such as cell proliferation, invasion, apoptosis, and drug resistance. These modifications, which include DNA modification, histone modification, RNA modification, chromatin remodeling, and non-coding RNAs, significantly affect the pathogenesis and progression of tumors. By targeting these epigenetic mechanisms, novel therapeutic strategies for combating cancer can be developed. The primary roles of epigenetic mechanisms in tumorigenesis and their further development are presented in the illustrator

Epigenetics and metabolic syndrome and related disorders

Metabolic syndrome encompasses a constellation of pathological conditions characterized by abnormal aggregation of metabolic components, notably abdominal obesity or overweight, dyslipidemia, insulin resistance and/or glucose tolerance abnormalities, and hypertension. 85 These metabolic dysfunctions significantly elevate the risk of developing diseases such as type 2 diabetes mellitus (T2DM), nonalcoholic fatty liver disease (NAFLD), and cardiovascular diseases. 86 Epigenetic modifications play a crucial role in nutrient metabolism under physiological conditions and also bridge the genetic and environmental factors contributing to metabolic disorders. 87 For instance, dietary patterns significantly influence epigenetic markers; studies have shown that a high-fat diet in mice leads to hypermethylation in the promoter regions of genes like Rac family small guanosine triphosphate hydrolase (GTPase) 1, which promotes the progression of diabetic retinopathy. 88 Dietary-induced epigenetic changes can impact subsequent generations, increasing their risk of glucose intolerance and diabetes. 89 Moreover, epigenetic alterations linked to diet are implicated in developing gout and NAFLD. 90 , 91

Additionally, the activity of epigenetics-modifying enzymes and their cofactors, such as TET and α-ketoglutarate (α-KG) from the tricarboxylic acid cycle (TCA), can be influenced by abnormal metabolite levels in patients with metabolic diseases, further disrupting epigenetic regulation and exacerbating disease progression. 92 Epigenetic markers, especially DNA methylation landscapes, also provide diagnostic tools; 93 in T2DM, for example, differential methylation in genes such as thioredoxin interacting protein, adenosine triphosphate (ATP)-binding cassette subfamily G member 1, peroxisome proliferator-activated receptor gamma-coactivator 1 alpha, and protein tyrosine phosphatase receptor type N2, can elucidate pathophysiological mechanisms. 94 Understanding these epigenetic mechanisms in metabolic diseases is thus pivotal for developing innovative prevention, diagnosis, and treatment strategies.

Epigenetics and immune system disease

Epigenetic modifications are integral to the development and differentiation of immune cells and the regulation of immune functions. These modifications influence the differentiation of functional B and T cell subpopulations and maintain the homeostasis of innate immune cells by controlling specific gene expressions. 95 – 97 Epigenetic dysregulation is closely linked to immune system diseases, including allergic reactions and autoimmune diseases, which have been extensively studied. 98 , 99 For instance, allergic bronchial asthma involves reduced TET2 expression in regulatory T cells, leading to hypermethylation in the promoter region of forkhead box protein P3 and impaired immune function in controlling inflammatory responses. 100 Additionally, low expression of METTL3 in monocyte-derived macrophages in allergy patients exacerbates airway inflammation through M2 macrophage polarization. 97 Histone modification also plays a critical role in sustaining the therapeutic effects of glucocorticoids in asthma; oxidative stress in severe asthma cases leads to reduced histone deacetylase (HDAC) levels in alveolar macrophages, contributing to glucocorticoid resistance. 101 Consequently, elevating HDAC levels in patients with severe, steroid-insensitive asthma could be a viable strategy to reduce airway hyperresponsiveness and restore steroid sensitivity. 102

Epigenetic mechanisms play a significant role in the pathogenesis and progression of autoimmune diseases. For instance, hypomethylation mediated by TET2 within the promoter region of absent in melanoma 2, a critical component of the inflammasome, influences T follicular helper cell-dependent humoral immune responses in systemic lupus erythematosus (SLE). 103 Additionally, altered patterns of miRNA in serum exosomes and immune cells have been identified, promising potential as biomarkers for diagnosis and indicators of disease severity. 104 , 105 Histone modifications also play a pivotal role in SLE, where the administration of HDAC inhibitors has been shown to reduce cytokine profiles and improve pathogenesis in SLE and other inflammatory conditions. 106 Moreover, the therapeutic potential of BET proteins in antibody-mediated diseases (e.g., SLE) has recently been evaluated. BET inhibitors alter the pro-inflammatory phenotypes of mononuclear phagocytes and impair the recruitment of dendritic cells in vitro. 107 Beyond SLE, epigenetic mechanisms are implicated in the progression of other autoimmune diseases such as rheumatoid arthritis, 108 autoimmune thyroid diseases, 109 multiple sclerosis, 110 T1DM, 111 and severe aplastic anemia, 112 highlighting the potential for epigenetics-modifying drugs in treatment strategies.

Epigenetics and neurodegenerative disease

Epigenetic modifications significantly influence learning, memory, and cognition, which are essential in maintaining synaptic plasticity. 113 , 114 Disruptions in epigenetic regulation lead to the abnormal expression of genes involved in protein aggregation, neuroinflammation, and neuronal apoptosis, contributing to the pathogenesis of neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’s disease (HD). 115 The deposits of extracellular Aβ plaques and tau phosphorylation, as well as the loss of plasticity, are basic pathogenesis of AD. In AD, aberrant histone modification patterns, particularly histone acetylation, have been observed in hippocampal neurons of AD mouse models, potentially driving cognitive decline and inadequate removal of Aβ plaques. 116 Lactylation modifications of histones H4K12 and H3K18 affect the metabolic activity of various glial cells, influencing the progression of the AD phenotype. 117 , 118 In addition, aberrant DNA-methylation patterns in the promoter regions of functional genes are linked to the accumulation of toxic peptides and the development of memory deficiency. 119 , 120 Recent studies also consider RNA modifications and ncRNAs as potential therapeutic targets and diagnostic biomarkers for AD. 121 , 122 PD is characterized by the misfolding and aggregation of α-synuclein, leading to the formation of Lewy bodies. Altered DNA methylation patterns have been observed in brain and blood samples from individuals with PD. 123 , 124 TET2 may play a critical pathogenic role in PD, where its inactivation has shown a neuroprotective effect on dopaminergic neurons. 125 Histone acetylation dysregulation is extensively studied in PD, associated with the accumulation of phosphorylated α-synuclein and mitochondrial respiratory dysfunction. 126 , 127 Dysregulation in ncRNAs, particularly long non-coding RNAs (lncRNAs) and miRNAs affects the mRNA levels of pathogenic factors post-transcriptionally and is linked with clinical symptoms such as non-motor symptoms, cognitive deficits, and inflammation, presenting potential targets for PD treatment. 128 In HD, epigenetic modification alterations are vital markers of its pathogenesis. Studies have shown the positive effects of using DNMT inhibitors, HDAC inhibitors, and extracellular vesicles loaded with miRNAs in preventing mutant huntingtin-induced neurotoxicity, emphasizing the potential roles of epigenetic dysregulations in HD. 129 – 131 Recently, the impact of aberrant m6A RNA methylation on the progression of HD has been increasingly recognized. Hyper-methylation of m6A in genes related to HD and synaptic function has been linked to memory deficits. Conversely, inhibition of the fat mass and obesity associated protein (FTO) in the hippocampal regions of HD mouse models has shown promise in reversing cognitive symptoms, suggesting a potential therapeutic target. 132

In summary, the dynamic nature of epigenetic modifications plays a crucial role in maintaining physiological functions and life cycle processes. During embryonic development, precise epigenetic regulation is crucial to cell differentiation and ensures proper tissue specialization by activating or suppressing specific genes. Furthermore, epigenetic modifications are closely linked to an individual’s adaptation to environmental influences such as nutritional status, stress, and toxin exposure, which can alter epigenetic landscapes and impact health and disease risk. On the other hand, understanding epigenetics offers a new perspective for disease prevention and treatment. The development and progression of many diseases, including cancer, metabolic disorders, immune system diseases, and neurodegenerative disorders, are closely associated with aberrant epigenetic modifications. A deeper understanding of epigenetic modulators could lead to novel therapeutic strategies, laying the groundwork for drug interventions targeting epigenetic processes.

Epigenetics-targeted drugs approved for clinical use

Epigenetic modifications and the enzymes involved can either activate or suppress the expression of specific genes at different levels (Table 1 ). Therefore, in contrast to traditional therapies, drugs targeting epigenetic-modifying enzymes have been developed with a focus on gene regulation. This unique mechanism provides epigenetic-targeted drugs with an advantage over other traditional treatments, especially for the treatment of tumors. More specifically, epigenetics-targeted drugs specifically target the abnormal epigenetic hallmarks of cancer cells, restoring their normal cellular function or enhancing the immune system’s recognition of tumor cells. 133 , 134 Compared to traditional radiotherapy and chemotherapy, which directly kill cancer cells or prevent their proliferation, or immunotherapy, which activates or enhances the patient’s own immune system, the administration of epigenetic agents achieves maximized damage to tumor cells with usually fewer side effects. 135 – 137 The application of these novel agents helps to reverse the progression of drug resistance caused by altered epigenetic characteristics in traditional antitumor therapies. 138 – 140 Hence, these features endow epigenetic agents with importance and possibilities as monotherapy or adjuvants in combination with other therapeutic methods. 141 Currently, some of these drugs have been approved for marketing, primarily for cancer treatmentt, and they exhibit exciting clinical potential. These drugs are categorized into four main types based on their mechanisms: DNMT inhibitors, HDAC inhibitors, isocitrate dehydrogenase (IDH) inhibitors, and enhancer of zeste homolog 2 (EZH2) inhibitors (Table 2 ). Table 1 Key examples of epigenetics-modifying enzymes that are considered targets for drug development and their major biological functions Epigenetic modification Type Epigenetics-modifying enzyme Biological processes Reference(s) DNA methylation Writer DNMT1 Maintains DNA methylation after replication 907 DNMT2 Binds to DNA with very weak methyltransferase activity; involved in RNA methylation 908 DNMT3A Promotes the genome-wide de novo DNA methylation 909 DNMT3B Promotes the genome-wide de novo DNA methylation 910 , 911 DNMT3L Increases the methyltransferase activity of DNMT3A or DNMT3B 912 Eraser TET1 Active DNA demethylation and binds to DNA via the CXXC zinc finger domain 913 TET2 Active DNA demethylation and binds to DNA via the interaction with DNA binding proteins 914 TET3 Active DNA demethylation and binds to DNA via the CXXC zinc finger domain 915 Reader MeCP1 Preferentially binds to methylated DNA and represses transcription 916 MeCP2 Binds to a single methyl-CpG pair, not influenced by sequences flanking the methyl-CpGs 917 MBD1 Recruits chromatin-modifying enzymes to both methylated and unmethylated CpG islands; largely silence transcription 918 , 919 MBD2 A transcriptional repressor or activator depending on the cellular context 920 MBD3 Interacts with NuRD complex to cause transcriptional repression 921 , 922 MBD4 Exerts DNA glycosylase activity and functions in DNA repair 923 UHRF1 Negatively regulates transcription via the binds to 5hmC and 5mC on DNA, as well as H3K9me3, and H3R2me0; recruits DNMT1 to methylate DNA 356 , 358 UHRF2 Allosterically activated by 5hmC and participates in DNA demethylation during neuronal commitment 924 – 926 Histone acetylation Writer HAT1 (KAT1) Acetylates H4K12/K5 predominantly; has less activity for H2A 927 – 929 GCN5 (KAT2A) Acetylates H3 and H4 and its primary sites are H3K14 930 PCAF (KAT2B) Acetylates H3 and H4 predominantly and its primary sites are H3K14; has less activity for H2A and HAB 387 CBP/P300 (KAT3A/KAT3B) Acetylates H2A, H2B, H3, H4 and its primary sites are H3K14/K18/K27 931 , 932 Eraser HDAC1 Removes acetylated modifications from H1, H2A, H2B type 1/2 and H3 933 HDAC2 Removes acetylated modifications from H1, H2A, H2B type 1/2 and H3 933 HDAC3 Removes acetylated modifications from H2BK12/K15/K16 933 HDAC4 A very weak deacetylase activity on histone 934 HDAC9 A very weak deacetylase activity on histone 935 SIRT1 Removes acetylated modifications from H1K2, H3K9, and H4K16 936 , 937 SIRT2 Removes acetylated modifications from histones during G2/M transition and mitosis 938 , 939 SIRT6 Removes acetylated modifications from H3K9 and H3K56 940 , 941 SIRT7 Removes acetylated modifications from H3K18 942 Reader BRD2 Recognizes H4K12ac preferentially 943 BRD4 Recognizes H3K27ac preferentially 944 , 945 ENL Recognizes H3K9/K18/27ac preferentially 946 AF9 Recognizes H3K9ac preferentially and H3K27/K18ac to a lesser extent 946 YEATS2 Recognizes H3K9ac preferentially; functions as a selective histone crotonylation reader 947 , 948 GAS41 Recognizes H3K18/K27ac preferentially; binds to H3K14 949 , 950 Histone methylation Writer EZH2 Catalyzes mono-, di-, and tri-methylation of H3K27 and H3K9, as well as non-histones substrates 951 DOT1L Catalyzes mono-, di-, and tri-methylation of H3K79 952 SETDB1 Catalyzes trimethylation of H3K9 953 GLP/G9a Catalyzes mono- or di-methylation of H3K9 and non-histone substrates 954 , 955 SMYD2 Catalyzes both trimethylation of H3K36 and non-histone substrates 956 , 957 NSD Catalyzes the dimethylation of H3K36 958 PRMT1 The member of type I PRMTs; the dominant enzyme catalyzing asymmetric dimethylarginine production in proteins and mainly functions as a transcriptional activator 959 PRMT5 The member of type II PRMTs; functions as a transcriptional suppressor or coactivator depending on the cellular context 960 , 961 Eraser LSD1(KDM1A) Removes methylation modifications at H3K4 and H3K9; acts as a coactivator or a corepressor depending on the cellular context 962 KDM2 Removes methylation modifications at H3K4; H3K9, and H3K36; stimulates and inhibits gene transcription 963 KDM7 Removes mono- and di-methylated modifications on H3K9 and H3K27 964 KDM3 Removes mono- and di-methylated modifications from lysine H3K9 965 KDM4 Removes methylated modifications from H3K9 and H3K36 965 , 966 KDM5 Removes di- and tri-methylated modifications ftom H3K4 967 KDM6A An X-linked protein removing methylated modifications from H3K27 968 KDM6B Removes trimethylated modifications from H3K27 969 Reader MBT Recognizes lysine residues on H3 and H4, and helps form monomethylated, dimethylated, or trimethylated modifications 970 Chromodomain Recognizes dimethylated lysine residues of H3K9 and H3K27 971 , 972 Tudor Recognizes methylated lysine and arginine residues on histones H3 and H4 973 PWWP Recognizes H3K36me2/3; binds to dsDNA in a non-specific manner 974 , 975 PHD Recognizes H3K4me2/3/0, H3K14ac or H3K27me0 to a lesser extent 976 WDR Recognizes lysine and arginine methylation of H3 977 RNA methylation writer METTL3 Catalyzes m6A methylation 978 METTL14 Binds to METTL3 and enhances the catalytic activity of METTL3 979 Eraser FTO RNA m6A demethylation; regulates RNA splicing 980 , 981 ALKBH5 RNA m6A demethylation; regulates RNA metabolism and export 982 ALKBH3 Removes the methyl group at the m6A from tRNA; functions an m1A demethylase 983 Reader YTHDF1 Responsible for mRNA translation 984 YTHDF2 Responsible for mRNA degradation 984 , 985 IGF2BP Regulates mRNA translation 714 Chromatin remodeling Mover SMARCA2 DNA-stimulated ATPase in the SWI/SNF complex 986 SMARCA4 DNA-stimulated ATPase in the SWI/SNF complex; binds to acetylated peptides on H3 and H4 986 , 987 Reader Polybromo-1 Recognizes H3K14ac preferentially 988 BRD7 Recognizes acetylated modifications on histones and non-histones substrates 989 , 990 BRD9 Recognizes butyryllysine, and crotonyllysine histone peptide modifications 991 AF9 acute lymphocytic leukemia 1 (ALL1)-fused gene from chromosome 9 protein, ALKBH ALKB homolog, ARID AT-rich interactive domain, ATPase adenosine triphosphate hydrolase, BAF BRG1-associated factor, BRD bromodomain-containing protein, CBP/P300 cyclic adenosine monophosphate-responsive element-binding protein (CREB)-binding protein/histone acetyltransferase P300, DNMT DNA methyltransferase, DOT1L disruptor of telomeric silencing-1-like, dsDNA double-stranded DNA, ENL eleven–nineteen leukemia, EZH2 enhancer of zeste homolog 2, FTO fat mass and obesity associated protein, GAS41 glioma amplified sequence 41, GCN5 general control non-depressible 5, GLP G9a-like protein, HAT histone acetyltransferase, HDAC histone deacetylase, H4K12ac histone 3 lysine 12 acetylation, H3K9me3 histone 3 lysine 9 trimethylation, IGF2BP insulin-like growth factor 2 mRNA-binding protein, KAT lysine acetyltransferase, LSD1(KDM1A) lysine-specific demethylase 1, m6A N6-methyladenosine, MBD methyl-CpG binding domain protein, MBT malignant brain tumor, MeCP methy-CpG-bindig protein, METTL methyltransferase-like, NSD nuclear receptor binding SET domain protein, NuRD nucleosome remodeling and deacetylase, PBAF polybromo, brahma-related gene 1-associated factor, PCAF P300/CBP associated factor, PHD plant homeodomain, PRMT protein arginine methyltransferase, PWWP proline-tryptophan-tryptophan-proline, SETDB1 SET domain bifurcated histone lysine methyltransferase 1, SIRT sirtuin, SMARCA2 SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin A2, SMYD2 SET and MYND domain containing 2, SWI/SNF Switch/Sucrose nonfermentable chromatin-modifying complex, TET ten-eleven translocation, UHRF1 ubiquitin-like with PHD and RING finger domains 1, WDR WD40 repeat, YEATS2 YAF9, eleven-nineteen-leukemia protein (ENL), acute lymphocytic leukemia 1-fused gene from chromosome 9 protein (AF9), TAF14, and SAS5 (YEATS) domain-containing 2, YTHDC1 YTH domain-containing protein 1, YTHDF1 YTH domain family protein 1, 5hmC 5-hydroxymethylcytosine, 5mC 5-methylcytosine Table 2 Broad indications and common treatment-related adverse events of marketed epigenetic-targeting drugs Drug(s) Target(s) Route(s) of administration FDA approval EMA/NMPA approvals Broad indications Common grades 3 or worse treatment-related adverse effects reported in clinical trials Reference(s) Azacitidine DNMT1 Intravenous/subcutaneous Yes — Juvenile myelomonocytic leukemia Thrombocytopenia, neutropenia, anemia, sepsis, infection, and pneumonia 992 – 994 Subcutaneous Not approved yet EMA AML; CMML; MDS Intravenous Not approved yet NMPA AML; MDS; Philadelphia chromosome positive CML Oral azacitidine DNMT1 Oral Yes — AML Febrile neutropenia, thrombocytopenia,leukopenia, pneumonia, respiratory failure, bacteraemia, and sepsis 149 , 995 Decitabine DNMT1 Intravenous Yes NMPA MDS Febrile neutropenia, thrombocytopenia, anemia, pneumonia, and infection 996 – 998 Intravenous Yes — CMML; Refractory anemia (with/without) excess blasts Intravenous Not approved yet EMA AML Decitabine/Cedazuridine DNMT1, CDA Oral Yes — MDS Thrombocytopenia, febrile neutropenia, pneumonia, respiratory failure, bacteraemia, and sepsis 831 , 997 , 999 Oral Not approved yet EMA AML Vorinostat HDACs Oral Yes — CTCL Cellulitis, pulmonary embolism, sepsis, anorexia, increased creatinine phosphokinase, rash, and thrombocytopenia 1000 , 1001 Romidepsin HDACs Intravenous Yes — CTCL; PTCL Lymphopenia, neutropenia, leukopenia, thrombocytopenia, infections, and tumor lysis syndrome 1002 – 1004 Belinostat HDACs Intravenous Yes — PTCL Anemia, thrombocytopenia, dyspnea, neutropenia, infections, tumor lysis syndrome, and ventricular fibrillation 180 , 1005 , 1006 Panobinostat HDACs Oral Canceled by the FDA in 2022 EMA MDS QTc prolongation, hemorrhage, thrombocytopenia, lymphopenia, and asthenia 1007 , 1008 Chidamide Class I HDAC Oral Not approved yet NMPA Breast cancer; DLBCL; PTCL Neutropenia, thrombocytopenia, anemia, leukopenia, diarrhea, and mucositis 202 , 1009 , 1010 Givinostat HDAC1, HDAC3 Oral Yes — DMD Diarrhea 207 Enasidenib IDH2 Oral Yes — AML Febrile neutropenia, IDH differentiation syndrome, and indirect hyperbilirubinemia 228 , 234 Ivosidenib IDH1 Oral Yes NMPA AML QT interval prolongation, IDH differentiation syndrome, anemia, and ascites 1011 , 1012 Oral Yes — Cholangiocarcinoma; MDS Oral Not approved yet EMA IDH1-mutated AML; IDH1-mutated cholangiocarcinoma Ivosidenib/Azacitidine IDH1/DNMT1 Oral; intravenous/subcutaneous Yes — IDH1-mutated AML Febrile neutropenia, neutropenia, bleeding events, infection, IDH differentiation syndrome, and QT interval prolongation 240 , 241 Olutasidenib IDH1 Oral Yes — IDH1-mutated AML Thrombocytopenia, febrile neutropenia, anemia, alanine aminotransferase increased, and aspartate aminotransferase increased 248 , 249 Tazemetostat EZH2 Oral Yes — FL; Sarcoma Hyperglycemia, hyponatremia, anemia, thrombocytopenia, neutropenia, lymphopenia, and weight loss 252 , 254 Valemetostat tosilate EZH2/EZH1 Oral Not approved yet * Only approved by the PMDA in Japan ATL Thrombocytopenia, anemia, lymphopenia, leukopenia, and neutropenia 261 AML acute myeloid leukemia, ATL adult T-cell leukemia/lymphoma, CDA cytidine deaminase, CML chronic myelogenous leukemia, CMML chronic myelomonocytic leukemia, CTCL cutaneous T-cell lymphoma, DLBCL diffuse large B-cell lymphoma, DMD Duchenne muscular dystrophy, DNMT1 DNA methyltransferase 1, EMA European Medicines Agency, EZH2 enhancer of zeste homolog 2, FDA Food and Drug Administration, FL follicular lymphoma, HDAC histone deacetylase, IDH isocitrate dehydrogenase, MDS myelodysplastic syndrome, NMPA National Medical Products Administration, PMDA Pharmaceuticals and Medical Devices Agency, PTCL peripheral T-cell lymphoma

DNMT inhibitors

Azacitidine and decitabine, known as hypomethylating agents (HMAs), target DNMT1 and were among the first epigenetics-targeted drugs approved for clinical use. The US FDA approved azacitidine in May 2004 and decitabine in June 2006 for treating myelodysplastic syndrome (MDS). 142 , 143 The clinical success of these HMAs has led to a focus on optimizing their dosing schedules and administration methods. Early studies involving azacitidine and decitabine assessed their therapeutic potential through continuous and/or frequent intravenous or subcutaneous injections, establishing standard doses and delivery methods in clinical settings. 144 – 146 Recent advancements have explored reduced dosages for patients at lower risk. In recent phase II clinical trials, azacitidine or decitabine was applied for three or five consecutive days in a 28-day cycle, exhibiting satisfactory therapeutic efficacy and tolerable safety. 147 , 148 Some patients who received decitabine experienced myelosuppression, and future efforts are required to take steps to avoid this. 147

Additionally, the development of oral formulations of azacitidine and decitabine, such as oral azacitidine (CC-486), approved in September 2020 for patients with acute myeloid leukemia (AML) who are not candidates for intensive curative therapy, has improved patient convenience and treatment adherence. 149 In a well-organized phase III randomized trial, the median overall survival and relapse-free survival of patients treated with CC-486 were greatly improved. 149 Importantly, fewer grades 3 or 4 adverse events were observed during CC-486 treatment, allowing the preservation of overall health-related quality of life. 149 The doses of CC-486 used in clinical settings are approximately four times higher than the standard doses administered by intravenous or subcutaneous routes due to their reduced bioavailability. 150 Meanwhile, the poor bioavailability of oral decitabine has led to the development of ASTX727, an oral combination of decitabine with cedazuridine. This cytidine deaminase enzyme inhibitor enhances decitabine exposure after oral administration. This combination has been approved for marketing in treating MDS and AML in some countries. 151 , 152 However, in China, the therapeutic potential of CC-486 and ASTX727 for AML and MDS is still under evaluation in clinical trials ( NCT05413018 , NCT04102020 , NCT06091267 , NCT02649790 ). Furthermore, there has been an increased focus on the synergistic effects of HMA and traditional antitumor treatments to enhance therapeutic outcomes and prevent resistance in hematologic malignancies refractory to monotherapy. This topic is further summarized in the subsequent section on drug combination applications.

Inspired by the successful application of HMAs in hematologic malignancies, their therapeutic potential in treating solid tumors is also being explored. However, as of now, HMAs are not approved for treating solid tumors. In 2017, Linnekamp et al. 153 conducted a systematic review to illustrate the clinical and biological effects of HMAs on solid tumors based on previously completed clinical trials. The efficacy of azacitidine and decitabine in solid tumors was less pronounced than in hematological malignancies, primarily because most study participants had advanced-stage tumors with short life expectancies. 153 Moreover, many early-stage studies were small-sized cohorts, lacking sufficient evidence to generalize therapeutic effects across different tumor types. With significant advances in optimizing HMA formulations and dosages, as well as the increasing number of combination therapies showing promising effects on solid tumors in vitro and in vivo, clinical trials of HMAs, particularly the oral formulations CC-486 and ASTX727, among patients with solid tumors, are being extensively conducted, and their results are eagerly anticipated. 154 – 156

HDAC inhibitors

Over the past two decades, substantial progress has been made in developing HDAC inhibitors, with six approved for clinical use. These include vorinostat (SAHA), romidepsin (FK228), belinostat (PXD101), and panobinostat (LBH589, although the FDA canceled it in 2022). These drugs have been approved by various regulatory bodies, such as the US FDA, the European Medicines Agency, and the Pharmaceuticals and Medical Devices Agency (PMDA). They are used to treat conditions such as multiple myeloma (MM), cutaneous T-cell lymphoma (CTCL), and peripheral T-cell lymphoma (PTCL). 157 , 158 Additionally, chidamide (tucidinostat) was approved by PMDA in Japan and National Medical Products Administration (NMPA) in China for the treatment of PTCL and advanced breast cancer, 159 , 160 and more recently, givinostat (ITF2357) was approved by the FDA in March 2024 as the first nonsteroidal treatment for Duchenne muscular dystrophy (DMD) for patients aged six years and older. 161

Vorinostat was the first pan-inhibitor of HDACs approved by the FDA in October 2006 for CTCL. 162 Soon after, in July 2011, it was also approved for clinical therapy by PMDA. In addition to CTCL, the application of vorinostat to AML, MM, malignant pleural mesothelioma, newly diagnosed high-grade glioma ( NCT01236560 ), and advanced non-small cell lung cancer ( NCT00473889 ) therapy has entered phase III clinical trials. 163 – 166 Disappointingly, though vorinostat exerts effective therapeutic effects in diverse hematological malignancies, limited efficacy has been observed in solid tumors. 166 Another thing to note when using vorinostat as a clinical medication is the potential adverse events that may occur. While generally mild, adverse events related to vorinostat can include thrombosis, QT interval prolongation, and potentially fatal ventricular tachycardia or torsional tachycardia. 167 – 169 These findings have driven the development of other HDAC inhibitors, with the expectation of elevated safety and efficacy in vivo.

Romidepsin, another pan-HDAC inhibitor, was approved by the FDA in November 2009 for CTCL and later for PTCL. It has shown a higher affinity to class I HDAC proteins. 170 Subsequently, it was approved for treating patients with PTCL by the FDA and PMDA. Phase III randomized controlled trials are performed to evaluate the therapeutic value of the first-line treatment of PTCL, referring to the combination of cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP), and romidepsin plus CHOP in patients with PTCL, while the addition of romidepsin failed to increase efficacy as expected. 171 , 172 However, after a six-year follow-up, the application of romidepsin shows beneficial effects in prolonging median progression-free survival. 171 In addition, the combination of romidepsin with other therapeutics, such as oral 5-azacytidine, tenalisib (an inhibitor of phosphoinositide-3-kinase and salt-inducible-kinase-3), and lenalidomide (a new generation of immune modulator) shows promising therapeutic potential in various types of T-cell lymphoma in the initial stages of clinical practice, supporting further exploration. 173 – 176 Meanwhile, investigations on the therapeutic effects of romidepsin against other diseases are ongoing, particularly in antiretroviral treatment in human immunodeficiency virus-1 (HIV-1) infection. 177 , 178

Belinostat was FDA-approved in July 2014 for relapsed or refractory (R/R) PTCL, showing pan-inhibitory effects on HDAC proteins. 179 Common adverse effects of belinostat include nausea, vomiting, diarrhea, dysgeusia, fatigue, and severe hematologic treatment-related adverse events. 180 , 181 Further, dosing considerations are needed for patients with hepatic impairment due to liver metabolism. 182 Belinostat is being explored for other myeloid malignancies and solid tumors, including glioblastoma and small-cell lung cancer. 183 – 186

Panobinostat, an oral broad-spectrum HDAC inhibitor approved in January 2015 for R/R MM in combination with dexamethasone and bortezomib, showed a slight overall survival benefit in phase II and III trials. 187 However, many participants experienced adverse events like thrombocytopenia, lymphopenia, asthenia, and fatigue, which raises concerns about its tolerability. 187 – 189 In a recent randomized phase II clinical trial, it was proposed that administering bortezomib via subcutaneous application rather than intravenous injection could improve the safety and tolerability of the triplet regimen, including panobinostat. 190 Beyond its primary indications, panobinostat is being explored for its efficacy in various other tumor diseases such as lymphoma, primary myelofibrosis, glioma, clear cell renal cell carcinoma, and prostate cancer, both as monotherapy and in combination with other tumor therapeutics, showing promising efficacy across multiple malignancies. 191 – 195 However, the safety of panobinostat continues to be a primary concern and requires further evaluation in advanced clinical studies.

Chidamide, the first orally administered selective HDAC inhibitor targeting HDAC1, HDAC2, HDAC3, and HDAC10, 160 is currently under investigation for a variety solid and hematological malignancies, autoimmune diseases, and neurodegenerative diseases. 196 – 201 It offers advantages over pan-inhibitors in the treatment of tumor diseases and in minimizing severe adverse effects. 160 Recent therapeutic strategies using chidamide in combination with a second antitumor intervention have shown promising prospects. For instance, a combination of chidamide and exemestane has proven effective as a neoadjuvant treatment for patients with stage II-III breast cancer that is hormone receptor-positive and human epidermal growth factor receptor 2-negative. 199 , 202 A recent phase III clinical trial reported an increased occurrence of grades 3–4 hematological adverse events in the tucidinostat plus exemestane group, while the median progression-free survival of these patients was notably improved. 202 Furthermore, synergistic effects have been observed when chidamide is used in conjunction with immunotherapy, endocrine therapy, or chemoradiation, offering novel adjuvant approaches for tumor therapy. 203 – 206

Givinostat, developed by Italfarmaco SpA, is a potent inhibitor of HDAC1 and HDAC3 recently approved for clinical use. In a pivotal, multicenter, randomized phase III clinical trial involving 179 patients with DMD aged at least six years, givinostat effectively delayed disease progression. 207 The most common adverse events reported were diarrhea and vomiting. 207 Additionally, givinostat shows promise as a treatment for polycythemia vera, particularly in patients unresponsive to hydroxycarbamide monotherapy. 208 In phase I/II clinical trials, givinostat demonstrated promising efficacy and tolerability in patients with polycythemia vera. 209 , 210 Subsequently, long-term follow-up over four years has further substantiated the therapeutic benefits and safety profile of givinostat. 211 Throughout the follow-up period, the overall response rate consistently exceeded 80% among patients with PV, while only 10% of these patients experienced grade 3 treatment-related adverse events, suggesting its potential for prolonged clinical use. 211

IDH inhibitors

IDH is a key enzyme in the TCA cycle that normally catalyzes the conversion of isocitrate to α-KG and carbon dioxide. In cells with mutated IDH, this enzyme instead produces 2-hydroxyglutarate (2-HG), a metabolite that inhibits α-KG-dependent epigenetic enzymes and contributes to the aberrant epigenetic landscape seen in various diseases, particularly tumors. 212 , 213 Currently, three IDH inhibitors are approved for clinical use: enasidenib (AG-221), ivosidenib (AG-120), and olutasidenib (FT-2102), targeting different forms of the enzyme mutation. 214 – 217 Additional IDH1/2 inhibitors that are allowed to be investigated in clinical practice include the dual inhibitor of mutant IDH1/2 vorasidenib (AG-881), 218 the irreversible mutant IDH1 inhibitor LY3410738 ( NCT06181045 , NCT06181084 ), and the pan-mutant-IDH1 inhibitor BAY1436032. 219 , 220

Enasidenib is an allosteric inhibitor targeting mutated IDH2, approved by the FDA in August 2017 for the treatment of R/R AML with IDH2 mutations. 221 Based on preliminary animal experiments and preclinical evidence, enasidinib effectively reduces the 2-HG levels derived from IDH2 mutations, reversing excessive histone and DNA methylation landscapes. 222 – 224 Subsequently, enasidinib has entered clinical trials and demonstrated good efficacy in treating AML and MDS patients, which is further considered a promising option for elderly AML patients over 60 years old, especially those who are not suitable for intensified chemotherapy. 225 – 230 Combination therapy with enasidenib and azacitidine has shown acceptable tolerability and potential to improve outcomes for patients with IDH-mutated AML. 229 , 231 , 232 However, potential severe adverse effects include hyperbilirubinemia, thrombocytopenia, pneumonia, and IDH differentiation syndrome, the latter of which can be life-threatening and requires careful management. 233 – 235 Noticeably, IDH differentiation syndrome is one of the potentially lethal entities that require prompt recognition and more appropriate management. 236 Enasidenib is also being explored for other conditions caused by IDH2 mutations, such as D-2-hydroxyglutaric aciduria type II, 237 chondrosarcoma, 238 angioimmunoblastic T-cell lymphoma ( NCT02273739 ), and malignant sinonasal or skull base tumors ( NCT06176989 ).

Ivosidenib, targeting mutated IDH1, was first approved by the FDA in July 2018 for R/R AML. 239 In April 2022, with the data from a completed phase III clinical trial being made public, the therapeutic potentials and good safety of the combination of azacitidine and ivosidinib among patients with AML received broader attention. 240 Subsequently, the FDA approved this regimen for elderly patients with newly diagnosed IDH1-mutated AML in May 2022. 241 Besides AML, ivosidenib is approved for MDS and cholangiocarcinoma, with ongoing phase III studies in unresectable or metastatic cholangiocarcinoma with IDH1 mutations. 216 , 242 The most significant adverse events include ascites and other severe conditions, necessitating vigilant monitoring. 242 Ivosidenib has also shown promising results in phase I clinical trials for IDH-mutated advanced glioma, with a daily dose of 500 mg proving effective in reducing 2-HG levels and controlling the disease. 243 – 246

Olutasidenib, an oral IDH1 inhibitor, was approved by the FDA in December 2022 for treating R/R AML with specific IDH1 mutations. It has also shown promise as a therapeutic option for patients with IDH1-mutated AML who are insensitive to venetoclax, offering a new avenue for treatment where previous therapies may have failed. 217 Clinical trials have demonstrated that olutasidenib, combined with azacitidine, provides comparable efficacy and tolerability in AML and MDS patients harboring mutant IDH1. 247 Treatment-emergent side effects of grade 3-4, such as febrile neutropenia, anemia, thrombocytopenia, and neutropenia, occur at a low frequency with olutasidenib monotherapy or in combination therapies, suggesting a manageable safety profile. 247 , 248 Beyond hematological malignancies, the therapeutic potential of olutasidenib is also being explored in other diseases, such as IDH-mutated R/R gliomas. In a multicenter, open-label, phase Ib/II clinical trial involving 26 patients, olutasidenib achieved a disease control rate of 48%. Notable grade 3-4 adverse events included increases in alanine aminotransferase and aspartate aminotransferase, indicating the need for careful liver function monitoring during treatment. 249

EZH2 inhibitors

Currently, two EZH2 inhibitors, tazemetostat (EPZ-6438) and valemetostat tosilate (DS-3201, DS-3201B), targeting EZH1/2 or EZH2 have been approved and are being utilized in various therapeutic strategies.

Tazemetostat, the first oral EZH2 inhibitor, was approved by the FDA in January 2020 for patients over 16 years of age with advanced epithelioid sarcoma that is ineligible for complete resection. 250 It is also the first targeted drug for epithelioid sarcoma treatment. 251 In a phase II clinical trial ( NCT02601950 ), tazemetostat demonstrated good tolerability and clinical activity, with a low incidence of severe treatment-related adverse events such as anemia and weight loss. 252 Tazemetostat has also been studied as a monotherapy in R/R follicular lymphoma (FL), showing promising, durable responses and an acceptable safety profile. 253 , 254 Common severe adverse events included thrombocytopenia, neutropenia, and anemia. 254 In Japan, a phase I/II trial evaluated tazemetostat 800 mg twice daily in R/R EZH2 mutation-positive FL, showing encouraging response rates and tolerability, which helped to accelerate its approval by the FDA and PMDA for this indication. 255 , 256 Furthermore, tazemetostat is being investigated as a single agent for malignant mesothelioma, with ongoing efforts to refine biomarkers for its activity in malignant pleural mesothelioma. 257 Research is also underway to assess the efficacy and tolerability of tazemetostat in combination with other therapeutic agents, including programmed cell death 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) inhibitors, chemotherapy, and targeted therapeutics across different tumor types. 258 – 260 Notably, phase III clinical trials are exploring tazemetostat in combination with lenalidomide and rituximab ( NCT04224493 ) or doxorubicin ( NCT04204941 ) focusing on R/R FL and epithelioid sarcoma, which are highly anticipated for their potential to redefine treatment paradigms.

Valemetostat tosilate is an innovative dual inhibitor of EZH1/2 that received approval from the PMDA in Japan for the treatment of R/R adult T-cell leukemia/lymphoma (ATL) in September 2022. 261 It is administered orally and should be taken on an empty stomach to avoid adverse food effects. 262 Dosage adjustments are necessary when valemetostat is used concurrently with strong inhibitors of cytochrome P450 3 A and P-glycoprotein, which can affect its metabolism and excretion. 263 In a multicenter phase 2 trial involving patients with R/R aggressive ATL, valemetostat demonstrated promising efficacy, even in heavily pretreated patients. The common treatment-associated adverse effects reported were manageable, including thrombocytopenia, anemia, alopecia, dysgeusia, neutropenia, lymphopenia, leukopenia, decreased appetite, and pyrexia. 264 However, resistance to valemetostat has been observed in some patients with ATL, potentially due to acquired mutations in the polycomb repressive complex 2 (PRC2) within tumor cells, highlighting a significant challenge in long-term treatment scenarios. 59 Currently, valemetostat and its analogs are also being investigated in various preclinical studies and animal models for conditions such as tumor protein p63 gene-rearranged lymphoma, sinonasal teratocarcinosarcoma, ibrutinib-resistant mantle cell lymphoma, and human T-cell leukemia virus type 1-associated myelopathy. These studies further expand the potential therapeutic applications of valemetostat and warrant continued exploration of valemetostat-based treatment strategies. 265 – 268

Other epigenetics-targeted drugs under research as clinical candidates

Although there have been many advances in the research of marketed drugs, they still belong to the tip of the iceberg relative to the entire field of epigenetics-targeting drug development. Many small molecule inhibitors and agonists targeting epigenetic-modifying enzymes are being identified and progressively advancing into the early stages of clinical trials. This section categorizes and summarizes these drugs based on their mechanisms, highlighting agents that show potential therapeutic value in clinical settings (Fig. 4 ). Fig. 4 The development direction and major categories of epigenetics-targeted drugs. a Epigenetics-targeted drugs are developed through the virtual screening of compound libraries, drug design based on molecular structure, and the exploration of potential mechanisms of known agents. Subsequently, applying PROTAC, CRISPR/Cas, and other technologies or mechanisms to optimize the physical properties, and inhibitory or agonistic effects of compounds. Finally, the druggability of possible agents should be improved in experimental, preclinical and clinical studies. b The classification of epigenetics-targeted drugs and their corresponding marketed representative agents are depicted in this section. Among them, epigenetics-targeted drugs that have already been approved and applied in clinical treatment are highlighted in corresponding colors

Epigenetics-targeted drugs and DNA methylation

This critical regulatory mechanism of gene expression involves adding methyl groups to DNA, primarily at cytosine bases in CpG dinucleotides, which generally leads to gene silencing. The process is dynamically regulated by DNMT and TET enzymes. The aberrant activity of these enzymes is closely linked with the pathogenesis of a wide range of diseases, not only cancers but also metabolic, inflammatory, and neurological disorders, underscoring the therapeutic relevance of targeting these pathways. 269 – 272 Therefore, DNA methylation provides a promising platform for developing epigenetics-targeted drugs in clinical practice (Table 3 ). Table 3 Summary of DNA methylation-targeted drugs for different diseases in clinical trials Type Drug Target(s) Condition(s) Status/outcome(s) Phase(s) Other intervention(s)/drug(s) Study ID/reference(s) DNMT inhibitor Guadecitabine DNMT1 Platinum refractory germ cell cancer Completed (exhibits tolerable safety and satisfied activity) Phase I In combination with Cisplatin NCT02429466 1013 Guadecitabine DNMT1 Liver cancer, pancreatic cancer, bile duct cancer, gallbladder cancer Active, not recruiting Phase I In combination with Durvalumab NCT03257761 Guadecitabine DNMT1 Lung cancer Active, not recruiting Phase I In combination with Pembrolizumab and Mocetinostat NCT03220477 Guadecitabine DNMT1 AML Completed (exhibits an overall unfavorable benefit-risk profile at the investigated dose levels) Phase I In combination with Atezolizumab NCT02892318 276 Guadecitabine DNMT1 Colorectal cancer Completed (no significant clinical activity of the Guadecitabine with Cy/GVAX is observed) Phase I CY/GVAX (active comparator/followed by Guadecitabine) NCT01966289 277 Guadecitabine DNMT1 Castration-resistant prostatic cancer, NSCLC Recruiting (helps to reverse resistance to immune checkpoint inhibitors according to early clinical data) Phase I ASTX727 (active comparator); in combination with Pembrolizumab NCT02998567 1014 Guadecitabine DNMT1 AML Completed (subcutaneous administration of large doses may be beneficial for improving treatment efficacy while increases the risk of adverse events) Phase I — NCT02293993 Guadecitabine DNMT1 Melanoma Completed (helps to achieve long-term clinical benefits) Phase I In combination with Ipilimumab NCT02608437 281 , 282 Guadecitabine DNMT1 SCLC Completed (unpublished) Phase I In combination with platinum-based first-line chemotherapy, Durvalumab, and Tremelimumab NCT03085849 Guadecitabine DNMT1 AML, MDS Terminated (not due to patient safety) Phase II — NCT03603964 Guadecitabine DNMT1 MDS Active, not recruiting Phase II — NCT02131597 Guadecitabine DNMT1 AML, MDS Unknown Phase II ASCT NCT03454984 Guadecitabine DNMT1 Paraganglioma, GIST, RCC, pheochromocytoma Terminated (exhibits manageable toxicity with low objective response rates) Phase II — NCT03165721 278 Guadecitabine DNMT1 SCLC Completed (exhibits good efficacy but with the possibility of adverse events) Phase II In combination with Cisplatin NCT03913455 1015 Guadecitabine DNMT1 Urothelial carcinoma Active, not recruiting (possibly prolongs patient survival) Phase II In combination with Atezolizumab NCT03179943 1016 Guadecitabine DNMT1 Philadelphia-negative myeloproliferative neoplasms Completed (helps improve quality of life and exhibits acceptable adverse events) Phase II — NCT03075826 Guadecitabine DNMT1 HCC Completed (high incidence of treatment-related adverse events) Phase II — NCT01752933 Guadecitabine DNMT1 AML Completed (exhibits comparable clinical response rates and safety) Phase II With or without Cladribine or Idarubicin NCT02096055 Guadecitabine DNMT1 Fallopian tube carcinoma, peritoneal carcinoma Completed (exhibits clinical benefit and possibly activates antitumor immunity) Phase II In combination with Pembrolizumab NCT02901899 1017 Guadecitabine DNMT1 MDS Completed (exhibits potential therapeutic effects on high-risk patients who failed azacitidine) Phase II — NCT02197676 1018 Guadecitabine DNMT1 AML, CMML, MDS Active, not recruiting Phase II In combination with donor lymphocytes NCT02684162 Guadecitabine DNMT1 Melanoma, NSCLC Not yet recruiting Phase II With or without Ipilimumab plus Nivolumab NCT04250246 Guadecitabine DNMT1 Central chondrosarcoma Active, not recruiting Phase II In combination with Belinostat or ASTX727 NCT04340843 1019 Guadecitabine DNMT1 Ovarian cancer Completed (helps to increase progression-free survival within six months) Phase II In combination with Carboplatin NCT01696032 1020 Guadecitabine DNMT1 Colorectal cancer Withdrawn (due to the insufficient funding) Phase I/II In combination with Nivolumab NCT03576963 Guadecitabine DNMT1 RCC Active, not recruiting (exhibits satisfied safety and tolerability) Phase I/II In combination with Durvalumab NCT03308396 1021 Guadecitabine DNMT1 AML, MDS, CMML Active, not recruiting (exhibits manageable adverse events and typical cytopenia-related safety concerns) Phase I/II In combination with Atezolizumab NCT02935361 1022 Guadecitabine DNMT1 AML, MDS, CMML Completed (exhibits well clinically active and acceptable tolerability) Phase I/II — NCT01261312 1023 – 1026 Guadecitabine DNMT1 Colorectal cancer Completed (exhibits comparable efficacy and safety profiles) Phase I/II In combination with Irinotecan; Regorafenib or TAS-102 (active comparator) NCT01896856 280 , 1027 Guadecitabine DNMT1 Platinum-resistant fallopian tube carcinoma, platinum-resistant ovarian carcinoma, platinum-resistant primary peritoneal carcinoma Active, not recruiting Phase I/II Atezolizumab (active comparator/followed by Guadecitabine); with or without CDX-1401 vaccine NCT03206047 Guadecitabine DNMT1 MDS, CMML Completed (exhibits comparable therapeutic effects and safety profiles) Phase III Low-dose Cytarabine/standard IC/BSC (active comparator) NCT02907359 Guadecitabine DNMT1 AML Completed (exhibits higher clinical response rates and comparable safety) Phase III High-dose Cytarabine/low-dose Cytarabine/BSC(active comparator) NCT02920008 279 Guadecitabine DNMT1 AML Completed (no significant clinical activity of the Guadecitabine and active comparators is observed) Phase III Low-dose Cytarabine/high-dose Cytarabine (active comparator) NCT02348489 283 MG98 DNMT1 Solid tumors Completed (exhibits early evidence of clinical activity with good tolerability) Phase I — NCT00003890 297 MG98 DNMT1 Metastatic renal carcinoma Terminated (exhibits no antitumor activities) Phase II — 298 Hydralazine DNMT1/3a/3b Lung cancer Completed (unpublished) Phase I In combination with Valproic acid NCT00996060 Hydralazine DNMT1/3a/3b Refractory solid tumors Completed (exhibits the potential to overcome chemotherapy resistance) Phase II In combination with Magnesium valproate NCT00404508 304 Hydralazine DNMT1/3a/3b Cervical cancer Completed (unpublished) Phase II In combination with Magnesium valproate and Cisplatin chemoradiation NCT00404326 Hydralazine DNMT1/3a/3b BC Terminated (treatment is well-tolerated) Phase II In combination with Magnesium valproate NCT00395655 301 Hydralazine DNMT1/3a/3b HCC Completed (exhibits good efficacy and manageable toxicities) Phase II In combination with Valproic acid TPVGH97-07-07 1028 Hydralazine DNMT1/3a/3b MDS Unknown Phase II In combination with Valproic acid; BSC (active comparator) NCT01356875 Hydralazine DNMT1/3a/3b BC Withdrawn (IRB request) Phase I/II — NCT00575978 Hydralazine DNMT1/3a/3b Rectal cancer Withdrawn (No enrollment) Phase I/II — NCT00575640 Hydralazine DNMT1/3a/3b Ovarian cancer Unknown Phase III In combination with Magnesium valproate; placebo-controlled NCT00533299 Hydralazine DNMT1/3a/3b Cervical cancer Completed (exhibits advantages in progression-free survival) Phase III In combination with Magnesium valproate; placebo-controlled NCT00532818 Hydralazine DNMT1/3a/3b Cervical cancer Unknown Phase III In combination with Magnesium valproate, Carboplatin, and Paclitaxel; placebo-controlled NCT02446652 TET agonist Vitamin C/Ascorbate TET1//2/3 MDS, AML Completed (enhances the biological effects of DNMT inhibitors) Pilot trial In combination with Azacitidine NCT02877277 335 Vitamin C/Ascorbate TET1//2/3 MDS, AML Completed (identifies an appropriate dose of the drug combination for phase II studies) Phase I In combination with Decitabine and Arsenic trioxide NCT00671697 336 Vitamin C/Ascorbate TET1//2/3 TET2-mutant MDS, TET2-mutant AML Completed (unpublished) Phase II In combination with Azacitidine NCT03397173 Vitamin C/Ascorbate TET1//2/3 TET2-mutant MDS Completed (exhibits good safety profiles and tolerability) Phase I/II — NCT03433781 AML acute myeloid leukemia, ASCT allogeneic stem cell transplant, BC breast cancer, BSC best supportive care, CMML chronic myelomonocytic leukemia, CY Cyclophosphamide/Cytoxan, DNMT DNA methyltransferase, GVAX colon cancer tumor vaccine, GIST gastrointestinal stromal tumor, HCC hepatocellular carcinoma, IC intensive chemotherapy, IRB institutional review board, MDS myelodysplastic syndrome, NSCLC non-small cell lung cancer, RCC renal cell carcinoma, SCLC small cell lung cancer, TET ten-eleven translocation

Targeting the writer of DNA methylation: DNMT

Current therapeutic strategies primarily involve DNMT inhibitors, which suppress the expression or enzymatic activities of DNMTs, thereby counteracting improper DNA methylation patterns. These inhibitors are crucial in correcting the abnormal addition of methyl groups to DNA, a common feature in many pathologies.

DNMT inhibitors

Most DNMT inhibitors under investigation are employed in treating hematological or solid tumors, with a smaller portion used for inflammatory or proliferative benign diseases. 153 , 273 DNMT inhibitors fall into two principal categories based on their mechanisms of action: nucleoside DNA methylation inhibitors and non-nucleoside DNA methylation inhibitors.

Among the nucleoside analogs, the FDA-approved drugs azacitidine and decitabine are noteworthy. These compounds integrate into the DNA structure and are recognized by DNMTs during DNA replication, thereby obstructing normal DNA methylation processes. 274 Another significant compound, guadecitabine (SGI110, an antimetabolite of decitabine), represents a second-generation DNA methylation inhibitor. It is an antinucleotide molecule that resists degradation by cytidine deaminase. 275 Research primarily focuses on its application against various malignant tumors. However, although guadecitabine has demonstrated good tolerance and favorable outcomes in many clinical trials, there is still clinical evidence indicating that its application may cause serious treatment-related adverse effects, such as pneumonia, sepsis, aspiration pneumonia, metabolic disorders, neutropenia, leukopenia, and pruritis. 276 , 277 Furthermore, a recent phase II clinical trial conducted among patients with succinate dehydrogenase-deficient tumors was terminated due to low objective response rates. 278 Additionally, when combined with traditional antitumor agents such as chemotherapeutic drugs and immune checkpoint blockade agents, guadecitabine demonstrates a potent synergistic effect, enhancing long-term clinical benefits. 279 – 282 Promisingly, its use in treating patients with AML has advanced to phase III clinical trials, indicating high response rates and comparable safety, positioning it as a promising future alternative. 279 , 283 Other nucleoside DNA methylation inhibitors include CP-4200, with cellular uptake less dependent on the nucleoside transporters involved in azacytidine uptake; 284 F-aza-T-dCyd (NSC801845), optimized structurally from T-dCyd, F-T-dCyd, and Aza-T-dCyd; 285 DHDAC, which is less cytotoxic and more stable; 286 NPEOC-DAC, a decitabine derivative modified at the N4 position of the azacitidine ring, displaying significantly reduced potency at low doses in inhibiting DNA methylation; 287 and zebularine, known for its high selectivity and better biocompatibility towards pathological cells, 288 demonstrating significant therapeutic effects not only on tumors but also on non-tumor diseases like renal fibrosis, 289 T2DM, 290 and NAFLD. 291 Additionally, clofarabine, an FDA-approved purine nucleoside analog for treating pediatric AML, primarily inhibits DNA biosynthesis and the ribonucleotide reductase enzyme and has shown potential in early-stage carcinogenesis through DNMT1 inhibition. 292

Beyond these, various non-nucleoside DNMT inhibitors have been identified. These include specific artificially synthesized inhibitors and naturally occurring agents with a demethylation function. 293 , 294 Enhancements to the physical properties of these natural compounds, such as solubility and stability, benefit the development of more effective DNMT-targeted inhibitors. 295 , 296 Non-nucleoside DNMT inhibitors are categorized based on their diverse mechanisms of action into competitors of S-adenosylmethionine (SAM), competitive or non-competitive inhibitors of DNMT, regulators of DNMT expression, and binders of DNA substrates. 53 MG98 and hydralazine are the only two drugs currently in clinical trials. MG98, an antisense oligodeoxynucleotide, reduces DNMT1 mRNA levels by targeting its 3’ untranslated region. However, several clinical trials are far from satisfactory. 297 A two-stage phase II clinical trial evaluated the antitumor efficacy of MG98 in seventeen patients with metastatic renal carcinoma. 298 However, it failed to detect a decrease in DNMT1 activity caused by MG98, urging caution against potential side effects like transaminase elevation and fatigue from excessive dosages during intravenous administration. 298 , 299 Hydralazine, a low molecular weight molecule, interacts with DNMT through a network of hydrogen bonds with arginine and glutamic acid residues. 300 Its combination with traditional chemotherapeutic agents has been found to mitigate the progression of both hematological malignancies and solid tumors. 301 – 304 In a completed phase II clinical trial, 15 patients with solid tumors qualified for the assessment of the therapeutic response to hydralazine and magnesium valproate. The majority of patients (80%), benefited from treatment and exhibited satisfactory clinical efficacy and tolerability. 304 These findings underpin the hypothesis that epigenetic aberrations induced by chemotherapeutic agents are a primary cause of chemoresistance, providing a theoretical basis for the combined use of epigenetics-targeted drugs and chemotherapy in tumor therapy.

Targeting the eraser of DNA methylation: TET

Due to the significant heterogeneity in the roles that TET enzymes play across various diseases, the effectiveness of targeting TET enzymes as a therapeutic strategy depends on the specific disease or even different stages within a disease. 305 While there are currently no epigenetic-targeted drugs that modulate TET available on the market, experimental studies and clinical trials suggest that reshaping methylation landscapes through TET inhibitors and agonists may be a viable approach to treating diseases.

TET inhibitors

To date, numerous small molecules have been identified that inhibit TET enzymes. Research into these TET inhibitors primarily focuses on elucidating their underlying molecular mechanisms. We categorize these inhibitors into three groups based on their distinct mechanisms of action, which will be discussed in detail below.

Auranofin, C35, and eltrombopag specifically target and bind to the catalytic domains of TET proteins, directly inhibiting their enzymatic activities. C35 exhibits potent inhibitory effects on all members of the TET family. 306 , 307 In contrast, the effects of auranofin and eltrombopag are specific to TET1 and TET2, respectively. 308 , 309 Notably, eltrombopag, a nonpeptidyl thrombopoietin receptor agonist approved by the US FDA for use in patients with aplastic anemia as an iron chelator. 310 Recently, Guan et al. 309 reported the negative effects of eltrombopag on TET2. Intriguingly, this mechanism is independent of its iron chelation properties, presenting it as a potential TET2-targeted epigenetic agent and providing new insights for epigenetics-oriented therapy. 309 Further, well-designed studies are essential to evaluate the clinical application potential of these molecular-level discoveries.

Itaconic acid, fumarate, and succinate are in vivo synthesized metabolites that indirectly impair TET catalytic activity by competitively binding to TET2 alongside α-KG, a crucial cofactor. 311 – 313 These metabolites are promising precursors for developing TET-targeted epigenetic drugs, as they are well tolerated in vivo. 314 , 315 However, considerable work is necessary before clinical application, such as designing appropriate carriers that can deliver these agents directly to pathological cells, given their potential impact on the vital activities of normal cells. Additionally, synthetic compounds like dimethyloxallylglycine and TETi76, which mimic the properties of α-KG, serve as competitive inhibitors of TET. 316 , 317 These agents represent a novel approach to developing TET inhibitors.

Bobcat339, 318 , 319 NSC-311068, 320 NSC-370284, 320 and UC-514321, 320 inhibit DNA methylation by reducing intracellular TET levels. Bobcat339 induces the degradation of TET3 directly, 318 and its inhibitory effects on TET1 and TET2 are observed only in the presence of coordinating copper(II). 321 NSC-370284 and UC-514321 bind directly to the DNA-binding domain of signal transducer and activator of transcription 3 (STAT3) or STAT5, transcriptional activators of TET1, leading to suppressed expression of TET1 in vivo. 320 This mechanism has been confirmed in mouse models of AML and medulloblastoma, showing synergistic effects with standard chemotherapy. 320 , 322 The therapeutic potential of these compounds in additional diseases is an exciting area for future research.

TET agonists

As previously discussed, TET inhibitors are highly valued for treating diseases. Conversely, research into TET agonists is also anticipated to yield promising breakthroughs and pave the way for clinical applications. Most TET agonists currently under investigation are drugs that upregulate cofactors of TET, such as vitamin C and enzymes involved in α-KG metabolism; other small molecules, including 3-nitroflavanones, 295 retinoic acid, 323 ioperamide hydrochloride, 324 and mitoxantrone, 325 are reported to directly upregulate TET expression.

Vitamin C, or ascorbate, uniquely interacts with the C-terminal catalytic domain of TET, positioning it as a novel epigenetic-modifying agent. 326 , 327 As an antioxidant, it also helps maintain the divalent state of iron ions, indirectly supporting TET activity. 323 Characterized by TET repair and increased 5hmC levels, vitamin C administration can exert therapeutic roles in various tumors and non-tumor diseases. 328 – 330 Furthermore, it has been used as an adjuvant, synergizing with other immunotherapeutic or chemotherapeutic agents. 331 – 334 The synergistic treatment of vitamin C with azacitidine or decitabine in clinical trials has shown positive outcomes for patients with myeloid tumors. 335 , 336 However, the optimal doses, frequency, and duration of vitamin C administration remain debated, with long-term treatment and follow-up required for further investigation. 337 Therefore, the full exploration of the therapeutic role of vitamin C as an epigenetic-modifying drug is crucial for its future clinical applications.

Inhibitors of IDH and α-KG dehydrogenase elevate α-KG levels. In tumor cells, IDH1/2 mutations lead to the production of the oncometabolite 2-HG, which competes with α-KG for binding sites on TET, potentially leading to reversible inhibition of TET proteins and dysregulation of DNA methylation levels. 338 , 339 The administration of enasidinib and siRNA against IDH2 has been shown to restore the low methylated state of the genome, consistent with the reactivation of TET enzymatic activities. 340 – 342 However, observations suggest that other α-KG-dependent enzymes, such as histone demethylases and prolyl hydroxylases, might play a more dominant role in the progression of IDH-mutant diseases. 343 These findings highlight the potential for developing TET agonists based on IDH inhibitors to reshape the epigenetic landscape, warranting further investigation. Additionally, inhibiting α-KG dehydrogenase enhances α-KG levels and TET activities, restoring DNA demethylation and ameliorating the progression of T2DM and breast cancer. 344 , 345 Similarly, IOX1, an inhibitor of α-KG oxygenases and a potent inhibitor of lysine demethylase 3 A (KDM3A) and KDM4A, has been found to reduce TET enzymatic activities in helper T cells, emerging as a potential epigenetic drug for various autoimmune diseases. 346 In conclusion, α-KG represents a promising target for TET-targeted drug development that should be further explored in clinical trials.

Targeting the reader of DNA methylation: MBD and UHRF1

With the discovery of proteins that read methylated DNA sites, burgeoning research has aimed to identify small molecules targeting these enzymes, sparking considerable enthusiasm for developing novel therapeutic targets.

MBD inhibitors

The MBD protein family, critical readers of DNA methylation, consists of six members: methyl-CpG-binding protein 1 (MeCP1), MeCP2, MBD1, MBD2, MBD3, and MBD4. 347 The aberrant activities and expression of these proteins observed in various diseases have recently positioned them as potential targets for epigenetic drugs. Current research predominantly focuses on MBD2 inhibitors, which are rapidly progressing.

The development of MBD2 inhibitors hinges on two prerequisite factors. Firstly, the knockdown of MBD2 or the application of targeted siRNA has demonstrated positive effects in tumor treatment, underscoring the therapeutic potential of targeting MBD2. 348 Secondly, successfully elucidating MBD2’s molecular structure and associated mechanisms lays the scientific groundwork for identifying and designing inhibitory molecules. MBD2 inhibitors can be categorized into three groups based on their mechanisms of action. The first group disrupts the binding of the N-terminal MBD to methylated DNA. 349 Through docking analysis, molecules such as CID3100583 and 8,8-ethylenebistheophylline have been identified to target the interaction between MBD2 and DNA. 350 The second category aims to block the interaction between the C-terminal coiled-coil domain and the GATA zinc finger domain containing 2A, which has shown potent inhibitory effects on MBD2-dependent DNA methylation. 351 However, no drugs based on this mechanism are currently in use, highlighting a gap in research that demands further exploration. The third group prevents the interaction with HDAC and the formation of the nucleosome remodeling and deacetylase complex via an intrinsically disordered region. 352 – 354 Utilizing this concept, Na et al. 355 developed a novel technique that efficiently discriminates potential compounds interacting with intrinsically disordered proteins through expanded virtual screening. This approach led to identifying two MBD2 inhibitors, ABA and APC. These findings provide a sound basis for a therapeutic strategy targeting MBD2 and advocate for more comprehensive in vivo studies to assess their efficacy and safety.

UHRF1 inhibitors

Ubiquitin-like with plant homeodomain (PHD) and RING finger domains 1 (UHRF1) plays a pivotal role in recruiting DNMT1 during replication, primarily through the recognition of hemimethylated DNA and the subsequent flipping of hemimethylated CpG sites via the SET and RING associated domain (SRA). 356 – 358 UHRF1 also interacts with HDAC1 and facilitates the di- and tri-methylation of H3, contributing to the ubiquitination of histones and the formation of heterochromatin. 359 The upregulation of UHRF1 has been observed in various pathologies, particularly in tumors, making it a promising target for therapeutic intervention. 360 , 361

The initial identification of small inhibitors targeting the SRA domain of UHRF1 was based on structure-based screening and computational analyses. Compounds such as NSC232003, 362 UM63, 363 UF146, 364 chicoric acid, 365 have been shown to block the interaction between UHRF1 and 5mC sites, effectively preventing the proliferation of diverse cancer cell lines. Advanced screening techniques, such as nonequilibrium capillary electrophoresis of the equilibrium mixture, have facilitated the identification of proanthocyanidins and baicalein as promising inhibitors. 366 Furthermore, Ciaco et al. 367 reported the development of novel UHRF1 inhibitors, AMSA2 and MPB7, based on the structure of UM63. These inhibitors suppress SRA-mediated base-flipping activities without DNA intercalation and demonstrate minimal effects on non-cancer cells, offering a basis for further optimization. In addition to the SRA domain, the tandem Tudor domain and PHD domain of UHRF1, which are involved in recognizing methylated lysine and arginine residues on H3, have also become targets for inhibitor design. 368 , 369 While some inhibitors targeting these domains have been reported, their effects have only been validated in vitro, and more evidence is needed before proceeding to clinical trials. 370 – 372 Current research suggests that inhibiting UHRF1 alone may not be sufficient to restore gene silencing affected by hypermethylation. However, combining UHRF1 inhibitors with other epigenetic inhibitors, such as HDAC inhibitors, can lead to synergistic effects and improved therapeutic outcomes. 373 , 374 Consequently, multi-target inhibitors have been developed and are emerging as clinical candidates for tumor therapy. 375 – 378 Additionally, the use of small molecules that act as UHRF1 degraders, such as diosgenin and MK2206, has been explored for prostate cancer treatment, representing a novel therapeutic approach. 379 , 380 Natural substances like hinokitiol have shown therapeutic effects in mouse models in a UHRF1 depletion-dependent manner although the underlying mechanisms remain to be fully elucidated and represent a direction for future research. 381

Epigenetics-targeted drugs and histone acetylation

The dynamic equilibrium and normal function of histone acetylation and deacetylation are regulated by the cooperative actions of the lysine acetyltransferase (KAT) and HDAC families, along with various reader proteins. Acetylation of lysine residues at the N-terminus of histones induces negative charges that trigger gene transcription, while decreased acetylation downregulates gene expression. Conversely, an imbalance in histone acetylation/deacetylation disrupts normal gene expression patterns, leading to the onset and progression of diseases. The development of related epigenetic drugs is ongoing, offering new therapeutic options for treating these conditions (Table 4 ). Table 4 Summary of histone acetylation-targeted drugs for different diseases in clinical trials Type Drug Target(s) Condition(s) Status/outcome(s) Phase(s) Other intervention(s)/drug(s) Study ID/reference(s) KAT inhibitor CCS1477 P300/CBP (KAT3A/KAT3B) NHL, MM, AML, MDS, PTCL Recruiting Phase I/II With or without Pomalidomide plus Dexamethasone, or Azacitidine plus Venetoclax NCT04068597 CCS1477 P300/CBP (KAT3A/KAT3B) CRPC, BC, NSCLC Recruiting Phase I/II With or without Abiraterone acetate or Enzalutamide or Darolutamide or Olaparib or Atezolizumab NCT03568656 FT-7051 P300/CBP (KAT3A/KAT3B) CRPC Terminated (due to sponsors’ decision) Phase I — NCT04575766 NEO2734 P300/CBP (KAT3A/KAT3B), BET CRPC, NUT carcinoma Recruiting Phase I — NCT05488548 PRI-724 CBP/β-catenin HCV-induced cirrhosis Completed (causes liver injury in the high-dose cohort) Phase I — NCT02195440 397 PRI-724 CBP/β-catenin PDAC Completed (unpublished) Phase I — NCT01764477 PRI-724 CBP/β-catenin Solid tumors Terminated (due to low enrollment) Phase I — NCT01302405 PRI-724 CBP/β-catenin HIV/HCV co-induced cirrhosis Completed (unpublished) Phase I — NCT04688034 PRI-724 CBP/β-catenin PBC Completed (unpublished) Phase I — NCT04047160 PRI-724 CBP/β-catenin HIV/HCV co-induced cirrhosis Recruiting Phase II — NCT06144086 PRI-724 CBP/β-catenin AML, CML Completed (unpublished) Phase I/II — NCT01606579 PRI-724 CBP/β-catenin HCV-induced cirrhosis, HBV-induced cirrhosis Completed (exhibits insufficient evidence of improvement in hepatic function) Phase I/II — NCT03620474 396 PF-07248144 KAT6 HR-positive, HER2-negative BC, CRPC, NSCLC Recruiting Phase I With or without Fulvestrant, or Letrozole plus Palbociclib, or Fulvestrant plus PF-07220060 NCT04606446 HDAC inhibitor Ivaltinostat Pan-HDAC Malignant tumors Active, not recruiting Phase I Placebo-controlled NCT05716919 Ivaltinostat Pan-HDAC Healthy volunteers Completed (the oral formulation of Ivaltinostat is well tolerated) Phase I Placebo-controlled NCT05345912 1029 Ivaltinostat Pan-HDAC PDAC Unknown (exhibits good efficacy and an acceptable safe profile according to disclosed data) Phase I/II In combination with Gemcitabine and Erlotinib NCT02737228 401 Ivaltinostat Pan-HDAC PDAC Recruiting Phase I/II Capecitabine (active comparator/in combination with Ivaltinostat) NCT05249101 Abexinostat Pan-HDAC High-grade glioma Recruiting Phase I In combination with Temozolomide NCT05698524 Abexinostat Pan-HDAC DLBCL, MCL Active, not recruiting Phase I In combination with Ibrutinib NCT03939182 Abexinostat Pan-HDAC Melanoma, squamous cell carcinoma of head and neck, urothelial carcinoma, NSCLC Completed (unpublished) Phase I In combination with Pembrolizumab NCT03590054 Abexinostat Pan-HDAC NHL, HL, MM Completed (unpublished) Phase I — NCT01149668 Abexinostat Pan-HDAC Solid tumors Active, not recruiting (exhibits good tolerability and antitumor effects according to disclosed data) Phase I In combination with Pazopanib NCT01543763 404 Abexinostat Pan-HDAC NHL, HL, MM Completed (unpublished) Phase I — NCT00562224 Abexinostat Pan-HDAC Malignant tumors Completed (unpublished) Phase I — NCT00473577 Abexinostat Pan-HDAC MDS, AML, ALL Terminated (due to limited clinical benefit) Phase I — ISRCTN 99680465 1030 Abexinostat Pan-HDAC FL Active, not recruiting Phase II — NCT03600441 Abexinostat Pan-HDAC DLBCL Recruiting Phase II — NCT03936153 Abexinostat Pan-HDAC FL Recruiting Phase II — NCT03934567 Abexinostat Pan-HDAC NHL Active, not recruiting Phase I/II — NCT04024696 Abexinostat Pan-HDAC NHL, HL Completed (exhibits tolerable safety and significant clinical activity in FL) Phase I/II — NCT00724984 406 Abexinostat Pan-HDAC Sarcoma Completed (exhibits manageable toxicities and tumor responses) Phase I/II In combination with Doxorubicin and GCSF NCT01027910 1031 Abexinostat Pan-HDAC B cell lymphoma, CML Completed (exhibits manageable toxicity and partial responses) Phase I/II — EudraCT 2009-013691-47 405 , 1032 Abexinostat Pan-HDAC RCC Recruiting Phase III Pazopanib (active comparator/in combination with Abexinostat) NCT03592472 AR-42 Pan-HDAC Vestibular schwannoma, meningioma, acoustic neuroma, neurofibromatosis type 2 Terminated (due to a lack in drug supply) Phase I — NCT02282917 AR-42 Pan-HDAC RCC, soft tissue sarcoma Terminated (due to a lack in drug supply) Phase I In combination with Pazopanib NCT02795819 AR-42 Pan-HDAC AML Completed (exits possibilities of serious treatment-associated adverse events) Phase I In combination with Decitabine NCT01798901 1033 AR-42 Pan-HDAC Hematologic malignancies Completed (exhibits tolerable safety) Phase I — NCT01129193 402 , 1034 AR-42 Pan-HDAC Plasma cell myeloma Completed (unpublished) Phase I In combination with Dexamethasone and Pomalidomide NCT02569320 AR-42 Pan-HDAC Neurofibromatosis type 2 Recruiting Phase II/III Placebo-controlled NCT05130866 Pracinostat HDAC class I/II/IV Healthy volunteers Completed (unpublished) Phase I — NCT03495934 Pracinostat HDAC class I/II/IV Healthy volunteers Completed (unpublished) Phase I Fasted or fed conditions NCT02058784 Pracinostat HDAC class I/II/IV Healthy volunteers Completed (unpublished) Phase I In combination with Ciprofloxacin or Itraconazole NCT02118909 Pracinostat HDAC class I/II/IV Solid tumors, leukemia Completed (unpublished) Phase I — NCT01184274 Pracinostat HDAC class I/II/IV Solid tumors, hematologic malignancies Completed (exhibits safety and modest single-agent activity in hematologic malignancies) Phase I With or without Azacitidine NCT00741234 1035 Pracinostat HDAC class I/II/IV AML Completed (unpublished) Phase I Gemtuzumab Ozogamicin (active comparator/in combination with Pracinostat) NCT03848754 Pracinostat HDAC class I/II/IV Solid tumors Completed (unpublished) Phase I — NCT00504296 Pracinostat HDAC class I/II/IV Solid tumors Completed (exhibits good tolerability and inhibitory effects) Phase I — SCS-PN0022 1036 Pracinostat HDAC class I/II/IV Solid tumors Completed (exhibits good tolerability) Phase I — 1037 Pracinostat HDAC class I/II/IV Solid tumors Completed (exhibits good tolerability and inhibitory effects) Phase II — NCT01912274 1038 Pracinostat HDAC class I/II/IV MDS Terminated (due to sponsors’ decision) Phase II In combination with Azacitidine NCT03151304 Pracinostat HDAC class I/II/IV Myelofibrosis Completed (worsening anemia and other adverse events do not support the continued development) Phase II In combination with Ruxolitinib and Questionnaire NCT02267278 1039 Pracinostat HDAC class I/II/IV MDS Completed (reduced doses exhibit improved tolerability and efficacy) Phase II In combination with Azacitidine and Decitabine NCT01993641 1040 Pracinostat HDAC class I/II/IV CRPC Completed (exhibits insufficient activity as a single agent) Phase II — NCT01075308 1041 Pracinostat HDAC class I/II/IV MDS Completed (fails to improve outcomes at the available dosing regimen) Phase II Azacitidine (active comparator/in combination with Pracinostat) NCT01873703 1042 Pracinostat HDAC class I/II/IV Myeloproliferative disorders Completed (exhibits reasonable tolerability and modest activity in myelofibrosis) Phase II — NCT01200498 1043 Pracinostat HDAC class I/II/IV Sarcoma Completed (premature stop due to the prolonged unavailability) Phase II — NCT01112384 1044 Pracinostat HDAC class I/II/IV AML Terminated (due to a lack of efficacy) Phase III Azacitidine (active comparator/in combination with Pracinostat) NCT03151408 1045 Resminostat HDAC class I/IIb/IV CTCL, MF Completed (unpublished) Phase I — NCT04955340 Resminostat HDAC class I/IIb/IV Biliary tract cancer, pancreatic cancer Completed (exhibits acceptable tolerability) Phase I In combination with chemotherapy JapicCTI-152864 1046 Resminostat HDAC class I/IIb/IV Solid tumors Completed (exhibits on-target pharmacodynamic activity at dose levels ≥400 mg and signs of antitumor efficacy) Phase I — 1047 Resminostat HDAC class I/IIb/IV CTCL, MF Active, not recruiting Phase II Placebo-controlled NCT02953301 Resminostat HDAC class I/IIb/IV HL Completed (exhibits acceptable safety and efficacy) Phase II — NCT01037478 1048 Resminostat HDAC class I/IIb/IV HCC Completed (exhibits early signs of efficacy and good tolerability) Phase II With or without Sorafenib NCT00943449 1049 Resminostat HDAC class I/IIb/IV Biliary tract cancer Completed (exhibits no significant improve in clinical activity) Phase II In combination with chemotherapy JapicCTI-183883 1050 Resminostat HDAC class I/IIb/IV HCC Completed (no significant efficacy advantage over sorafenib monotherapy) Phase I/II Sorafenib (active comparator/in combination with Resminostat) NCT02400788 1051 Resminostat HDAC class I/IIb/IV NSCLC Completed (fails to improve progression-free survival and increases toxicity) Phase I/II In combination with Docetaxel JapicCTI-132123 1052 Resminostat HDAC class I/IIb/IV Colorectal carcinoma Completed (unpublished) Phase I/II Chemotherapy (active comparator/in combination with Resminostat) NCT01277406 Tacedinaline HDAC class I/II/III Solid tumors Completed (exhibits antitumor activity) Phase I In combination with Carboplatin and Paclitaxel 1053 Tacedinaline HDAC class I/II/III Solid tumors Completed (thrombocytopenia is the main principal dose-limiting toxicity) Phase I In combination with Capecitabine 1054 Tacedinaline HDAC class I/II/III Solid tumors Completed (exhibits preliminary efficacy and potential adverse events) Phase I In combination with Gemcitabine hydrochloride 1055 Tacedinaline HDAC class I/II/III Solid tumors Completed (exhibits preliminary efficacy and potential adverse events) Phase I — 1056 Tacedinaline HDAC class I/II/III MM Completed (unpublished) Phase II — NCT00005624 Tacedinaline HDAC class I/II/III Pancreatic cancer Completed (exhibits no evidence for improving efficacy) Phase II In combination with Gemcitabine hydrochloride; placebo-controlled NCT00004861 1057 Tacedinaline HDAC class I/II/III NSCLC Completed (unpublished) Phase III In combination with Gemcitabine hydrochloride; placebo-controlled NCT00005093 FRM-0334 HDAC class I/II Frontotemporal dementia with granulin mutation Unknown (exhibits tolerable safety while insufficient efficacy according to disclosed data) Phase II Placebo-controlled NCT02149160 1058 Trichostatin A HDAC class I/II Hematologic malignancies Unknown Phase I — NCT03838926 Quisinostat HDAC class I/II Leukemia, MDS Terminated (due to sponsors’ decision) Phase I — NCT00676728 Quisinostat HDAC class I/II Solid tumors, lymphomas Completed (intermittent schedules exhibit better tolerated than continuous schedules) Phase I — NCT00677105 1059 Quisinostat HDAC class I/II NSCLC, ovarian cancer Completed (unpublished) Phase I In combination with Cisplatin plus Gemcitabine, or Paclitaxel plus Carboplatin NCT02728492 Quisinostat HDAC class I/II MM Completed (exhibits efficacy and tolerable safety) Phase I In combination with Dexamethasone and Bortezonib NCT01464112 1060 Quisinostat HDAC class I/II CTCL Completed (exhibits an acceptable safety profile) Phase II — NCT01486277 1061 Quisinostat HDAC class I/II Ovarian cancer Completed (unpublished) Phase II In combination with Paclitaxel and Carboplatin NCT02948075 CXD101 HDAC class I Malignant tumors Completed (exhibits acceptable tolerability with efficacy in HL, T cell lymphoma, and FL) Phase I — NCT01977638 1062 CXD101 HDAC class I HCC Recruiting Phase II In combination with Geptanolimab, Lenvatinib and Sorafenib (active comparator) NCT05873244 CXD101 HDAC class I Colorectal carcinoma Unknown (exhibits good tolerability and efficacy according to disclosed data) Phase I/II In combination with Nivolumab NCT03993626 1063 CXD101 HDAC class I DLBCL Withdrawn (due to insufficent funds) Phase I/II In combination with Pembrolizumab NCT03873025 Magnesium valproate HDAC class I Solid tumors Completed (exhibits the potential to overcome chemotherapy resistance) Phase II In combination with Hydralazine NCT00404508 304 Magnesium valproate HDAC class I Cervical cancer Completed (unpublished) Phase II In combination with Hydralazine NCT00404326 Magnesium valproate HDAC class I Colorectal carcinoma Recruiting Phase II With or without Panitumumab and Cetuximab NCT05694936 Magnesium valproate HDAC class I BC Terminated (treatment is well-tolerated) Phase II In combination with Hydralazine NCT00395655 301 Magnesium valproate HDAC class I Ovarian cancer Unknown Phase III In combination with Hydralazine, placebo-controlled NCT00533299 Magnesium valproate HDAC class I Cervical cancer Completed (exhibits advantages in progression-free survival) Phase III In combination with Hydralazine; placebo-controlled NCT00532818 Magnesium valproate HDAC class I Cervical cancer Unknown Phase III In combination with Hydralazine, Carboplatin, and Paclitaxel; placebo-controlled NCT02446652 OBP-801 HDAC class I Solid tumors Unknown (large-scale trials should be hold according to disclosed data) Phase I — NCT02414516 1064 Nanatinostat HDAC class I Malignant tumors (excluding gastrointestinal tumors) Recruiting Phase I With or without Valganciclovir NCT06302140 Nanatinostat HDAC class I EBV-associated lymphoma, PTCL, PTLD Recruiting Phase II In combination with Valganciclovir NCT05011058 Nanatinostat HDAC class I EBV-associated lymphoma Completed (exhibits encouraging efficacy) Phase I/II In combination with Valganciclovir NCT03397706 1065 Nanatinostat HDAC class I EBV-associated solid tumors Recruiting Phase I/II In combination with Valganciclovir, with or without Pembrolizumab NCT05166577 Entinostat HDAC class 1 TNBC Terminated (due to funding withdrawn) Early phase I — NCT03361800 Entinostat HDAC class 1 Healthy volunteers Completed (unpublished) Phase I — NCT02922946 Entinostat HDAC class 1 Healthy volunteers; renal impairment Completed (unpublished) Phase I — NCT03192111 Entinostat HDAC class 1 Solid tumors Completed (unpublished) Phase I Placebo-controlled NCT02897778 Entinostat HDAC class 1 CRPC Completed (exhibits an acceptable safety profile) Phase I In combination with Enzalutamide NCT03829930 1066 Entinostat HDAC class 1 HR-positive HER2-negative BC Completed (exhibits reasonable safety, tolerability, and encouraging efficacy) Phase I In combination with Exemestane NCT02833155 1067 Entinostat HDAC class 1 MM, MDS, myeloproliferative diseases Completed (exhibits effective inhibition on HDAC in vivo) Phase I — NCT00015925 1068 Entinostat HDAC class 1 Solid tumors, lymphomas Completed (exhibits good tolerability at the studied doses) Phase I — NCT00020579 1069 Entinostat HDAC class 1 Healthy volunteers; renal impairment Completed (unpublished) Phase I In combination with Midazolam NCT03187015 Entinostat HDAC class 1 Solid tumors Completed (unpublished) Phase I In combination with Pembrolizumab NCT02909452 Entinostat HDAC class 1 MDS Active, not recruiting (exhibits limited clinical efficacy and substantial toxicity according to disclosed data) Phase I In combination with Pembrolizumab NCT02936752 1070 Entinostat HDAC class 1 BC Completed (unpublished) Phase I In combination with Capecitabine NCT03473639 Entinostat HDAC class 1 Ovarian cancer, peritoneal cancer, fallopian tube cancer Terminated (due to changes in participant landscape and other treatment availability) Phase I In combination with Olaparib NCT03924245 Entinostat HDAC class 1 HR-positive BC Completed (unpublished) Phase I In combination with Exemestane NCT02820961 Entinostat HDAC class 1 HR-positive BC, NSCLC Completed (results published along with phase II studies) Phase I In combination with Erlotinib and Exemestane NCT01594398 Entinostat HDAC class 1 Lymphoma Completed (exhibits tolerable safety) Phase I In combination with Isotretinoin NCT00098891 1071 Entinostat HDAC class 1 AML, MDS, CMML Completed (increases toxicity in treating myeloid neoplasms) Phase I In combination with Azacitidine NCT00101179 1072 – 1074 Entinostat HDAC class 1 Healthy volunteers Completed (unpublished) Phase I Dietary supplements (Omeprazole and Famotidine) NCT02922933 Entinostat HDAC class 1 HR-positive BC Completed (exhibits no additional safety concerns) Phase I In combination with KHK2375 NCT02623751 1075 Entinostat HDAC class 1 Colorectal carcinoma Completed (the combination is poorly tolerated without evident activity) Phase I In combination with Hydroxychloroquine and Regorafenib NCT03215264 413 Entinostat HDAC class 1 SCLC Completed (further exploration should not be applied) Phase I In combination with Atezolizumab, Carboplatin, and Etoposide NCT04631029 414 Entinostat HDAC class 1 CNS tumors, lymphoma Completed (exhibits good tolerability) Phase I — NCT02780804 1076 Entinostat HDAC class 1 Endometrial endometrioid adenocarcinoma Completed (no immediate effect on the regulation of progesterone receptor) Phase I With or without Medroxyprogesterone acetate NCT03018249 415 Entinostat HDAC class 1 HER2-positive BC, TNBC Terminated (due to slow accrual and company reasons) Phase I M7824 and Ado-trastuzumab emtansine (active comparator/in combination with Entinostat) NCT04296942 Entinostat HDAC class 1 HER2-positive BC Completed (exhibits acceptable tolerability and antitumor activity) Phase I In combination with Lapatinib ditosylate NCT01434303 1077 Entinostat HDAC class 1 ALL, ABL Completed (exhibits less activities in relapsed/refractory patients) Phase I In combination with Clofarabine NCT01132573 416 Entinostat HDAC class 1 Solid tumors Terminated (exhibits good tolerability according to disclosed data) Phase I In combination with Sorafenib NCT01159301 1078 Entinostat HDAC class 1 NSCLC Terminated Phase I In combination with Azacitidine NCT01886573 Entinostat HDAC class 1 RCC Active, not recruiting (exhibits acceptable safety and efficacy according to disclosed data) Phase I In combination with Aldesleukin NCT01038778 Entinostat HDAC class 1 BC Terminated Phase I — NCT00754312 Entinostat HDAC class 1 HR-positive BC, TNBC Active, not recruiting (exhibits good efficacy according to disclosed data) Phase I In combination with Ipilimumab and Nivolumab NCT02453620 1079 Entinostat HDAC class 1 BC Completed (exhibits acceptable safety) Phase II Exemestane (active comparator/in combination with Entinostat); placebo-controlled NCT03291886 1080 Entinostat HDAC class 1 Uveal melanoma Completed (exhibits durable responses in a subset of patients) Phase II In combination with Pembrolizumab NCT02697630 1081 , 1082 Entinostat HDAC class 1 TNBC Active, not recruiting (exhibits good tolerability but fails to meet primary endpoint according to disclosed data) Phase II In combination with Azacitidine NCT01349959 Entinostat HDAC class 1 HL Terminated (due to corporate decision) Phase II — NCT00866333 1083 Entinostat HDAC class 1 MDS, AML Completed (increases toxicity in treating myeloid neoplasms) Phase II Azacitidine (active comparator/in combination with Entinostat) NCT00313586 1072 , 1084 Entinostat HDAC class 1 HR-positive BC Completed (exhibits good tolerability and clinical activity) Phase II Exemestane (active comparator); placebo-controlled NCT00676663 1085 Entinostat HDAC class 1 Neuroendocrine tumors Terminated (due to a lack of funding and drug supply) Phase II — NCT03211988 Entinostat HDAC class 1 Cholangiocarcinoma, PDAC Completed (exhibits promising efficacy) Phase II In combination with Nivolumab NCT03250273 Entinostat HDAC class 1 Melanoma Completed (unpublished) Phase II — NCT00185302 Entinostat HDAC class 1 Lymphomas Active, not recruiting Phase II In combination with Pembrolizumab NCT03179930 Entinostat HDAC class 1 RCC Active, not recruiting Phase II Interleukin-2 (active comparator/in combination with Entinostat) NCT03501381 Entinostat HDAC class 1 Melanoma Completed (exhibits preliminary antitumor effects) Phase II In combination with Pembrolizumab NCT03765229 Entinostat HDAC class 1 Bladder cancer Active, not recruiting Phase II Pembrolizumab (active comparator/in combination with Entinostat) NCT03978624 Entinostat HDAC class 1 RCC Active, not recruiting Phase II In combination with Nivolumab and Ipilimumab NCT03552380 Entinostat HDAC class 1 AML, ALL Completed (exhibits preliminary antitumor effects) Phase II In combination with Sargramostim NCT00462605 Entinostat HDAC class 1 NSCLC Terminated (due to business reasons) Phase II In combination with Erlotinib NCT00750698 Entinostat HDAC class 1 AML Active, not recruiting Phase II In combination with Azacitidine NCT01305499 Entinostat HDAC class 1 NSCLC Terminated (due to slow accrual) Phase II In combination with Azacitidine NCT01207726 Entinostat HDAC class 1 Colon cancer, rectal cancer Completed (exhibits preliminary antitumor effects) Phase II In combination with Azacitidine NCT01105377 Entinostat HDAC class 1 HR-positive BC Completed (risks of treatment-associated adverse events are high) Phase II In combination with Aromatase inhibitor NCT00828854 Entinostat HDAC class 1 NSCLC Completed (combination is a promising tool in future exploration) Phase II In combination with Azacitidine and Nivolumab; Nivolumab with or without CC-486 300 (active comparator) NCT01928576 Entinostat HDAC class 1 TNBC Terminated (due to slow accrual) Phase II In combination with Anastrozole NCT01234532 Entinostat HDAC class 1 NSCLC Terminated Phase II In combination with Azacitidine and chemotherapy; chemotherapy (active comparator) NCT01935947 Entinostat HDAC class 1 NSCLC Completed (exhibits clinically meaningful benefit) Phase I/II In combination with Pembrolizumab NCT02437136 1086 Entinostat HDAC class 1 CNS tumors Recruiting Phase I/II In combination with Nivolumab; placebo-controlled NCT03838042 1087 Entinostat HDAC class 1 RCC Active, not recruiting (exhibits promising clinical activities according to disclosed data) Phase I/II In combination with Aldesleukin NCT01038778 1088 Entinostat HDAC class 1 NSCLC Completed (exhibits improvement in progression-free rates and overall survival) Phase I/II With or without Azacitidine NCT00387465 1089 Entinostat HDAC class 1 NSCLC Completed (the combination fails to improve the outcomes) Phase I/II Erlotinib (active comparator/in combination with Entinostat); placebo-controlled NCT00602030 1090 Entinostat HDAC class 1 Ovarian cancer, peritoneal cancer, fallopian tube cancer Completed (exhibits comparable efficacy and tolerability) Phase I/II Avelumab (active comparator/in combination with Entinostat); placebo-controlled NCT02915523 Entinostat HDAC class 1 BC Completed (exhibits clinical activity) Phase I/II Atezolizumab (active comparator/in combination with Entinostat); placebo-controlled NCT02708680 Entinostat HDAC class 1 RCC Suspended (due to major review underway) Phase I/II In combination with Atezolizumab and Bevacizumab NCT03024437 Entinostat HDAC class 1 HPV-associated malignancies, small bowel cancer,colon cancer Recruiting Phase I/II In combination with Bintrafusp Alfa/NHS-IL12, or NHS-IL12 NCT04708470 Entinostat HDAC class 1 Solid tumors Recruiting Phase I/II In combination with ZEN-3694 NCT05053971 Entinostat HDAC class 1 Esophageal cancer Suspended (due to revisions to design) Phase I/II In combination with Nivolumab, Montanide(R) ISA-51 VG Adjuvant, and H1299 Cell Lysates NCT05898828 Entinostat HDAC class 1 ALL Terminated (due to low accrual) Phase I/II In combination with Imatinib mesylate NCT01383447 Entinostat HDAC class 1 BC Active, not recruiting Phase I/II Umbrella study NCT03280563 Entinostat HDAC class 1 HR-positive HER2-negative BC Active, not recruiting (the combination fails to improve survival according to disclosed data) Phase III Exemestane/Goserelin/Goserelin acetate (active comparator/in combination with Entinostat); placebo-controlled NCT02115282 1091 , 1092 Entinostat HDAC class 1 HR-positive BC Unknown (exhibits encouraging outcomes according to disclosed data) Phase III Exemestane (active comparator/in combination with Entinostat); placebo-controlled NCT03538171 412 Mocetinostat HDAC class 1 CRPC, BC, NSCLC Terminated (due to terminated collaboration) Phase I In combination with Docetaxel NCT00511576 Mocetinostat HDAC class 1 MDS, lymphomas Completed (unpublished) Phase I Given twice weekly NCT00324194 Mocetinostat HDAC class 1 MDS, lymphomas Completed (dose-limiting toxicities of fatigue, nausea, vomiting, and diarrhea observed at higher doses) Phase I Given three-times weekly NCT00324129 1093 Mocetinostat HDAC class 1 NHL Completed (unpublished) Phase I Given twice weekly NCT00323934 Mocetinostat HDAC class 1 Squamous cell carcinoma of head and neck, squamous cell carcinoma of oral cavity Withdrawn (due to a change in internal prioritization) Phase I In combination with Durvalumab NCT02993991 Mocetinostat HDAC class 1 Rhabdomyosarcoma Recruiting Phase I In combination with Vinorelbine NCT04299113 Mocetinostat HDAC class 1 Lung cancer Active, not recruiting Phase I In combination with Pembrolizumab and Guadecitabine NCT03220477 Mocetinostat HDAC class 1 Melanoma Terminated (exhibits favorable response rates but with high levels of toxicity according to disclosed data) Phase I In combination with Ipilimumab and Nivolumab NCT03565406 1094 Mocetinostat HDAC class 1 Urothelial carcinoma Completed (exhibits modest clinical activity) Phase II — NCT02236195 1095 Mocetinostat HDAC class 1 HL Terminated (exhibits single-agent clinical activity with manageable toxicity according to disclosed data) Phase II — NCT00358982 1096 Mocetinostat HDAC class 1 Lymphoma Completed (exhibits limited single-agent activity in DLBCL and FL but long-term clinical benefit) Phase II — NCT00359086 1097 Mocetinostat HDAC class 1 AML, MDS Terminated (due to terminated collaboration) Phase II Azacitidine (active comparator/in combination with Mocetinostat) NCT00666497 Mocetinostat HDAC class 1 NHL, HL Terminated (due to terminated collaboration) Phase II In combination with Azacitidine NCT00543582 Mocetinostat HDAC class 1 CLL Completed (exhibits limited activity) Phase II — NCT00431873 1098 Mocetinostat HDAC class 1 AML, MDS Terminated (due to the re-evaluation of clinical development program) Phase II — NCT00374296 Mocetinostat HDAC class 1 Leiomyosarcoma Completed (exhibits insufficient activity) Phase II In combination with Gemcitabine NCT02303262 Mocetinostat HDAC class 1 NSCLC Terminated (due to sponsors’ decision) Phase II In combination with Nivolumab; Nivolumab with Sitravatinib or Glesatinib (active comparator) NCT02954991 Mocetinostat HDAC class 1 Malignant tumors Completed (exhibits significant toxicities in advanced pancreatic cancer) Phase I/II In combination with Gemcitabine NCT00372437 1099 Mocetinostat HDAC class 1 DLBCL,lymphomas Terminated (due to slow accrual) Phase I/II — NCT02282358 1100 Mocetinostat HDAC class 1 NSCLC, solid tumors Terminated (due to sponsors’ decision) Phase I/II In combination with Durvalumab NCT02805660 1101 Mocetinostat HDAC class 1 MDS, AML Completed (unpublished) Phase I/II — NCT00324220 Mocetinostat HDAC class 1 MDS Completed (unpublished) Phase I/II In combination with Azacitidine NCT02018926 Mocetinostat HDAC class 1 HL Completed (exhibits preliminary clinical activity) Phase I/II In combination with Brentuximab vedotin NCT02429375 Domatinostat LSD1/HDAC Hematologic malignancies Completed (exhibits safety and early signs of antitumor activity) Phase I — NCT01344707 1102 Domatinostat LSD1/HDAC GastrointEstinal cancer Unknown (exhibits an acceptable safety profile according to disclosed data) Phase II In combination with Avelumab NCT03812796 1103 Domatinostat LSD1/HDAC Merkel cell carcinoma Withdrawn (due to sponsors’ decision) Phase II In combination with Avelumab NCT04874831 Domatinostat LSD1/HDAC Merkel cell carcinoma Completed (unpublished) Phase II In combination with Avelumab NCT04393753 Domatinostat LSD1/HDAC Melanoma Active, not recruiting (Domatinostat addition fails to increase treatment efficacy according to disclosed data) Phase I/II Nivolumab (active comparator/in combination with Domatinostat); in combination with Nivolumab and Ipilimumab NCT04133948 424 CUDC101 EGFR/HER2/HDAC Solid tumors Terminated Phase I — NCT01702285 CUDC101 EGFR/HER2/HDAC Squamous cell carcinoma of head and neck, gastric cancer, BC, HCC, NSCLC Completed (exhibits acceptable safety) Phase I — NCT01171924 CUDC101 EGFR/HER2/HDAC Squamous cell carcinoma of head and neck Completed (the combination exhibits promising feasibility) Phase I In combination with Cisplatin and radiation therapy NCT01384799 420 CUDC101 EGFR/HER2/HDAC Solid tumors Completed (exhibits good tolerability and antitumor activity) Phase I — NCT00728793 421 CUDC-907 PI3K/HDAC Lymphoma Completed (exhibits tolerable safety profile and durable antitumor activity) Phase I With or without Rituximab or Venetoclax NCT01742988 422 , 1104 CUDC-907 PI3K/HDAC Diffuse intrinsic pontine glioma, medulloblastoma, high-grade glioma Active, not recruiting Phase I — NCT03893487 CUDC-907 PI3K/HDAC TNBC, ovarian cancer, NUT carcinoma Completed (unpublished) Phase I — NCT02307240 CUDC-907 PI3K/HDAC CNS tumors, lymphoma Active, not recruiting Phase I — NCT02909777 CUDC-907 PI3K/HDAC DLBCL Completed (exhibits preliminary antitumor effects) Phase II — NCT02674750 423 CUDC-907 PI3K/HDAC Cushing disease Not yet recruiting Phase II — NCT05971758 CUDC-907 PI3K/HDAC Thyroid cancer Terminated (due to investigator’s reasons) Phase II — NCT03002623 Sodium phenylbutyrate PRKCA/HDAC MCAD deficiency Recruiting Phase II — NCT06069375 Tinostamustine DNA/HDAC Melanoma Unknown Phase I — NCT03903458 Tinostamustine DNA/HDAC Glioblastoma multiforme Active, not recruiting Phase I — NCT05432375 Tinostamustine DNA/HDAC MM, HL, CTCL Active, not recruiting Phase I — NCT02576496 Tinostamustine DNA/HDAC MGMT-promoter unmethylated glioblastoma Completed (unpublished) Phase I With or without radiation therapy NCT03452930 Tinostamustine DNA/HDAC DLBCL Withdrawn (given the safety data on drug) Phase I In combination with Pembrolizumab and Rituximab NCT04279938 Tinostamustine DNA/HDAC MM Terminated (due to sponsors’ decision based on adverse events) Phase I/II ASCT NCT03687125 Tinostamustine DNA/HDAC SCLC, soft tissue sarcoma, TNBC, ovarian cancer, endometrial cancer Completed (unpublished) Phase I/II — NCT03345485 GSK3117391 Esterase-sensitive motif RA Terminated (due to development portfolio) Phase II Placebo-controlled NCT02965599 Tefinostat Esterase-sensitive motif Hematologic malignancies Completed (exhibits early signs of efficacy and absence of significant toxicity) Phase I — NCT00820508 1105 Tefinostat Esterase-sensitive motif HCC Unknown Phase I/II — NCT02759601 HDAC agonist Theophylline Pan-HDAC COPD Completed (exhibits an increase in total HDAC activity and potential clinical benefit) Phase II With or without Fluticasone propionate NCT00241631 1106 Theophylline Pan-HDAC COPD Completed (fails to enhance the anti-inflammatory properties of ICS) Phase III In combination with ICS; placebo-controlled NCT01599871 426 Theophylline Pan-HDAC Bronchiectasis Completed (unpublished) Phase IV With or without Formoterol-budesonide NCT01769898 Theophylline Pan-HDAC COPD Completed (exhibits an increase in total HDAC activity and potential clinical benefit) Not applicable With or without standard therapy NCT00671151 1107 Sirtuin agonist Resveratrol SIRT1 T2DM Completed (H3K56ac is located in the key position between SIRT1 and T2DM) Phase III Placebo-controlled NCT02244879 1108 BET inhibitor ZEN-3694 Pan-BET Colorectal carcinoma Recruiting Phase I In combination with Capecitabine NCT05803382 ZEN-3694 Pan-BET Endometrial carcinoma Recruiting Phase I In combination with Tuvusertib NCT05950464 ZEN-3694 Pan-BET Platinum-resistant ovarian carcinoma Recruiting Phase I In combination with Nivolumab or Nivolumab plus Ipilimumab NCT04840589 ZEN-3694 Pan-BET Colorectal carcinoma Recruiting Phase I In combination with Cetuximab and Encorafenib NCT06102902 ZEN-3694 Pan-BET BC, NUT carcinoma Recruiting Phase I In combination with Abemaciclib NCT05372640 ZEN-3694 Pan-BET Ovarian cancer, solid tumors Recruiting Phase I In combination with Niraparib NCT06161493 ZEN-3694 Pan-BET Ovarian cancer, solid tumors Recruiting Phase I In combination with Binimetinib NCT05111561 ZEN-3694 Pan-BET CRPC Completed (unpublished) Phase I — NCT02705469 ZEN-3694 Pan-BET CRPC Recruiting Phase II In combination with Enzalutamide and Pembrolizumab NCT04471974 ZEN-3694 Pan-BET Solid tumors Recruiting Phase II In combination with Talazoparib NCT05327010 ZEN-3694 Pan-BET CRPC Recruiting Phase II Enzalutamide (active comparator/in combination with ZEN-3694) NCT04986423 ZEN-3694 Pan-BET Squamous cell lung cancer Recruiting Phase II — NCT05607108 ZEN-3694 Pan-BET Ovarian cancer, peritoneal cancer, fallopian tube cancer Recruiting Phase II In combination with Talazoparib NCT05071937 ZEN-3694 Pan-BET TNBC Terminated (based on results from an interim futility analysis and not due to safety concerns) Phase II In combination with Talazoparib NCT03901469 485 ZEN-3694 Pan-BET NUT carcinoma Recruiting Phase I/II In combination with Cisplatin and Etoposide NCT05019716 ZEN-3694 Pan-BET Solid tumors, lymphomas Recruiting Phase I/II In combination with Entinostat NCT05053971 ZEN-3694 Pan-BET CRPC Completed (exhibits acceptable safety and efficacy) Phase I/II In combination with Enzalutamide NCT02711956 486 ZEN-3694 Pan-BET CRPC Enrolling by invitation Phase I/II In combination with Enzalutamide NCT04145375 Trotabresib Pan-BET HER2-positive BC with CNS metastasis and leptomeningeal disease Withdrawn (due to sponsors’ decision) Phase I In combination with Vinorelbine and radiation therapy NCT06137651 Trotabresib Pan-BET Astrocytoma, glioblastoma Terminated (due to a change in business objectives) Phase I — NCT04047303 1109 Trotabresib Pan-BET Solid tumors, NHL Active, not recruiting (exhibits good tolerability and single-agent activity in advanced solid tumors according to disclosed data) Phase I — NCT03220347 1110 , 1111 Trotabresib Pan-BET Pediatric cancer Active, not recruiting Phase I BMS-986158 (active comparator) NCT03936465 Trotabresib Pan-BET Solid tumors Withdrawn (due to a change in business objectives) Phase I — NCT05678283 Trotabresib Pan-BET Glioblastoma Active, not recruiting Phase I In combination with Temozolomide and radiation therapy; radiation therapy (active comparator) NCT04324840 Alobresib Pan-BET Solid tumors, lymphomas, HR-positive BC Completed (reports pharmacokinetics and pharmacodynamics) Phase I With or without Exemestane or Fulvestrant NCT02392611 Alobresib Pan-BET CRPC Terminated (exhibits acceptable tolerability) Phase I/II With or without Enzalutamide NCT02607228 GSK3358699 Pan-BET Healthy volunteers Terminated (due to strategic reasons) Phase I Placebo-controlled NCT03426995 1112 TEN-010 Pan-BET AML, MDS Completed (exhibits insufficient activity as a single agent) Phase I — NCT02308761 1113 TEN-010 Pan-BET Solid tumors Completed (exhibits evidence of target engagement and preliminary single-agent activity) Phase I — NCT01987362 1114 TEN-010 Pan-BET Ovarian cancer, TNBC Terminated (due to development portfolio) Phase I In combination with Atezolizumab NCT03292172 TEN-010 Pan-BET MM Completed (exhibits infrequent and short duration of clinical response rates) Phase I With or without Daratumumab NCT03068351 1115 TEN-010 Pan-BET DLBCL Completed (unpublished) Phase I In combination with Venetoclax and Rituximab NCT03255096 1116 ODM-207 Pan-BET Solid tumors Completed (exhibits safety at doses up to 2 mg/kg but has a narrow therapeutic window) Phase I/II — NCT03035591 1117 ABBV-744 Pan-BET Myelofibrosis Terminated (due to strategic reasons) Phase I — NCT03360006 ABBV-744 Pan-BET AML Active, not recruiting Phase I With or without Ruxolitinib or Navitoclax NCT04454658 Birabresib BRD2/3/4 Solid tumors Completed (exhibits a favorable safety profile with clinical activity in NUT carcinoma) Phase I — NCT02259114 1118 Birabresib BRD2/3/4 AML, ALL, DLBCL, MM Completed (exhibits evidence of clinical activity though does not meet objective response criteria in non-leukemia cohort) Phase I — NCT01713582 1119 , 1120 Birabresib BRD2/3/4 AML, DLBCL Terminated (due to limited efficacy) Phase I — NCT02698189 Birabresib BRD2/3/4 NUT carcinoma, TNBC, NSCLC, CRPC Terminated (due to limited efficacy) Phase I — NCT02698176 Birabresib BRD2/3/4 GBM Terminated (due to limited efficacy) Phase II — NCT02296476 Birabresib BRD2/3/4 AML Withdrawn Phase I/II Azacitidine (active comparator/in combination with Birabresib) NCT02303782 Molibresib BRD2/3/4 Solid tumors, lymphomas Withdrawn (due to disapproved protocal) Phase I In combination with Entinostat NCT03925428 Molibresib BRD2/3/4 NUT carcinoma, solid tumors Completed (exhibits acceptable safety) Phase I — NCT01587703 1121 , 1122 Molibresib BRD2/3/4 HR-positive HER2-negative BC Terminated (due to meeting protocol-defined futility) Phase I In combination with Fulvestrant; placebo-controlled NCT02964507 1123 Molibresib BRD2/3/4 CRPC Terminated (due to meeting protocol-defined futility) Phase I In combination with Abiraterone plus Prednisone or Enzalutamide NCT03150056 Molibresib BRD2/3/4 Healthy volunteers Completed (CYP3A enzymes play a major role in the elimination of Molibresib) Phase I In combination with Itraconazole or Rifampicin NCT02706535 1124 Molibresib BRD2/3/4 Hematologic malignancies Completed (exhibits antitumor activity but is limited by gastrointestinal and thrombocytopenia toxicities) Phase II — NCT01943851 1125 Molibresib BRD2/3/4 SCLC, solid tumors Withdrawn (due to reevaluation) Phase II In combination with Trametinib NCT03266159 Molibresib BRD2/3/4 NUT carcinoma Withdrawn (due to disapproved protocal) Phase I/II In combination with Cisplatin, Etoposide, and Etoposide phosphate NCT04116359 Mivebresib BRD2/4/T Myelofibrosis Terminated (due to strategic reasons) Phase I WIth or without Ruxolitinib or Navitoclax NCT04480086 Mivebresib BRD2/4/T BC, NSCLC, AML, MM PC, SCLC, NHL Completed (exhibits good tolerability and potential efficacy in advanced solid tumors) Phase I With or without Venetoclax NCT02391480 1126 , 1127 BAY1238097 BRD4-BD1; BRD2/3 Malignant tumors Terminated Phase I — NCT02369029 PLX-2853 BRD4 AML, MDS Completed (unpublished) Phase I — NCT03787498 PLX-2853 BRD4 Malignant tumors Completed (unpublished) Phase I — NCT03297424 PLX-2853 BRD4 CRPC Terminated (due to business realignment) Phase I/II In combination with Abiraterone acetate plus Prednisone, or Olaparib NCT04556617 PLX-2853 BRD4 Uveal melanoma Withdrawn (drug company has withdrawn support) Phase I/II In combination with Trametinib NCT05677373 PLX-2853 BRD4 Platinum-resistant ovarian carcinoma Terminated (due to business realignment) Phase I/II With or without Carboplatin NCT04493619 INCB054329 BRD4 Solid tumors, hematologic malignancies Terminated (due to interindividual pharmacokinetic variability) Phase I/II — NCT02431260 1128 SYHA1801 BRD4 Solid tumors Unknown Phase I — NCT04309968 CC-95775 BRD4 AML, MDS, NHL Completed (unpublished) Phase I With or without Azacitidine NCT02543879 CC-95775 BRD4 Solid tumors, NHL Completed (unpublished) Phase I — NCT04089527 PLX51107 BRD4 Solid tumors, hematologic malignancies Terminated (due to business reasons) Phase I — NCT02683395 PLX51107 BRD4 AML, MDS Completed (unpublished) Phase I In combination with Azacitidine NCT04022785 PLX51107 BRD4 Acute GVHD Terminated (due to sponsors’ decision) Phase I/II — NCT04910152 BMS-986158 BRD4 Pediatric Cancer Active, not recruiting Phase I BMS-986378 (active comparator) NCT03936465 BMS-986158 BRD4 Myelofibrosis Active, not recruiting Phase I/II In combination with Ruxolitinib or Fedratinib NCT04817007 BMS-986158 BRD4 Solid tumors, hematologic malignancies Completed (exhibits insufficient evidence of improvement) Phase I/II With or without Nivolumab NCT02419417 BMS-986158 BRD4 MM Recruiting Phase I/II In combination with Tazemetostat plus Dexamethasone or BMS-986158 plus Dexamethasone or Trametinib plus Dexamethasone, or Dexamethasone NCT05372354 AZD5153 BRD4 Solid tumors, lymphomas Completed (exhibits tolerable safety as monotherapy and in combination) Phase I With or without Olaparib NCT03205176 1129 AZD5153 BRD4 NHL, DLBCL Completed (unpublished) Phase I In combination with Acalabrutinib; Acalabrutinib, Rituximab, plus Hu5F9-G4 (active comparator) NCT03527147 AZD5153 BRD4 AML Recruiting Phase I/II Umbrella study NCT03013998 BI894999 BRD4-BD1/BD2 Malignant tumors, NUT carcinoma Completed (exhibits preliminary antitumor effects and reports the maximum tolerated dose at different cohorts) Phase I — NCT02516553 1130 Apabetalone BRD4-BD2 PAH Completed (exhibits good tolerability and clinical benefits) Early phase I — NCT03655704 1131 Apabetalone BRD4-BD2 PAH Not yet recruiting Phase II Placebo-controlled NCT04915300 Apabetalone BRD4-BD2 Atherosclerosis, CAD Completed (exhibits good tolerability) Phase II Placebo-controlled NCT01058018 1132 Apabetalone BRD4-BD2 T2DM Completed (exhibits potential to against the disease development) Phase II Placebo-controlled NCT01728467 1133 Apabetalone BRD4-BD2 Dyslipidemia, CAD Completed (exhibits good tolerability) Phase II Placebo-controlled NCT01423188 1134 Apabetalone BRD4-BD2 CAD Completed (exhibits no significant improvement) Phase II Placebo-controlled NCT01067820 1134 – 1137 Apabetalone BRD4-BD2 Dyslipidemia, CAD Terminated Phase II In combination with Rosuvastatin or Atorvastatin NCT01863225 Apabetalone BRD4-BD2 Chronic kidney failure Not yet recruiting Phase I/II Placebo-controlled NCT03160430 Apabetalone BRD4-BD2 Fabry disease Withdrawn (due to changed development priorities) Phase I/II — NCT03228940 Apabetalone BRD4-BD2 Healthy volunteers, dyslipidemia, atherosclerosis, CAD Completed (unpublished) Phase I/II Placebo-controlled NCT00768274 Apabetalone BRD4-BD2 T2DM, CAD Completed (fails to reduce the risk of major adverse cardiovascular events) Phase III In combination with Rosuvastatin or Atorvastatin; placebo-controlled NCT02586155 477 , 1137 – 1142 Apabetalone BRD4-BD2 COVID-19 infection Terminated (fails to recruit subjects) Phase II/III Standard of care (active comparator/in combination with Apabetalone) NCT04894266 NUV-868 BRD4-BD2 Solid tumors Recruiting Phase I/II With or without Olaparib or Enzalutamide NCT05252390 Pelabresib BRD4-BD1 Malignant tumors Completed (unpublished) Phase I — NCT05391022 Pelabresib BRD4-BD1 Lymphoma Completed (exhibits good tolerability and inhibitory effects) Phase I — NCT01949883 1143 Pelabresib BRD4-BD1 MM Completed (unpublished) Phase I — NCT02157636 Pelabresib BRD4-BD1 Peripheral nerve tumor Withdrawn (due to a lack of enrollment) Phase II — NCT02986919 Pelabresib BRD4-BD1 Myelofibrosis, AML, MDS, myeloproliferative disorders Active, not recruiting (exhibits potential disease-modifying activity in myelofibrosis according to disclosed data) Phase I/II With or without Ruxolitinib NCT02158858 484 , 1144 Pelabresib BRD4-BD1 Malignant tumors Not yet recruiting Phase III Placebo-controlled NCT06401356 Pelabresib BRD4-BD1 Myelofibrosis Active, not recruiting Phase III In combination with Ruxolitinib, placebo-controlled NCT04603495 TQB3617 BET Malignant tumors Unknown Phase I — NCT05110807 TQB3617 BET Myelofibrosis Recruiting Phase I/II In combination with TQ05105 NCT06122831 TQB3617 BET Esophageal squamous cell carcinoma Not yet recruiting Phase I/II In combination with TQB2618, Paclitaxel, and Cisplatin, or Paclitaxel plus Cisplatin, or TQB2618 plus Penpulimab NCT05834543 EP31670 P300(CBP)/BET CRPC, NUT carcinoma Recruiting Phase I — NCT05488548 1145 ABL acute biphenotypic leukemia, ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, ASCT autologous stem cell transplant, BC breast cancer, BD bromodomain, BET bromodomain and extraterminal domain, BRD bromodomain containing protein, CAD coronary artery disease, CBP cyclic adenosine monophosphate-responsive element-binding protein (CREB)-binding protein, CLL chronic lymphocytic leukemia, CML chronic myeloid leukemia, CMML chronic myelomonocytic leukemia, CNS central nervous system, COPD chronic obstructive pulmonary disease, COVID-19 corona virus disease 2019, CRPC Castration-resistant prostate cancer, CTCL cutaneous T cell lymphoma, CYP3A cytochrome P4503A, DLBCL diffuse large B cell lymphoma, EBV Epstein-Barr virus, EGFR epidermal growth factor receptor, FL follicular lymphoma, GBM glioblastoma multiforme, GCSF granulocyte colony-stimulating factor, GVHD graft versus host disease, HCC hepatocellular carcinoma, HDAC histone deacetylase, HCV hepatitis C virus, HER2 human epidermal growth factor receptor 2, HIV human immunodeficiency virus, H3K56ac histone 3 acetylation at the 56 lysine residue, HL Hodgkin lymphoma, HPV human papilloma virus, HR hormone receptor, ICS inhaled corticosteroid, KAT lysine acetyltransferase, LSD1 lysine specific demethylase 1, MCL mantle cell lymphoma, MCAD medium-chain acyl-CoA dehydrogenase, MDS myelodysplastic syndrome, MF mycosis fungoides, MGMT O 6 -methylguanine-DNA methyltransferase, MM multiple myeloma, NHL non-Hodgkin lymphoma, NSCLC non-small cell lung cancer, NUT nuclear protein in testis carcinoma, PAH pulmonary arterial hypertension, PBC primary biliary cholangitis, PDAC pancreatic ductal adenocarcinoma, PI3K phosphoinositide 3-kinase, PRKCA protein kinase C alpha, PTCL peripheral T cell lymphoma, PTLD post-transplant lymphoproliferative disorder, RA rheumatoid arthritis, RCC renal cell carcinoma, SIRT1 Sirtuin1, T2DM type 2 diabetes, TNBC triple-negative breast cancer

Targeting the writer of histone acetylation: KAT

Histone acetylation serves various functions within cells. However, aberrant acetylation catalyzed by KAT can trigger the pathogenesis of various human diseases, including neurodegenerative diseases, metabolic diseases, and tumors. 382 – 385 Developing epigenetic drugs that regulate KAT activity is a promising avenue for treating these diseases.

KAT inhibitors

Numerous inhibitors targeting KAT have been developed, primarily focusing on the P300/CBP, GNAT/PCAF, and MYST classes. 386 – 388 These enzymes contain two accessible domains: the acetyl-lysine binding BD and the catalytic domain, utilizing acetyl CoA as a cofactor to transfer acetyl groups. Thus, designed inhibitors can target the enzymatic activity and the binding sites for acetyl CoA. Moreover, research into KAT degraders is advancing with the advent of proteolysis-targeting chimeras (PROTACs). These degraders are ternary complexes comprising ligands for targeted proteins and E3 ubiquitin ligase, along with a connecting linker, allowing targeted degradation via a ubiquitination-dependent method. 389

Five KAT inhibitors have entered clinical practice, including CCS1477, FT-7051, NEO2734, PRI-724, and PF-07248144. CCS1477 targets the P300/CBP (KAT3A/KAT3B) via interaction with the BD fragment, exhibiting potent antitumor effects in cancer cell lines and animal models. 390 , 391 This has led to its application in monotherapy and in combination with chemotherapeutic drugs in phase I and II clinical trials ( NCT04068597 , NCT03568656 ), with the potential to improve therapeutic strategies for both advanced solid tumors and hematological malignancies. FT-7051, another P300/CBP inhibitor targeting the BD domain, has been shown to reduce H3K27Ac at specific promoter sites and is currently under study in a phase I clinical trial for patients with hormone receptor-positive prostate cancer. 392 NEO2734, a dual P300/CBP and BET inhibitor, demonstrates therapeutic potential comparable to the combination of a BET inhibitor and a P300/CBP inhibitor in treating certain cancers. 393 , 394 It is currently being evaluated in a phase I clinical trial focusing on castration-resistant prostate cancer and other advanced solid tumors to assess its maximum tolerated oral dose ( NCT05488548 ). PRI-724 effectively disrupts the interaction between β-catenin and CBP, ameliorating various diseases by inhibiting the Wnt/β-catenin signaling pathway. 395 Its safety, tolerability, and antifibrotic effects have been further evaluated in two completed clinical trials among patients with hepatitis C virus (HCV)- and HBV-induced cirrhosis. 396 , 397 However, PRI-724 fails to exhibit sufficient evidence of improvement in hepatic function according to existing data. 396 Lastly, PF-07248144, a selective inhibitor of KAT6 (a member of the MOZ/MORF family), is currently under clinical investigation for the treatment of advanced breast cancer ( NCT04606446 ). In summary, KATs represent compelling targets for therapeutic strategies, and developing novel and high-quality inhibitors with improved safety and efficacy is reaching an exciting phase.

Targeting the eraser of histone acetylation: HDAC

Zn 2+ -dependent classical HDACs and nicotinamide adenine dinucleotide (NAD) + -dependent HDACs (sirtuins) are crucial for dynamic deacetylation modifications on histones and non-histone proteins, playing significant roles in ontogeny and tumorigenesis. Despite the HDAC family’s broad substrate range in vitro, their specific subcellular localization restricts their biological functions and target proteins. Using inhibitors and agonists of HDACs and sirtuins to correct abnormal acetylation patterns is a promising therapeutic strategy. 398 , 399 Notably, the therapeutic effectiveness of these interventions, in an epigenetic-dependent manner, hinges on the participation of target enzymes in histone deacetylation.

HDAC inhibitors

HDAC inhibitors are designed based on the spatial structure of their targets, characterized by highly conserved and homologous catalytic domains, including a catalytic channel, a zinc cation, and secondary pockets. Most HDAC inhibitors consist of a surface binding region, binding to the catalytic channel, and a zinc-binding group along with the linker, chelating the zinc ion. 400 Four main categories of HDAC inhibitors are extensively studied: pan-inhibitors, selective inhibitors, multitarget agents, and PROTACs-based HDAC degraders. 398 We will now discuss the recent applications of these HDAC inhibitors in clinical trials.

Four FDA-approved HDAC inhibitors—vorinostat, romidepsin, belinostat, and panobinostat—demonstrate a pan-inhibitory effect on almost all HDAC members and have made significant progress in treating some hematological malignancies. This success has fueled enthusiasm for developing additional pan-inhibitors to expand the clinical indications of these drugs. Currently, several pan-inhibitors, including ivaltinostat ( CG200745 ), AR-42, abexinostat (PCI-24781), bisthianostat (CF-367), and sodium valproate, are under clinical trials for various tumors. The phase II study on ivaltinostat for advanced pancreatic ductal adenocarcinoma reports enhanced sensitivity of tumor cells to gemcitabine and erlotinib, presenting it as a potential treatment option. 401 Another phase II study aims to determine the maximum tolerated dose and dose-limiting toxicity of ivaltinostat in combination with gemcitabine and erlotinib in patients with advanced pancreatic cancer, although clinical data have not been publicly disclosed, suggesting potential challenges ( NCT02737228 ). In phase I trials, single-agent AR-42 has shown promise in treating type 2-associated meningiomas and schwannomas, with patients exhibiting good tolerance and therapeutic potential. 402 , 403 However, a phase I trial focusing on advanced sarcoma and kidney cancer was terminated early due to observed dose-limiting toxicities in six patients ( NCT02795819 ). Abexinostat, an oral small pan-inhibitor, whether used as monotherapy or in combination with chemotherapeutic agents, has shown promising therapeutic potential and acceptable safety profiles in solid tumors and hematological malignancies. 404 – 406 Notably, a phase III study on abexinostat for locally advanced or metastatic renal cell carcinoma is ongoing in various regions, highlighting its potential as a clinical candidate ( NCT03592472 ). Bisthianostat, a novel bisthiazole-derived pan-HDAC inhibitor, was studied in phase 1a clinical trial. 407 Although preliminary data suggested modest efficacy and tolerability as a single agent in patients with R/R MM, this study has been terminated for undisclosed reasons ( NCT03618602 ).

The non-selective inhibition characteristic of pan-HDAC inhibitors often leads to a broad spectrum of adverse effects and off-target toxicities, which restrict their widespread clinical application. 408 Given the diverse roles of different HDAC classes, there is increasing interest in developing selective HDAC inhibitors, viewed as promising alternatives with better tolerance. 409 , 410 However, due to a lack of evidence supporting the involvement of HDAC5/6/7/8/10 in histone deacetylation, selective inhibitors targeting these enzymes are not typically included in summaries of epigenetic-targeted drugs. 411 Chidamide and givinostat, both FDA-approved selective inhibitors, have shown superior therapeutic efficacy and safety profiles. Givinostat, in particular, has promisingly expanded the clinical indications of HDAC inhibitors to include non-tumor diseases. Beyond these marketed drugs, several selective inhibitors have entered clinical practice. Notably, four such inhibitors are undergoing phase III clinical trials: pracinostat ( NCT03151408 ), entinostat, 412 magnesium valproate ( NCT00533299 ), and tacedinaline ( NCT00005093 ). Among these, only the phase III trial of entinostat combined with exemestane in treating hormone receptor-positive advanced breast cancer has shown satisfactory efficacy and manageable toxicities. 412 However, among patients with other types of tumors such as colorectal carcinoma, lung cancer, endometrial endometrioid adenocarcinoma, and hematologic malignancies, entinostat fails to improve survival despite exhibiting good clinical efficacy. 413 – 416 Importantly, according to an early-terminated, phase I clinical trial that evaluated the combination of entinostat, hydroxychloroquine, and regorafenib, the drug regimen among patients with metastatic colorectal carcinoma was poorly tolerated, with higher risks of weight loss, fatigue, and anorexia. 413 Despite these advancements, selective inhibitors still face significant developmental challenges as they emerge as the next generation of HDAC inhibitors.

Recently, multitarget agents-based HDAC inhibitors have gained attention and have been posited to perform versatile roles in disease treatment. 417 – 419 Various such agents, including those dual-targeting HDACs and kinases, receptors, DNA, transcriptional factors, and apoptosis-related proteins, are under preclinical investigation. Examples include curcumin (previously mentioned as a DNMT/METTL3 inhibitor), CUDC-101, tinostamustine (EDO-S101), fimepinostat (CUDC-907), domatinostat (4SC-202), and dacinostat (NVP-LAQ824, LAQ824), all of which are involved in various clinical trials. 398 It has been widely reported that these multitarget agents enhance safety and reduce drug resistance in various diseases, both as monotherapy and in combination with radiotherapy or chemotherapy. 420 – 423 However, emerging research offers a contrasting perspective. In a recent phase Ib clinical trial focusing on domatinostat (a dual inhibitor of LSD1/HDAC) in patients with advanced melanoma, the drug failed to enhance the efficacy of treatments targeting anti-PD-1 and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) while unexpected severe skin toxicity was observed. 424 Furthermore, as current knowledge about these multitarget agents is still primarily derived from early-stage clinical trials, extensive investigations are necessary to validate their therapeutic value in a broader population.

HDAC agonists

While HDAC inhibitors have been extensively studied, research on HDAC agonists has been less prevalent. However, the therapeutic value of these agents in specific diseases has been demonstrated. Theophylline, used initially as an inhibitor of phosphodiesterase and adenosine receptors in treating asthma and chronic obstructive pulmonary disease, has recently shown activated effects on HDAC in low doses. These effects synergistically enhance the anti-inflammatory properties of cortisol in asthma and chronic obstructive pulmonary disease treatments. 425 Nonetheless, a phase III clinical study revealed that additional administration of low-dose theophylline, along with inhaled long-acting β 2 -agonists and corticosteroids, failed to enhance HDAC activity in vivo. This left no significant difference from the anti-inflammatory properties of standard therapy. 426

SIRT inhibitors and agonists

The sirtuin family’s role in developing various diseases, including inflammation, cardiovascular diseases, metabolic disorders, neurodegenerative diseases, and cancer, underscores the importance of exploring molecules that modulate their activity. Notably, SIRT2 is involved in the deacetylation of histone H4 during the G2/M transition and mitosis but is predominantly found in the cytosol, where it participates in non-histone deacetylation. 427 , 428 SIRT3-5 are mainly located in mitochondria and possess a mitochondrial targeting sequence, 429 while SIRT7 is primarily found in the nucleus, though fewer studies have addressed molecules that regulate its activity. 430 Consequently, the inhibitors and agonists of SIRT1 and SIRT6 are highlighted as promising epigenetics-targeted drugs with significant potential.

From a mechanistic perspective, five classes of inhibitors of SIRT1 have been identified: First, competitive inhibitors that vie for acylated substrates at the binding sites, exemplified by natural products such as sirtinol, splitomicin, and cambinol analogs; 431 , 432 Second, competitive inhibitors that challenge NAD + for binding sites, including selisistat (EX-527) and Sosbo; 433 – 435 Third, adenosine analogs such as Ro 31-8220; 436 , 437 Further, binary inhibitors that compete with substrates or cofactors at separate binding sites, represented by ELT-31, a non-selective SIRT1-3 inhibitor; 438 And the last, non-competitive inhibitors, including nicotinamide and its analogs, tenovins, thioacetyl-lysine peptides, and other small peptides. 439 – 441 EX527, one of the few sirtuin inhibitors in clinical use, has demonstrated antitumor effects in vitro and potential as an adjunct in tumor therapy. 442 Additionally, it has proven safe and well-tolerated within the therapeutic concentration range for treating neurodegenerative diseases. 443 However, minimal therapeutic effects were observed in a phase I clinical trial focusing on early-stage HD, with further large-scale trials needed to explore its clinical potential. 444 Ongoing research also investigates EX-527’s potential roles in improving other metabolic diseases, including endotoxemia, 445 diabetic nephropathy, 446 and infertility ( NCT04184323 ) remains ongoing. Utilizing computational tools to predict potential allosteric sites has led to the identification of some allosteric SIRT6 inhibitors, including JYQ-42, 447 compound 11e, 448 and a pyrrole-pyridinimidazole derivative. 449 , 450 Given that histone deacetylation catalyzed by SIRT6 promotes both tumor and non-tumor diseases, designing and in-depth study of these allosteric SIRT6 inhibitors represent a promising research field for human disease treatment. 451 , 452

The agonists of the sirtuin family have been widely studied since the discovery of the first SIRT1 agonist, resveratrol, in 2003. 453 The initially discovered sirtuin agonists mainly upregulate target enzyme activity through allosteric effects and are classified into two primary categories based on their origins. The first category comprises natural products extracted from plants, including resveratrol and other polyphenolic molecules. 454 – 459 The second category consists of synthesized agonists that exhibit greater selectivity, focusing particularly on SIRT1, such as SRT1460, SRT1720, SRT2104, SRT2183, and SRT3025, as well as those targeting SIRT6, including UBCS039 and MDL-800. 460 Additionally, compounds that are suggested to upregulate SIRT1 expression have been identified. These are predominantly involved in the activation of the mitogen-activated protein kinase pathway, including DDIT3, 461 phloretin, 462 puerarin, 463 and atractylenolide III. 464 Other reported agonists include include astragaloside intravenous, 465 hesperidin, 466 caffeic acid phenethyl ester, 467 agomelatine, 468 ligustilide, 469 tanshinone IIA, 470 and farnesol. 471 These studies emphasize the role of SIRT1 activation in the deacetylation of various non-histones. However, the potential of these molecules as epigenetics-targeted drugs requires further exploration. Moreover, NAD + -enhancing molecules, which promote NAD + generation or rescue their levels, represent a novel class of sirtuin agonists. These molecules may activate all sirtuin members with a single compound, attracting considerable attention. 472 Given the diverse roles of NAD + in multiple signaling pathways, additional discussion is needed to determine whether drugs that increase NAD + levels have therapeutic effects in a sirtuin-dependent manner.

Targeting the reader of histone acetylation: BET, YEATS, and PHD

BET, YAF9, eleven-nineteen-leukemia protein (ENL), acute lymphocytic leukemia 1-fused gene from chromosome 9 protein (AF9), TAF14, and SAS5 (YEATS) domain, and PHD finger proteins are critical “readers” of acetylated residues and play essential roles as epigenetics-modifying enzymes in the transcription of downstream target genes. Drugs that target aberrant levels or activities of acetyl-recognition domain-containing proteins represent an emerging class of therapies for various diseases.

BET inhibitors

In recent years, a substantial number of BET inhibitors have been identified, encompassing pan-inhibitors, BD1/BD2 selective inhibitors, dual inhibitors of kinases and BET, and PROTACs-based inhibitors. 60 , 473 , 474 From a therapeutic standpoint, BET inhibitors are primarily developed for treating tumors, with some also showing potential in non-tumor diseases, such as VYN-201 and VYN-202, among other BD2 selective inhibitors. 475

More than twenty BET inhibitors have progressed to clinical trials, with several undergoing advanced phase evaluations. Notably, apabetalone (RVX-208) stands out as the sole BD2-selective inhibitor in phase III trials for addressing cardiovascular diseases and metabolic disorders such as T2DM. 476 – 478 Apabetalone demonstrates significant anti-inflammatory properties, providing a robust scientific basis for its ongoing clinical evaluation. 479 – 481 Another BET inhibitor, pelabresib (CPI-0610), has also reached phase III trials and shows promise as a treatment for myelofibrosis. 482 In earlier phase II studies, pelabresib combined with ruxolitinib surpassed the efficacy of Janus kinase inhibitor monotherapy in treating symptomatic myelofibrosis while maintaining a manageable safety profile. 483 , 484 ZEN-3694, a leading pan-BET inhibitor, has advanced to phase II trials, demonstrating efficacy when used with cyclin-dependent kinases (CDKs) inhibitors and conventional chemotherapy in cancer treatment. 485 Preliminary phase Ib/IIa trials indicate that ZEN-3694, in combination with enzalutamide, is beneficial for patients with metastatic castration-resistant prostate cancer. 486 An increasing number of trials focusing on ZEN-3694 are currently underway, which will provide further data to evaluate its therapeutic promise. Furthermore, recent reports highlight dinaciclib, a well-known CDK inhibitor, now recognized for its novel activity in BET suppression. 487 The dual inhibitory capability of dinaciclib presents a potential strategy to counteract BET resistance in AML treatment. 487 These developments underscore the potential of these drugs to achieve market approval for broad clinical use. However, some BET inhibitors as single-agent therapies have shown mixed outcomes in clinical trials for distinct cancer settings, despite their excellent results in preclinical models. 488 For example, several phases 1 and 2 clinical trials investigating the therapeutic effect of birabresib on solid or hematological malignancies were terminated prematurely because of limited efficacy ( NCT02698176 , NCT02698189 , NCT02698176 , NCT02296476 ). Therefore, combining BET inhibitors with other traditional drugs may open new possibilities for the development of antitumor strategies.

Numerous novel BET inhibitors have been identified recently, enhancing the landscape of therapeutic options. These include OPN-51107, a pan-BET inhibitor that mitigates T cell dysfunction in chronic lymphocytic leukemia; 489 XL-126, a BD1-selective inhibitor noted for its potent anti-inflammatory effects; 490 and DW-71177, another BD1-selective inhibitor geared towards AML treatment. 491 Additional developments involve brain-permeable BD1-selective inhibitors for multiple sclerosis treatment, 492 compounds with dual HDAC/BET inhibitory action for challenging tumors, 493 phenoxyaryl pyridone derivatives as BD2-selective inhibitors for AML, 494 and SRX3177, a potent triple-action CDK4/6-phosphoinositide 3-kinase-BET inhibitor for respiratory diseases linked to β-coronavirus. 495 These advancements significantly contribute to understanding BET-targeted drug development, designing small molecule inhibitors tailored to the diverse pathological characteristics of human diseases.

YEATS domain inhibitors

Identified in 2014, the YEATS domain-comprising YAF9, ENL, AF9, TAF14, and SAS5—serves as a novel reader for histone acetylation. This domain also recognizes histone crotonylation and benzoylation, which are critical in regulating gene expression. 496 – 498 The human genome encodes four YEATS domain-containing proteins: ENL, YEATS domain-containing 2 (YEATS2), AF9, and glioma amplified sequence 41 (GAS41). These proteins are primarily implicated in the pathogenesis of tumors, particularly hematologic malignancies, and represent promising targets for epigenetic therapies. 499 – 502 Research has shown that the YEATS domain binds to acylated lysine side chains through a common binding pocket and engages in π-π-π stacking interactions, providing a structural and theoretical foundation for developing targeted inhibitors. 503 A significant milestone was the identification of the first small-molecule chemical probe, SGC-iMLLT, which targets ENL and its paralog AF9. This probe’s inhibitory effects were validated in biological assays. 504 Furthermore, another approach involves blocking the protein-protein interaction (PPI) between YEATS domain proteins and disruptor of telomeric silencing 1-like (DOT1L), effectively suppressing the activity of YEATS domain proteins. 505 , 506 Current research is focused on developing selective inhibitors for various YEATS domain proteins, with the deepest insights into ENL inhibitors. In 2022, Liu et al. 507 highlighted the promising potential of the oral ENL inhibitor TDI-11055 in treating AML in mouse models, advancing the clinical application of ENL inhibitors for AML treatment. Additionally, combination therapies involving ENL inhibitors with KAT or BET inhibitors have been emphasized. 508 , 509 In 2020, Jiang et al. 510 introduced the first selective inhibitor targeting the AF9 YEATS domain, presenting a novel cyclopeptide for in-depth exploration of the functional similarities and differences between AF9 and ENL, thereby laying the groundwork for novel YEATS domain inhibitor development. An optimized method for the solid-phase synthesis of these inhibitory cyclopeptides has since been proposed, significantly reducing preparation time and enhancing yield. 510 Moreover, the study of amide-π interactions between histone acyl-lysine and the AF9 YEATS domain has led to the development of chemical compounds that disrupt this noncovalent interaction, notably those incorporating urea or aromatic rings. 511 , 512 In 2021, the first selective GAS41 inhibitor was reported; this synthesized molecule binds to dimerized GAS41 YEATS domains and blocks interaction with acetylated histone H3 in cancer cell lines. 513

PHD finger domain inhibitors

BD and PHD finger-containing protein (BRPF) and BD and PHD finger transcription factor (BPTF) are crucial targets involved in tumor progression and the development of resistance to molecularly targeted therapy drugs, such as kinase inhibitors and poly ADP-ribose polymerase (PARP) inhibitors. 514 – 516 To date, an array of BRPF inhibitors featuring distinctive scaffolds—such as 3-acetyl-indole, 1,3-dimethylquinolin-2-one, 1,3-dimethyl benzimidazole, 1-(indolin-1-yl)ethan-1-one, 1,3-dimethylquinolin-2-one, and 2,3-dioxo-quinoxaline—has been identified. These compounds represent novel avenues for therapeutic innovation. 517 – 522 However, as the inhibitory effects of these agents have primarily been confirmed in vitro, extensive efforts are required to advance these drugs to clinical trials. BPTF inhibitor development has not kept pace with those targeting other proteins with BD motifs, primarily remaining within fragment-based drug discovery. Only a handful have been tested in vivo or in vitro to demonstrate their inhibitory actions and therapeutic potential. AU1, the first small molecule selective for BPTF, has shown effectiveness in mouse models of gastric cancer and neuroblastoma. 516 , 523 , 524 Bromosporine has exhibited significant antitumor effects in breast cancer and melanoma, suggesting promising therapeutic strategies for solid tumors. 525 , 526 The novel selective inhibitor C620-0696 has shown cytotoxic effects in non-small-cell lung cancer cells overexpressing BPTF. 527 The continued exploration of these inhibitors in oncology is highly anticipated.

Epigenetics-targeted drugs and histone methylation

Histone methylation is a highly dynamic regulator crucial for activating or suppressing gene transcription. Histone methyltransferases, demethylases, and reader proteins modify and maintain epigenetic signals that influence chromatin structure and cellular functions. Their dysregulation is linked to a variety of diseases, particularly malignant tumors. Recent advances in biochemistry and understanding of pathogenesis have led to identifying and developing small-molecule inhibitors that target aberrant demethylation patterns (Table 5 ). Table 5 Summary of histone methylation-targeted drugs for different diseases in clinical trials Type Drug Target(s) Condition(s) Status/outcome(s) Phase(s) Other intervention(s)/drug(s) Study ID/reference(s) KMT inhibitor CPI-1205 EZH2 B cell lymphoma Completed (unpublished) Phase I — NCT02395601 CPI-1205 EZH2 Melanoma, NSCLC, RCC, urothelial carcinoma Completed (unpublished) Phase I In combination with Ipilimumab NCT03525795 CPI-1205 EZH2 Castration-resistant prostate cancer Unknown Phase I/II In combination with Enzalutamide or Abiraterone/Prednisone NCT03480646 CPI-0209 EZH2/EZH1 Ovarian cancer Recruiting Phase I In combination with Carboplatin NCT05942300 CPI-0209 EZH2/EZH1 MF/Sezary syndrome Recruiting Phase I — NCT05944562 CPI-0209 EZH2/EZH1 Urothelial carcinoma, ovarian cancer, endometrial carcinoma, DLBCL, PTCL, mesothelioma Recruiting Phase I/II — NCT04104776 SHR2554 EZH2 Healthy volunteers Completed (metabolizing enzymes in vivo regulates the plasma concentration of SHR2554) Phase I In combination with Itraconazole NCT04627129 542 SHR2554 EZH2 Healthy volunteers Unknown Phase I — NCT05049083 SHR2554 EZH2 Healthy volunteers Completed (unpublished) Phase I — NCT06010680 SHR2554 EZH2 Healthy volunteers Completed (unpublished) Phase I In combination with Fluconazole NCT05661591 SHR2554 EZH2 Healthy volunteers Completed (unpublished) Phase I In combination with Omeprazole NCT06093945 SHR2554 EZH2 Healthy volunteers Completed (drug exposures are essentially the same in fasted and fed states) Phase I Following a high-fat diet or fasting status NCT04335266 SHR2554 EZH2 Healthy volunteers Completed (metabolizing enzymes in vivo regulates the plasma concentration of SHR2554) Phase I In combination with Rifampin NCT04577885 SHR2554 EZH2 Mature lymphoid neoplasms Unknown (exhibits satisfied efficacy and acceptable adverse effects according to available data) Phase I — NCT03603951 540 , 541 SHR2554 EZH2 FL Not yet recruiting Phase II — NCT06368167 SHR2554 EZH2 HR-positive, HER2-negative, endocrine-resistant advanced BC Recruiting Phase II Umbrella study NCT04355858 SHR2554 EZH2 PTCL Recruiting Phase I/II Umbrella study NCT05559008 SHR2554 EZH2 TNBC Recruiting Phase I/II Umbrella study NCT03805399 SHR2554 EZH2 B cell lymphoma, solid tumors Recruiting Phase I/II SHR1701 (active comparator/followed by SHR2554) NCT04407741 SHR2554 EZH2 HL Recruiting Phase I/II SHR1701 (active comparator/followed by SHR2554) NCT05896046 SHR2554 EZH2 PTCL Recruiting Phase I/II In combination with CHOP NCT06173999 SHR2554 EZH2 Castration-resistant prostate cancer Completed (unpublished) Phase I/II With or without SHR3680 NCT03741712 SHR2554 EZH2 PTCL Recruiting Phase III Chidamide (active comparator) NCT06122389 PF-06821497 EZH2 Castration-resistant prostate cancer, SCLC, FL Recruiting Phase I — NCT03460977 GSK126 EZH2 DLBCL, FL, MM, solid tumors Terminated (the maximal dose and schedule shows insufficient evidence of clinical activity) Phase I — NCT02082977 546 XNW5004 EZH2 Squamous cell carcinoma of head and neck, urothelial carcinoma, prostate cancer, SCLC, NSCLC, cervical cancer Recruiting Phase I/II In combination with Pembrolizumab NCT06022757 AXT-1003 EZH2 NHL Recruiting Phase I — NCT05965505 EPZ-5676 DOT1L AML, ALL Completed (unpublished) Phase I — NCT02141828 EPZ-5676 DOT1L AML, ALL, MDS, myeloproliferative disorders Completed (exhibits good safety profiles while unsatisfied efficacy) Phase I — NCT01684150 1146 EPZ-5676 DOT1L AML with an 11q23 translocation or partial tandem duplication Completed (large-scale trials should be hold) Phase I/II In combination with Azacitidine NCT03701295 EPZ-5676 DOT1L ALL Terminated (due to the study agent is no longer available) Phase I/II In combination with Cytarabine and Daunorubicin NCT03724084 EZM0414 SETD2 MM, DLBCL Recruiting Phase I — NCT05121103 KTX-1001 NSD2 MM Recruiting Phase I — NCT05651932 PRMT inhibitor GSK3368715 PRMT1 DLBCL, PDAC, bladder cancer, NSCLC Terminated (due to a lack in observed clinical efficacy and the unfavorable risk/benefit analysis) Phase I — NCT03666988 561 CTS-2190 PRMT1 PDAC, NSCLC, TNBC Recruiting Phase I/II — NCT06224387 GSK3326595 PRMT5 TNBC, TCC, GBM, NHL, ACC, HR-positive BC, HPV-positive solid tumors, NSCLC Completed (unpublished) Phase I With or without Pembrolizumab NCT02783300 GSK3326595 PRMT5 BC Completed (unpublished) Phase II Blank-controlled NCT04676516 GSK3326595 PRMT5 MDS, AML Terminated (due to an internal review of clinical data) Phase I/II With or without Azacitidine NCT03614728 JNJ64619178 PRMT5 NHL, MDS, solid tumors Active, not recruiting (clinical benefit is limited) Phase I — NCT03573310 568 JNJ64619178 PRMT5 Solid tumors Completed (exhibits manageable dose-dependent toxicity with limited clinical benefit) Phase I — 1147 PF06939999 PRMT5 NSCLC, urothelial carcinoma, squamous cell carcinoma of head and neck Terminated (exhibits tolerable safety profiles and objective clinical responses in a subset of patients) Phase I With or without Docetaxel NCT03854227 569 , 1148 TNG908 PRMT5 NSCLC, mesothelioma, PDAC, sarcoma, GBM Recruiting Phase I/II — NCT05275478 MRTX1719 PRMT5 Mesothelioma, PDAC, NSCLC, malignant peripheral nerve sheath tumor Recruiting Phase I/II — NCT05245500 571 PRT543 PRMT5 DLBCL, myelodysplasia, myelofibrosis, ACC, MCL, AML, CMML Completed (exhibits limited efficacy in ACC) Phase I — NCT03886831 572 PRT811 PRMT5 Solid tumors, CNS lymphoma, gliomas Completed (unpublished) Phase I — NCT04089449 SKL27969 PRMT5 Solid tumors Terminated (due to portfolio prioritization) Phase I/II — NCT05388435 AMG193 PRMT5 Biliary tract cancer, PDAC Recruiting Phase I In combination with Gemcitabine/Cisplatin/Pembrolizumab, or Gemcitabine/Nab-paclitaxel, or modified FOLFIRINOX NCT06360354 AMG193 PRMT5 NSCLC Recruiting Phase I With or withought Carboplatin/Paclitaxel/Pembrolizumab, or Carboplatin/Pembrolizumab/Pemetrexed, or Pembrolizumab, or Sotorasib NCT06333951 AMG193 PRMT5 MTAP-null solid tumors Recruiting Phase I/II With or without Docetaxel NCT05094336 AMG193 PRMT5 MTAP-null solid tumors Recruiting Phase I/II In combination with IDE397 NCT05975073 SH3765 PRMT5 Advanced malignant tumors Not yet recruiting Phase I — NCT05015309 TNG462 PRMT5 MTAP-null solid tumors Recruiting Phase I/II — NCT05732831 SCR6920 PRMT5 Solid tumors, NHL Recruiting Phase I — NCT05528055 SYHX-2001 PRMT5 Solid tumors Recruiting Phase I — NCT05407909 KDM inhibitor Tranylcypromine LSD1 Non-APL AML subtypes, MDS Completed (unpublished) Phase I In combination with ATRA NCT02273102 Tranylcypromine LSD1 Non-APL AML subtypes Unknown Phase I/II In combination with ATRA NCT02261779 Tranylcypromine LSD1 Non-APL AML subtypes Unknown Phase I/II In combination with ATRA and Cytarabine NCT02717884 ORY-1001 LSD1 AML, MDS Recruiting Phase I In combination with Azacitidine and Venetoclax NCT06357182 ORY-1001 LSD1 AML Recruiting Phase I In combination with Gilteritinib NCT05546580 ORY-1001 LSD1 SCLC Not yet recruiting Phase I/II Atezolizumab and Durvalumab (active comparator/followed by ORY-1001) NCT06287775 ORY-1001 LSD1 AML Completed (exhibits a good safety profile without significant extra-hematologic toxicity) Phase I — EudraCT 2013-002447-29 ORY-1001 LSD1 AML Completed (unpublished) Phase II In combination with Azacitidine EudraCT 2018-000482-36 624 ORY-2001 LSD1 Healthy volunteers Completed (exhibits good safety and tolerability) Phase I Placebo-controlled EUDRACT 2015-003721-33 627 ORY-2001 LSD1 MS Ongoing (exhibits safety and tolerability according to early clinical data) Phase II Placebo-controlled EudraCT 2017-002838-23 ORY-2001 LSD1 AD Completed (exhibits good efficacy and tolerability) Phase II Placebo-controlled EudraCT 2017-004893-32 ORY-2001 LSD1 ADHD, BPD, ASD Completed (exhibits good efficacy and tolerability) Phase II — EudraCT 2018-002140-88 ORY-2001 LSD1 AD Completed (exhibits good efficacy and tolerability) Phase II Placebo-controlled EudraCT 2019-001436-54 ORY-2001 LSD1 ARDS Completed (exhibits good efficacy and tolerability) Phase II In combination with standard care treatment EudraCT 2020-001618-39 ORY-2001 LSD1 AD Completed (unpublished) Phase II Placebo-controlled NCT03867253 ORY-2001 LSD1 BPD Completed (unpublished) Phase II Placebo-controlled NCT04932291 GSK-2879552 LSD1 SCLC Terminated (due to the unfavorable risk/benefit analysis) Phase I — NCT02034123 GSK-2879552 LSD1 AML Terminated (due to the unfavorable risk/benefit analysis) Phase I In combination with ATRA NCT02177812 GSK-2879552 LSD1 MDS Terminated (due to the unfavorable risk/benefit analysis) Phase I/II With or without Azacitidine NCT02929498 IMG-7289 LSD1 AML Recruiting Phase I In combination with Venetoclax NCT05597306 IMG-7289 LSD1 AML, MDS Completed (exhibits a good safe profile) Phase I/II With or without ATRA NCT02842827 IMG-7289 LSD1 SCLC Active, not recruiting Phase I/II In combination with Atezolizumab NCT05191797 INCB059872 LSD1 Ewing sarcoma Terminated (due to business decision) Phase I — NCT03514407 INCB059872 LSD1 AML, MDS, SCLC, myelofibrosis, Ewing sarcoma, poorly differentiated neuroendocrine tumors Terminated (due to business decision) Phase I/II With or without ARTA, Azacitidine, and Nivolumab NCT02712905 INCB059872 LSD1 NSCLC, colorectal cancer Terminated (due to sponsors’ decision) Phase I/II In combination with Pembrolizumab and Epacadostat NCT02959437 SP-2577 LSD1 Solid tumors Completed (unpublished) Phase I — NCT03895684 SP-2577 LSD1 Ewing sarcoma, myxoid liposarcoma, desmoplastic small round cell tumor Active, not recruiting Phase I With or without Cyclophosphamide and Topotecan NCT03600649 SP-2577 LSD1 Ovarian cancer, endometrial cancer Withdrawn (due to salaries discontinued support) Phase I In combination with Pembrolizumab NCT04611139 SP-2577 LSD1 CMML, MDS Recruiting Phase I/II In combination with Azacytidine NCT04734990 SP-2577 LSD1 Ewing sarcoma, myxoid liposarcoma, desmoplastic small round cell tumor Enrolling by invitation Phase I/II — NCT05266196 CC-90011 LSD1 AML Terminated (due to business decision) Phase I Azacitidine and Venetoclax (active comparator/followed by CC-90011) NCT04748848 CC-90011 LSD1 Castration-resistant prostate cancer Completed (unpublished) Phase I In combination with Abiraterone and Prednisone NCT04628988 CC-90011 LSD1 NHL, solid tumors Terminated (due to business decision) Phase I In combination with Rifampicin NCT02875223 1149 , 1150 CC-90011 LSD1 SCLC Active, not recruiting Phase I In combination with Cisplatin and Etoposide NCT03850067 CC-90011 LSD1 SCLC, NSCLC Completed (unpublished) Phase II In combination with Nivolumab NCT04350463 4SC-202 LSD1 AML, ALL, MDS, CLL, MM Completed (exhibits a good safety profile and antitumor activities) Phase I — NCT01344707 1102 4SC-202 LSD1 Oesophagogastric adenocarcinoma, colorectal cancer Unknown (oesophagogastric adenocarcinoma cohort meets the criteria to expand to stage 2 according to disclosed data) Phase II In combination with Avelumab NCT03812796 1103 4SC-202 LSD1 Melanoma Completed (unpublished) Phase I/II In combination with Pembrolizumab NCT03278665 4SC-202 LSD1 Melanoma Active, not recruiting (4SC-202 addition does not increase treatment efficacy according to early clinical data) Phase I/II Nivolumab (active comparator/in combination with 4SC-202); in combination with Nivolumab/Ipilimumab NCT04133948 424 JBI-802 LSD1, HDAC6 SCLC and other neuroendocrine-derived cancers Recruiting Phase I/II — NCT05268666 TAK-418 LSD1 Healthy volunteers Completed (exhibits good tolerability, pharmacokinetic and pharmacodynamic effects) Phase I Placebo-controlled NCT03228433 638 TAK-418 LSD1 Healthy volunteers Terminated (due to business decision) Phase I Placebo-controlled NCT03501069 638 TAK-418 LSD1 Healthy volunteers Terminated (due to administrative reasons) Phase I In combination with [18 F]MNI-1054 (radiotracer) NCT04202497 LH-1802 LSD1 AML, MDS Ongoing Phase I — CTR20222026 SYHA1807 LSD1 SCLC Unknown Phase I — NCT04404543 WDR domain inhibitor MAK683 EED DLBCL Active, not recruiting Phase I — NCT02900651 ACC adenoid cystic carcinoma, AD Alzheimer’s disease, ADHD attention deficit hyperactivity disorder, ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, APL acute promyelocytic leukemia, ARDS acute respiratory distress syndrome, ASD autism spectrum disorder, ATRA all-trans-retinoicacid, BC breast cancer, BPD borderline personality disorder, CHOP Cyclophosphamide, Hydroxydoxorubicin, Oncovin, and Prednisone, CLL chronic lymphocytic leukemia, CMML chronic myelomonocytic leukemia, CNS central nervous system, DLBCL diffuse large B cell lymphoma, DOT1L disruptor of telomeric silencing 1-like, EED embryonic ectoderm development, EZH2 enhancer of zeste homolog 2, FL follicular lymphoma, GBM glioblastoma multiforme, HDAC histone deacetylase, HER2 human epidermal growth factor receptor 2, HL Hodgkin lymphoma, HPV human papillomavirus, HR hormone receptor, KDM lysine demethylase, KMT lysine methyltransferase, LSD1 lysine specific demethylase 1, MCL mantle cell lymphoma, MDS myelodysplastic syndrome, MF mycosis fungoides, MM multiple myeloma, MS multiple sclerosis, MTAP methyl-thioadenosine phosphorylase, NHL non-Hodgkin lymphoma, NSD nuclear receptor binding SET domain protein, NSCLC non-small cell lung cancer, PDAC pancreatic ductal adenocarcinoma, PRMT protein arginine methyltransferase, PTCL peripheral T cell lymphoma, RCC renal cell carcinoma, SCLC small cell lung cancer, SETD2 SET domain-containing histone lysine methyltransferase 2, TCC transitional cell carcinoma of the urinary system, TNBC triple-negative breast cancer, WDR WD40 repeat

Targeting the writer of histone methylation: KMT and PRMT

Histone methyltransferases (HMTs), including KMTs and protein arginine methyltransferases (PRMTs), are central to regulating histone methylation and are implicated in numerous biological and pathological processes. Inhibitors of HMTs are extensively researched as potential therapeutic agents. Notably, innovative drug discovery strategies for HMT proteins—such as covalent inhibition independent of SAM-competitive or substrate-competitive mechanisms, dual-target inhibition, and targeted degradation strategies—have received considerable attention and have rapidly progressed. 528 – 530 These inhibitors, in addition to marketed drugs, are being advanced to clinical practice for further evaluation and oversight.

EZH2 inhibitors

Since the identification of the suppressor of variegation 3-9 homolog 1 (SUV39H1), the inaugural histone KMT8 discovered in 2000, numerous proteins mediating histone methylation have been reported. These include EZH1/2, euchromatic histone-lysine N-methyltransferase 2 (G9a/EHMT2), G9a-like protein (GLP/EHMT1), DOT1L, and various SET domain-containing histone lysine methyltransferase (SETD) and nuclear receptor binding SET domain protein (NSD) families. 531 – 533 Over recent decades, considerable efforts have focused on developing efficient and selective inhibitors targeting various histone KMT subfamilies with potential therapeutic applications in disease treatment. 534 – 537

In addition to the two marketed drugs summarized in the previous section, tazemetostat (EPZ-6438) and valemetostat (DS-3201b), numerous novel EZH2 inhibitors are under investigation, with several advances in clinical studies, particularly compounds featuring the 2-pyridone moiety which encompass both bicyclic heteroaromatic and monocyclic aromatic rings. 538 CPI-1205 (lirametostat) has undergone evaluation in three clinical trials ( NCT03480646 , NCT03525795 , NCT02395601 ) to assess its tolerance and therapeutic potential. Although CPI-1205 has shown good tolerability in phase I stages, phase II trials have yet to provide sufficient data to confirm its antitumor efficacy. CPI-0209 (tulmimetostat), an oral, next-generation dual EZH2/EZH1 inhibitor developed by the same company, is currently under clinical trial for treating both solid tumors and hematological malignancies ( NCT05944562 , NCT05942300 , NCT04104776 ). SHR2554, a highly selective EZH2 inhibitor, has demonstrated potent efficacy both in vitro and in vivo. 539 Its first-in-human, dose-escalation, and dose-expansion phase 1 trial conducted at 13 hospitals in China in 2018 indicated good tolerance and promising antitumor activity in patients with R/R lymphomas. 540 , 541 A pharmacokinetic study revealed that combining itraconazole, an inhibitor of CYP3A4-metabolizing enzymes, with SHR2554 improves its plasma concentration while maintaining a favorable safety profile, suggesting a new therapeutic strategy. 542 PF-06821497, a lactam-derived EZH2 inhibitor, was optimized from a series of similar compounds using ligand-based and physicochemical-property-based strategies, showing optimal inhibitory and therapeutic effects in mouse models. 543 It also has demonstrated synergistic effects in combination with HDAC inhibitors, inhibiting proliferation and inducing apoptosis in cancer cell lines. 544 Currently, two clinical studies are exploring appropriate administration methods for PF-06821497, such as intravenous injection or oral intake, and whether it can be consumed with food ( NCT06392230 , NCT05767905 ). In addition to demonstrating a strong therapeutic effect in tumor treatment in animal models, GSK126 has also achieved significant breakthroughs in enhancing β-like cell regeneration among patients with T1DM. 111 , 545 However, a terminated phase I clinical trial revealed insufficient evidence of clinical activity for GSK126 at tolerable doses. 546 XNW5004 ( NCT06022757 ) and AXT-1003 ( NCT05965505 ) are innovative EZH2 inhibitors currently in clinical trials, reflecting ongoing advancements in this therapeutic area. Moreover, astemizole, originally an antiallergy medication inhibiting histamine receptor H1, has recently been shown to disrupt the EZH2-embryonic ectoderm development (EED) PPI within the PRC2, offering new perspectives in developing EZH2/PRC2 inhibitors. 547

DOT1L inhibitors

EPZ-5676 (pinometostat), EPZ004777, and SGC0946 are three selective inhibitors of DOT1L that are currently under extensive research. EPZ-004777 was the first SAM-competitive inhibitor of DOT1L to demonstrate in vivo efficacy. 548 Despite showing promising therapeutic effects in various subtypes of AML through cell experiments and animal models, EPZ-004777’s preclinical application has been largely constrained by its pharmacokinetic characteristics. 549 , 550 EPZ-5676 has been developed to improve selectivity and inhibition effects, showing potential as a therapeutic agent for mixed lineage leukemia (MLL). 551 Early investigations using patient-derived xenografts and mouse models have indicated that EPZ-5676 exhibits potent antileukemic activities, facilitating further evaluation. 552 , 553 In three completed clinical trials ( NCT01684150 , NCT02141828 , NCT03701295 ), EPZ-5676 has been assessed for safety, tolerability, and preliminary antitumor activity in pediatric patients with MLL, with the combination of EPZ-5676 and azacytidine in a phase Ib/II study expected to show synergistic antiproliferative activities ( NCT03701295 ). SGC0946, a brominated analog, serves as another selective inhibitor of DOT1L. Its therapeutic potential, either as monotherapy or in combination with other inhibitors such as HDACs and the mitogen-activated protein kinase pathway, has been observed in various solid tumors, setting the groundwork for clinical trials of SGC0946. 554 – 556

Beyond EZH2 and DOT1L, several inhibitors targeting other subfamilies are being investigated in clinical studies, including EZM0414 and KTX-1001. EZM0414, a novel inhibitor of SETD2 derived from the optimization of EPZ-719, exhibits improved pharmacokinetic properties and potent pharmacodynamic activity in mouse xenograft models. 557 A phase I/Ib clinical trial is currently underway to explore the safety, tolerability, and therapeutic efficacy of EZM0414 in patients with R/R MM and R/R diffuse large B-cell lymphoma ( NCT05121103 ). KTX-1001, a selective NSD2 inhibitor, has been FDA-approved for clinical trials since 2022 and is being studied in a phase I trial to treat patients with R/R MM ( NCT05651932 ). These meticulously organized clinical trials focusing on KMTs are drawing increasing attention, leading to significant breakthroughs in understanding the relationship between human diseases and aberrant histone methylation.

PRMT inhibitors

Significant progress has been made in developing inhibitors for type I PRMTs (PRMT1-4, 6, and 8) and a selective inhibitor targeting PRMT5, with several agents entering the early phases of clinical trials.

Two type I PRMTs inhibitors are already in clinical stages, including GSK3368715 and CTS-2190. GSK3368715 (EPZ019997), an oral, reversible inhibitor of PRMT1/6/8 developed for treating tumors and pulmonary disorders. 558 – 560 GSK3368715 underwent a phase 1 clinical trial for treating solid tumors and diffuse large B-cell lymphoma in 2018. However, the first clinical application of a PRMT1 inhibitor did not meet expectations and was terminated early in 2022 due to its ineffectivenes. 561 Given the adverse events potentially caused by high and sustained concentrations of the inhibitor in vivo, research into PROTAC-based degraders of GSK3368715 has intensified, potentially offering therapeutic benefits at lower doses and reducing adverse effects. 562 CTS-2190, another inhibitor targeting PRMT1/3/4/6, received clinical trial approvals from the US FDA and China NMPA in February and April 2023, respectively. A phase I/II clinical trial is being conducted to evaluate its tolerability and preliminary antitumor activity in healthy participants and patients with solid tumors ( NCT06224387 ).

Thirteen PRMT5 inhibitors have advanced to phase I and II clinical trials. Among these, GSK3326595, JNJ64619178, and PF06939999 were the earliest selective PRMT5 inhibitors to receive clinical trial approvals. GSK3326595 is a substrate-competitive inhibitor, while JNJ64619178 and PF-06939999 function as SAM-competitive agents. 563 – 565 The efficacy and understanding of GSK3326595 primarily rely on animal model data due to a lack of published results from completed clinical trials. This inhibitor has been shown to induce DNA damage in cancer cells and enhance the antiproliferative effects of poly ADP-ribose polymerase inhibitors, such as niraparib; 566 however, long-term or chronic use of GSK3326595 is associated with potential liver-related adverse effects. 567 A completed phase I clinical trial of JNJ-64619178 determined that a daily dose of 0.5 mg was better tolerated by participants with R/R B cell non-Hodgkin lymphoma, though it demonstrated limited therapeutic effects. 568 Conversely, PF-06939999 has shown an acceptable safety profile and clinical efficacy in its phase I trial. 569 TNG908 and MRTX1719, both brain-penetrant PRMT5 inhibitors, have shown promise in selectively targeting cancer cells deficient in methylthioadenosine phosphorylase in both preclinical models and clinical trials. 570 , 571 Phase I/II clinical trials for these drugs recruit participants to assess their therapeutic effects on various solid tumors ( NCT05245500 ). Prelude Therapeutics has developed PRT543 and PRT811, leading oral PRMT5 inhibitors whose safety profiles and preliminary therapeutic potential have been evaluated in phase I clinical trials ( NCT04089449 , NCT03886831 ). PRT543 has demonstrated good tolerance and efficacy among patients with adenoid cystic carcinoma, warranting further advanced clinical testing. 572 A phase I/II clinical trial of SKL27969 began in 2022 to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in patients with advanced solid tumors. However, this study was terminated in 2024 due to portfolio prioritization, with no significant safety trends or issues identified during its execution ( NCT05388435 ). Other PRMT5 inhibitors, such as AMG193, SH3765, TNG462, SCR6920, and SYHX-2001, are currently under investigation in clinical trials and are in the “recruiting” phase. Given that most of the small molecules or core scaffolds of PRMT5 inhibitors have been examined only in cellular experiments, there remains a significant gap in knowledge regarding their efficacy and therapeutic effects in vivo. Therefore, it is imperative to bridge the crucial divide between fundamental research and clinical application.

Targeting the eraser of histone methylation: KDM

KDMs are enzymes that remove histone and nonhistone methylation. They can be divided into two categories based on their molecular structures: flavin adenine dinucleotide-dependent KDM (KDM1) and Fe(II)- and α-KG-dependent KDM (KDM2-7), also called Jumonji C (JmjC)-KDMs. 573 Both upregulation and downregulation of KDMs can affect the expression of pathological genes in cancers or other disorders. Currently, representative inhibitors of diverse KDM proteins are being investigated. Based on catalytic mechanisms, lysine specific demethylase 1 (LSD1/KDM1A) inhibitors can be divided into irreversible and reversible inhibitors; KDM2-7 inhibitors are classified into four types: α-KG cofactor mimics or inhibitors of α-KG oxygenases (such as N-oxalylglycine), metal cofactor disruptors, histone substrate competitive inhibitors, and other substrate- and cofactor-independent inhibitors. 574

KDM2/7 inhibitors

KDM2 and KDM7 proteins, which belong to the JmjC-KDM subfamilies, share high similarity in their Fe(II)- and α-KG-binding residues. 575 The development of inhibitors for KDM7 and KDM2 has typically co-occurred. In 2013, a series of hydroxamate analogs featuring an alkyl chain were identified. These compounds demonstrated antiproliferative activity in cancer cells by inhibiting KDM2A, KDM7A, and KDM7B. 576 Similarly, Gerken et al. 577 developed a series of novel KDM2A/7A inhibitors characterized by saturated indoline ring systems. These indoline-containing compounds exhibited potent and selective effects on KDM2A/7A at low micromolar concentrations, with notable cellular activity. Nonetheless, addressing limitations such as cytotoxicity and off-target effects remains challenging for future research. Other selective inhibitors have also been identified, including a cyclic peptide inhibitor, OC9, designed to target the PHD finger domain of KDM7. This inhibitor results in the inhibition of KDM7B and the activation of KDM7A. 578 Through virtual screening of α-KG oxygenases, daminozide, a plant growth regulator, was found to selectively inhibit KDM2A. The therapeutic potential of daminozide was observed in mouse models of osteoarthritis, pointing to new directions for developing 2KG-competed inhibitors with enhanced selectivity, although its use in humans is unlikely. 579 , 580

KDM3 inhibitors

In addition to IOX1, various inhibitors of the KDM3 family have been identified, most exhibiting a pan-inhibitory effect across all family members. Through virtual screening of natural products and traditional Chinese medicine components, compounds JDI-4, JDI-12, and JDI-16 selectively bind to the JmjC domains of KDM3B and KDM3C. 581 Subsequent in vitro and in vivo studies confirmed the inhibitory effect and antitumor potential of JDI-16 in a KDM3-dependent manner. 581 Another compound, JDM-7, also identified from this screening, inhibits KDM3A and KDM3B in AML cell lines, although initial observations indicated limited effects on the KDM3 family. 582 Additionally, through high-throughput screening of benzhydryl amine derivatives, CBA-1 was found to be a potent inhibitor of KDM3A, exhibiting antiproliferative effects on colorectal cancer cell lines. 583 The use of CBA-1 in zebrafish models also showed minimal toxicity, suggesting its potential as a promising drug for clinical application. 583

KDM4 inhibitors

Given the critical roles of KDM4s in cancers and the inherent complexity of the KDM4 subfamily, significant efforts have been dedicated to developing KDM4 inhibitors. These inhibitors are categorized into four previously reviewed classes: α-KG cofactor mimics, Metal cofactor disruptors, histone substrate competitive inhibitors, and inhibitors targeted reader domains, having been summarized extensively in previous work. 584 , 585 In addition to these established categories, we emphasize the progress in novel inhibitors that have not yet been summarized, further expanding the scope of therapeutic options against KDM4-related cancers.

TACH101 is a novel pan-inhibitor of KDM4A-D, competitively inhibiting α-KG without affecting other KDM subfamilies. The therapeutic effects of TACH101 have been demonstrated in organoids and xenograft models, suggesting its potential as an anticancer agent worthy of further investigation in animal studies. 586 SD49-7, a derivative of SD70, is another novel KDM4 inhibitor. It has shown a stronger effect than SD70 in suppressing the proliferation of AML cell lines and enhancing the progression of resistant tumors in mouse models. 587 Based on virtual screening, 2-(methylcarbamoyl)isonicotinic acid has been identified as an initial active fragment specifically inhibiting KDM4A by preventing its binding to H3K9me3 in a substrate-competitive manner. 588 Molecular docking and dynamics approaches have recently revealed that a series of natural products containing sugars, aromatic rings, and OH or O − groups can interact with KDM4 and inhibit its activities. 589 However, the mechanisms of these interactions remain unclear, underscoring the need for further development of these potential drugs.

KDM5 inhibitors

KDM5 inhibitors have shown significant therapeutic potential, though many compounds still lack sufficient evidence to confirm their efficacy and safety in vivo.

A prevailing approach in KDM5 inhibition involves designing small molecules that compete with α-KG for binding sites. 590 Among these, KDOAM-25 is a potent and selective inhibitor affecting MM and triple-negative breast cancer cells, with minimal adverse effects observed in vivo applications. Nevertheless, its poor cell membrane permeability hinders its efficacy. 591 RS3195 exhibits inhibitory effects on KDM5B and KDM5D in vitro. Due to potential toxicity, RS5033 was developed as an alternative, featuring a phenyl ring instead of a pyrrole nucleus to improve tolerance. 592 KDM5-C49, an analog of 2,4-PDCA, binds to KDM5B in vitro and inhibits its enzymatic activities. 593 To enhance cell membrane permeability and selectivity, derivatives KDM5-C48 and KDM5-C70 have been developed. 593 – 595 Through high-throughput virtual screening, a series of cyclopenta[c]chromen derivatives targeting KDM5A have been identified as promising drugs due to their potent inhibitory effects and low toxicity. 596 N70, a thienopyridine-based selective KDM5A inhibitor, displays α-KG-competitive inhibition, while its analog, N71, binds irreversibly to KDM5A through covalent modifications. 597

Numerous compounds, identified through virtual screening and optimization of reported inhibitory molecules, employ different mechanisms of action. 598 , 599 Among these, KDM5-inh1 and CPI-455 are broadly studied pan-inhibitors of KDM5. Using either KDM5-inh1 or CPI-455 has demonstrated therapeutic effects on cancer cell lines and has facilitated synergistic interactions with conventional antitumor agents. 600 , 601 Further research should explore the potential for this synergy in animal models. GS-5801, designed from GS-080—one of the most potent KDM5 inhibitors—shows significant anti-HBV activity. Despite its promise, the in vivo effects of GS-5801 have not met expectations, underscoring the need for additional studies to enhance its efficacy. 602 Utilizing the AlphaScreen method, ryuvidine was identified as an inhibitor of KMD5A/B/C, exhibiting substantial therapeutic impact on drug-tolerant cells. 603 Dexmedetomidine, recently identified as a KDM5 inhibitor, is utilized to manage acute kidney injury in a KDM5-dependent manner. 604 A novel approach was introduced by Yang et al., 605 who reported the first selective metal-based KDM5A inhibitor, rhodium(III) complex1. This compound disrupts the interaction between KDM5A and H3K4me2/3, offering a new scaffold for optimizing KDM5A-targeted drugs. The screening of imidazopyridine-analogs of zolpidem led to the discovery of O4I3, a novel chemical inhibitor of KDM5A. O4I3 generates and sustains patient-specific induced pluripotent stem cells in vitro. 606 Additionally, TK-129, a pyrazole-based KDM5B inhibitor, is applied in treating cardiovascular diseases. 607 High-throughput screening technology has facilitated the identification of PBIT, another novel KDM5B inhibitor. Despite its promising attributes, PBIT exhibits unstable therapeutic effects across different cell lines, necessitating careful consideration of its application in treatment. 608 Similarly, several pyrazole derivatives that inhibit KDM5B have been recognized, with several demonstrating potent activity in cells, suggesting new therapeutic strategies. 609 Furthermore, Iida et al. 610 designed a selective KDM5C inhibitor with a triazole scaffold and subsequently synthesized a KDM5C degrader using PROTAC techniques. This selective degrader shows enhanced inhibitory effects on prostate cancer cell lines compared to its prodrug, thus expanding the possibilities for anticancer agent design.

KDM6 inhibitors

The KDM6 subfamily has gained attention as a therapeutic target for various diseases. GSK-J1 and GSK-J4 are two well-studied classical inhibitors of KDM6B, showing significant potential in treating autoimmune diseases, metabolic disorders, and tumors, and enhancing the effectiveness of traditional antitumor agents. 611 – 614 Using optimized delivery systems for GSK-J1 has further advanced the development of effective in vivo strategies. 615 Beyond these compounds, novel inhibitors have been introduced. For instance, KDOBA67, a hydroxyl derivative of GSK-J4, demonstrates favorable cell permeability in chordoma cell lines and inhibits the progression of chordoma. 616 Employing a virtual fragment screening approach, Giordano et al. 617 identified a series of benzoxazole scaffold compounds that bind to the KDM6B subfamily with high affinity, showing therapeutic promise in melanoma cell lines. Zhang et al. 618 developed a simple capillary electrophoresis method for screening KDM6B inhibitors, leading to the identification of salvianic acid A and puerarin 6”-O-xyloside as effective agents. Additionally, Jones et al. 619 used computational methods to develop an optimized peptide derived from the H3 C-terminus, which may enhance selectivity when linked with known inhibitors.

LSD1 inhibitors

Extensive research has been conducted on the biological and pathological functions of LSD1 and its inhibitors. Compared to other KDM subfamilies, LSD1 inhibitors have seen significant advances. 620 Currently, several LSD1 inhibitors such as tranylcypromine (TCP), ORY‐1001 (ladademstat), ORY‐2001, GSK‐2879552, IMG-7289 (bomedemstat), INCB059872, SP‐2577 (seclidemstat), CC-90011 (pulrodemstat), 4SC‐202 (domatinostat), JBI‐802, TAK-418, LH‐1802, and SYHA1807, are undergoing clinical trials.

TCP, an irreversible inhibitor, is being used in clinical practice among patients with AML and MDS, showing promising effects either alone or in combination with all-trans-retinoic acid in phase I/II clinical trials, with overall response rates exceeding 20%. 621 , 622 Building on TCP’s structure, novel inhibitors like ORY-1001, ORY-2001, GSK-2879552, INCB059872, and IMG-7289 have been developed, which also bind irreversibly to LSD1. 623 These advancements have broadened the spectrum of treatable diseases with LSD1 inhibitors. Notably, ORY-1001 and ORY-2001, both orally administered, have been evaluated for their effectiveness in R/R hematologic malignancies and neurological disorders such as borderline personality disorder and AD. 624 – 628 In completed phase I clinical trials, ORY-1001 exhibited a good safety profile without significant extrahematologic toxicity among healthy volunteers and patients with AML, indicating good therapeutic potential. 624 , 627 GSK2879552 has shown antitumor efficacy in animal models, 629 yet several clinical trials have been terminated due to a high incidence of adverse events. 630 , 631 Similarly, clinical trials for INCB059872 were halted due to business decisions, among other reasons ( NCT02959437 , NCT03514407 , NCT03132324 , NCT02712905 ). Greater attention must be dedicated to evaluating the tolerability and efficacy of novel treatments. According to completed clinical trials, IMG-7289 demonstrates potential in ameliorating several blood disorders ( NCT04254978 , NCT03136185 , NCT02842827 ), with numerous recent registrations for novel clinical trials concerning this drug. SP-2577 and CC-9001 are reversible LSD1 inhibitors, 632 which, compared to their irreversible counterparts, exhibit enhanced safety profiles and have been extensively studied in both solid tumors and hematological malignancies. 633 , 634 Domatinostat and JBI-802, dual inhibitors targeting LSD1 and HDAC, selectively interact with class I HDAC isoenzymes and HDAC6, respectively. 620 Although promising antitumor effects have been observed in cancer cell lines, the therapeutic potential of domatinostat requires further exploration due to its unfavorable toxicity. 424 , 635 TAK-418, a novel LSD1 inhibitor noted for its effective brain penetration, is considered a potential treatment for central nervous system disorders. 636 , 637 The administration of TAK-418 was well tolerated by healthy volunteers in a phase I clinical trial, laying a solid foundation for further investigation. 638 LH-1802 and SYHA1807, novel inhibitors, are currently under clinical trial evaluation for metastatic prostate cancer and small-cell lung cancer, respectively ( NCT03678025 , NCT04404543 ). The encouraging outcomes from these clinical-stage applications have spurred greater interest in the development of LSD1 inhibitors, with ongoing efforts to discover effective and tolerable agents.

Targeting the reader of histone methylation: reader domains

The identification of histone lysine and arginine methylation is attributed to proteins possessing malignant brain tumor (MBT) domains, chromodomains, Tudor domains, proline-tryptophan-tryptophan-proline (PWWP) domains, PHD fingers, and WD40 repeat (WDR) domains. 639 Notably, enzymes that serve as writers or erasers for histone methylation may also contain these reader modules, such as PHD fingers and Tudor domains, aiding in recognizing residues they catalyze. 640 Although numerous inhibitors targeting reader domains have been discovered, nearly half of these originate from structure-based virtual screenings and lack in vivo evaluation of their inhibitory effects and therapeutic activity. 641 Encouragingly, MAK683, an inhibitor targeting EED—a representative histone methylation reader containing the WDR domain—has entered clinical trials. 642 Currently, MAK683 is in a phase I clinical trial for treating diffuse large B-cell lymphoma ( NCT02900651 ). Inspired by this milestone, many potent and selective inhibitors of EDD and other molecules targeting reader domain proteins are expected to advance into clinical trials as promising therapeutic strategies.

Epigenetics-targeted drugs and m6A

RNA m6A methylation, a prevalent and conserved modification in eukaryotic RNAs, is crucial in determining transcript fate at the post-transcriptional level through RNA processing, export, degradation, and translation. Dysregulated m6A regulators contribute to various pathological conditions, particularly in the pathogenesis of diverse tumors. 643 With the identification of various enzymes involved in m6A modification—including writers, erasers, and readers—the reversibility of m6A modification has been increasingly recognized, providing a foundation for developing epigenetics-targeted drugs that regulate RNA m6A as a core mechanism.

Targeting the writer of m6A: METTL3

METTL3 plays a critical role in the m6A modification process by transferring methyl groups from SAM to target RNA, catalyzing the conversion of adenosine to methyladenosine. This function of METTL3, the most extensively studied m6A writer, has been linked to the development of various pathologies, notably various tumors. 644 Recent research has highlighted a range of inhibitors and agonists targeting METTL3, with several epigenetic drugs demonstrating promising efficacy both in vitro and in vivo, thus reinforcing the significance of METTL3 regulation in disease pathology and its potential as a therapeutic target.

METTL3 inhibitors

The study of METTL3 inhibitors has attracted increasing attention due to their diverse roles in regulating gene expression across different diseases. These inhibitors are categorized into competitive and allosteric inhibitors and gene expression suppressors, each leveraging distinct mechanisms of action.

SAM analog is the dominant part of the competitive inhibitors, initially developed based on a fulfilled screening of compounds containing the adenosine moiety (the fragment responsible for the combination with METTL3 at the binding sites for SAM). In 2020, Bedi et al. 645 performed a series of docking studies on over 4000 adenosine-moiety compounds, identifying seven molecules with potential binding affinity to METTL3; however, their inhibitory effects in vivo were minimal. Similarly, Moroz-Omori et al. 646 and Dolbois et al. 647 reported on adenine-based libraries, identifying UZH1a and UZH2 as compounds that occupy the catalytic pocket of METTL3, suggesting their role as potential competitive inhibitors in vitro. Cpd-564, an METTL3 inhibitor identified from ChemDiv and MCE screening libraries, has shown significant reno-protective effects in mouse models of acute kidney injury induced by cisplatin and ischemia-reperfusion. 648 Coptisine chloride, identified via molecular docking-based virtual screening from the Vitas-M chemical library, displayed high affinity to METTL3, exerting competitive inhibitory effects by occupying the SAM binding pocket. 649 STM2457 and STM3006 are novel small molecules that bind non-covalently to the catalytic center of METTL3, reducing its enzymatic activity. 650 , 651 Specifically, STM2457 has demonstrated promising antitumor effects and tolerability in mouse models, improving drug resistance to chemotherapy. 650 , 652 – 654 In comparison, although STM3006 exhibits enhanced cellular potency, its in vivo efficacy is constrained by its shorter half-life. 651 In 2023, STC-15, an oral inhibitor optimized from STM2457, became the first and the only RNA m6A target drug to be applied in phase I clinical trials ( NCT05584111 ). Through detailed studies on the spatial structure of the catalytic domain of METTL3, a series of branched, Y-shaped molecules are designed. These were synthesized by integrating chemical fragments from the most effective inhibitors, resulting in molecules with selectivity and binding affinities surpassing those of STM2457, the only commercially available METTL3 inhibitor. 655 This advancement not only underscores the potential of METTL3 as a therapeutic target but also guides future drug design. Additionally, several natural products with METTL3-inhibitory capabilities have been identified. Quercetin, known as a DNMT inhibitor, has been found to interact with the adenosine moiety pocket in METTL3, forming a stable complex that reduces its catalytic activity. 656 This interaction decreases METTL3 hyperactivation and lowers m6A levels in protein kinase D2 mRNA, improving insulin sensitivity under palmitic acid stimulation—a benefit in hyperinsulinemia conditions. 657 Other natural compounds like berberine and curcumin, also noted for DNMT/HDAC inhibition, have shown METTL3 inhibitory activity, though their mechanisms require further clarification. 658 , 659 Moreover, molecules F039-0002 and 7460-0250 have been designed to target METTL3’s catalytic pocket, showing potential in treating inflammatory bowel disease. 660 Several candidates identified through silico analysis of South African natural products—SANCDB0370, SANCDB0867, and SANCDB1033—also exhibit METTL3 inhibitory properties, with further validation needed. 661 More recently, Li et al. 662 designed a stapled peptide inhibitor, RSM3, targeting the PPI at the METTL3-METTL14 interface. This inhibitor offers a unique approach compared to other small-molecule competitive inhibitors, providing a novel avenue for therapeutic intervention.

Allosteric inhibitors prevent METTL3/14-dependent m6A methylation in a non-competitive manner. To date, three allosteric inhibitors have been identified. The first two allosteric inhibitors are CDIBA and CDIBA-43n, which initially function as cytosolic phospholipase A2 inhibitors preventing inflammation. They show an inhibitory effect in the presence of METTL3/14 complex, instead of separate METTL3 and METTL14 subunits. 663 The third compound, eltrombopag (previously mentioned as a TET agonist), is recently reported to bind with the METTL3 subunit at an allosteric site and has shown potential in treating AML. 663 , 664

Metformin, traditionally used as a first-line treatment for T2DM, has recently been found to inhibit METTL3 expression, possibly contributing to its beneficial effects in patients with malignant tumors. 665 The role of metformin in inhibiting METTL3 expression, at the post-transcriptional level, in breast tumors, is first reported in breast cancer. 666 Subsequently, the application of metformin is also found to inhibit METTL3 expression at the transcriptional level, mediated by the recruitment of DNMT. 667 This dual action of metformin, combined with chemotherapy, offers potential benefits for patients resistant to traditional chemotherapy, potentially mitigating poor prognoses. 667 , 668 Given its safety profile, metformin is a promising candidate as an epigenetic drug targeting METTL3.

METTL3 agonists

While research has predominantly focused on METTL3 inhibitors, there is also interest in agonists, given their potential benefits in DNA damage repair, tumor therapies, and regenerative medicine. 669 – 672 In 2019, Selberg et al. 673 predicted interactions between four small-molecule ligands with METTL3 involving piperidine and piperazine rings, similar to SAM’s binding. These interactions enhanced cell viability and promoted proliferation, although differing onset times among the compounds suggest the need for further development of more effective METTL3 complex activators. 673 Melatonin seems to act as an agonist of METTL3. Lv et al. 674 proposed that melatonin pretreatment can upregulate the expression level of METTL3, restore m6A levels in spermatogonial stem cells, and help them resist the destructive effect of Cr(VI) on reproductive function. However, this viewpoint has recently been questioned. In mouse models with colon inflammation, melatonin inhibits METTL3 expression through melatonin receptor 1B. 675 Further research is necessary to clarify melatonin’s role in METTL3 regulation.

Targeting the eraser of m6A: FTO and ALKBH5

FTO and alkB homolog 5 (ALKBH5) are established m6A erasers, each playing significant roles in epigenetic regulation. FTO is primarily involved in energy homeostasis, demethylating m6A in various RNA species, including cellular mRNA, which impacts multiple biological processes. 676 ALKBH5 not only demethylates m6A-marked mRNA but also m6A-marked single-stranded DNA (ssDNA), influencing oncogenic or tumor-suppressive activities. 677 Over the years, numerous small molecules targeting these m6A writers have been identified and designed, showing promising therapeutic efficacy in vitro and in vivo and advancing the development of epigenetic drugs.

FTO inhibitors

Current strategies for developing FTO inhibitors are multifaceted. Based on the spatial structure of FTO, competitive or non-competitive inhibitors that bind to FTO covalently or non-covalently have been developed. With a deeper understanding of FTO functionality, metabolites in vivo possibly related to FTO have been identified, represented by D-2-HG, a metabolite produced by mutant IDH. 678 Furthermore, exploring the mechanisms underlying medical agents that treat FTO-related diseases provides a theoretical foundation for drug discovery. 679 Subsequently, optimizing the molecular structures of these initially detected compounds will contribute to the development of FTO inhibitors with high selectivity and inhibitory effects, providing promise for the clinical application of FTO inhibitors in the future. Here, we summarize the typical drugs that inhibit FTO, which are the foundation for developing novel inhibitors through constant iterations.

In 2012, the first FTO inhibitor, rhein, was identified. Rhein impairs FTO activity by disrupting its interaction with ssDNA at the catalytic domain. 680 Although rhein increases m6A levels in vitro, its weak selectivity and low inhibitory efficacy have limited its clinical potential, highlighting the need for more effective FTO inhibitors. 680 New FTO inhibitors need to be designed to overcome these drawbacks. Meclofenamic acid (MA), an FDA-approved nonsteroidal anti-inflammatory drug, binds selectively to similar sites on FTO. 681 MA and its prodrug, MA2, have shown promising results in reversing tumor progression and enhancing the efficacy of chemotherapeutic drugs, significantly prolonging survival. 681 , 682 Inspired by MA, various compounds have been developed, such as the fluorescein derivative FL1, which retains the benzyl carboxylic acid structure critical for interaction with FTO. The complex formed between FTO and FL1 inhibits the enzyme’s activity and facilitates the study of FTO-related signaling pathways through fluorescein labeling. 683 Other optimization molecules include GNPIPP12-MA, 684 13a, 685 FB23/FB23-2, 686 Dac-51/Dac-85, 687 ZLD115, 688 and FTO-02/FTO-04/FTO-43. 689 , 690 These compounds significantly improve MA in inhibitory activity, cell permeability, and biosafety while reducing off-target effects and potential resistance. Another similar mechanism inhibitor is diacerein, a structural analog of rhein, which has shown antitumor effects in breast cell lines. 691

In addition to interfering with the interaction between ssDNA and FTO, inhibitors of this enzyme also compete with cofactors such as α-KG and iron(II). For instance, fumarate hydrazide 2 and compounds with the aminohydroxyfuranone core exemplify this approach. 692 , 693 Furthermore, the discovery of N-CDPCB, a competitive inhibitor that binds to non-conserved fragments of FTO, provides novel insights into the development of inhibitory agents. Mechanistically, compounds like benzene-1,3-diol and 4-Cl-1,3-diol are crucial in mediating and enhancing the specific interaction between FTO and N-CDPCB. 694 Additional potential inhibitors, such as CHTB and radicicol, have been identified through virtual screening; these compounds have similar structures. 695 , 696 However, related evidence is lacking to exhibit their efficacy. Moreover, Su et al. 697 reported on CS1 and CS2, which tightly bind to the catalytic pocket of FTO, activating immune checkpoint genes and reversing immune evasion in tumor diseases. Clausine E, another FTO inhibitor, targets the enzyme’s hydrophobic cavity, exhibiting antitumor activity. 698

These ongoing discoveries provide a deeper understanding of the diverse structures of molecules interacting with FTO and their mechanisms of action, promoting large-scale virtual screenings to identify more potential inhibitors. For example, mupirocin, entacapone, compounds “18,077” and “18,079”, several quinolone derivatives, and a series of 1,2,3-triazole analogs have been identified as potential FTO inhibitors. 699 – 703 Notably, quinolone derivatives and their antitumor properties have shown the potential to improve symptoms in neurodegenerative diseases by inhibiting FTO activity. 702 These findings broaden the potential clinical applications of FTO inhibitors.

FTO agonists

Recent studies have identified that certain tricyclic antidepressants, such as imipramine and amitriptyline, exert their antidepressant effects by activating FTO in N2a cells. 704 This emerging area of research highlights the potential therapeutic benefits of FTO activators and calls for more attention to their development and evaluation.

ALKBH5 inhibitors

The RNA demethylase ALKBH5 is recognized as a pro-oncogene, playing a vital role in the post-transcriptional regulation of various targets in cancer biology. 677 Interest in targeting ALKBH5 for therapeutic purposes has significantly increased. We classify the identified ALKBH5 inhibitors into three main categories based on their mechanisms of action. The first category comprises typical competitive inhibitors that compete with cofactors for binding sites. These agents consist of IOX1 (also known as a TET/KDM inhibitor), MV1035, and Ena21, which exhibit the therapeutic potential of targeting ALKBH5 in antitumor therapies. 705 – 707 Compounds that non-covalently interact with the active pocket of ALKBH5 are classified as the second group. Through structure-based virtual screening and optimization, the current compounds include DDO-2728, 2-((1-hydroxy-2-oxo-2-phenylethyl)thio)acetic acid, and 4-((furan-2-ylmethyl)amino)tetrahydropyridazine-3,6-dione. 708 , 709 The third category includes molecules that bind to the m6A-binding pocket of ALKBH5, directly disrupting the interaction between the enzyme and its substrates. For instance, compounds 20 m and TD19 are representative of this type. 710 , 711 Some compounds still exist whose potential mechanisms for inhibiting ALKBH5 have not been elucidated, such as ALK-04, Ena15, ZINC78774792, and ZINC00546946, although their antiproliferative effects have been revealed in vitro and in vivo. 707 , 712 , 713 In brief, the continued development and in-depth research into ALKBH5 inhibitors hold significant potential for disease treatment, necessitating further efforts.

Targeting the reader of m6A: IGF2BP and YTH domain family

The discovery of m6A readers with specific motifs has spurred significant interest in developing drugs targeting these proteins, expanding the possibilities for therapeutic interventions.

IGF2BP inhibitors

Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs) are newly identified m6A readers that enhance the stability and maintenance of their target mRNAs. 714 IGF2BP plays an oncogenic role in various cancers, making its inhibition a promising strategy for antitumor therapy. 715

Six IGF2BP inhibitors have been developed, demonstrating antitumor effects by disrupting IGF2BP-RNA interactions. BTYNB, the first identified IGF2BP1 inhibitor, suppresses melanoma and ovarian cancer cell proliferation by blocking IGF2BP1’s interaction with c-Myc mRNA. 716 BTYNB’s therapeutic effects are being studied across various tumor models, including esophageal squamous carcinoma, 717 neuroblastoma, 718 and cholangiocarcinoma. 719 CWI1-2 and JX5 are novel IGF2BP2 inhibitors with antileukemic activities that inactivate the Notch1 signaling pathway. CWI1-2 forms a hydrophobic interaction with IGF2BP2’s RNA-binding core, while JX5 binds tightly to the protein. Further research is needed to enhance their safety and reduce cytotoxicity. 720 , 721 Cucurbitacin B, a natural product, exerts a pharmacological allosteric effect on IGF2BP1. In hepatocellular carcinoma mouse models, it modifies IGF2BP1’s configuration, reducing its efficacy. 722 Another compound, “7773,” specifically disrupts the IGF2BP1-Kras mRNA interaction, effectively inhibiting IGF2BP1’s pro-oncogenic activity. 723 Isoliquiritigenin is the only small molecule identified targeting IGF2BP3. 724 Derived from the Chinese herb licorice, it downregulates IGF2BP3 expression, showing promise in treating non-small cell lung cancer. 724

YTH domain family inhibitors

YTH domain family (YTHDF) comprises a group of readers featuring a YTH domain at the C-terminus. This domain forms a hydrophobic pocket essential for recognizing m6A modifications. 725 Elevated levels of YTHDF proteins have been associated with the progression of various cancers. 726 Conversely, reducing these proteins can synergistically enhance the effectiveness of ionizing radiation and anti-PD-L1 therapies in reducing cancer burdens. 727 , 728 This underscores the potential of YTHDF inhibitors as a promising direction for improving antitumor treatments.

The binding sites between YTHDF proteins and m6A modifications are primary targets for most YTHDF inhibitors. 729 The successful elucidation of the crystallographic structures of the YTH domains in YTHDF proteins has provided critical opportunities for drug design. 730 High-throughput screening technology has identified three small molecules—ebselen, DC-Y13, and DC-Y13-27—as effective YTHDF inhibitors. 727 , 731 Ebselen targets YTHDF1 and YTHDF2, either covalently or non-covalently binding to the YTH domain. 731 DC-Y13 and DC-Y13-27, particularly the latter, act as selective inhibitors of YTHDF2, offering therapeutic benefits. 727 Additionally, studies have shown that disrupting O-GlcNAcylation of YTHDF proteins can also decrease their stability and enzymatic activities, providing new avenues for identifying YTH-inhibiting small molecules. 732 , 733

Epigenetics-targeted drugs and chromatin remodeling

SWI/SNF complexes are intricate multimeric structures composed of diverse, variable subunits that play distinct roles, emphasizing the importance of personalized characteristics and frequent mutations in these subunits in various human diseases. Recently, the design of small molecules targeting different components of the SWI/SNF complex has expanded, yielding numerous potential therapeutic interventions. Those that have progressed to clinical trials are detailed in Table 6 . Table 6 Summary of chromatin remodeling-targeted drugs for different diseases in clinical trials Drug Target(s)/mechanisms(s) Condition(s) Status/outcome(s) Phase(s) Other intervention(s)/drug(s) Study ID FHD-286 SMARCA4/2 allosteric inhibitor Metastatic uveal melanoma Terminated (due to business reasons) Phase I — NCT04879017 FHD-286 SMARCA4/2 allosteric inhibitor AML, MDS, CMML Recruiting Phase I With or without low-dose Cytarabine or Decitabine NCT04891757 PRT3789 PROTACs-based SMARCA2 degrader NSCLC and other solid tumors with SMARCA4 gene mutation Recruiting Phase I With or without Docetaxel NCT05639751 FHD-609 PROTACs-based BRD9 degrader Advanced synovial sarcoma Terminated (due to sponsors’ decision) Phase I — NCT04965753 CFT8634 PROTACs-based BRD9 degrader Synovial sarcoma and other SMARCB1-perturbed soft tissue sarcomas Terminated (no significant clinical activity with CFT8634 as a single agent) Phase I/II — NCT05355753 AML acute myeloid leukemia, BRD9 bromodomain containing 9, CMML chronic myelomonocytic leukemia, MDS myelodysplastic syndrome, NSCLC non-small cell lung cancer, PROTAC proteolysis-targeting chimeras, SMARCA4 SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin A4

The active DNA-dependent ATPase A domain inhibitor (ADAADi) was the first discovered inhibitor targeting the SWI/SNF complex. It was identified during studies on mammalian cell resistance to certain antibiotics in vitro. 734 ADAADi binds to specific motifs in the enzyme complex, inducing conformational changes that inhibit SWI2/SNF2’s catalytic activities. 734 Currently, ADAADi shows promising therapeutic effects in prostate cancer in preclinical studies, laying the groundwork for further development of SWI/SNF-targeted epigenetic drugs. 735

Research has also focused on specific inhibitors targeting the SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin A4 (SMARCA4) and its paralog SMARCA2, which are DNA-stimulated ATPases within the SWI/SNF complexes. SMARCA4, commonly mutated in various tumors, is associated with reduced sensitivity to traditional cancer treatments. 736 , 737 Inhibiting SMARCA4/2 is an effective strategy for curbing tumor growth and improving patient outcomes. Papillon et al. 738 reported the earliest selective allosteric inhibitors of the SMARCA4/SMARCA2 subunits, with confirmed effects on pediatric H3K27M diffuse midline glioma and AML in both in vivo and in vitro settings. 739 , 740 FHD-286, a novel orally bioavailable SMARCA4/SMARCA2 allosteric inhibitor, has shown preclinical efficacy. Combined treatment with FHD-286 and other epigenetic drugs, such as decitabine, BET inhibitors, and menin inhibitors, has demonstrated synergistic effects in reducing AML burden without significant toxicity. 741 Notably, FHD-286 has entered clinical development for treating various malignant tumors, including metastatic uveal melanoma ( NCT04879017 ) and several malignant hematological disorders ( NCT04891757 ).

An alternative approach to inhibiting SMARCA4/SMARCA2 involves using specific inhibitors that target their BDs. This strategy extends to other BD-containing proteins within the SWI/SNF complexes, such as polybromo-1 (PBRM1), BD containing 7 (BRD7), and BRD9, also considered promising targets for epigenetic drug development. Notably, SMARCA4/SMARCA2 and BRD9/BRD7 each contain one BD, whereas PBRM1 contains six tandem BDs, providing numerous potential interaction points for inhibitors. 742 Current research primarily focuses on inhibitors for family VIII BD in SMARCA4/SMARCA2 and PBRM1, with four major classes of inhibitors reported: salicylic acid fragment hits such as PFI-3; 743 – 745 aminopyridazines represented by GNE-064; 746 quinazolinones represented by LM146, 747 , 748 and dihydroquinazolinones represented by compound16 and GNE-235. 749 , 750 These inhibitors are categorized as either pan-inhibitors, affecting multiple proteins, or selective inhibitors, targeting specific proteins. PFI-3, its analogs, and GNE-064 are pan-inhibitors, whereas LM146 shows a higher affinity for SMARCA2, and compound16 and GNE-235 are selective for PBRM1. The therapeutic applications of these inhibitors, particularly the pan-inhibitors, have been extensively studied in various diseases. 751 – 755 However, the efficacy of PFI-3 as a standalone treatment for malignancies has been less satisfactory. The application of compound16, on the other hand, demonstrates promising therapeutic effects in PBRM1-dependent prostate cancer, suggesting its potential as a foundational treatment for PBRM1-driven cancers. 749 As for the other molecules, though their binding ability and inhibitory effects have been validated at the molecular level, sufficient evidence is still lacking in vivo or in vitro to demonstrate their clinical value. Furthermore, targeting family IV BD of BRD9 and BRD7 has led to the development of many selective inhibitors. Current research includes inhibitors like BI-7271, 756 BI-7273, 756 BI-9564, 756 I-BRD9, 757 iBRD9, 758 GNE-375, 759 and newly identified inhibitors developed through integrated computational approaches. 760 Selective inhibitors for BRD7, such as 1-78 and 2-77, 761 and molecules like LP99, TP-472, 4-acylpyrroles, and GSK6776, which inhibit both BRD9 and BRD7, are being evaluated for their therapeutic effects in various pathologies. 762 – 765

PROTAC technology plays a significant role in developing SWI/SNF inhibitors, with novel agents such as AU-24118 and AU-15330 being tested in preclinical studies and clinical trials. AU-24118 and AU-15330 are degraders targeting family VIII BD in SMARCA4/SMARCA2 and PBRM1, which are valuable tools in castration-resistant prostate cancer treatment. 766 , 767 AU-24118 has shown promise in inducing tumor regression at therapeutic doses. 766 However, long-term treatment at high doses can lead to mutations in the BD and overexpression of ATP-binding cassette subfamily B member 1 (ABCB1), which contributes to drug resistance development. 766 Combining these treatments with ABCB1 inhibitors could potentially mitigate resistance to SMARCA4/SMARCA2 inhibitors in vivo. Additionally, applying PROTACs to previously reported inhibitors can enhance their selectivity and reduce off-target effects. For instance, the linkage of BI-7273 with an E3 ubiquitin ligase has led to the design of dBRD9-A, the first BRD9-directed degrader, which is undergoing optimization. 768 , 769 The current focus on dBRD9-A, which is being tested for its efficacy in AML, MM, and interferon-induced inflammation in animal models, highlights its potential as a promising therapeutic for both tumor and non-tumor conditions. 768 , 770 , 771 Additional PROTACs-based SWI/SNF inhibitors, such as those derived from dihydropyrrolo-quinazolin scaffolds (targeting SMARCA4, SMARCA2, and PBRM1), 747 A947 (targeting SMARCA2), 772 VZ-185 (targeting BRD9 and BRD7), 773 CFT8634 as well as FHD-609 (targeting BRD9), further illustrate the breadth of ongoing research. 774 Notably, FHD-609 have recently advanced to clinical trials for synovial sarcoma ( NCT04965753 ), underscoring the critical role of drug development targeting mutations in SWI/SNF complexes. Moreover, CFT8634 was originally planned for investigation in a phase 1/2 clinical trial of synovial sarcoma and other SMARCB1-perturbed soft-tissue sarcomas ( NCT05355753 ). However, the clinical trial was terminated because of the less significant clinical activity of CFT8634 as a single agent. Considering the prevalence of mutations in SWI/SNF complexes in cancers, continued research into the in vivo therapeutic effects, potential applications, and long-term risks of these drugs is essential for assessing their clinical utility.

Epigenetics-targeted drugs and non-coding RNA

A deep understanding of ncRNA’s role in disease progression, particularly in various cancers, has led to innovative epigenetic strategies for disease management. 775 RNA interference (RNAi) technologies, which utilize small double-stranded RNA to selectively interact and degrade specific intracellular RNAs, mimic gene deletion phenotypes. 776 , 777 RNAi-based therapies targeting ncRNA are categorized based on their action mechanisms and intended outcomes: silencing overexpressed ncRNAs to curb disease-related expressions, restoring downregulated ncRNAs to regain lost functions, and blocking ncRNA localization to prevent ncRNA from functioning by interfering with its subcellular localization. RNAi-oriented drugs altering ncRNA patterns have been widely studied and applied in clinical practice (Table 7 ). Herein, we summarize the emerging technologies for ncRNA-targeted agent development, aiming at supplementing the current understanding of drug design. Table 7 Summary of non-coding RNA drugs for different diseases in clinical trials Drug Target/Mechanism Condition(s) Status/outcome(s) Phase(s) Other intervention(s)/drug(s) Study ID/references MRG-106 MiR-155 inhibitor CTCL, MF, CLL, DLBCL, and ATCL Completed (unpublished) Phase I Stable background therapy (simultaneously applied in few participants) NCT02580552 MRG-106 MiR-155 inhibitor CTCL, MF Terminated (due to business reasons) Phase II Vorinostat (active comparator) NCT03713320 MRG-106 MiR-155 inhibitor CTCL, MF Terminated (due to eligible subjects receiving treatment in a crossover arm of NCT03713320 ) Phase II — NCT03837457 MRG-110 MiR-92a-3p inhibitor Healthy volunteers Completed (unpublished) Phase I Placebo-controlled NCT03603431 MRG-110 MiR-92a-3p inhibitor Healthy volunteers Completed (significant inhibition on targeted miRNA in vivo) Phase I Placebo-controlled NCT03494712 1151 RG-012 MiR-21 inhibitor AS Completed (unpublished) Phase I — NCT03373786 MRG-201 MiR-29b mimic Healthy volunteers Completed (unpublished) Phase I Placebo-controlled NCT02603224 MRG-201 MiR-29b mimic Keloid Completed (exhibits therapeutic effects and manageable adverse events) Phase II Placebo-controlled NCT03601052 MRX34 MiR-34a mimic Liver cancer, SCLC, lymphoma, melanoma, MM, RCC, NSLCL Terminated (due to serious immune-related adverse events) Phase I — NCT01829971 804 , 1152 MRX34 MiR-34a mimic Melanoma Withdrawn (due to immune-related serious adverse events in the phase I study) Phase I/II Dexamethasone premedication NCT02862145 TargomiRs MiR-16 mimic MPM, NSCLC Completed (exhibits acceptable safety profile and early signs of therapeutic activity) Phase I — NCT02369198 1153 INT-1B3 MiR-193a-3p mimic Advanced solid tumors Terminated (due to the insufficient funding) Phase I — NCT04675996 AS Alport syndrome, ATCL adult T cell leukemia/lymphoma, CLL chronic lymphocytic leukemia, CTCL cutaneous T cell lymphoma, DLBCL diffuse large B cell lymphoma, MF mycosis fungoides, Mi-R microRNA MM multiple myeloma, MPM malignant pleural mesothelioma, NSCLC non-small cell lung cancer, RCC renal cell carcinoma, SCLC small cell lung cancer

Significant advancements in molecular editing and delivery systems have bolstered the clinical viability of these innovative ncRNA-targeted therapies. 778 , 779 One pivotal development has been the chemical modification of synthetic nucleic acids to enhance their stability and delivery efficiency. The initial focus on replacing phosphodiester bonds with phosphorothioate has been a cornerstone in numerous FDA-approved oligonucleotide therapies, 780 although concerns about inflammation and toxicity in vivo have prompted research into alternative modifications for RNA-targeted based on RNAi. 781 Over the years, various modification strategies have emerged, including those based on 2’-O-methyl, 2’-O-methoxyethyl, 2’-fluoro, and n-acetylgalactosaminyl, aiming to preserve the therapeutic attributes of nucleic acids while enhancing their stability. 782 Locked nucleic acids (LNAs) represent a notable innovation, linking the 2’ and 4’ carbons of ribose rings with methylene bridges, thus improving hybridization affinity and resistance to nucleases. 783 Cobomarsen, an LNA-based inhibitor targeting miR-155, exemplifies this technology’s potential, having shown promising results in preclinical studies for hematological malignancies and solid tumors and exhibiting positive effects in mycosis fungoides patients. 784 – 788 In addition, the therapeutic efficacy of cobomarsen has been further validated in patients with mycosis fungoides, indicating well-tolerated and positive clinical potentials ( NCT03713320 ).

Furthermore, integrating nanomedicine-based delivery systems, such as lipid-based, polymeric, inorganic, and biomimetic nanoparticles, has significantly advanced the development of RNAi drugs. These delivery techniques enhance the stability and bioavailability of oligonucleotide drugs and improve their efficacy in modulating target ncRNA expression and functionality. 789 The recent emphasis on nanoparticles designed for targeted delivery of therapeutic nucleic acids to specific subcellular organelles marks a significant advancement in ncRNA therapy. As ncRNAs are present not only in the cytoplasm but also the nucleus and various organelles, targeting these subcellular locations can enhance the efficacy of treatments. 790 , 791 Researchers are exploring opportunities to integrate subcellular organelle-targeting signals into nanoparticle delivery systems. Current studies have reported RNAi nanoparticle systems designed to target the nucleus, mitochondria, endoplasmic reticulum, and Golgi apparatus. 792 – 795 Though nucleus-targeted nanoparticles have been studied in regulating ncRNAs, only a few of them have proposed the incorporation of nucleus-targeting TAT peptide and nucleus-targeting peptide amphiphile into nanoparticle delivery systems to achieve active transportation. 792 Many researchers have only reported the high concentrations of therapeutic oligonucleotides in the nucleus without elucidating the mechanisms involved in nucleus-targeting. This approach leaves a gap in our understanding of the complex and precise intracellular delivery processes that involve biomembrane systems and cytoskeletal interactions. 796 The variability in cell types, delivery materials, and therapeutic nucleic acids means that successful results in specific contexts may not universally apply, highlighting the challenges in translating these strategies from experimental to clinical settings.

Additionally, the integration of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated system (CRISPR/Cas) technologies, particularly CRISPR/Cas9, into ncRNA research offers novel avenues for manipulating ncRNA expression, including lncRNAs and microRNAs (miRNAs). 797 – 800 CRISPR/Cas9’s flexibility and high specificity make it an advantageous tool for gene-targeted cancer therapies, such as CRISPR interference, activation, and knockout strategies, now moving into preclinical trials. This gene-editing technology promises to enhance the efficacy of traditional cancer treatments and aims to minimize off-target effects, thus fostering the development of personalized medicine. 801 , 802

However, several challenges persist despite the growing number of ncRNAs identified as potential therapeutic targets. Technological advancements are still needed, and safety concerns must be rigorously addressed. 803 The premature termination of the Phase I clinical trial for MRX34, a liposomal mimic of miR-34a, due to severe immune reactions and fatalities, underscores the critical need for comprehensive preclinical data and cautious progression to clinical trials. 804

Practical challenges in the epigenetic drug development and application

Massive efforts have been made in epigenetics-targeting drug development, whether approved in different countries for the treatment of specific indications or currently identified and further evaluated in fundamental experiments or clinical trials, exhibiting notable potential. However, there are still practical issues that should be dealt with when applying them to a large scale in clinical practice.

First of all, a thorough understanding of epigenetic mechanisms is crucial for successfully applying epigenetic-targeted drugs. Alterations in epigenetic enzymes can change DNA, histones, or chromatin structures, impacting cellular processes like transcription, replication, and DNA repair. Even minor modifications in epigenetic enzyme activity can significantly affect cellular functions. Therefore, deepening our understanding of epigenetic biology is essential. However, gaps remain in our knowledge, particularly regarding the roles of epigenetic regulation and its proteins in mammals, such as new DNA modifications like m6A, RNA modifications beyond m6A, novel reader domains, and PPI networks related to epigenetic regulation. These areas represent potential targets for novel epigenetic drugs but require further exploration. 805 – 810 Second, many molecules identified through virtual screening and molecular docking techniques are primarily used as molecular probes to study enzyme localization and function. However, transitioning from a potent molecular probe to a viable therapeutic agent involves rigorous in vivo evaluation to confirm their inhibitory effects and therapeutic potential. This step is crucial as it determines whether these compounds can be safely and effectively used in clinical settings. 811 , 812 These small molecules are potent probes to detect the localization and function of targeted enzymes, and their potential for medical use needs confirmation. Notably, another challenge that needs to be overcome is associated with the precise localization and targeted activity of epigenetics-targeted drugs is critical for enhancing their clinical efficacy and reducing potential side effects. The need for precise delivery of epigenetic drugs to subcellular structures is underscored by the diverse localizations and functions of their target enzymes and ncRNAs. For instance, enzymes responsible for histone modifications are found both in the nucleus, where they modify histones, and in the cytoplasm, where they regulate non-histones and related signaling pathways at the post-translational level. 813 , 814 Similarly, the function of ncRNAs depends significantly on their localization and distribution within the cell. 790 To address these challenges, a deeper understanding of the intracellular trafficking mechanisms is required. Additionally, developing sophisticated drug delivery systems, such as lipid-based nanoparticles or targeted delivery vehicles, can enhance the specificity and efficiency of these therapies by directing them to their precise intracellular sites of action. Furthermore, the challenge of achieving selective inhibition within the HDAC family exemplifies the broader issue of specificity in drug design. Many drugs targeting epigenetic enzymes exhibit pan-inhibitory effects, leading to significant off-target effects and adverse reactions, particularly when the drugs indiscriminately affect multiple members of an enzyme family. 408 This necessitates the development of more selective inhibitors that specifically target single proteins or subfamilies of proteins. By focusing on selective inhibition, researchers can potentially improve the safety and efficacy of these treatments, minimizing unwanted interactions and enhancing their therapeutic impact.

Importantly, the possibility of developing resistance to epigenetic-targeted drugs, which is another factor limiting their further application, cannot be ignored. Several studies have investigated the mechanisms involved in the development of resistance to epigenetic agents in different cancers. 815 – 817 The activation of certain signaling pathways and gene mutations in tumor cells play an indispensable role in inducing the development of drug resistance to epigenetic agents. Research has shown that the activation of enhanced Wingless/Integrated (Wnt)/β-catenin signaling contributes to developing resistance to BET inhibitors in leukemia cells. However, inhibition of this pathway helps rescue drug sensitivity in vitro and in vivo. 818 , 819 Furthermore, enhanced activity of the protein kinase B (AKT)/mTOR complex 1 (mTORC1) signaling pathway is also responsible for drug resistance to BET inhibitors in prostate cancer. 820 In another study on HDAC resistance in solid tumors, the potential role of the activation of some kinases and downstream pathways was also reported. 821 Additionally, altered TME may be one of the culprits in promoting drug resistance. Tumor-associated macrophage (TAM), a pivotal mediator in inducing tumor cells to develop resistance to traditional antitumor therapies, has recently been proposed to be involved in the occurrence of epigenetic drug resistance. 822 , 823 A 2020 study on triple-negative breast cancer reported that interleukin-6 (IL-6) and IL-10 derived from TAM activated STAT3 signaling in tumor cells, conferring them with drug resistance to BET inhibitors. 823 Additionally, these findings pave a theoretical foundation for the combination of epigenetics-targeted drugs and other pharmaceutical molecules to optimize their long-term efficacy. 824 The relationship between drug resistance to epigenetic agents and mutations in certain genes is observed in tumor cells, especially in the case of applying EZH2 and IDH inhibitors. 59 , 825 , 826 Based on this idea, the loss-of-function mutation of specific genes by CRISPR/Cas techniques may provide better platforms for coping with drug resistance.

In conclusion, for epigenetics-targeted drugs, it is crucial to balance pharmacokinetics (how the drug is processed in the body), tolerability (how well the drug is tolerated), and therapeutic efficacy (how to avoid off-target off-target toxicities and resistance). Developing optimal dosing regimens that maximize efficacy while minimizing side effects and resistance requires a thorough understanding of the drug’s behavior in the body, including its absorption, distribution, metabolism, and excretion. Innovative dosing strategies, possibly involving controlled release formulations or real-time monitoring of drug levels, could play a vital role in achieving this balance. Continued research into the biological and pathological roles of targets for epigenetic drugs is essential.

Developing trends and forthcoming prospects in epigenetics-targeted drugs

Research on epigenetics-targeted drugs has progressed rapidly, with a growing focus on their potential as next-generation clinical candidates. Current trends, illustrated in Fig. 5 , emphasize the synergy between these agents and other therapeutic modalities such as chemotherapy, radiotherapy, kinase inhibitors, and immunotherapy. This integration promotes precision medicine and personalized treatment strategies and enhances the overall effectiveness of cancer therapies. 827 , 828 Furthermore, developing epigenetic degraders, which can hydrolyze targeted proteins, complements the inhibitory functions of traditional epigenetic drugs. 829 Notably, the swift advancement of sequencing technology has empowered the detection of epigenetic irregularities with growing efficacy, substantially enhancing the integration of epigenetics into personalized medicine. Fig. 5 The promising trends and practical challenges in the clinical application of epigenetics-targeted drugs. From the perspective of clinical practice, epigenetic agents are expected to become promising adjuvants in combination with traditional antitumor therapeutics, contributing to superior efficacy and decreased resistance. Based on this idea, multitarget anticancer agents inhibiting both HDAC and other pathological molecules have gained much attention as a new strategy. Further, epigenetic degraders based on PROTAC or other techniques responsible for TPD help supplement the catalytic function of epigenetic inhibitors. Notably, the successful transport of epigenetic regulators to specific tissues or cells, or even the finite subcellular structures, is the prerequisite for exerting therapeutic effects. The further optimization of different types of nanoparticles makes them inspiring tools for the delivery system

Epigenetics-based combination therapy in cancer cells

The integration of epigenetics-targeted drugs with conventional cancer therapies—such as chemotherapy, targeted therapy, immunotherapy, and hormone therapy—is emerging as a promising strategy for cancer treatment. Increasing experimental studies and clinical trials are assessing the safety and efficacy of various combination regimens. The benefits of these combinations can be categorized into two primary aspects:

Epigenetic drugs can synergize with other cancer therapies by modulating the metabolic and pathological characteristics of cancer cells, immune cells, and stromal cells within the TME. 830 Although immune checkpoint inhibitors (ICIs), which target immune checkpoint proteins (ICPs), such as PD-L1, PD-1, and CTLA-4, show significant potential, their effectiveness may be limited by factors such as insufficient antigen presentation and suboptimal T cell responses in the TME. 831 , 832 Epigenetic modifications can enhance the expression of tumor antigens and ICPs, overcoming these limitations. The use of epigenetic therapies not only disrupts immunosuppressive pathways but also enhances the recruitment of tumor-reactive immune cells, resulting in synergistic effects with ICIs. 136 , 833 – 835

Interfering with aberrant epigenetic features is crucial for combating drug resistance, a major challenge in oncology. Chemoresistance often correlates with changes in DNA methylation and histone acetylation, among other epigenetic characteristics. 139 , 836 , 837 Combining chemotherapeutic agents with epigenetic drugs has become an important strategy to address resistance, 838 , 839 also helping to mitigate chemotherapy-related side effects. 840 , 841 Additionally, reversing epigenetic alterations in chemoresistant tumor cells can restore their sensitivity to conventional therapies, offering a renewed opportunity for treatment. 842 In the context of targeted therapy, inhibitors of mutant kinases initially provide rapid benefits but often lead to the development of resistance over time. 843 The potential of epigenetic treatments, particularly HDAC and DNMT inhibitors, to reverse such resistance is currently being explored. 844 , 845 The development of dual inhibitors, like CUDC907, CUDC101, and 4SC-202, shows promising results in overcoming resistance in kinase-driven cancers and warrants further investigation. 846 For hormone-dependent cancers, such as estrogen receptor-positive breast cancer and androgen receptor-positive prostate cancer, endocrine therapy remains a crucial treatment option. 847 However, epigenetic alterations can lead to resistance during endocrine therapy. 848 , 849 Targeting these epigenetic changes can help sustain the effectiveness of endocrine therapies and reduce the proliferation of cancer cells. 848 , 850

At present, various combination regimens based on HMA and traditional anticancer drugs have entered clinical trials, gaining the potential to become an alternative for patients with certain diseases. For example, the combination of the oral B-cell leukemia/lymphoma 2 inhibitor venetoclax with HMAs has become a standard regimen among patients with AML or MDS who are ineligible for intensive chemotherapy. In November 2018, the FDA approved this combination for AML therapy. 851 – 853 Further, triplet regimens that include HMAs, venetoclax, and other targeted agents are being developed for AML with specific gene mutations. 229 , 854 – 856 Early results from these clinical trials have demonstrated a good safety profile and promising effects, with ongoing studies needed to confirm their efficacy and potential adverse events. In May 2022, the combination of ivosidenib, an IDH1 inhibitor, and azacitidine was approved by the FDA for older patients with newly diagnosed IDH1-mutated AML. 240 Other drugs being combined with HMAs include HDAC inhibitors, polo-like kinase 1 inhibitors, T-cell immunoglobulin domain and mucin domain-3 antibodies, and PD-L1 antibodies. 857 – 860 These combinations are currently under evaluation in ongoing registrational clinical trials across different stages, with promising results anticipated for updating clinical strategies. Additionally, the combination of HMAs with targeted therapy and immunotherapy, as well as chemotherapy, is showing promising application prospects, especially in hematologic malignancies with acquired chemoresistance caused by aberrant DNA methylation. 861 , 862 Currently, azacitidine is approved in multiple countries and is widely used in patients with myeloproliferative disorders, such as MDS, AML, chronic myelomonocytic leukemia (CMML), and juvenile myelomonocytic leukemia, whereas decitabine is approved for the treatment of MDS, AML, and CMML. 863 – 865

Small molecules serving as epigenetics-targeted degraders

As an emerging therapeutic strategy, epigenetics-targeted degraders for targeted protein degradation (TPD), respected by molecules based on PROTAC, autophagy-targeting chimera (AUTAC), hydrophobic tagging (HyT), molecular glue (MG), and other novel techniques for drug discovery are worth trying as a remarkable alternative presenting pioneering approaches. 866

PROTACs, first proposed in 2001, are considered revolutionary technologies in drug discovery. They consist of a ligand for targeted proteins, a ligand for E3 ubiquitin ligase, such as Von Hippel-Lindau and Cereblon (CRBN), and a linker connecting the two ligands. 867 Many degraders targeting diverse epigenetic enzymes have been developed, including the newly designed or derived from the optimization of known selective inhibitors. 868 , 869 This technology has led to the creation of various degraders targeting a wide range of epigenetic enzymes, enhancing their potency, duration of action, safety profile, and ability to counteract resistance mechanisms compared to conventional inhibitors. 867 – 869 For instance, dBET1, derived from the BRD inhibitor JQ-1, was the first PROTAC-based degrader targeting BET proteins. It has demonstrated superior anticancer effects in both AML cell lines and mouse xenograft models compared to JQ-1 alone. 836 , 870 Further optimization led to dBET6, which increased cell permeability significantly improved survival rates in solid tumor models, and reduced the emergence of resistance. 836 Innovative approaches to enhance the selectivity and safety of PROTACs include antibody-PROTAC technology, which combines monoclonal antibodies targeting specific pathological cells with degraders. This strategy facilitates targeted delivery, minimizing side effects while maximizing efficacy. Antibody-PROTACs have been developed for breast cancer cells overexpressing human epidermal growth factor receptor 2 and prostate cancer cells expressing six transmembrane epithelial antigens of the prostate 1, showing enhanced degradation specificity in these cell types. 871 , 872 Compared with general degradation agents, these small molecules present the preferential degradation of target proteins in specific cell lines. Additionally, integrating control elements into PROTAC molecules allows for activation in specific physiological or pathological conditions, reducing potential off-target effects. 873 Techniques such as photocaged PROTACs, photo-switchable PROTACs, and radiotherapy-triggered PROTAC prodrugs represent cutting-edge strategies in this area. These methods ensure that the degradation activity of PROTACs can be spatially and temporally controlled, enhancing their clinical applicability and safety. 874 – 876 Overall, the evolution of PROTACs and other PROTACs-oriented TPD strategies is shaping a promising future for epigenetics-targeted therapies, offering more precise and effective treatment modalities for various diseases, particularly cancer.

Other types of epigenetics-targeted degraders, such as AUTAC-based agents, HyT-based degraders, and MG, offer innovative alternatives to PROTACs for TPD. Each technology employs distinct mechanisms and offers unique advantages for therapeutic applications. Unlike PROTACs, which utilize the proteasomal degradation pathway, AUTAC agents promote lysosome-dependent degradation of target proteins. 877 One of the key benefits of AUTAC degraders is their enhanced membrane permeability due to their typically low molecular weights, making them potent therapeutic candidates. 878 For instance, AUTAC-based degraders targeting BRD4, developed from the covalent interaction between autophagy key proteins and JQ-1, have shown significant antiproliferative activity across multiple tumor cell lines. This demonstrates their potential as effective medical tools for treating various diseases. 879 Introduced in 2011, HyT technology uses small molecules composed of a targeted protein ligand, a hydrophobic tag, and a linker. Unlike PROTACs that often target the ubiquitin-proteasome system, HyT-based degraders work by increasing the hydrophobicity of the target protein, facilitating its degradation. 880 MS1943, an EZH2 HyT degrader, illustrates this technology’s effectiveness. 881 It has shown superior inhibitory effects on tumor cell lines and greater selectivity towards cancer cells over normal cells, demonstrating significant tumor suppression and good tolerance in mouse models. 881 Other HyT-based degraders are also developed, including those targeting HDAC and YEATS domain readers, providing therapeutic strategies for diseases caused by mutations or dysfunction in specific proteins. 882 – 884 Further development of HyT-based degraders is ongoing, with efforts to improve their bioavailability and therapeutic effects in vivo by exploring new hydrophobic labels. 885 MG differs fundamentally from PROTACs and other degraders by inducing degradation through promoting tight binding between the target protein and proteasome components, leading to the protein’s subsequent degradation. 886 , 887 A notable example is the MG-based degrader DD-1-073, targeting HDAC1/3, derived from SAHA (a known HDAC inhibitor). This was among the first applications of MG in HDAC degrader development. 888 Similarly, another MG-based agent targeting BRD4, termed JP-2-197, is further established as an optimal derivative of JQ-1. 888 Due to their low molecular weights, DD-1-073 and JP-2-197 have favorable pharmacokinetic properties, enhancing cell permeability and drug-ability. 888 Despite their potential, the development of MG-based agents faces challenges due to the lack of systematic strategies for their design and identification, making large-scale screening and optimization difficult.

Developing epigenetic-targeting degraders, especially those targeting HDACs and epigenetic readers, has made significant progress, opening new avenues for clinical practice. These novel small molecules offer promising therapeutic alternatives, but several challenges and limitations must be addressed to enhance their clinical applicability and effectiveness.

Combining epigenetics-targeted drugs and sequencing technology

Owing to the substantial relationship among epigenetic signatures, lifestyle choices, and environmental influences, drugs that target epigenetic mechanisms are highly promising for advancing personalized medicine. 889 However, leveraging these drugs in this field is challenging. As disease research enters a new phase owing to advancements in sequencing technologies, the potential for epigenetic therapies to enhance personalized healthcare is being progressively realized. 890

The advent of these cutting-edge technologies, ranging from whole-genome sequencing to single-cell analysis, has facilitated the detection of gene mutations and expression alterations associated with epigenetic changes throughout disease progression. 891 This advancement significantly enhances our understanding of the heterogeneity in epigenetic modifications across various cell types, thereby revealing new therapeutic targets for clinical application. In recent years, advancements in single-cell methodologies have allowed researchers to further explore the multiple dimensions of the epigenome, including chromatin accessibility, DNA methylation patterns, histone modification profiles, and chromatin interaction networks. 892 – 894 Collectively known as “single-cell epigenomics”, this burgeoning field offers an enhanced comprehension of epigenomic regulation in physiological and pathological settings at the level of individual cells from a more intuitive perspective. 895 – 897 These comprehensive “omic” profilings support the distinct biological identity of individuals, thus providing a solid theoretical foundation for refining therapeutic strategies to achieve individual targeting. 898 Furthermore, by integrating CRISPR/cas9 gene-editing technology with various sequencing, researchers can conduct high-throughput functional genomic screens and identify pathological genes that are responsive to epigenetic therapies. This step not only aids in identifying novel targets for epigenetic agents but also promotes the assessment of therapeutic responses of target tissues or cells. 899 , 900 For example, these methods may help detect the occurrence of drug resistance and optimize the efficacy of epigenetic interventions. 901

The significant potential of epigenetics in customizing personalized medicine has generated high enthusiasm, and advancements in this field have been consistently focused in medical research. Notably, the introduction of sequencing technologies has enabled us to investigate the correlation between epigenetic markers and disease pathology more comprehensively, thus facilitating the development of targeted therapeutic strategies. Nonetheless, the current epigenetic technologies used in the laboratory present several technical challenges that require refinement, such as the necessity for high-demand algorithms, 902 sufficient amounts of training data, 903 limited genome coverage per cell, 904 , 905 and uncertain reproducibility. 906 These techniques require significant improvement before they can be effectively used in clinical practice.

Conclusions and perspectives

Since the term “epigenetics” was first introduced in 1942, there has been a significant focus on elucidating the mechanisms and pivotal roles of epigenetic modifications and their associated enzymes in human physiology and pathology. Drugs targeting epigenetic enzymes have shown promising potential for treating diseases, particularly cancers. This review comprehensively examines the major epigenetic mechanisms involved in the pathogenesis and progression of various diseases. It also highlights recent advances in epigenetics-targeted drugs, underscoring their potential in clinical settings. Additionally, we explore the integration of novel technologies in drug development and the synergistic value of these drugs in conjunction with other cancer therapies, pointing to the future direction of epigenetics-oriented therapeutic strategies. Despite these advancements, significant challenges remain. For instance, certain enzymes that regulate the epigenetic landscape still lack effective targeted drugs, and those identified through virtual screening require further in vivo and in vitro investigation to validate their efficacy and safety profiles. Addressing these gaps will be crucial for integrating epigenetics-targeted drugs into clinical practice.

Advances in in-depth understanding of epigenetics have largely enhanced possibilities of curing disease. To date, the application of epigenetics-modifying drugs in preclinical and clinical setting has provided promise for the beginning of the era of epigenetic-orientated therapeutic strategies. Given the future needs in this field, great attention should be focused on exploring the heterogeneity of epigenetic hallmarks in different diseases to design and develop epigenetics-targeted drugs with high selectivity and improved targeting efficiency, based on the elucidation for the biological and pathological roles of epigenetics. These results are imperative for designing and developing agonists and inhibitors of epigenetic enzymes with enhanced selectivity and bioactivity. Furthermore, apart from the knowledge based on experimental research and preclinical studies, assessing the therapeutic potential of epigenetic drugs for specific diseases, particularly in advanced clinical trials, is also vital for advancing this field. Concurrently, emphasis should be placed on the clinical potential of integrating innovative drug discovery technologies into developing epigenetic-based drugs. Moreover, while capitalizing on unique strengths of epigenetics, efforts should be made to combine these novel agents with traditional therapeutic modalities, with a view to achieving synergic effects in treating disease, especially in the case of tumors with genomic complexity. In conclusion, we believe that deepened research in this field will catalyze innovation in treatment approaches for diseases involving epigenetic mechanisms, offering new hope to patients.

These authors contributed equally: Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, Renhao Guo, Peng Bai.

Acknowledgements

This work was supported by the National Natural Science Foundation grant of China (No. 82371647, 82071607, 82071651, 82403489); National Key Research and Development Program (2022YFC3600304, 2022YFC2704700); Science and Technology Department of Sichuan Province (23ZDYF2489); Cadre Health Care Committee of Sichuan Province, China (2023-1701); Chengdu Science and Technology Bureau (2021-YF05-02106-SN, 2017-GH02-00030-HZ); Outstanding Scientific Fund of Shengjing Hospital (No. 202003); Sichuan University 0-1 Innovation Research project (2023SCUH0019); The Frontiers Medical Center, Tianfu Jincheng Laboratory Foundation (T FJC2023010001); China Postdoctoral Science Foundation (No. 2023M733902, 2023M743909); PHD Research Initiated Fund Project in Liaoning Province (No. 2023-BSBA-331, 2023-BSBA-352); Science and Technology Plan of Liaoning Province (2022JH2/20200066); 345 Talent Project of Shengjing Hospital of China Medical University (No. M1344).

Author contributions

D.L., X.X., and Z.N. proposed the topic and main idea. W.D., X.Q., and Y.F. wrote the original manuscript and drew the figures. W.D., R.G., and P.B. were responsible for the revision of the manuscript. W.D., X.Q., Y.F., and S.L. were responsible for collecting data and making tables. W.D., T.L., Y.J., and S.W. were responsible for the literature search. D.L., X.X., and Z.N. commented on and revised the manuscript. All authors have read and approved the article.

Competing interests

The authors declare no competing interests.

References

1. Allis CD Jenuwein T The molecular hallmarks of epigenetic control Nat. Rev. Genet. 2016 17 487 500 10.1038/nrg.2016.59 27346641 Allis, C. D. & Jenuwein, T. The molecular hallmarks of epigenetic control. Nat. Rev. Genet. 17 , 487–500 (2016). 27346641 10.1038/nrg.2016.59

2. Parry A Rulands S Reik W Active turnover of DNA methylation during cell fate decisions Nat. Rev. Genet. 2021 22 59 66 10.1038/s41576-020-00287-8 33024290 Parry, A., Rulands, S. & Reik, W. Active turnover of DNA methylation during cell fate decisions. Nat. Rev. Genet. 22 , 59–66 (2021). 33024290 10.1038/s41576-020-00287-8

3. Millán-Zambrano G Burton A Bannister AJ Schneider R Histone post-translational modifications - cause and consequence of genome function Nat. Rev. Genet. 2022 23 563 580 10.1038/s41576-022-00468-7 35338361 Millán-Zambrano, G., Burton, A., Bannister, A. J. & Schneider, R. Histone post-translational modifications - cause and consequence of genome function. Nat. Rev. Genet. 23 , 563–580 (2022). 35338361 10.1038/s41576-022-00468-7

4. Delaunay S Helm M Frye M RNA modifications in physiology and disease: towards clinical applications Nat. Rev. Genet. 2024 25 104 122 10.1038/s41576-023-00645-2 37714958 Delaunay, S., Helm, M. & Frye, M. RNA modifications in physiology and disease: towards clinical applications. Nat. Rev. Genet. 25 , 104–122 (2024). 37714958 10.1038/s41576-023-00645-2

5. Eustermann S Energy-driven genome regulation by ATP-dependent chromatin remodellers Nat. Rev. Mol. Cell. Biol. 2024 25 309 332 10.1038/s41580-023-00683-y 38081975 PMC12303036 Eustermann, S. et al. Energy-driven genome regulation by ATP-dependent chromatin remodellers. Nat. Rev. Mol. Cell. Biol. 25 , 309–332 (2024). 38081975 10.1038/s41580-023-00683-y PMC12303036

6. Tian Y Exploring non-coding RNA mechanisms in hepatocellular carcinoma: implications for therapy and prognosis Front. Immunol. 2024 15 1400744 10.3389/fimmu.2024.1400744 38799446 PMC11116607 Tian, Y. et al. Exploring non-coding RNA mechanisms in hepatocellular carcinoma: implications for therapy and prognosis. Front. Immunol. 15 , 1400744 (2024). 38799446 10.3389/fimmu.2024.1400744 PMC11116607

7. Wang Y Epigenetic modification of m(6)A regulator proteins in cancer Mol. Cancer 2023 22 102 10.1186/s12943-023-01810-1 37391814 PMC10311752 Wang, Y. et al. Epigenetic modification of m(6)A regulator proteins in cancer. Mol. Cancer 22 , 102 (2023). 37391814 10.1186/s12943-023-01810-1 PMC10311752

8. Liu R Methylation across the central dogma in health and diseases: new therapeutic strategies Signal. Transduct. Target. Ther. 2023 8 310 10.1038/s41392-023-01528-y 37620312 PMC10449936 Liu, R. et al. Methylation across the central dogma in health and diseases: new therapeutic strategies. Signal. Transduct. Target. Ther. 8 , 310 (2023). 37620312 10.1038/s41392-023-01528-y PMC10449936

9. Gourisankar S Krokhotin A Wenderski W Crabtree GR Context-specific functions of chromatin remodellers in development and disease Nat. Rev. Genet. 2024 25 340 361 10.1038/s41576-023-00666-x 38001317 PMC11867214 Gourisankar, S., Krokhotin, A., Wenderski, W. & Crabtree, G. R. Context-specific functions of chromatin remodellers in development and disease. Nat. Rev. Genet. 25 , 340–361 (2024). 38001317 10.1038/s41576-023-00666-x PMC11867214

10. Zhou S Targeting tumor endothelial cells with methyltransferase inhibitors: mechanisms of action and the potential of combination therapy Pharmacol. Ther. 2023 247 108434 10.1016/j.pharmthera.2023.108434 37172786 Zhou, S. et al. Targeting tumor endothelial cells with methyltransferase inhibitors: mechanisms of action and the potential of combination therapy. Pharmacol. Ther. 247 , 108434 (2023). 37172786 10.1016/j.pharmthera.2023.108434

11. Zhang X Zhang Y Wang C Wang X TET (Ten-eleven translocation) family proteins: structure, biological functions and applications Signal. Transduct. Target. Ther. 2023 8 297 10.1038/s41392-023-01537-x 37563110 PMC10415333 Zhang, X., Zhang, Y., Wang, C. & Wang, X. TET (Ten-eleven translocation) family proteins: structure, biological functions and applications. Signal. Transduct. Target. Ther. 8 , 297 (2023). 37563110 10.1038/s41392-023-01537-x PMC10415333

12. Shi J The concurrence of DNA methylation and demethylation is associated with transcription regulation Nat. Commun. 2021 12 5285 10.1038/s41467-021-25521-7 34489442 PMC8421433 Shi, J. et al. The concurrence of DNA methylation and demethylation is associated with transcription regulation. Nat. Commun. 12 , 5285 (2021). 34489442 10.1038/s41467-021-25521-7 PMC8421433

13. Lin TC Light-activatable MBD-readers of 5-methylcytosine reveal domain-dependent chromatin association kinetics in vivo Adv. Sci. 2024 11 e2307930 10.1002/advs.202307930 PMC10953577 38164822 Lin, T. C. et al. Light-activatable MBD-readers of 5-methylcytosine reveal domain-dependent chromatin association kinetics in vivo. Adv. Sci. 11 , e2307930 (2024). 10.1002/advs.202307930 PMC10953577 38164822

14. Zhang P Methyl-CpG binding domain protein 1 regulates localization and activity of Tet1 in a CXXC3 domain-dependent manner Nucl. Acids Res. 2017 45 7118 7136 10.1093/nar/gkx281 28449087 PMC5499542 Zhang, P. et al. Methyl-CpG binding domain protein 1 regulates localization and activity of Tet1 in a CXXC3 domain-dependent manner. Nucl. Acids Res. 45 , 7118–7136 (2017). 28449087 10.1093/nar/gkx281 PMC5499542

15. Martin BJE Global identification of SWI/SNF targets reveals compensation by EP400 Cell 2023 186 5290 5307.e5226 10.1016/j.cell.2023.10.006 37922899 PMC11307202 Martin, B. J. E. et al. Global identification of SWI/SNF targets reveals compensation by EP400. Cell 186 , 5290–5307.e5226 (2023). 37922899 10.1016/j.cell.2023.10.006 PMC11307202

16. Nemeth K Bayraktar R Ferracin M Calin GA Non-coding RNAs in disease: from mechanisms to therapeutics Nat. Rev. Genet. 2024 25 211 232 10.1038/s41576-023-00662-1 37968332 Nemeth, K., Bayraktar, R., Ferracin, M. & Calin, G. A. Non-coding RNAs in disease: from mechanisms to therapeutics. Nat. Rev. Genet. 25 , 211–232 (2024). 37968332 10.1038/s41576-023-00662-1

17. Fabbri M Girnita L Varani G Calin GA Decrypting noncoding RNA interactions, structures, and functional networks Genom. Res. 2019 29 1377 1388 10.1101/gr.247239.118 PMC6724670 31434680 Fabbri, M., Girnita, L., Varani, G. & Calin, G. A. Decrypting noncoding RNA interactions, structures, and functional networks. Genom. Res. 29 , 1377–1388 (2019). 10.1101/gr.247239.118 PMC6724670 31434680

18. Wilkinson AL Zorzan I Rugg-Gunn PJ Epigenetic regulation of early human embryo development Cell. Stem Cell. 2023 30 1569 1584 10.1016/j.stem.2023.09.010 37858333 Wilkinson, A. L., Zorzan, I. & Rugg-Gunn, P. J. Epigenetic regulation of early human embryo development. Cell. Stem Cell. 30 , 1569–1584 (2023). 37858333 10.1016/j.stem.2023.09.010

19. van Voorden AJ EP300 facilitates human trophoblast stem cell differentiation Proc. Natl Acad. Sci. USA 2023 120 e2217405120 10.1073/pnas.2217405120 37406095 PMC10334808 van Voorden, A. J. et al. EP300 facilitates human trophoblast stem cell differentiation. Proc. Natl Acad. Sci. USA 120 , e2217405120 (2023). 37406095 10.1073/pnas.2217405120 PMC10334808

20. Gao L Structure of DNMT3B homo-oligomer reveals vulnerability to impairment by ICF mutations Nat. Commun. 2022 13 4249 10.1038/s41467-022-31933-w 35869095 PMC9307851 Gao, L. et al. Structure of DNMT3B homo-oligomer reveals vulnerability to impairment by ICF mutations. Nat. Commun. 13 , 4249 (2022). 35869095 10.1038/s41467-022-31933-w PMC9307851

21. Tsang E Ketogenic diet modifies ribosomal protein dysregulation in KMT2D Kabuki syndrome EBioMedicine 2024 104 105156 10.1016/j.ebiom.2024.105156 38768529 PMC11134553 Tsang, E. et al. Ketogenic diet modifies ribosomal protein dysregulation in KMT2D Kabuki syndrome. EBioMedicine 104 , 105156 (2024). 38768529 10.1016/j.ebiom.2024.105156 PMC11134553

22. Duan JE Methylome dynamics of bovine gametes and in vivo early embryos Front. Genet. 2019 10 512 10.3389/fgene.2019.00512 31191619 PMC6546829 Duan, J. E. et al. Methylome dynamics of bovine gametes and in vivo early embryos. Front. Genet. 10 , 512 (2019). 31191619 10.3389/fgene.2019.00512 PMC6546829

23. Miura F Enomoto Y Dairiki R Ito T Amplification-free whole-genome bisulfite sequencing by post-bisulfite adaptor tagging Nucleic Acids Res. 2012 40 e136 10.1093/nar/gks454 22649061 PMC3458524 Miura, F., Enomoto, Y., Dairiki, R. & Ito, T. Amplification-free whole-genome bisulfite sequencing by post-bisulfite adaptor tagging. Nucleic Acids Res. 40 , e136 (2012). 22649061 10.1093/nar/gks454 PMC3458524

24. Greenberg MVC Bourc’his D The diverse roles of DNA methylation in mammalian development and disease Nat. Rev. Mol. Cell. Biol. 2019 20 590 607 10.1038/s41580-019-0159-6 31399642 Greenberg, M. V. C. & Bourc’his, D. The diverse roles of DNA methylation in mammalian development and disease. Nat. Rev. Mol. Cell. Biol. 20 , 590–607 (2019). 31399642 10.1038/s41580-019-0159-6

25. Lee HJ Hore TA Reik W Reprogramming the methylome: erasing memory and creating diversity Cell. Stem Cell. 2014 14 710 719, 10.1016/j.stem.2014.05.008 24905162 PMC4051243 Lee, H. J., Hore, T. A. & Reik, W. Reprogramming the methylome: erasing memory and creating diversity. Cell. Stem Cell. 14 , 710–719, (2014). 24905162 10.1016/j.stem.2014.05.008 PMC4051243

26. Wu K Dynamics of histone acetylation during human early embryogenesis Cell. Discov. 2023 9 29 10.1038/s41421-022-00514-y 36914622 PMC10011383 Wu, K. et al. Dynamics of histone acetylation during human early embryogenesis. Cell. Discov. 9 , 29 (2023). 36914622 10.1038/s41421-022-00514-y PMC10011383

27. Regadas I A unique histone 3 lysine 14 chromatin signature underlies tissue-specific gene regulation Mol. Cell. 2021 81 1766 1780.e1710 10.1016/j.molcel.2021.01.041 33631105 Regadas, I. et al. A unique histone 3 lysine 14 chromatin signature underlies tissue-specific gene regulation. Mol. Cell. 81 , 1766–1780.e1710 (2021). 33631105 10.1016/j.molcel.2021.01.041

28. Yu H Dynamic reprogramming of H3K9me3 at hominoid-specific retrotransposons during human preimplantation development Cell. Stem Cell. 2022 29 1031 1050.e1012 10.1016/j.stem.2022.06.006 35803225 Yu, H. et al. Dynamic reprogramming of H3K9me3 at hominoid-specific retrotransposons during human preimplantation development. Cell. Stem Cell. 29 , 1031–1050.e1012 (2022). 35803225 10.1016/j.stem.2022.06.006

29. Ovadia, S. et al. SWI/SNF complexes are required for retinal pigmented epithelium differentiation and for the inhibition of cell proliferation and neural differentiation programs. Development 150 , dev201488 (2023). 10.1242/dev.201488 PMC10482007 37522516

30. Saha D Animireddy S Bartholomew B The SWI/SNF ATP-dependent chromatin remodeling complex in cell lineage priming and early development Biochem. Soc. Trans. 2024 52 603 616 10.1042/BST20230416 38572912 PMC11088921 Saha, D., Animireddy, S. & Bartholomew, B. The SWI/SNF ATP-dependent chromatin remodeling complex in cell lineage priming and early development. Biochem. Soc. Trans. 52 , 603–616 (2024). 38572912 10.1042/BST20230416 PMC11088921

31. Yao Y Regulatory role of m(6)A epitranscriptomic modifications in normal development and congenital malformations during embryogenesis Biomed. Pharmacother. 2024 173 116171 10.1016/j.biopha.2024.116171 38394844 Yao, Y. et al. Regulatory role of m(6)A epitranscriptomic modifications in normal development and congenital malformations during embryogenesis. Biomed. Pharmacother. 173 , 116171 (2024). 38394844 10.1016/j.biopha.2024.116171

32. Wang MK Gao CC Yang YG Emerging roles of RNA methylation in development Acc. Chem. Res. 2023 56 3417 3427 10.1021/acs.accounts.3c00448 37965760 Wang, M. K., Gao, C. C. & Yang, Y. G. Emerging roles of RNA methylation in development. Acc. Chem. Res. 56 , 3417–3427 (2023). 37965760 10.1021/acs.accounts.3c00448

33. Han Y A Mettl16/m(6)A/mybl2b/Igf2bp1 axis ensures cell cycle progression of embryonic hematopoietic stem and progenitor cells EMBO J. 2024 43 1990 2014 10.1038/s44318-024-00082-9 38605226 PMC11099167 Han, Y. et al. A Mettl16/m(6)A/mybl2b/Igf2bp1 axis ensures cell cycle progression of embryonic hematopoietic stem and progenitor cells. EMBO J. 43 , 1990–2014 (2024). 38605226 10.1038/s44318-024-00082-9 PMC11099167

34. Guo J Zebrafish Mbd5 binds to RNA m5C and regulates histone deubiquitylation and gene expression in development metabolism and behavior Nucleic Acids Res. 2024 52 4257 4275 10.1093/nar/gkae093 38366571 PMC11077058 Guo, J. et al. Zebrafish Mbd5 binds to RNA m5C and regulates histone deubiquitylation and gene expression in development metabolism and behavior. Nucleic Acids Res. 52 , 4257–4275 (2024). 38366571 10.1093/nar/gkae093 PMC11077058

35. Zhang M DNA methylation regulates RNA m(6)A modification through transcription factor SP1 during the development of porcine somatic cell nuclear transfer embryos Cell. Prolif. 2024 57 e13581 10.1111/cpr.13581 38095020 PMC11056710 Zhang, M. et al. DNA methylation regulates RNA m(6)A modification through transcription factor SP1 during the development of porcine somatic cell nuclear transfer embryos. Cell. Prolif. 57 , e13581 (2024). 38095020 10.1111/cpr.13581 PMC11056710

36. Hupalowska A CARM1 and paraspeckles regulate pre-implantation mouse embryo development Cell 2018 175 1902 1916.e1913 10.1016/j.cell.2018.11.027 30550788 PMC6292842 Hupalowska, A. et al. CARM1 and paraspeckles regulate pre-implantation mouse embryo development. Cell 175 , 1902–1916.e1913 (2018). 30550788 10.1016/j.cell.2018.11.027 PMC6292842

37. Wang J Asymmetric expression of lincGET biases cell fate in two-cell mouse embryos Cell 2018 175 1887 1901.e1818 10.1016/j.cell.2018.11.039 30550787 Wang, J. et al. Asymmetric expression of lincGET biases cell fate in two-cell mouse embryos. Cell 175 , 1887–1901.e1818 (2018). 30550787 10.1016/j.cell.2018.11.039

38. Wang, J. et al. Alternative splicing of CARM1 regulated by LincGET-guided paraspeckles biases the first cell fate in mammalian early embryos. Nat. Struct. Mol. Biol . 31 , 1341–1354 (2024). 10.1038/s41594-024-01292-9 PMC11402786 38658621

39. Reza A Roles of microRNAs in mammalian reproduction: from the commitment of germ cells to peri-implantation embryos Biol. Rev. Camb. Philos. Soc. 2019 94 415 438 10.1111/brv.12459 30151880 PMC7379200 Reza, A. et al. Roles of microRNAs in mammalian reproduction: from the commitment of germ cells to peri-implantation embryos. Biol. Rev. Camb. Philos. Soc. 94 , 415–438 (2019). 30151880 10.1111/brv.12459 PMC7379200

40. Kong X LncRNA-Smad7 mediates cross-talk between Nodal/TGF-β and BMP signaling to regulate cell fate determination of pluripotent and multipotent cells Nucleic Acids Res. 2022 50 10526 10543 10.1093/nar/gkac780 36134711 PMC9561265 Kong, X. et al. LncRNA-Smad7 mediates cross-talk between Nodal/TGF-β and BMP signaling to regulate cell fate determination of pluripotent and multipotent cells. Nucleic Acids Res. 50 , 10526–10543 (2022). 36134711 10.1093/nar/gkac780 PMC9561265

41. Hazra R Platr4 is an early embryonic lncRNA that exerts its function downstream on cardiogenic mesodermal lineage commitment Dev. Cell. 2022 57 2450 2468.e2457 10.1016/j.devcel.2022.10.002 36347239 PMC9680017 Hazra, R. et al. Platr4 is an early embryonic lncRNA that exerts its function downstream on cardiogenic mesodermal lineage commitment. Dev. Cell. 57 , 2450–2468.e2457 (2022). 36347239 10.1016/j.devcel.2022.10.002 PMC9680017

42. Movahed E Aberrant expression of miR-29a/29b and methylation level of mouse embryos after in vitro fertilization and vitrification at two-cell stage J. Cell. Physiol. 2019 234 18942 18950 10.1002/jcp.28534 30916357 Movahed, E. et al. Aberrant expression of miR-29a/29b and methylation level of mouse embryos after in vitro fertilization and vitrification at two-cell stage. J. Cell. Physiol. 234 , 18942–18950 (2019). 30916357 10.1002/jcp.28534

43. Wilson VL Jones PA DNA methylation decreases in aging but not in immortal cells Science 1983 220 1055 1057 10.1126/science.6844925 6844925 Wilson, V. L. & Jones, P. A. DNA methylation decreases in aging but not in immortal cells. Science 220 , 1055–1057 (1983). 6844925 10.1126/science.6844925

44. Yang JH Loss of epigenetic information as a cause of mammalian aging Cell 2023 186 305 326.e327 10.1016/j.cell.2022.12.027 36638792 PMC10166133 Yang, J. H. et al. Loss of epigenetic information as a cause of mammalian aging. Cell 186 , 305–326.e327 (2023). 36638792 10.1016/j.cell.2022.12.027 PMC10166133

45. Johnstone SE Gladyshev VN Aryee MJ Bernstein BE Epigenetic clocks, aging, and cancer Science 2022 378 1276 1277 10.1126/science.abn4009 36548410 Johnstone, S. E., Gladyshev, V. N., Aryee, M. J. & Bernstein, B. E. Epigenetic clocks, aging, and cancer. Science 378 , 1276–1277 (2022). 36548410 10.1126/science.abn4009

46. Tao Y Aging-like spontaneous epigenetic silencing facilitates wnt activation, stemness, and braf(V600E)-induced tumorigenesis Cancer Cell. 2019 35 315 328.e316 10.1016/j.ccell.2019.01.005 30753828 PMC6636642 Tao, Y. et al. Aging-like spontaneous epigenetic silencing facilitates wnt activation, stemness, and braf(V600E)-induced tumorigenesis. Cancer Cell. 35 , 315–328.e316 (2019). 30753828 10.1016/j.ccell.2019.01.005 PMC6636642

47. Amatori S Bagaloni I Viti D Fanelli M Premature senescence induced by DNA demethylating agent (Decitabine) as therapeutic option for malignant pleural mesothelioma Lung Cancer 2011 71 113 115 10.1016/j.lungcan.2010.10.016 21095037 Amatori, S., Bagaloni, I., Viti, D. & Fanelli, M. Premature senescence induced by DNA demethylating agent (Decitabine) as therapeutic option for malignant pleural mesothelioma. Lung Cancer 71 , 113–115 (2011). 21095037 10.1016/j.lungcan.2010.10.016

48. Bi S SIRT7 antagonizes human stem cell aging as a heterochromatin stabilizer Protein Cell. 2020 11 483 504 10.1007/s13238-020-00728-4 32504224 PMC7305295 Bi, S. et al. SIRT7 antagonizes human stem cell aging as a heterochromatin stabilizer. Protein Cell. 11 , 483–504 (2020). 32504224 10.1007/s13238-020-00728-4 PMC7305295

49. Zhang, N. et al. Dual Inhibition of H3K9me2 and H3K27me3 Promotes Tumor Cell Senescence without Triggering the Secretion of SASP. Int. J. Mol. Sci . 23 , 3911 (2022). 10.3390/ijms23073911 PMC8999616 35409271

50. Rossi M Increased PTCHD4 expression via m6A modification of PTCHD4 mRNA promotes senescent cell survival Nucleic Acids Res. 2024 52 7261 7278 10.1093/nar/gkae322 38721764 PMC11229380 Rossi, M. et al. Increased PTCHD4 expression via m6A modification of PTCHD4 mRNA promotes senescent cell survival. Nucleic Acids Res. 52 , 7261–7278 (2024). 38721764 10.1093/nar/gkae322 PMC11229380

51. Heissenberger, C. et al. The ribosomal RNA m(5)C methyltransferase NSUN-1 modulates healthspan and oogenesis in Caenorhabditis elegans. Elife . 9 , (2020). 10.7554/eLife.56205 PMC7746234 33289480

52. Krarup, J. et al . A brain anti-senescence transcriptional program triggered by hypothalamic-derived exosomal microRNAs. Int J Mol Sci . 25 , e56205 (2024). 10.3390/ijms25105467 PMC11122052 38791505

53. Lee AV Nestler KA Chiappinelli KB Therapeutic targeting of DNA methylation alterations in cancer Pharmacol. Ther. 2024 258 108640 10.1016/j.pharmthera.2024.108640 38570075 Lee, A. V., Nestler, K. A. & Chiappinelli, K. B. Therapeutic targeting of DNA methylation alterations in cancer. Pharmacol. Ther. 258 , 108640 (2024). 38570075 10.1016/j.pharmthera.2024.108640

54. Yamaguchi K Non-canonical functions of UHRF1 maintain DNA methylation homeostasis in cancer cells Nat. Commun. 2024 15 2960 10.1038/s41467-024-47314-4 38580649 PMC10997609 Yamaguchi, K. et al. Non-canonical functions of UHRF1 maintain DNA methylation homeostasis in cancer cells. Nat. Commun. 15 , 2960 (2024). 38580649 10.1038/s41467-024-47314-4 PMC10997609

55. Janic A Abad E Amelio I Decoding p53 tumor suppression: a crosstalk between genomic stability and epigenetic control? Cell Death Differ. 2024 2024 1 8 10.1038/s41418-024-01259-9 PMC11742645 38379088 Janic, A., Abad, E. & Amelio, I. Decoding p53 tumor suppression: a crosstalk between genomic stability and epigenetic control? Cell Death Differ. 2024 , 1–8 (2024). 10.1038/s41418-024-01259-9 PMC11742645 38379088

56. Xue, F., Liu, L., Tao, X. & Zhu, W. TET3-mediated DNA demethylation modification activates SHP2 expression to promote endometrial cancer progression through the EGFR/ERK pathway. J. Gynecol. Oncol . 35 , e64 (2024). 10.3802/jgo.2024.35.e64 PMC11390245 38456588

57. Brückmann NH Pedersen CB Ditzel HJ Gjerstorff MF Epigenetic reprogramming of pericentromeric satellite DNA in premalignant and malignant lesions Mol. Cancer Res. 2018 16 417 427 10.1158/1541-7786.MCR-17-0477 29330295 Brückmann, N. H., Pedersen, C. B., Ditzel, H. J. & Gjerstorff, M. F. Epigenetic reprogramming of pericentromeric satellite DNA in premalignant and malignant lesions. Mol. Cancer Res. 16 , 417–427 (2018). 29330295 10.1158/1541-7786.MCR-17-0477

58. Ma S Recent advances in targeting histone H3 lysine 36 methyltransferases for cancer therapy Eur. J. Med. Chem. 2024 274 116532 10.1016/j.ejmech.2024.116532 38805937 Ma, S. et al. Recent advances in targeting histone H3 lysine 36 methyltransferases for cancer therapy. Eur. J. Med. Chem. 274 , 116532 (2024). 38805937 10.1016/j.ejmech.2024.116532

59. Yamagishi M Mechanisms of action and resistance in histone methylation-targeted therapy Nature 2024 627 221 228 10.1038/s41586-024-07103-x 38383791 PMC10917674 Yamagishi, M. et al. Mechanisms of action and resistance in histone methylation-targeted therapy. Nature 627 , 221–228 (2024). 38383791 10.1038/s41586-024-07103-x PMC10917674

60. Wang ZQ Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy Signal. Transduct. Target. Ther. 2023 8 420 10.1038/s41392-023-01647-6 37926722 PMC10625992 Wang, Z. Q. et al. Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy. Signal. Transduct. Target. Ther. 8 , 420 (2023). 37926722 10.1038/s41392-023-01647-6 PMC10625992

61. Guo J Zheng Q Peng Y BET proteins: biological functions and therapeutic interventions Pharmacol. Ther. 2023 243 108354 10.1016/j.pharmthera.2023.108354 36739915 Guo, J., Zheng, Q. & Peng, Y. BET proteins: biological functions and therapeutic interventions. Pharmacol. Ther. 243 , 108354 (2023). 36739915 10.1016/j.pharmthera.2023.108354

62. Wang X Bromodomain protein BRDT directs ΔNp63 function and super-enhancer activity in a subset of esophageal squamous cell carcinomas Cell. Death Differ. 2021 28 2207 2220 10.1038/s41418-021-00751-w 33658703 PMC8257622 Wang, X. et al. Bromodomain protein BRDT directs ΔNp63 function and super-enhancer activity in a subset of esophageal squamous cell carcinomas. Cell. Death Differ. 28 , 2207–2220 (2021). 33658703 10.1038/s41418-021-00751-w PMC8257622

63. Lee JK Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma Ann. Oncol. 2017 28 890 897 10.1093/annonc/mdw686 28203693 PMC5378225 Lee, J. K. et al. Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma. Ann. Oncol. 28 , 890–897 (2017). 28203693 10.1093/annonc/mdw686 PMC5378225

64. Hu Y Lactylation: the novel histone modification influence on gene expression, protein function, and disease Clin. Epigenetics 2024 16 72 10.1186/s13148-024-01682-2 38812044 PMC11138093 Hu, Y. et al. Lactylation: the novel histone modification influence on gene expression, protein function, and disease. Clin. Epigenetics 16 , 72 (2024). 38812044 10.1186/s13148-024-01682-2 PMC11138093

65. Zhang Y Song H Li M Lu P Histone lactylation bridges metabolic reprogramming and epigenetic rewiring in driving carcinogenesis: oncometabolite fuels oncogenic transcription Clin. Transl. Med. 2024 14 e1614 10.1002/ctm2.1614 38456209 PMC10921234 Zhang, Y., Song, H., Li, M. & Lu, P. Histone lactylation bridges metabolic reprogramming and epigenetic rewiring in driving carcinogenesis: oncometabolite fuels oncogenic transcription. Clin. Transl. Med. 14 , e1614 (2024). 38456209 10.1002/ctm2.1614 PMC10921234

66. Wei S Histone lactylation promotes malignant progression by facilitating USP39 expression to target PI3K/AKT/HIF-1α signal pathway in endometrial carcinoma Cell. Death Discov. 2024 10 121 10.1038/s41420-024-01898-4 38459014 PMC10923933 Wei, S. et al. Histone lactylation promotes malignant progression by facilitating USP39 expression to target PI3K/AKT/HIF-1α signal pathway in endometrial carcinoma. Cell. Death Discov. 10 , 121 (2024). 38459014 10.1038/s41420-024-01898-4 PMC10923933

67. Li F Positive feedback regulation between glycolysis and histone lactylation drives oncogenesis in pancreatic ductal adenocarcinoma Mol. Cancer 2024 23 90 10.1186/s12943-024-02008-9 38711083 PMC11071201 Li, F. et al. Positive feedback regulation between glycolysis and histone lactylation drives oncogenesis in pancreatic ductal adenocarcinoma. Mol. Cancer 23 , 90 (2024). 38711083 10.1186/s12943-024-02008-9 PMC11071201

68. De Leo A Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma Immunity 2024 57 1105 1123.e1108 10.1016/j.immuni.2024.04.006 38703775 PMC11114377 De Leo, A. et al. Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma. Immunity 57 , 1105–1123.e1108 (2024). 38703775 10.1016/j.immuni.2024.04.006 PMC11114377

69. Chen XY CircUGGT2 downregulation by METTL14-dependent m(6)A modification suppresses gastric cancer progression and cisplatin resistance through interaction with miR-186-3p/MAP3K9 axis Pharmacol. Res. 2024 204 107206 10.1016/j.phrs.2024.107206 38729588 Chen, X. Y. et al. CircUGGT2 downregulation by METTL14-dependent m(6)A modification suppresses gastric cancer progression and cisplatin resistance through interaction with miR-186-3p/MAP3K9 axis. Pharmacol. Res. 204 , 107206 (2024). 38729588 10.1016/j.phrs.2024.107206

70. Jin H YTHDF2 favors protumoral macrophage polarization and implies poor survival outcomes in triple negative breast cancer iScience 2024 27 109902 10.1016/j.isci.2024.109902 38812540 PMC11134561 Jin, H. et al. YTHDF2 favors protumoral macrophage polarization and implies poor survival outcomes in triple negative breast cancer. iScience 27 , 109902 (2024). 38812540 10.1016/j.isci.2024.109902 PMC11134561

71. Wang S ALKBH5-mediated m6A modification of circFOXP1 promotes gastric cancer progression by regulating SOX4 expression and sponging miR-338-3p Commun. Biol. 2024 7 565 10.1038/s42003-024-06274-7 38745044 PMC11094028 Wang, S. et al. ALKBH5-mediated m6A modification of circFOXP1 promotes gastric cancer progression by regulating SOX4 expression and sponging miR-338-3p. Commun. Biol. 7 , 565 (2024). 38745044 10.1038/s42003-024-06274-7 PMC11094028

72. Wang Q The demethylase ALKBH5 mediates ZKSCAN3 expression through the m(6)A modification to activate VEGFA transcription and thus participates in MNNG-induced gastric cancer progression J. Hazard. Mater. 2024 473 134690 10.1016/j.jhazmat.2024.134690 38781857 Wang, Q. et al. The demethylase ALKBH5 mediates ZKSCAN3 expression through the m(6)A modification to activate VEGFA transcription and thus participates in MNNG-induced gastric cancer progression. J. Hazard. Mater. 473 , 134690 (2024). 38781857 10.1016/j.jhazmat.2024.134690

73. Zhao, L. et al. Abnormal changes in metabolites caused by m(6)A methylation modification: the leading factors that induce the formation of immunosuppressive tumor microenvironment and their promising potential for clinical application. J. Adv. Res . S2090-1232 (2024). 10.1016/j.jare.2024.04.016 38677545

74. Feng G Small molecule inhibitors targeting m(6)A regulators J. Hematol. Oncol. 2024 17 30 10.1186/s13045-024-01546-5 38711100 PMC11075261 Feng, G. et al. Small molecule inhibitors targeting m(6)A regulators. J. Hematol. Oncol. 17 , 30 (2024). 38711100 10.1186/s13045-024-01546-5 PMC11075261

75. Calin GA Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia Proc. Natl Acad. Sci. USA 2002 99 15524 15529 10.1073/pnas.242606799 12434020 PMC137750 Calin, G. A. et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 99 , 15524–15529 (2002). 12434020 10.1073/pnas.242606799 PMC137750

76. Wells AC Let-7 enhances murine anti-tumor CD8 T cell responses by promoting memory and antagonizing terminal differentiation Nat. Commun. 2023 14 5585 10.1038/s41467-023-40959-7 37696797 PMC10495470 Wells, A. C. et al. Let-7 enhances murine anti-tumor CD8 T cell responses by promoting memory and antagonizing terminal differentiation. Nat. Commun. 14 , 5585 (2023). 37696797 10.1038/s41467-023-40959-7 PMC10495470

77. Chen H LINC00355 promotes gastric carcinogenesis by scaffolding p300 to activate CDC42 transcription and enhancing HNRNPA2B1 to stabilize CDC42 mRNA dependent on m6A Mol. Carcinog. 2024 63 430 447 10.1002/mc.23662 37983727 Chen, H. et al. LINC00355 promotes gastric carcinogenesis by scaffolding p300 to activate CDC42 transcription and enhancing HNRNPA2B1 to stabilize CDC42 mRNA dependent on m6A. Mol. Carcinog. 63 , 430–447 (2024). 37983727 10.1002/mc.23662

78. Luongo M The molecular conversations of sarcomas: exosomal non-coding RNAs in tumor’s biology and their translational prospects Mol. Cancer 2024 23 172 10.1186/s12943-024-02083-y 39174949 PMC11340101 Luongo, M. et al. The molecular conversations of sarcomas: exosomal non-coding RNAs in tumor’s biology and their translational prospects. Mol. Cancer 23 , 172 (2024). 39174949 10.1186/s12943-024-02083-y PMC11340101

79. Li Y Sui S Goel A Extracellular vesicles associated microRNAs: their biology and clinical significance as biomarkers in gastrointestinal cancers Semin. Cancer Biol. 2024 99 5 23 10.1016/j.semcancer.2024.02.001 38341121 PMC11774199 Li, Y., Sui, S. & Goel, A. Extracellular vesicles associated microRNAs: their biology and clinical significance as biomarkers in gastrointestinal cancers. Semin. Cancer Biol. 99 , 5–23 (2024). 38341121 10.1016/j.semcancer.2024.02.001 PMC11774199

80. Kumar MA Extracellular vesicles as tools and targets in therapy for diseases Signal. Transduct. Target. Ther. 2024 9 27 10.1038/s41392-024-01735-1 38311623 PMC10838959 Kumar, M. A. et al. Extracellular vesicles as tools and targets in therapy for diseases. Signal. Transduct. Target. Ther. 9 , 27 (2024). 38311623 10.1038/s41392-024-01735-1 PMC10838959

81. Peng, X. X. et al. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer. J Immunother Cancer . 8 , e000376 (2020). 10.1136/jitc-2019-000376 PMC7057418 31959728

82. Mjelle R Serum small RNAs in metastatic colorectal cancer predict response to chemotherapy and characterize high-risk patients Mol. Cancer 2024 23 133 10.1186/s12943-024-02042-7 38937787 PMC11209991 Mjelle, R. et al. Serum small RNAs in metastatic colorectal cancer predict response to chemotherapy and characterize high-risk patients. Mol. Cancer 23 , 133 (2024). 38937787 10.1186/s12943-024-02042-7 PMC11209991

83. Yang CK EV-miRome-wide profiling uncovers miR-320c for detecting metastatic colorectal cancer and monitoring the therapeutic response Cell. Oncol. 2022 45 621 638 10.1007/s13402-022-00688-3 PMC9424175 35849310 Yang, C. K. et al. EV-miRome-wide profiling uncovers miR-320c for detecting metastatic colorectal cancer and monitoring the therapeutic response. Cell. Oncol. 45 , 621–638 (2022). 10.1007/s13402-022-00688-3 PMC9424175 35849310

84. Su Y Plasma extracellular vesicle long RNA profiles in the diagnosis and prediction of treatment response for breast cancer NPJ Breast Cancer 2021 7 154 10.1038/s41523-021-00356-z 34893642 PMC8664804 Su, Y. et al. Plasma extracellular vesicle long RNA profiles in the diagnosis and prediction of treatment response for breast cancer. NPJ Breast Cancer 7 , 154 (2021). 34893642 10.1038/s41523-021-00356-z PMC8664804

85. Alberti KG Zimmet P Shaw J The metabolic syndrome–a new worldwide definition Lancet 2005 366 1059 1062, 10.1016/S0140-6736(05)67402-8 16182882 Alberti, K. G., Zimmet, P. & Shaw, J. The metabolic syndrome–a new worldwide definition. Lancet 366 , 1059–1062, (2005). 16182882 10.1016/S0140-6736(05)67402-8

86. Han Y New advances of adiponectin in regulating obesity and related metabolic syndromes J. Pharmacol. Anal. 2024 14 100913 10.1016/j.jpha.2023.12.003 PMC11127227 38799237 Han, Y. et al. New advances of adiponectin in regulating obesity and related metabolic syndromes. J. Pharmacol. Anal. 14 , 100913 (2024). 10.1016/j.jpha.2023.12.003 PMC11127227 38799237

87. Wu YL Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study Signal. Transduct. Target. Ther. 2023 8 98 10.1038/s41392-023-01333-7 36864020 PMC9981733 Wu, Y. L. et al. Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study. Signal. Transduct. Target. Ther. 8 , 98 (2023). 36864020 10.1038/s41392-023-01333-7 PMC9981733

88. Alka K Mohammad G Kowluru RA Regulation of serine palmitoyl-transferase and Rac1-Nox2 signaling in diabetic retinopathy Sci. Rep. 2022 12 16740 10.1038/s41598-022-20243-2 36202842 PMC9537524 Alka, K., Mohammad, G. & Kowluru, R. A. Regulation of serine palmitoyl-transferase and Rac1-Nox2 signaling in diabetic retinopathy. Sci. Rep. 12 , 16740 (2022). 36202842 10.1038/s41598-022-20243-2 PMC9537524

89. Zhang Q A maternal high-fat diet induces dna methylation changes that contribute to glucose intolerance in offspring Front. Endocrinol. 2019 10 871 10.3389/fendo.2019.00871 PMC6923194 31920981 Zhang, Q. et al. A maternal high-fat diet induces dna methylation changes that contribute to glucose intolerance in offspring. Front. Endocrinol. 10 , 871 (2019). 10.3389/fendo.2019.00871 PMC6923194 31920981

90. Georgel PT Georgel P Where epigenetics meets food intake: their interaction in the development/severity of gout and therapeutic perspectives Front. Immunol. 2021 12 752359 10.3389/fimmu.2021.752359 34603340 PMC8484966 Georgel, P. T. & Georgel, P. Where epigenetics meets food intake: their interaction in the development/severity of gout and therapeutic perspectives. Front. Immunol. 12 , 752359 (2021). 34603340 10.3389/fimmu.2021.752359 PMC8484966

91. Chen HC Chen YZ Wang CH Lin FJ The nonalcoholic fatty liver disease-like phenotype and lowered serum VLDL are associated with decreased expression and DNA hypermethylation of hepatic ApoB in male offspring of ApoE deficient mothers fed a with Western diet J. Nutr. Biochem. 2020 77 108319 10.1016/j.jnutbio.2019.108319 31926452 Chen, H. C., Chen, Y. Z., Wang, C. H. & Lin, F. J. The nonalcoholic fatty liver disease-like phenotype and lowered serum VLDL are associated with decreased expression and DNA hypermethylation of hepatic ApoB in male offspring of ApoE deficient mothers fed a with Western diet. J. Nutr. Biochem. 77 , 108319 (2020). 31926452 10.1016/j.jnutbio.2019.108319

92. Davison GW Irwin RE Walsh CP The metabolic-epigenetic nexus in type 2 diabetes mellitus Free Radic. Biol. Med. 2021 170 194 206 10.1016/j.freeradbiomed.2020.12.025 33429021 Davison, G. W., Irwin, R. E. & Walsh, C. P. The metabolic-epigenetic nexus in type 2 diabetes mellitus. Free Radic. Biol. Med. 170 , 194–206 (2021). 33429021 10.1016/j.freeradbiomed.2020.12.025

93. Domínguez-Barragán J Blood DNA methylation signature of diet quality and association with cardiometabolic traits Eur. J. Prev. Cardiol. 2024 31 191 202 10.1093/eurjpc/zwad317 37793095 PMC10809172 Domínguez-Barragán, J. et al. Blood DNA methylation signature of diet quality and association with cardiometabolic traits. Eur. J. Prev. Cardiol. 31 , 191–202 (2024). 37793095 10.1093/eurjpc/zwad317 PMC10809172

94. Nadiger N Veed JK Chinya Nataraj P Mukhopadhyay A DNA methylation and type 2 diabetes: a systematic review Clin. Epigenetics 2024 16 67 10.1186/s13148-024-01670-6 38755631 PMC11100087 Nadiger, N., Veed, J. K., Chinya Nataraj, P. & Mukhopadhyay, A. DNA methylation and type 2 diabetes: a systematic review. Clin. Epigenetics 16 , 67 (2024). 38755631 10.1186/s13148-024-01670-6 PMC11100087

95. Xiao F Epigenetic regulation of B cells and its role in autoimmune pathogenesis Cell. Mol. Immunol. 2022 19 1215 1234 10.1038/s41423-022-00933-7 36220996 PMC9622816 Xiao, F. et al. Epigenetic regulation of B cells and its role in autoimmune pathogenesis. Cell. Mol. Immunol. 19 , 1215–1234 (2022). 36220996 10.1038/s41423-022-00933-7 PMC9622816

96. Liu H Regulation of T cell differentiation and function by epigenetic modification enzymes Semin. Immunopathol. 2019 41 315 326 10.1007/s00281-019-00731-w 30963214 Liu, H. et al. Regulation of T cell differentiation and function by epigenetic modification enzymes. Semin. Immunopathol. 41 , 315–326 (2019). 30963214 10.1007/s00281-019-00731-w

97. Han X RNA m(6)A methylation modulates airway inflammation in allergic asthma via PTX3-dependent macrophage homeostasis Nat. Commun. 2023 14 7328 10.1038/s41467-023-43219-w 37957139 PMC10643624 Han, X. et al. RNA m(6)A methylation modulates airway inflammation in allergic asthma via PTX3-dependent macrophage homeostasis. Nat. Commun. 14 , 7328 (2023). 37957139 10.1038/s41467-023-43219-w PMC10643624

98. Ahmadi M Epigenetic modifications and epigenetic based medication implementations of autoimmune diseases Biomed. Pharmacother. 2017 87 596 608 10.1016/j.biopha.2016.12.072 28086135 Ahmadi, M. et al. Epigenetic modifications and epigenetic based medication implementations of autoimmune diseases. Biomed. Pharmacother. 87 , 596–608 (2017). 28086135 10.1016/j.biopha.2016.12.072

99. Cardenas A Fadadu RP Koppelman GH Epigenome-wide association studies of allergic disease and the environment J. Allergy Clin. Immunol. 2023 152 582 590 10.1016/j.jaci.2023.05.020 37295475 PMC10564109 Cardenas, A., Fadadu, R. P. & Koppelman, G. H. Epigenome-wide association studies of allergic disease and the environment. J. Allergy Clin. Immunol. 152 , 582–590 (2023). 37295475 10.1016/j.jaci.2023.05.020 PMC10564109

100. Yue X Control of Foxp3 stability through modulation of TET activity J. Exp. Med. 2016 213 377 397 10.1084/jem.20151438 26903244 PMC4813667 Yue, X. et al. Control of Foxp3 stability through modulation of TET activity. J. Exp. Med. 213 , 377–397 (2016). 26903244 10.1084/jem.20151438 PMC4813667

101. Souza NH Low-level laser therapy suppresses the oxidative stress-induced glucocorticoids resistance in U937 cells: relevance to cytokine secretion and histone deacetylase in alveolar macrophages J. Photochem. Photobiol. B 2014 130 327 336 10.1016/j.jphotobiol.2013.12.010 24419178 Souza, N. H. et al. Low-level laser therapy suppresses the oxidative stress-induced glucocorticoids resistance in U937 cells: relevance to cytokine secretion and histone deacetylase in alveolar macrophages. J. Photochem. Photobiol. B 130 , 327–336 (2014). 24419178 10.1016/j.jphotobiol.2013.12.010

102. Kim RY MicroRNA-21 drives severe, steroid-insensitive experimental asthma by amplifying phosphoinositide 3-kinase-mediated suppression of histone deacetylase 2 J. Allergy Clin. Immunol. 2017 139 519 532 10.1016/j.jaci.2016.04.038 27448447 Kim, R. Y. et al. MicroRNA-21 drives severe, steroid-insensitive experimental asthma by amplifying phosphoinositide 3-kinase-mediated suppression of histone deacetylase 2. J. Allergy Clin. Immunol. 139 , 519–532 (2017). 27448447 10.1016/j.jaci.2016.04.038

103. Wu H The IL-21-TET2-AIM2-c-MAF pathway drives the T follicular helper cell response in lupus-like disease Clin. Transl. Med. 2022 12 e781 10.1002/ctm2.781 35343082 PMC8958352 Wu, H. et al. The IL-21-TET2-AIM2-c-MAF pathway drives the T follicular helper cell response in lupus-like disease. Clin. Transl. Med. 12 , e781 (2022). 35343082 10.1002/ctm2.781 PMC8958352

104. Chen F Circulating exosomal microRNAs as biomarkers of lupus nephritis Front. Immunol. 2023 14 1326836 10.3389/fimmu.2023.1326836 38223506 PMC10785001 Chen, F. et al. Circulating exosomal microRNAs as biomarkers of lupus nephritis. Front. Immunol. 14 , 1326836 (2023). 38223506 10.3389/fimmu.2023.1326836 PMC10785001

105. Jog NR Neutrophils isolated from systemic lupus erythematosus patients exhibit a distinct functional phenotype Front. Immunol. 2024 15 1339250 10.3389/fimmu.2024.1339250 38524128 PMC10957542 Jog, N. R. et al. Neutrophils isolated from systemic lupus erythematosus patients exhibit a distinct functional phenotype. Front. Immunol. 15 , 1339250 (2024). 38524128 10.3389/fimmu.2024.1339250 PMC10957542

106. Regna NL Class I and II histone deacetylase inhibition by ITF2357 reduces SLE pathogenesis in vivo Clin. Immunol. 2014 151 29 42 10.1016/j.clim.2014.01.002 24503172 PMC3963170 Regna, N. L. et al. Class I and II histone deacetylase inhibition by ITF2357 reduces SLE pathogenesis in vivo. Clin. Immunol. 151 , 29–42 (2014). 24503172 10.1016/j.clim.2014.01.002 PMC3963170

107. Banham GD Bromodomain inhibitors modulate FcγR-mediated mononuclear phagocyte activation and chemotaxis Front. Immunol. 2022 13 885101 10.3389/fimmu.2022.885101 35619690 PMC9127238 Banham, G. D. et al. Bromodomain inhibitors modulate FcγR-mediated mononuclear phagocyte activation and chemotaxis. Front. Immunol. 13 , 885101 (2022). 35619690 10.3389/fimmu.2022.885101 PMC9127238

108. Fang Y Epigenetic regulatory axis MIR22-TET3-MTRNR2L2 represses fibroblast-like synoviocyte-mediated inflammation in rheumatoid arthritis Arthritis Rheumatol. 2024 76 845 856 10.1002/art.42795 38221658 Fang, Y. et al. Epigenetic regulatory axis MIR22-TET3-MTRNR2L2 represses fibroblast-like synoviocyte-mediated inflammation in rheumatoid arthritis. Arthritis Rheumatol. 76 , 845–856 (2024). 38221658 10.1002/art.42795

109. Lee HJ Stefan-Lifshitz M Li CW Tomer Y Genetics and epigenetics of autoimmune thyroid diseases: translational implications Best. Pr. Res. Clin. Endocrinol. Metab. 2023 37 101661 10.1016/j.beem.2022.101661 PMC9550878 35459628 Lee, H. J., Stefan-Lifshitz, M., Li, C. W. & Tomer, Y. Genetics and epigenetics of autoimmune thyroid diseases: translational implications. Best. Pr. Res. Clin. Endocrinol. Metab. 37 , 101661 (2023). 10.1016/j.beem.2022.101661 PMC9550878 35459628

110. Lee HG Disease-associated astrocyte epigenetic memory promotes CNS pathology Nature 2024 627 865 872 10.1038/s41586-024-07187-5 38509377 PMC11016191 Lee, H. G. et al. Disease-associated astrocyte epigenetic memory promotes CNS pathology. Nature 627 , 865–872 (2024). 38509377 10.1038/s41586-024-07187-5 PMC11016191

111. Al-Hasani K EZH2 inhibitors promote β-like cell regeneration in young and adult type 1 diabetes donors Signal. Transduct. Target. Ther. 2024 9 2 10.1038/s41392-023-01707-x 38161208 PMC10757994 Al-Hasani, K. et al. EZH2 inhibitors promote β-like cell regeneration in young and adult type 1 diabetes donors. Signal. Transduct. Target. Ther. 9 , 2 (2024). 38161208 10.1038/s41392-023-01707-x PMC10757994

112. Qi W Abnormal histone acetylation of CD8(+) T cells in patients with severe aplastic anemia Int. J. Hematol. 2016 104 540 547 10.1007/s12185-016-2061-8 27485471 Qi, W. et al. Abnormal histone acetylation of CD8(+) T cells in patients with severe aplastic anemia. Int. J. Hematol. 104 , 540–547 (2016). 27485471 10.1007/s12185-016-2061-8

113. Lavertu-Jolin M Acan downregulation in parvalbumin GABAergic cells reduces spontaneous recovery of fear memories Mol. Psychiatry 2023 28 2946 2963 10.1038/s41380-023-02085-0 37131076 PMC10615765 Lavertu-Jolin, M. et al. Acan downregulation in parvalbumin GABAergic cells reduces spontaneous recovery of fear memories. Mol. Psychiatry 28 , 2946–2963 (2023). 37131076 10.1038/s41380-023-02085-0 PMC10615765

114. Gomez-Pinilla F Thapak P Exercise epigenetics is fueled by cell bioenergetics: supporting role on brain plasticity and cognition Free Radic. Biol. Med. 2024 220 43 55 10.1016/j.freeradbiomed.2024.04.237 38677488 PMC11144461 Gomez-Pinilla, F. & Thapak, P. Exercise epigenetics is fueled by cell bioenergetics: supporting role on brain plasticity and cognition. Free Radic. Biol. Med. 220 , 43–55 (2024). 38677488 10.1016/j.freeradbiomed.2024.04.237 PMC11144461

115. Prasanth, M. I. et al. Role of epigenetic modulation in neurodegenerative diseases: implications of phytochemical interventions. Antioxidants 13 , 606.(2024). 10.3390/antiox13050606 PMC11118909 38790711

116. Xu DC Histone acetylation in an Alzheimer’s disease cell model promotes homeostatic amyloid-reducing pathways Acta Neuropathol. Commun. 2024 12 3 10.1186/s40478-023-01696-6 38167174 PMC10759377 Xu, D. C. et al. Histone acetylation in an Alzheimer’s disease cell model promotes homeostatic amyloid-reducing pathways. Acta Neuropathol. Commun. 12 , 3 (2024). 38167174 10.1186/s40478-023-01696-6 PMC10759377

117. Pan RY Positive feedback regulation of microglial glucose metabolism by histone H4 lysine 12 lactylation in Alzheimer’s disease Cell. Metab. 2022 34 634 648.e636 10.1016/j.cmet.2022.02.013 35303422 Pan, R. Y. et al. Positive feedback regulation of microglial glucose metabolism by histone H4 lysine 12 lactylation in Alzheimer’s disease. Cell. Metab. 34 , 634–648.e636 (2022). 35303422 10.1016/j.cmet.2022.02.013

118. Wei L H3K18 lactylation of senescent microglia potentiates brain aging and Alzheimer’s disease through the NFκB signaling pathway J. Neuroinflammation 2023 20 208 10.1186/s12974-023-02879-7 37697347 PMC10494370 Wei, L. et al. H3K18 lactylation of senescent microglia potentiates brain aging and Alzheimer’s disease through the NFκB signaling pathway. J. Neuroinflammation 20 , 208 (2023). 37697347 10.1186/s12974-023-02879-7 PMC10494370

119. Park H CRISPR/dCas9-Dnmt3a-mediated targeted DNA methylation of APP rescues brain pathology in a mouse model of Alzheimer’s disease Transl. Neurodegener. 2022 11 41 10.1186/s40035-022-00314-0 36109806 PMC9476342 Park, H. et al. CRISPR/dCas9-Dnmt3a-mediated targeted DNA methylation of APP rescues brain pathology in a mouse model of Alzheimer’s disease. Transl. Neurodegener. 11 , 41 (2022). 36109806 10.1186/s40035-022-00314-0 PMC9476342

120. Bie B Epigenetic suppression of neuroligin 1 underlies amyloid-induced memory deficiency Nat. Neurosci. 2014 17 223 231 10.1038/nn.3618 24441681 Bie, B. et al. Epigenetic suppression of neuroligin 1 underlies amyloid-induced memory deficiency. Nat. Neurosci. 17 , 223–231 (2014). 24441681 10.1038/nn.3618

121. Jörg M N1-methylation of adenosine (m(1)A) in ND5 mRNA leads to complex I dysfunction in Alzheimer’s disease Mol. Psychiatry 2024 29 1427 1439 10.1038/s41380-024-02421-y 38287100 PMC11189808 Jörg, M. et al. N1-methylation of adenosine (m(1)A) in ND5 mRNA leads to complex I dysfunction in Alzheimer’s disease. Mol. Psychiatry 29 , 1427–1439 (2024). 38287100 10.1038/s41380-024-02421-y PMC11189808

122. Lahiri DK The seeds of its regulation: natural antisense transcripts as single-gene control switches in neurodegenerative disorders Ageing Res. Rev. 2024 99 102336 10.1016/j.arr.2024.102336 38740308 PMC11492926 Lahiri, D. K. et al. The seeds of its regulation: natural antisense transcripts as single-gene control switches in neurodegenerative disorders. Ageing Res. Rev. 99 , 102336 (2024). 38740308 10.1016/j.arr.2024.102336 PMC11492926

123. Gonzalez-Latapi P Alterations in blood methylome as potential epigenetic biomarker in sporadic Parkinson’s disease Ann. Neurol. 2024 95 1162 1172 10.1002/ana.26923 38563317 Gonzalez-Latapi, P. et al. Alterations in blood methylome as potential epigenetic biomarker in sporadic Parkinson’s disease. Ann. Neurol. 95 , 1162–1172 (2024). 38563317 10.1002/ana.26923

124. Navarro-Sánchez, L., Águeda-Gómez, B., Aparicio, S. & Pérez-Tur, J. Epigenetic study in Parkinson’s disease: a pilot analysis of DNA methylation in candidate genes in brain. Cells . 7 , 150 (2018). 10.3390/cells7100150 PMC6210421 30261625

125. Marshall LL Epigenomic analysis of Parkinson’s disease neurons identifies Tet2 loss as neuroprotective Nat. Neurosci. 2020 23 1203 1214 10.1038/s41593-020-0690-y 32807949 Marshall, L. L. et al. Epigenomic analysis of Parkinson’s disease neurons identifies Tet2 loss as neuroprotective. Nat. Neurosci. 23 , 1203–1214 (2020). 32807949 10.1038/s41593-020-0690-y

126. Guhathakurta S Targeted attenuation of elevated histone marks at SNCA alleviates α-synuclein in Parkinson’s disease EMBO Mol. Med. 2021 13 e12188 10.15252/emmm.202012188 33428332 PMC7863397 Guhathakurta, S. et al. Targeted attenuation of elevated histone marks at SNCA alleviates α-synuclein in Parkinson’s disease. EMBO Mol. Med. 13 , e12188 (2021). 33428332 10.15252/emmm.202012188 PMC7863397

127. Huang, M. et al. Mitochondrial dysfunction-induced H3K27 hyperacetylation perturbs enhancers in Parkinson’s disease. JCI Insight . 6 , e138088 (2021). 10.1172/jci.insight.138088 PMC8492320 34494552

128. Thapa R ncRNAs and their impact on dopaminergic neurons: autophagy pathways in Parkinson’s disease Ageing Res. Rev. 2024 98 102327 10.1016/j.arr.2024.102327 38734148 Thapa, R. et al. ncRNAs and their impact on dopaminergic neurons: autophagy pathways in Parkinson’s disease. Ageing Res. Rev. 98 , 102327 (2024). 38734148 10.1016/j.arr.2024.102327

129. Zsindely, N., Siági, F. & Bodai, L. DNA methylation in Huntington’s disease. Int. J. Mol. Sci . 22 , 4529 (2021). 10.3390/ijms222312736 PMC8657460 34884540

130. Hecklau K The effects of selective inhibition of histone deacetylase 1 and 3 in Huntington’s disease mice Front. Mol. Neurosci. 2021 14 616886 10.3389/fnmol.2021.616886 33679321 PMC7925995 Hecklau, K. et al. The effects of selective inhibition of histone deacetylase 1 and 3 in Huntington’s disease mice. Front. Mol. Neurosci. 14 , 616886 (2021). 33679321 10.3389/fnmol.2021.616886 PMC7925995

131. Beatriz M Extracellular vesicles improve GABAergic transmission in Huntington’s disease iPSC-derived neurons Theranostics 2023 13 3707 3724 10.7150/thno.81981 37441602 PMC10334823 Beatriz, M. et al. Extracellular vesicles improve GABAergic transmission in Huntington’s disease iPSC-derived neurons. Theranostics 13 , 3707–3724 (2023). 37441602 10.7150/thno.81981 PMC10334823

132. Pupak A Altered m6A RNA methylation contributes to hippocampal memory deficits in Huntington’s disease mice Cell. Mol. Life Sci. 2022 79 416 10.1007/s00018-022-04444-6 35819730 PMC9276730 Pupak, A. et al. Altered m6A RNA methylation contributes to hippocampal memory deficits in Huntington’s disease mice. Cell. Mol. Life Sci. 79 , 416 (2022). 35819730 10.1007/s00018-022-04444-6 PMC9276730

133. Pang, L. et al. Epigenetic regulation of tumor immunity. J. Clin. Investig . 134 , e178540 (2024). 10.1172/JCI178540 PMC11178542 39133578

134. Mabe NW Perry JA Malone CF Stegmaier K Pharmacological targeting of the cancer epigenome Nat. Cancer 2024 5 844 865 10.1038/s43018-024-00777-2 38937652 PMC11936478 Mabe, N. W., Perry, J. A., Malone, C. F. & Stegmaier, K. Pharmacological targeting of the cancer epigenome. Nat. Cancer 5 , 844–865 (2024). 38937652 10.1038/s43018-024-00777-2 PMC11936478

135. Watanabe, J. et al. BET bromodomain inhibition potentiates radiosensitivity in models of H3K27-altered diffuse midline glioma. J. Clin. Investig . 134 , e174794 (2024). 10.1172/JCI174794 PMC11213469 38771655

136. Qin S New insights into immune cells in cancer immunotherapy: from epigenetic modification, metabolic modulation to cell communication MedComm 2024 5 e551 10.1002/mco2.551 38783893 PMC11112485 Qin, S. et al. New insights into immune cells in cancer immunotherapy: from epigenetic modification, metabolic modulation to cell communication. MedComm 5 , e551 (2024). 38783893 10.1002/mco2.551 PMC11112485

137. Tang F Therapeutic applications of histone deacetylase inhibitors in sarcoma Cancer Treat. Rev. 2017 59 33 45 10.1016/j.ctrv.2017.06.006 28732326 PMC5581728 Tang, F. et al. Therapeutic applications of histone deacetylase inhibitors in sarcoma. Cancer Treat. Rev. 59 , 33–45 (2017). 28732326 10.1016/j.ctrv.2017.06.006 PMC5581728

138. Zhuang H The role of m6A methylation in therapy resistance in cancer Mol. Cancer 2023 22 91 10.1186/s12943-023-01782-2 37264402 PMC10233906 Zhuang, H. et al. The role of m6A methylation in therapy resistance in cancer. Mol. Cancer 22 , 91 (2023). 37264402 10.1186/s12943-023-01782-2 PMC10233906

139. Bharti R Cell surface CD55 traffics to the nucleus leading to cisplatin resistance and stemness by inducing PRC2 and H3K27 trimethylation on chromatin in ovarian cancer Mol. Cancer 2024 23 121 10.1186/s12943-024-02028-5 38853277 PMC11163727 Bharti, R. et al. Cell surface CD55 traffics to the nucleus leading to cisplatin resistance and stemness by inducing PRC2 and H3K27 trimethylation on chromatin in ovarian cancer. Mol. Cancer 23 , 121 (2024). 38853277 10.1186/s12943-024-02028-5 PMC11163727

140. Xu Y ZNF397 deficiency triggers TET2-driven lineage plasticity and AR-targeted therapy resistance in prostate cancer Cancer Discov. 2024 14 1496 1521 10.1158/2159-8290.CD-23-0539 38591846 PMC11285331 Xu, Y. et al. ZNF397 deficiency triggers TET2-driven lineage plasticity and AR-targeted therapy resistance in prostate cancer. Cancer Discov. 14 , 1496–1521 (2024). 38591846 10.1158/2159-8290.CD-23-0539 PMC11285331

141. Wang F Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial Nat. Med. 2024 30 1035 1043 10.1038/s41591-024-02813-1 38438735 Wang, F. et al. Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial. Nat. Med. 30 , 1035–1043 (2024). 38438735 10.1038/s41591-024-02813-1

142. Issa, J. P. & Kantarjian, H. Azacitidine. Nat Rev Drug Discov . Suppl , S6-S7, (2005). 10.1038/nrd1726 15962522

143. Gore SD Jones C Kirkpatrick P Decitabine Nat. Rev. Drug. Discov. 2006 5 891 892 10.1038/nrd2180 17117522 Gore, S. D., Jones, C. & Kirkpatrick, P. Decitabine. Nat. Rev. Drug. Discov. 5 , 891–892 (2006). 17117522 10.1038/nrd2180

144. Silverman LR Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B J. Clin. Oncol. 2002 20 2429 2440 10.1200/JCO.2002.04.117 12011120 Silverman, L. R. et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. 20 , 2429–2440 (2002). 12011120 10.1200/JCO.2002.04.117

145. Fenaux P Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Lancet Oncol. 2009 10 223 232 10.1016/S1470-2045(09)70003-8 19230772 PMC4086808 Fenaux, P. et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 10 , 223–232 (2009). 19230772 10.1016/S1470-2045(09)70003-8 PMC4086808

146. Kantarjian H Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study Cancer 2006 106 1794 1803 10.1002/cncr.21792 16532500 Kantarjian, H. et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106 , 1794–1803 (2006). 16532500 10.1002/cncr.21792

147. Jabbour E Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN Blood 2017 130 1514 1522 10.1182/blood-2017-06-788497 28774880 PMC5620419 Jabbour, E. et al. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood 130 , 1514–1522 (2017). 28774880 10.1182/blood-2017-06-788497 PMC5620419

148. Kantarjian H Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia Blood 2007 109 52 57 10.1182/blood-2006-05-021162 16882708 Kantarjian, H. et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109 , 52–57 (2007). 16882708 10.1182/blood-2006-05-021162

149. Wei AH Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission N. Engl. J. Med. 2020 383 2526 2537 10.1056/NEJMoa2004444 33369355 Wei, A. H. et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N. Engl. J. Med. 383 , 2526–2537 (2020). 33369355 10.1056/NEJMoa2004444

150. Savona MR Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies Am. J. Hematol. 2018 93 1199 1206 10.1002/ajh.25216 30016552 PMC6221082 Savona, M. R. et al. Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies. Am. J. Hematol. 93 , 1199–1206 (2018). 30016552 10.1002/ajh.25216 PMC6221082

151. Dhillon S Decitabine/cedazuridine: first approval Drugs 2020 80 1373 1378 10.1007/s40265-020-01389-7 32860582 PMC7708383 Dhillon, S. Decitabine/cedazuridine: first approval. Drugs 80 , 1373–1378 (2020). 32860582 10.1007/s40265-020-01389-7 PMC7708383

152. Candoni A Fully oral regimen with decitabine and cedazuridine plus venetoclax: a new step forward for older or unfit patients with acute myeloid leukaemia Lancet Haematol. 2024 11 e245 e246 10.1016/S2352-3026(24)00060-7 38452789 Candoni, A. Fully oral regimen with decitabine and cedazuridine plus venetoclax: a new step forward for older or unfit patients with acute myeloid leukaemia. Lancet Haematol. 11 , e245–e246 (2024). 38452789 10.1016/S2352-3026(24)00060-7

153. Linnekamp JF Clinical and biological effects of demethylating agents on solid tumours—a systematic review Cancer Treat. Rev. 2017 54 10 23 10.1016/j.ctrv.2017.01.004 28189913 Linnekamp, J. F. et al. Clinical and biological effects of demethylating agents on solid tumours—a systematic review. Cancer Treat. Rev. 54 , 10–23 (2017). 28189913 10.1016/j.ctrv.2017.01.004

154. Von Hoff DD Phase I study of CC-486 alone and in combination with carboplatin or nab-paclitaxel in patients with relapsed or refractory solid tumors Clin. Cancer Res. 2018 24 4072 4080 10.1158/1078-0432.CCR-17-3716 29764853 PMC6853187 Von Hoff, D. D. et al. Phase I study of CC-486 alone and in combination with carboplatin or nab-paclitaxel in patients with relapsed or refractory solid tumors. Clin. Cancer Res. 24 , 4072–4080 (2018). 29764853 10.1158/1078-0432.CCR-17-3716 PMC6853187

155. Luke JJ Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors Br. J. Cancer 2023 128 2227 2235 10.1038/s41416-023-02267-1 37087488 PMC10241827 Luke, J. J. et al. Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors. Br. J. Cancer 128 , 2227–2235 (2023). 37087488 10.1038/s41416-023-02267-1 PMC10241827

156. Ye C Epigenetic therapy: research progress of decitabine in the treatment of solid tumors Biochim. Biophys. Acta Rev. Cancer 2024 1879 189066 10.1016/j.bbcan.2023.189066 38163523 Ye, C. et al. Epigenetic therapy: research progress of decitabine in the treatment of solid tumors. Biochim. Biophys. Acta Rev. Cancer 1879 , 189066 (2024). 38163523 10.1016/j.bbcan.2023.189066

157. Pu J Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives Exp. Hematol. Oncol. 2024 13 45 10.1186/s40164-024-00507-5 38654286 PMC11040994 Pu, J. et al. Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives. Exp. Hematol. Oncol. 13 , 45 (2024). 38654286 10.1186/s40164-024-00507-5 PMC11040994

158. West AC Johnstone RW New and emerging HDAC inhibitors for cancer treatment J. Clin. Investig. 2014 124 30 39 10.1172/JCI69738 24382387 PMC3871231 West, A. C. & Johnstone, R. W. New and emerging HDAC inhibitors for cancer treatment. J. Clin. Investig. 124 , 30–39 (2014). 24382387 10.1172/JCI69738 PMC3871231

159. Shi Y Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China J. Hematol. Oncol. 2017 10 69 10.1186/s13045-017-0439-6 28298231 PMC5351273 Shi, Y. et al. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. J. Hematol. Oncol. 10 , 69 (2017). 28298231 10.1186/s13045-017-0439-6 PMC5351273

160. Sun Y Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment Front. Pharmacol. 2022 13 932914 10.3389/fphar.2022.932914 36120308 PMC9481063 Sun, Y. et al. Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment. Front. Pharmacol. 13 , 932914 (2022). 36120308 10.3389/fphar.2022.932914 PMC9481063

161. Mozzetta C Sartorelli V Steinkuhler C Puri PL HDAC inhibitors as pharmacological treatment for Duchenne muscular dystrophy: a discovery journey from bench to patients Trends Mol. Med. 2024 30 278 294 10.1016/j.molmed.2024.01.007 38408879 PMC11095976 Mozzetta, C., Sartorelli, V., Steinkuhler, C. & Puri, P. L. HDAC inhibitors as pharmacological treatment for Duchenne muscular dystrophy: a discovery journey from bench to patients. Trends Mol. Med. 30 , 278–294 (2024). 38408879 10.1016/j.molmed.2024.01.007 PMC11095976

162. Grant S Easley C Kirkpatrick P Vorinostat Nat. Rev. Drug. Discov. 2007 6 21 22 10.1038/nrd2227 17269160 Grant, S., Easley, C. & Kirkpatrick, P. Vorinostat. Nat. Rev. Drug. Discov. 6 , 21–22 (2007). 17269160 10.1038/nrd2227

163. Garcia-Manero G A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML Leukemia 2024 38 58 66 10.1038/s41375-023-02073-x 37935977 PMC11729399 Garcia-Manero, G. et al. A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML. Leukemia 38 , 58–66 (2024). 37935977 10.1038/s41375-023-02073-x PMC11729399

164. Dimopoulos M Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study Lancet Oncol. 2013 14 1129 1140 10.1016/S1470-2045(13)70398-X 24055414 Dimopoulos, M. et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol. 14 , 1129–1140 (2013). 24055414 10.1016/S1470-2045(13)70398-X

165. Jenner MW The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma XI’, a multicentre, open-label, randomised, phase III trial Br. J. Haematol. 2023 201 267 279 10.1111/bjh.18600 36541152 PMC10952726 Jenner, M. W. et al. The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma XI’, a multicentre, open-label, randomised, phase III trial. Br. J. Haematol. 201 , 267–279 (2023). 36541152 10.1111/bjh.18600 PMC10952726

166. Krug LM Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial Lancet Oncol. 2015 16 447 456 10.1016/S1470-2045(15)70056-2 25800891 Krug, L. M. et al. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 16 , 447–456 (2015). 25800891 10.1016/S1470-2045(15)70056-2

167. Duvic M Vu J Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma Expert Opin. Investig. Drugs 2007 16 1111 1120 10.1517/13543784.16.7.1111 17594194 Duvic, M. & Vu, J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin. Investig. Drugs 16 , 1111–1120 (2007). 17594194 10.1517/13543784.16.7.1111

168. Mann BS Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma Clin. Cancer Res. 2007 13 2318 2322 10.1158/1078-0432.CCR-06-2672 17438089 Mann, B. S. et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin. Cancer Res. 13 , 2318–2322 (2007). 17438089 10.1158/1078-0432.CCR-06-2672

169. Lynch DR Jr. Washam JB Newby LK QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature Cardiol. J. 2012 19 434 438 10.5603/CJ.2012.0078 22825908 Lynch, D. R. Jr., Washam, J. B. & Newby, L. K. QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature. Cardiol. J. 19 , 434–438 (2012). 22825908

170. Bertino EM Otterson GA Romidepsin: a novel histone deacetylase inhibitor for cancer Expert Opin. Investig. Drugs 2011 20 1151 1158 10.1517/13543784.2011.594437 21699444 Bertino, E. M. & Otterson, G. A. Romidepsin: a novel histone deacetylase inhibitor for cancer. Expert Opin. Investig. Drugs 20 , 1151–1158 (2011). 21699444 10.1517/13543784.2011.594437

171. Camus V Romidepsin plus cyclophosphamide, doxorubicin, vincristine, and prednisone versus cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated peripheral T-cell lymphoma: final analysis of the Ro-CHOP trial J. Clin. Oncol. 2024 42 1612 1618 10.1200/JCO.23.01687 38364196 Camus, V. et al. Romidepsin plus cyclophosphamide, doxorubicin, vincristine, and prednisone versus cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated peripheral T-cell lymphoma: final analysis of the Ro-CHOP trial. J. Clin. Oncol. 42 , 1612–1618 (2024). 38364196 10.1200/JCO.23.01687

172. Bachy E Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (Conducted by LYSA) J. Clin. Oncol. 2022 40 242 251 10.1200/JCO.21.01815 34843406 Bachy, E. et al. Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (Conducted by LYSA). J. Clin. Oncol. 40 , 242–251 (2022). 34843406 10.1200/JCO.21.01815

173. Falchi L Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study Blood 2021 137 2161 2170 10.1182/blood.2020009004 33171487 Falchi, L. et al. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood 137 , 2161–2170 (2021). 33171487 10.1182/blood.2020009004

174. Iyer SP Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study Haematologica 2024 109 209 219 37439343 10.3324/haematol.2022.281875 PMC10772524 Iyer, S. P. et al. Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study. Haematologica 109 , 209–219 (2024). 37439343 10.3324/haematol.2022.281875 PMC10772524

175. Mehta-Shah N Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: combined analysis of two phase I studies with expansion cohorts Am. J. Hematol. 2021 96 1211 1222 10.1002/ajh.26288 34251048 PMC8811706 Mehta-Shah, N. et al. Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: combined analysis of two phase I studies with expansion cohorts. Am. J. Hematol. 96 , 1211–1222 (2021). 34251048 10.1002/ajh.26288 PMC8811706

176. Ruan J Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma Blood Adv. 2023 7 5771 5779 10.1182/bloodadvances.2023009767 37327113 PMC10561000 Ruan, J. et al. Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma. Blood Adv. 7 , 5771–5779 (2023). 37327113 10.1182/bloodadvances.2023009767 PMC10561000

177. Gruell H Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial Lancet Microbe 2022 3 e203 e214 10.1016/S2666-5247(21)00239-1 35544074 PMC10293654 Gruell, H. et al. Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial. Lancet Microbe 3 , e203–e214 (2022). 35544074 10.1016/S2666-5247(21)00239-1 PMC10293654

178. Gunst JD Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial Nat. Med. 2022 28 2424 2435 10.1038/s41591-022-02023-7 36253609 PMC10189540 Gunst, J. D. et al. Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial. Nat. Med. 28 , 2424–2435 (2022). 36253609 10.1038/s41591-022-02023-7 PMC10189540

179. Poole RM Belinostat: first global approval Drugs 2014 74 1543 1554 10.1007/s40265-014-0275-8 25134672 Poole, R. M. Belinostat: first global approval. Drugs 74 , 1543–1554 (2014). 25134672 10.1007/s40265-014-0275-8

180. Shafer D Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies Cancer Chemother. Pharmacol. 2023 91 281 290 10.1007/s00280-023-04511-0 36864346 PMC10807611 Shafer, D. et al. Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies. Cancer Chemother. Pharmacol. 91 , 281–290 (2023). 36864346 10.1007/s00280-023-04511-0 PMC10807611

181. O’Connor OA Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study J. Clin. Oncol. 2015 33 2492 2499 10.1200/JCO.2014.59.2782 26101246 PMC5087312 O’Connor, O. A. et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J. Clin. Oncol. 33 , 2492–2499 (2015). 26101246 10.1200/JCO.2014.59.2782 PMC5087312

182. Takebe N A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction Br. J. Clin. Pharmacol. 2019 85 2499 2511 10.1111/bcp.14054 31271459 PMC6848909 Takebe, N. et al. A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. Br. J. Clin. Pharmacol. 85 , 2499–2511 (2019). 31271459 10.1111/bcp.14054 PMC6848909

183. Holkova B Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome Leuk. Lymphoma 2021 62 1187 1194 10.1080/10428194.2020.1861270 33356689 PMC8106643 Holkova, B. et al. Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome. Leuk. Lymphoma 62 , 1187–1194 (2021). 33356689 10.1080/10428194.2020.1861270 PMC8106643

184. Xu K Final report on clinical outcomes and tumor recurrence patterns of a pilot study assessing efficacy of belinostat (PXD-101) with chemoradiation for newly diagnosed glioblastoma Tomography 2022 8 688 700 10.3390/tomography8020057 35314634 PMC8938806 Xu, K. et al. Final report on clinical outcomes and tumor recurrence patterns of a pilot study assessing efficacy of belinostat (PXD-101) with chemoradiation for newly diagnosed glioblastoma. Tomography 8 , 688–700 (2022). 35314634 10.3390/tomography8020057 PMC8938806

185. Balasubramaniam S Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung Anticancer Drugs 2018 29 457 465 10.1097/CAD.0000000000000596 29420340 PMC6631369 Balasubramaniam, S. et al. Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung. Anticancer Drugs 29 , 457–465 (2018). 29420340 10.1097/CAD.0000000000000596 PMC6631369

186. Thomas A A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study Clin. Cancer Res. 2014 20 5392 5402 10.1158/1078-0432.CCR-14-0968 25189481 PMC4216756 Thomas, A. et al. A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study. Clin. Cancer Res. 20 , 5392–5402 (2014). 25189481 10.1158/1078-0432.CCR-14-0968 PMC4216756

187. San-Miguel JF Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial Lancet Oncol. 2014 15 1195 1206 10.1016/S1470-2045(14)70440-1 25242045 San-Miguel, J. F. et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 15 , 1195–1206 (2014). 25242045 10.1016/S1470-2045(14)70440-1

188. Rathkopf DE A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer Cancer Chemother. Pharmacol. 2013 72 537 544 10.1007/s00280-013-2224-8 23820963 PMC3970811 Rathkopf, D. E. et al. A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer. Cancer Chemother. Pharmacol. 72 , 537–544 (2013). 23820963 10.1007/s00280-013-2224-8 PMC3970811

189. San-Miguel JF Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial Lancet Haematol. 2016 3 e506 e515 10.1016/S2352-3026(16)30147-8 27751707 San-Miguel, J. F. et al. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. Lancet Haematol. 3 , e506–e515 (2016). 27751707 10.1016/S2352-3026(16)30147-8

190. Laubach JP Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study Lancet Oncol. 2021 22 142 154 10.1016/S1470-2045(20)30680-X 33301738 Laubach, J. P. et al. Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. Lancet Oncol. 22 , 142–154 (2021). 33301738 10.1016/S1470-2045(20)30680-X

191. Wieduwilt MJ Histone deacetylase inhibition with panobinostat combined with intensive induction chemotherapy in older patients with acute myeloid leukemia: phase I study results Clin. Cancer Res. 2019 25 4917 4923 10.1158/1078-0432.CCR-19-0171 31152020 Wieduwilt, M. J. et al. Histone deacetylase inhibition with panobinostat combined with intensive induction chemotherapy in older patients with acute myeloid leukemia: phase I study results. Clin. Cancer Res. 25 , 4917–4923 (2019). 31152020 10.1158/1078-0432.CCR-19-0171

192. Mascarenhas J A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post–polycythemia vera/essential thrombocythemia myelofibrosis (post–PV/ET MF) Leuk. Res. 2020 88 106272 10.1016/j.leukres.2019.106272 31778911 Mascarenhas, J. et al. A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post–polycythemia vera/essential thrombocythemia myelofibrosis (post–PV/ET MF). Leuk. Res. 88 , 106272 (2020). 31778911 10.1016/j.leukres.2019.106272

193. Monje M Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: a report from the pediatric brain tumor consortium (PBTC-047) Neuro Oncol. 2023 25 2262 2272 10.1093/neuonc/noad141 37526549 PMC10708931 Monje, M. et al. Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: a report from the pediatric brain tumor consortium (PBTC-047). Neuro Oncol. 25 , 2262–2272 (2023). 37526549 10.1093/neuonc/noad141 PMC10708931

194. Wood A Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma Investig. New. Drugs 2020 38 1108 1116 10.1007/s10637-019-00864-7 31654285 PMC7182475 Wood, A. et al. Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma. Investig. New. Drugs 38 , 1108–1116 (2020). 31654285 10.1007/s10637-019-00864-7 PMC7182475

195. Ferrari AC Epigenetic therapy with panobinostat combined with bicalutamide rechallenge in castration-resistant prostate cancer Clin. Cancer Res. 2019 25 52 63 10.1158/1078-0432.CCR-18-1589 30224345 Ferrari, A. C. et al. Epigenetic therapy with panobinostat combined with bicalutamide rechallenge in castration-resistant prostate cancer. Clin. Cancer Res. 25 , 52–63 (2019). 30224345 10.1158/1078-0432.CCR-18-1589

196. Wang T Second-line endocrine therapy of hormone receptor-positive/her2- negative advanced breast cancer: a systematic review and network meta-analysis Curr. Cancer Drug. Targets 2023 23 718 730 10.2174/1568009623666230407101128 37026492 Wang, T. et al. Second-line endocrine therapy of hormone receptor-positive/her2- negative advanced breast cancer: a systematic review and network meta-analysis. Curr. Cancer Drug. Targets 23 , 718–730 (2023). 37026492 10.2174/1568009623666230407101128

197. Rai S Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results Haematologica 2023 108 811 821 10.3324/haematol.2022.280996 36200417 PMC9973490 Rai, S. et al. Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results. Haematologica 108 , 811–821 (2023). 36200417 10.3324/haematol.2022.280996 PMC9973490

198. Li L Chidamide enhances T-cell-mediated anti-tumor immune function by inhibiting NOTCH1/NFATC1 signaling pathway in ABC-type diffuse large B-cell lymphoma Leuk. Lymphoma 2024 65 895 910 10.1080/10428194.2024.2328227 38497543 Li, L. et al. Chidamide enhances T-cell-mediated anti-tumor immune function by inhibiting NOTCH1/NFATC1 signaling pathway in ABC-type diffuse large B-cell lymphoma. Leuk. Lymphoma 65 , 895–910 (2024). 38497543 10.1080/10428194.2024.2328227

199. Zhao H Tucidinostat plus exemestane as a neoadjuvant in early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer Oncologist 2024 29 e763 e770 10.1093/oncolo/oyae033 38459836 PMC11144976 Zhao, H. et al. Tucidinostat plus exemestane as a neoadjuvant in early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. Oncologist 29 , e763–e770 (2024). 38459836 10.1093/oncolo/oyae033 PMC11144976

200. Zhao HY Low-dose chidamide restores immune tolerance in ITP in mice and humans Blood 2019 133 730 742 10.1182/blood-2018-05-847624 30552097 Zhao, H. Y. et al. Low-dose chidamide restores immune tolerance in ITP in mice and humans. Blood 133 , 730–742 (2019). 30552097 10.1182/blood-2018-05-847624

201. Dennison, J. et al. Low-dose chidamide treatment displays sex-specific differences in the 3xTg-AD mouse. Biomolecules . 13 , 1324 (2023). 10.3390/biom13091324 PMC10526199 37759724

202. Jiang Z Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Oncol. 2019 20 806 815 10.1016/S1470-2045(19)30164-0 31036468 Jiang, Z. et al. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20 , 806–815 (2019). 31036468 10.1016/S1470-2045(19)30164-0

203. Tonozuka Y The combination of brentuximab vedotin and chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis Cancer Chemother. Pharmacol. 2024 93 137 149 10.1007/s00280-023-04609-5 37921901 PMC10853311 Tonozuka, Y. et al. The combination of brentuximab vedotin and chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis. Cancer Chemother. Pharmacol. 93 , 137–149 (2024). 37921901 10.1007/s00280-023-04609-5 PMC10853311

204. Zhang P Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors BMC Med. 2022 20 435 10.1186/s12916-022-02598-5 36352411 PMC9648046 Zhang, P. et al. Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors. BMC Med. 20 , 435 (2022). 36352411 10.1186/s12916-022-02598-5 PMC9648046

205. Zhou J Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer Breast 2022 66 255 261 10.1016/j.breast.2022.10.018 36375386 PMC9661714 Zhou, J. et al. Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer. Breast 66 , 255–261 (2022). 36375386 10.1016/j.breast.2022.10.018 PMC9661714

206. Chai Y First-line chemoradiation with or without chidamide (tucidinostat) in patients with intermediate- and high-risk early-stage extranodal nasal-type natural killer/T-cell lymphoma: a randomized phase 2 study in China Int. J. Radiat. Oncol. Biol. Phys. 2022 113 833 844 10.1016/j.ijrobp.2022.04.001 35452752 Chai, Y. et al. First-line chemoradiation with or without chidamide (tucidinostat) in patients with intermediate- and high-risk early-stage extranodal nasal-type natural killer/T-cell lymphoma: a randomized phase 2 study in China. Int. J. Radiat. Oncol. Biol. Phys. 113 , 833–844 (2022). 35452752 10.1016/j.ijrobp.2022.04.001

207. Mercuri E Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Lancet Neurol. 2024 23 393 403 10.1016/S1474-4422(24)00036-X 38508835 Mercuri, E. et al. Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 23 , 393–403 (2024). 38508835 10.1016/S1474-4422(24)00036-X

208. Chifotides HT Bose P Verstovsek S Givinostat: an emerging treatment for polycythemia vera Expert Opin. Investig. Drugs 2020 29 525 536 10.1080/13543784.2020.1761323 32693648 PMC7534842 Chifotides, H. T., Bose, P. & Verstovsek, S. Givinostat: an emerging treatment for polycythemia vera. Expert Opin. Investig. Drugs 29 , 525–536 (2020). 32693648 10.1080/13543784.2020.1761323 PMC7534842

209. Rambaldi A Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study Leukemia 2020 34 2234 2237 10.1038/s41375-020-0735-y 32047238 PMC7387307 Rambaldi, A. et al. Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study. Leukemia 34 , 2234–2237 (2020). 32047238 10.1038/s41375-020-0735-y PMC7387307

210. Finazzi G A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy Br. J. Haematol. 2013 161 688 694 10.1111/bjh.12332 23573950 Finazzi, G. et al. A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. Br. J. Haematol. 161 , 688–694 (2013). 23573950 10.1111/bjh.12332

211. Rambaldi A Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program Blood Cancer J. 2021 11 53 10.1038/s41408-021-00445-z 33677466 PMC7936975 Rambaldi, A. et al. Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program. Blood Cancer J. 11 , 53 (2021). 33677466 10.1038/s41408-021-00445-z PMC7936975

212. Xu W Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases Cancer Cell. 2011 19 17 30 10.1016/j.ccr.2010.12.014 21251613 PMC3229304 Xu, W. et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell. 19 , 17–30 (2011). 21251613 10.1016/j.ccr.2010.12.014 PMC3229304

213. Tommasini-Ghelfi S Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human disease Sci. Adv. 2019 5 eaaw4543 10.1126/sciadv.aaw4543 31131326 PMC6530995 Tommasini-Ghelfi, S. et al. Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human disease. Sci. Adv. 5 , eaaw4543 (2019). 31131326 10.1126/sciadv.aaw4543 PMC6530995

214. Enasidenib Approved for AML, but Best Uses Unclear. Cancer Discov . 7 , Of4, (2017). 10.1158/2159-8290.CD-NB2017-117 28818952

215. Ivosidenib Gets Go-Ahead for AML. Cancer Discov . 8 , Of3, (2018). 10.1158/2159-8290.CD-NB2018-107 30093505

216. Lavacchi D Ivosidenib in IDH1-mutated cholangiocarcinoma: clinical evaluation and future directions Pharmacol. Ther. 2022 237 108170 10.1016/j.pharmthera.2022.108170 35296436 Lavacchi, D. et al. Ivosidenib in IDH1-mutated cholangiocarcinoma: clinical evaluation and future directions. Pharmacol. Ther. 237 , 108170 (2022). 35296436 10.1016/j.pharmthera.2022.108170

217. Kang C Olutasidenib: first approval Drugs 2023 83 341 346 10.1007/s40265-023-01844-1 36848032 Kang, C. Olutasidenib: first approval. Drugs 83 , 341–346 (2023). 36848032 10.1007/s40265-023-01844-1

218. Mellinghoff IK Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; results of a first-in-human phase I trial Clin. Cancer Res. 2021 27 4491 4499 10.1158/1078-0432.CCR-21-0611 34078652 PMC8364866 Mellinghoff, I. K. et al. Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; results of a first-in-human phase I trial. Clin. Cancer Res. 27 , 4491–4499 (2021). 34078652 10.1158/1078-0432.CCR-21-0611 PMC8364866

219. Wick A Phase I assessment of safety and therapeutic activity of BAY1436032 in patients with IDH1-mutant solid tumors Clin. Cancer Res. 2021 27 2723 2733 10.1158/1078-0432.CCR-20-4256 33622704 Wick, A. et al. Phase I assessment of safety and therapeutic activity of BAY1436032 in patients with IDH1-mutant solid tumors. Clin. Cancer Res. 27 , 2723–2733 (2021). 33622704 10.1158/1078-0432.CCR-20-4256

220. Heuser M Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results Leukemia 2020 34 2903 2913 10.1038/s41375-020-0996-5 32733012 PMC7584476 Heuser, M. et al. Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results. Leukemia 34 , 2903–2913 (2020). 32733012 10.1038/s41375-020-0996-5 PMC7584476

221. Kim ES Enasidenib: first global approval Drugs 2017 77 1705 1711 10.1007/s40265-017-0813-2 28879540 Kim, E. S. Enasidenib: first global approval. Drugs 77 , 1705–1711 (2017). 28879540 10.1007/s40265-017-0813-2

222. Quek L Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib Nat. Med. 2018 24 1167 1177 10.1038/s41591-018-0115-6 30013198 PMC6925974 Quek, L. et al. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Nat. Med. 24 , 1167–1177 (2018). 30013198 10.1038/s41591-018-0115-6 PMC6925974

223. Thomas D Majeti R Optimizing next-generation AML therapy: activity of mutant IDH2 inhibitor AG-221 in preclinical models Cancer Discov. 2017 7 459 461 10.1158/2159-8290.CD-17-0270 28461409 PMC5456121 Thomas, D. & Majeti, R. Optimizing next-generation AML therapy: activity of mutant IDH2 inhibitor AG-221 in preclinical models. Cancer Discov. 7 , 459–461 (2017). 28461409 10.1158/2159-8290.CD-17-0270 PMC5456121

224. Amatangelo MD Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response Blood 2017 130 732 741 10.1182/blood-2017-04-779447 28588019 PMC5553578 Amatangelo, M. D. et al. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood 130 , 732–741 (2017). 28588019 10.1182/blood-2017-04-779447 PMC5553578

225. Positive First Trial of Enasidenib for AML. Cancer Discov . 7 , Of1, (2017). 10.1158/2159-8290.CD-NB2017-098 28659444

226. DiNardo CD Wei AH How I treat acute myeloid leukemia in the era of new drugs Blood 2020 135 85 96 10.1182/blood.2019001239 31765470 DiNardo, C. D. & Wei, A. H. How I treat acute myeloid leukemia in the era of new drugs. Blood 135 , 85–96 (2020). 31765470 10.1182/blood.2019001239

227. Santini V Enasidenib: a magic bullet for myelodysplastic syndromes? Lancet Haematol. 2020 7 e275 e276 10.1016/S2352-3026(20)30039-9 32145770 Santini, V. Enasidenib: a magic bullet for myelodysplastic syndromes? Lancet Haematol. 7 , e275–e276 (2020). 32145770 10.1016/S2352-3026(20)30039-9

228. de Botton S Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial Blood 2023 141 156 167 10.1182/blood.2021014901 35714312 PMC10644040 de Botton, S. et al. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial. Blood 141 , 156–167 (2023). 35714312 10.1182/blood.2021014901 PMC10644040

229. Venugopal S Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy Blood Cancer J. 2022 12 10 10.1038/s41408-021-00604-2 35078972 PMC8789767 Venugopal, S. et al. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J. 12 , 10 (2022). 35078972 10.1038/s41408-021-00604-2 PMC8789767

230. Pollyea DA Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia Leukemia 2019 33 2575 2584 10.1038/s41375-019-0472-2 30967620 PMC9724489 Pollyea, D. A. et al. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia 33 , 2575–2584 (2019). 30967620 10.1038/s41375-019-0472-2 PMC9724489

231. DiNardo CD Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial Lancet Oncol. 2021 22 1597 1608 10.1016/S1470-2045(21)00494-0 34672961 DiNardo, C. D. et al. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol. 22 , 1597–1608 (2021). 34672961 10.1016/S1470-2045(21)00494-0

232. Cai SF A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML Blood Adv. 2024 8 429 440 10.1182/bloodadvances.2023010563 37871309 PMC10827405 Cai, S. F. et al. A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML. Blood Adv. 8 , 429–440 (2024). 37871309 10.1182/bloodadvances.2023010563 PMC10827405

233. Stein EM Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib Blood 2019 133 676 687 10.1182/blood-2018-08-869008 30510081 PMC6384189 Stein, E. M. et al. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood 133 , 676–687 (2019). 30510081 10.1182/blood-2018-08-869008 PMC6384189

234. Stein EM Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia Blood 2017 130 722 731 10.1182/blood-2017-04-779405 28588020 PMC5572791 Stein, E. M. et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 130 , 722–731 (2017). 28588020 10.1182/blood-2017-04-779405 PMC5572791

235. Stein EM Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial Lancet Haematol. 2020 7 e309 e319 10.1016/S2352-3026(19)30284-4 32145771 Stein, E. M. et al. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. Lancet Haematol. 7 , e309–e319 (2020). 32145771 10.1016/S2352-3026(19)30284-4

236. Fathi AT Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2: analysis of a phase 1/2 study JAMA Oncol. 2018 4 1106 1110 10.1001/jamaoncol.2017.4695 29346478 PMC5885269 Fathi, A. T. et al. Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2: analysis of a phase 1/2 study. JAMA Oncol. 4 , 1106–1110 (2018). 29346478 10.1001/jamaoncol.2017.4695 PMC5885269

237. Geoerger B Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation Nat. Med. 2023 29 1358 1363 10.1038/s41591-023-02382-9 37248298 Geoerger, B. et al. Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation. Nat. Med. 29 , 1358–1363 (2023). 37248298 10.1038/s41591-023-02382-9

238. Rey V A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma EBioMedicine 2024 102 105090 10.1016/j.ebiom.2024.105090 38547578 PMC10990714 Rey, V. et al. A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma. EBioMedicine 102 , 105090 (2024). 38547578 10.1016/j.ebiom.2024.105090 PMC10990714

239. Norsworthy KJ FDA approval summary: ivosidenib for relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-1 mutation Clin. Cancer Res. 2019 25 3205 3209 10.1158/1078-0432.CCR-18-3749 30692099 Norsworthy, K. J. et al. FDA approval summary: ivosidenib for relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-1 mutation. Clin. Cancer Res. 25 , 3205–3209 (2019). 30692099 10.1158/1078-0432.CCR-18-3749

240. Montesinos P Ivosidenib and Azacitidine in IDH1-mutated acute myeloid leukemia N. Engl. J. Med. 2022 386 1519 1531 10.1056/NEJMoa2117344 35443108 Montesinos, P. et al. Ivosidenib and Azacitidine in IDH1-mutated acute myeloid leukemia. N. Engl. J. Med. 386 , 1519–1531 (2022). 35443108 10.1056/NEJMoa2117344

241. Woods A FDA approval summary: ivosidenib in combination with azacitidine for treatment of patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation Clin. Cancer Res. 2024 30 1226 1231 10.1158/1078-0432.CCR-23-2234 38010220 PMC10984783 Woods, A. et al. FDA approval summary: ivosidenib in combination with azacitidine for treatment of patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation. Clin. Cancer Res. 30 , 1226–1231 (2024). 38010220 10.1158/1078-0432.CCR-23-2234 PMC10984783

242. Zhu AX Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical clarIDHy trial JAMA Oncol. 2021 7 1669 1677 10.1001/jamaoncol.2021.3836 34554208 PMC8461552 Zhu, A. X. et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical clarIDHy trial. JAMA Oncol. 7 , 1669–1677 (2021). 34554208 10.1001/jamaoncol.2021.3836 PMC8461552

243. Rudà R IDH inhibition in gliomas: from preclinical models to clinical trials Nat. Rev. Neurol. 2024 20 395 407 10.1038/s41582-024-00967-7 38760442 Rudà, R. et al. IDH inhibition in gliomas: from preclinical models to clinical trials. Nat. Rev. Neurol. 20 , 395–407 (2024). 38760442 10.1038/s41582-024-00967-7

244. Mellinghoff IK Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma J. Clin. Oncol. 2020 38 3398 3406 10.1200/JCO.19.03327 32530764 PMC7527160 Mellinghoff, I. K. et al. Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma. J. Clin. Oncol. 38 , 3398–3406 (2020). 32530764 10.1200/JCO.19.03327 PMC7527160

245. Tap WD Phase I study of the mutant IDH1 inhibitor ivosidenib: safety and clinical activity in patients with advanced chondrosarcoma J. Clin. Oncol. 2020 38 1693 1701 10.1200/JCO.19.02492 32208957 PMC7238491 Tap, W. D. et al. Phase I study of the mutant IDH1 inhibitor ivosidenib: safety and clinical activity in patients with advanced chondrosarcoma. J. Clin. Oncol. 38 , 1693–1701 (2020). 32208957 10.1200/JCO.19.02492 PMC7238491

246. Mellinghoff IK Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial Nat. Med. 2023 29 615 622 10.1038/s41591-022-02141-2 36823302 PMC10313524 Mellinghoff, I. K. et al. Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. Nat. Med. 29 , 615–622 (2023). 36823302 10.1038/s41591-022-02141-2 PMC10313524

247. Watts JM Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial Lancet Haematol. 2023 10 e46 e58 10.1016/S2352-3026(22)00292-7 36370742 PMC12250719 Watts, J. M. et al. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. Lancet Haematol. 10 , e46–e58 (2023). 36370742 10.1016/S2352-3026(22)00292-7 PMC12250719

248. de Botton S Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML Blood Adv. 2023 7 3117 3127 10.1182/bloodadvances.2022009411 36724515 PMC10362540 de Botton, S. et al. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood Adv. 7 , 3117–3127 (2023). 36724515 10.1182/bloodadvances.2022009411 PMC10362540

249. de la Fuente MI Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: a multicenter, open-label, phase Ib/II trial Neuro Oncol. 2023 25 146 156 10.1093/neuonc/noac139 35639513 PMC9825299 de la Fuente, M. I. et al. Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: a multicenter, open-label, phase Ib/II trial. Neuro Oncol. 25 , 146–156 (2023). 35639513 10.1093/neuonc/noac139 PMC9825299

250. Hoy SM Tazemetostat: first approval Drugs 2020 80 513 521 10.1007/s40265-020-01288-x 32166598 Hoy, S. M. Tazemetostat: first approval. Drugs 80 , 513–521 (2020). 32166598 10.1007/s40265-020-01288-x

251. First EZH2 Inhibitor Approved-for Rare Sarcoma. Cancer Discov . 10 , 333-334, (2020). 10.1158/2159-8290.CD-NB2020-006 32041739

252. Gounder M Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study Lancet Oncol. 2020 21 1423 1432 10.1016/S1470-2045(20)30451-4 33035459 Gounder, M. et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 21 , 1423–1432 (2020). 33035459 10.1016/S1470-2045(20)30451-4

253. Italiano A Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study Lancet Oncol. 2018 19 649 659 10.1016/S1470-2045(18)30145-1 29650362 Italiano, A. et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 19 , 649–659 (2018). 29650362 10.1016/S1470-2045(18)30145-1

254. Morschhauser F Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial Lancet Oncol. 2020 21 1433 1442 10.1016/S1470-2045(20)30441-1 33035457 PMC8427481 Morschhauser, F. et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 21 , 1433–1442 (2020). 33035457 10.1016/S1470-2045(20)30441-1 PMC8427481

255. Munakata W Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma Cancer Sci. 2021 112 1123 1131 10.1111/cas.14822 33492746 PMC7935786 Munakata, W. et al. Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma. Cancer Sci. 112 , 1123–1131 (2021). 33492746 10.1111/cas.14822 PMC7935786

256. Izutsu K Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan Cancer Sci. 2021 112 3627 3635 10.1111/cas.15040 34159682 PMC8409398 Izutsu, K. et al. Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan. Cancer Sci. 112 , 3627–3635 (2021). 34159682 10.1111/cas.15040 PMC8409398

257. Zauderer MG EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study Lancet Oncol. 2022 23 758 767 10.1016/S1470-2045(22)00277-7 35588752 Zauderer, M. G. et al. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. Lancet Oncol. 23 , 758–767 (2022). 35588752 10.1016/S1470-2045(22)00277-7

258. Liu J Sunitinib attenuates reactive MDSCs enhancing anti-tumor immunity in HNSCC Int. Immunopharmacol. 2023 119 110243 10.1016/j.intimp.2023.110243 37137265 Liu, J. et al. Sunitinib attenuates reactive MDSCs enhancing anti-tumor immunity in HNSCC. Int. Immunopharmacol. 119 , 110243 (2023). 37137265 10.1016/j.intimp.2023.110243

259. Zhou L Targeting EZH2 enhances antigen presentation, antitumor immunity, and circumvents anti-PD-1 resistance in head and neck cancer Clin. Cancer Res. 2020 26 290 300 10.1158/1078-0432.CCR-19-1351 31562203 PMC6942613 Zhou, L. et al. Targeting EZH2 enhances antigen presentation, antitumor immunity, and circumvents anti-PD-1 resistance in head and neck cancer. Clin. Cancer Res. 26 , 290–300 (2020). 31562203 10.1158/1078-0432.CCR-19-1351 PMC6942613

260. Nastoupil LJ When to use targeted therapy for the treatment of follicular lymphoma Curr. Hematol. Malig. Rep. 2021 16 45 51 10.1007/s11899-021-00617-5 33797691 Nastoupil, L. J. When to use targeted therapy for the treatment of follicular lymphoma. Curr. Hematol. Malig. Rep. 16 , 45–51 (2021). 33797691 10.1007/s11899-021-00617-5

261. Keam SJ Valemetostat tosilate: first approval Drugs 2022 82 1621 1627 10.1007/s40265-022-01800-5 36380144 PMC9705507 Keam, S. J. Valemetostat tosilate: first approval. Drugs 82 , 1621–1627 (2022). 36380144 10.1007/s40265-022-01800-5 PMC9705507

262. Tachibana M Safety, tolerability, and pharmacokinetics of valemetostat tablets and the effect of food on valemetostat pharmacokinetics in healthy subjects: two phase 1 studies Clin. Pharmacol. Drug. Dev. 2024 13 77 86 10.1002/cpdd.1315 37565616 Tachibana, M. et al. Safety, tolerability, and pharmacokinetics of valemetostat tablets and the effect of food on valemetostat pharmacokinetics in healthy subjects: two phase 1 studies. Clin. Pharmacol. Drug. Dev. 13 , 77–86 (2024). 37565616 10.1002/cpdd.1315

263. Tachibana M Effect of itraconazole and fluconazole on the pharmacokinetics of valemetostat: an open-label, phase I study in healthy subjects Clin. Transl. Sci. 2023 16 2153 2162 10.1111/cts.13613 37705321 PMC10651645 Tachibana, M. et al. Effect of itraconazole and fluconazole on the pharmacokinetics of valemetostat: an open-label, phase I study in healthy subjects. Clin. Transl. Sci. 16 , 2153–2162 (2023). 37705321 10.1111/cts.13613 PMC10651645

264. Izutsu K An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma Blood 2023 141 1159 1168 10.1182/blood.2022016862 36150143 PMC10651775 Izutsu, K. et al. An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma. Blood 141 , 1159–1168 (2023). 36150143 10.1182/blood.2022016862 PMC10651775

265. Wu G TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependence Sci. Transl. Med. 2023 15 eadi7244 10.1126/scitranslmed.adi7244 37729434 PMC11014717 Wu, G. et al. TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependence. Sci. Transl. Med. 15 , eadi7244 (2023). 37729434 10.1126/scitranslmed.adi7244 PMC11014717

266. Lorenzo-Guerra, S. L. et al. Characterization of a preclinical in vitro model derived from a SMARCA4-mutated sinonasal teratocarcinosarcoma. Cells . 13 , 81 (2023). 10.3390/cells13010081 PMC10778008 38201285

267. Kagiyama Y CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib Cancer Sci. 2021 112 2314 2324 10.1111/cas.14905 33792119 PMC8177787 Kagiyama, Y. et al. CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib. Cancer Sci. 112 , 2314–2324 (2021). 33792119 10.1111/cas.14905 PMC8177787

268. Koseki A EZH1/2 dual inhibitors suppress HTLV-1-infected cell proliferation and hyperimmune response in HTLV-1-associated myelopathy Front. Microbiol. 2023 14 1175762 10.3389/fmicb.2023.1175762 37378292 PMC10291084 Koseki, A. et al. EZH1/2 dual inhibitors suppress HTLV-1-infected cell proliferation and hyperimmune response in HTLV-1-associated myelopathy. Front. Microbiol. 14 , 1175762 (2023). 37378292 10.3389/fmicb.2023.1175762 PMC10291084

269. Chavali V Tyagi SC Mishra PK MicroRNA-133a regulates DNA methylation in diabetic cardiomyocytes Biochem. Biophys. Res. Commun. 2012 425 668 672 10.1016/j.bbrc.2012.07.105 22842467 PMC4077351 Chavali, V., Tyagi, S. C. & Mishra, P. K. MicroRNA-133a regulates DNA methylation in diabetic cardiomyocytes. Biochem. Biophys. Res. Commun. 425 , 668–672 (2012). 22842467 10.1016/j.bbrc.2012.07.105 PMC4077351

270. Hedrich CM Mäbert K Rauen T Tsokos GC DNA methylation in systemic lupus erythematosus Epigenomics 2017 9 505 525 10.2217/epi-2016-0096 27885845 PMC6040049 Hedrich, C. M., Mäbert, K., Rauen, T. & Tsokos, G. C. DNA methylation in systemic lupus erythematosus. Epigenomics 9 , 505–525 (2017). 27885845 10.2217/epi-2016-0096 PMC6040049

271. Nakano K Boyle DL Firestein GS Regulation of DNA methylation in rheumatoid arthritis synoviocytes J. Immunol. 2013 190 1297 1303 10.4049/jimmunol.1202572 23277489 PMC3552038 Nakano, K., Boyle, D. L. & Firestein, G. S. Regulation of DNA methylation in rheumatoid arthritis synoviocytes. J. Immunol. 190 , 1297–1303 (2013). 23277489 10.4049/jimmunol.1202572 PMC3552038

272. Yang L Functional characterization of age-dependent p16 epimutation reveals biological drivers and therapeutic targets for colorectal cancer J. Exp. Clin. Cancer Res. 2023 42 113 10.1186/s13046-023-02689-y 37143122 PMC10157929 Yang, L. et al. Functional characterization of age-dependent p16 epimutation reveals biological drivers and therapeutic targets for colorectal cancer. J. Exp. Clin. Cancer Res. 42 , 113 (2023). 37143122 10.1186/s13046-023-02689-y PMC10157929

273. Hoang NM Rui L DNA methyltransferases in hematological malignancies J. Genet Genom. 2020 47 361 372 10.1016/j.jgg.2020.04.006 PMC7704698 32994141 Hoang, N. M. & Rui, L. DNA methyltransferases in hematological malignancies. J. Genet Genom. 47 , 361–372 (2020). 10.1016/j.jgg.2020.04.006 PMC7704698 32994141

274. Mahfouz RZ Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy Clin. Cancer Res. 2013 19 938 948 10.1158/1078-0432.CCR-12-1722 23287564 PMC3577958 Mahfouz, R. Z. et al. Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy. Clin. Cancer Res. 19 , 938–948 (2013). 23287564 10.1158/1078-0432.CCR-12-1722 PMC3577958

275. Tellez CS SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome Int. J. Cancer 2014 135 2223 2231 10.1002/ijc.28865 24668305 Tellez, C. S. et al. SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome. Int. J. Cancer 135 , 2223–2231 (2014). 24668305 10.1002/ijc.28865

276. Prebet T A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia Leuk. Lymphoma 2022 63 2180 2188 10.1080/10428194.2022.2057484 35491816 Prebet, T. et al. A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia. Leuk. Lymphoma 63 , 2180–2188 (2022). 35491816 10.1080/10428194.2022.2057484

277. Bever KM A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint Clin. Epigenetics 2021 13 25 10.1186/s13148-021-01014-8 33531075 PMC7856736 Bever, K. M. et al. A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint. Clin. Epigenetics 13 , 25 (2021). 33531075 10.1186/s13148-021-01014-8 PMC7856736

278. Ligon JA A phase II trial of guadecitabine in children and adults with SDH-deficient GIST, pheochromocytoma, paraganglioma, and HLRCC-associated renal cell carcinoma Clin. Cancer Res. 2023 29 341 348 10.1158/1078-0432.CCR-22-2168 36302175 PMC9851965 Ligon, J. A. et al. A phase II trial of guadecitabine in children and adults with SDH-deficient GIST, pheochromocytoma, paraganglioma, and HLRCC-associated renal cell carcinoma. Clin. Cancer Res. 29 , 341–348 (2023). 36302175 10.1158/1078-0432.CCR-22-2168 PMC9851965

279. Roboz GJ Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial Blood Adv. 2024 8 2020 2029 10.1182/bloodadvances.2023012062 38231126 PMC11103175 Roboz, G. J. et al. Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial. Blood Adv. 8 , 2020–2029 (2024). 38231126 10.1182/bloodadvances.2023012062 PMC11103175

280. Lee V A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS-102 in irinotecan-refractory metastatic colorectal cancer patients Int. J. Cancer 2024 154 1794 1801 10.1002/ijc.34845 38312102 Lee, V. et al. A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS-102 in irinotecan-refractory metastatic colorectal cancer patients. Int. J. Cancer 154 , 1794–1801 (2024). 38312102 10.1002/ijc.34845

281. Noviello TMR Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial Nat. Commun. 2023 14 5914 10.1038/s41467-023-40994-4 37739939 PMC10516894 Noviello, T. M. R. et al. Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial. Nat. Commun. 14 , 5914 (2023). 37739939 10.1038/s41467-023-40994-4 PMC10516894

282. Amaro A Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells J. Exp. Clin. Cancer Res. 2023 42 67 10.1186/s13046-023-02628-x 36934257 PMC10024396 Amaro, A. et al. Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells. J. Exp. Clin. Cancer Res. 42 , 67 (2023). 36934257 10.1186/s13046-023-02628-x PMC10024396

283. Fenaux P Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study Blood Adv. 2023 7 5027 5037 10.1182/bloodadvances.2023010179 37276510 PMC10471926 Fenaux, P. et al. Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study. Blood Adv. 7 , 5027–5037 (2023). 37276510 10.1182/bloodadvances.2023010179 PMC10471926

284. Brueckner B Delivery of 5-azacytidine to human cancer cells by elaidic acid esterification increases therapeutic drug efficacy Mol. Cancer Ther. 2010 9 1256 1264 10.1158/1535-7163.MCT-09-1202 20442313 Brueckner, B. et al. Delivery of 5-azacytidine to human cancer cells by elaidic acid esterification increases therapeutic drug efficacy. Mol. Cancer Ther. 9 , 1256–1264 (2010). 20442313 10.1158/1535-7163.MCT-09-1202

285. Morris J F-aza-T-dCyd (NSC801845), a novel cytidine analog, in comparative cell culture and xenograft studies with the clinical candidates T-dCyd, F-T-dCyd, and Aza-T-dCyd Mol. Cancer Ther. 2021 20 625 631 10.1158/1535-7163.MCT-20-0738 33811149 PMC8030693 Morris, J. et al. F-aza-T-dCyd (NSC801845), a novel cytidine analog, in comparative cell culture and xenograft studies with the clinical candidates T-dCyd, F-T-dCyd, and Aza-T-dCyd. Mol. Cancer Ther. 20 , 625–631 (2021). 33811149 10.1158/1535-7163.MCT-20-0738 PMC8030693

286. Matoušová M 2 ' -deoxy-5,6-dihydro-5-azacytidine—a less toxic alternative of 2 ' -deoxy-5-azacytidine: a comparative study of hypomethylating potential Epigenetics 2011 6 769 776 10.4161/epi.6.6.16215 21566456 PMC3142367 Matoušová, M. et al. 2 ' -deoxy-5,6-dihydro-5-azacytidine—a less toxic alternative of 2 ' -deoxy-5-azacytidine: a comparative study of hypomethylating potential. Epigenetics 6 , 769–776 (2011). 21566456 10.4161/epi.6.6.16215 PMC3142367

287. Byun, H. M. et al. 2'-Deoxy-N4-[2-(4-nitrophenyl)ethoxycarbonyl]-5-azacytidine: a novel inhibitor of DNA methyltransferase that requires activation by human carboxylesterase 1. Cancer Lett . 266 , 238–248 (2008). 10.1016/j.canlet.2008.02.069 PMC2528876 18499340

288. Takemura Y Satoh M Hatanaka K Kubota S Zebularine exerts its antiproliferative activity through S phase delay and cell death in human malignant mesothelioma cells Biosci. Biotechnol. Biochem. 2018 82 1159 1164 10.1080/09168451.2018.1459466 29685095 Takemura, Y., Satoh, M., Hatanaka, K. & Kubota, S. Zebularine exerts its antiproliferative activity through S phase delay and cell death in human malignant mesothelioma cells. Biosci. Biotechnol. Biochem. 82 , 1159–1164 (2018). 29685095 10.1080/09168451.2018.1459466

289. Koh, E. S. et al. The protective effect of zebularine, an inhibitor of DNA methyltransferase, on renal tubulointerstitial inflammation and fibrosis. Int. J. Mol. Sci . 23 , 14045 (2022). 10.3390/ijms232214045 PMC9697081 36430531

290. Shah R Reversal of dual epigenetic repression of non-canonical Wnt-5a normalises diabetic corneal epithelial wound healing and stem cells Diabetologia 2023 66 1943 1958 10.1007/s00125-023-05960-1 37460827 PMC10474199 Shah, R. et al. Reversal of dual epigenetic repression of non-canonical Wnt-5a normalises diabetic corneal epithelial wound healing and stem cells. Diabetologia 66 , 1943–1958 (2023). 37460827 10.1007/s00125-023-05960-1 PMC10474199

291. Pant R Pharmacological inhibition of DNMT1 restores macrophage autophagy and M2 polarization in Western diet-induced nonalcoholic fatty liver disease J. Biol. Chem. 2023 299 104779 10.1016/j.jbc.2023.104779 37142224 PMC10248527 Pant, R. et al. Pharmacological inhibition of DNMT1 restores macrophage autophagy and M2 polarization in Western diet-induced nonalcoholic fatty liver disease. J. Biol. Chem. 299 , 104779 (2023). 37142224 10.1016/j.jbc.2023.104779 PMC10248527

292. Lubecka-Pietruszewska K Clofarabine, a novel adenosine analogue, reactivates DNA methylation-silenced tumour suppressor genes and inhibits cell growth in breast cancer cells Eur. J. Pharmacol. 2014 723 276 287 10.1016/j.ejphar.2013.11.021 24296317 Lubecka-Pietruszewska, K. et al. Clofarabine, a novel adenosine analogue, reactivates DNA methylation-silenced tumour suppressor genes and inhibits cell growth in breast cancer cells. Eur. J. Pharmacol. 723 , 276–287 (2014). 24296317 10.1016/j.ejphar.2013.11.021

293. Vrânceanu, M. et al. The anticancer potential of plant-derived nutraceuticals via the modulation of gene expression. Plants 11 , 2524 (2022). 10.3390/plants11192524 PMC9571524 36235389

294. Qadir Nanakali NM The role of dietary polyphenols in alternating DNA methylation in cancer Crit. Rev. Food Sci. Nutr. 2023 63 12256 12269 10.1080/10408398.2022.2100313 35848113 Qadir Nanakali, N. M. et al. The role of dietary polyphenols in alternating DNA methylation in cancer. Crit. Rev. Food Sci. Nutr. 63 , 12256–12269 (2023). 35848113 10.1080/10408398.2022.2100313

295. Marques-Magalhães  Anti-neoplastic and demethylating activity of a newly synthetized flavanone-derived compound in renal cell carcinoma cell lines Biomed. Pharmacother. 2021 141 111681 10.1016/j.biopha.2021.111681 34139552 Marques-Magalhães, Â. et al. Anti-neoplastic and demethylating activity of a newly synthetized flavanone-derived compound in renal cell carcinoma cell lines. Biomed. Pharmacother. 141 , 111681 (2021). 34139552 10.1016/j.biopha.2021.111681

296. Wang L Design and synthesis of water-soluble grifolin prodrugs for DNA methyltransferase 1 (DNMT1) down-regulation RSC Adv. 2021 11 38907 38914 10.1039/D1RA06648J 35493211 PMC9044205 Wang, L. et al. Design and synthesis of water-soluble grifolin prodrugs for DNA methyltransferase 1 (DNMT1) down-regulation. RSC Adv. 11 , 38907–38914 (2021). 35493211 10.1039/d1ra06648j PMC9044205

297. Stewart DJ A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly Ann. Oncol. 2003 14 766 774 10.1093/annonc/mdg216 12702532 Stewart, D. J. et al. A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. Ann. Oncol. 14 , 766–774 (2003). 12702532 10.1093/annonc/mdg216

298. Winquist E Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study Investig. New. Drugs 2006 24 159 167 10.1007/s10637-006-5938-1 16502349 Winquist, E. et al. Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study. Investig. New. Drugs 24 , 159–167 (2006). 16502349 10.1007/s10637-006-5938-1

299. Davis AJ Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks Investig. New. Drugs 2003 21 85 97 10.1023/A:1022976528441 12795533 Davis, A. J. et al. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Investig. New. Drugs 21 , 85–97 (2003). 12795533 10.1023/a:1022976528441

300. Singh N Dueñas-González A Lyko F Medina-Franco JL Molecular modeling and molecular dynamics studies of hydralazine with human DNA methyltransferase 1 ChemMedChem 2009 4 792 799 10.1002/cmdc.200900017 19322801 Singh, N., Dueñas-González, A., Lyko, F. & Medina-Franco, J. L. Molecular modeling and molecular dynamics studies of hydralazine with human DNA methyltransferase 1. ChemMedChem 4 , 792–799 (2009). 19322801 10.1002/cmdc.200900017

301. Arce C A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer PLoS ONE 2006 1 e98 10.1371/journal.pone.0000098 17183730 PMC1762324 Arce, C. et al. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS ONE 1 , e98 (2006). 17183730 10.1371/journal.pone.0000098 PMC1762324

302. Coronel J A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results Med. Oncol. 2011 28 Suppl 1 S540 S546 10.1007/s12032-010-9700-3 20931299 Coronel, J. et al. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. Med. Oncol. 28 (Suppl 1), S540–S546 (2011). 20931299 10.1007/s12032-010-9700-3

303. Candelaria M Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial Ann. Hematol. 2011 90 379 387 10.1007/s00277-010-1090-2 20922525 Candelaria, M. et al. Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial. Ann. Hematol. 90 , 379–387 (2011). 20922525 10.1007/s00277-010-1090-2

304. Candelaria M A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors Ann. Oncol. 2007 18 1529 1538 10.1093/annonc/mdm204 17761710 Candelaria, M. et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann. Oncol. 18 , 1529–1538 (2007). 17761710 10.1093/annonc/mdm204

305. Wu X Zhang Y TET-mediated active DNA demethylation: mechanism, function and beyond Nat. Rev. Genet. 2017 18 517 534 10.1038/nrg.2017.33 28555658 Wu, X. & Zhang, Y. TET-mediated active DNA demethylation: mechanism, function and beyond. Nat. Rev. Genet. 18 , 517–534 (2017). 28555658 10.1038/nrg.2017.33

306. Ghosh K DNA demethylation in the hypothalamus promotes transcription of Agtr1a and Slc12a2 and hypertension development J. Biol. Chem. 2024 300 105597 10.1016/j.jbc.2023.105597 38160798 PMC10830874 Ghosh, K. et al. DNA demethylation in the hypothalamus promotes transcription of Agtr1a and Slc12a2 and hypertension development. J. Biol. Chem. 300 , 105597 (2024). 38160798 10.1016/j.jbc.2023.105597 PMC10830874

307. Singh AK Selective targeting of TET catalytic domain promotes somatic cell reprogramming Proc. Natl. Acad. Sci. USA 2020 117 3621 3626 10.1073/pnas.1910702117 32024762 PMC7035619 Singh, A. K. et al. Selective targeting of TET catalytic domain promotes somatic cell reprogramming. Proc. Natl. Acad. Sci. USA 117 , 3621–3626 (2020). 32024762 10.1073/pnas.1910702117 PMC7035619

308. Chen L Direct inhibition of dioxygenases TET1 by the rheumatoid arthritis drug auranofin selectively induces cancer cell death in T-ALL J. Hematol. Oncol. 2023 16 113 10.1186/s13045-023-01513-6 37993905 PMC10666452 Chen, L. et al. Direct inhibition of dioxygenases TET1 by the rheumatoid arthritis drug auranofin selectively induces cancer cell death in T-ALL. J. Hematol. Oncol. 16 , 113 (2023). 37993905 10.1186/s13045-023-01513-6 PMC10666452

309. Guan, Y. et al. Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia. J. Clin. Investig . 132 , e149856 (2022). 10.1172/JCI149856 PMC8843742 35085104

310. Gilreath J Lo M Bubalo J Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists Drugs 2021 81 1285 1305 10.1007/s40265-021-01553-7 34160821 PMC8318934 Gilreath, J., Lo, M. & Bubalo, J. Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists. Drugs 81 , 1285–1305 (2021). 34160821 10.1007/s40265-021-01553-7 PMC8318934

311. Chen LL Itaconate inhibits TET DNA dioxygenases to dampen inflammatory responses Nat. Cell. Biol. 2022 24 353 363 10.1038/s41556-022-00853-8 35256775 PMC9305987 Chen, L. L. et al. Itaconate inhibits TET DNA dioxygenases to dampen inflammatory responses. Nat. Cell. Biol. 24 , 353–363 (2022). 35256775 10.1038/s41556-022-00853-8 PMC9305987

312. Sciacovelli M Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition Nature 2016 537 544 547 10.1038/nature19353 27580029 PMC5136292 Sciacovelli, M. et al. Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition. Nature 537 , 544–547 (2016). 27580029 10.1038/nature19353 PMC5136292

313. Carey BW Intracellular α-ketoglutarate maintains the pluripotency of embryonic stem cells Nature 2015 518 413 416 10.1038/nature13981 25487152 PMC4336218 Carey, B. W. et al. Intracellular α-ketoglutarate maintains the pluripotency of embryonic stem cells. Nature 518 , 413–416 (2015). 25487152 10.1038/nature13981 PMC4336218

314. O’Neill LAJ Artyomov MN Itaconate: the poster child of metabolic reprogramming in macrophage function Nat. Rev. Immunol. 2019 19 273 281 10.1038/s41577-019-0128-5 30705422 O’Neill, L. A. J. & Artyomov, M. N. Itaconate: the poster child of metabolic reprogramming in macrophage function. Nat. Rev. Immunol. 19 , 273–281 (2019). 30705422 10.1038/s41577-019-0128-5

315. Mills EL Kelly B O’Neill LAJ Mitochondria are the powerhouses of immunity Nat. Immunol. 2017 18 488 498 10.1038/ni.3704 28418387 Mills, E. L., Kelly, B. & O’Neill, L. A. J. Mitochondria are the powerhouses of immunity. Nat. Immunol. 18 , 488–498 (2017). 28418387 10.1038/ni.3704

316. Zhao B Redox-active quinones induces genome-wide DNA methylation changes by an iron-mediated and Tet-dependent mechanism Nucl. Acids Res. 2014 42 1593 1605 10.1093/nar/gkt1090 24214992 PMC3919571 Zhao, B. et al. Redox-active quinones induces genome-wide DNA methylation changes by an iron-mediated and Tet-dependent mechanism. Nucl. Acids Res. 42 , 1593–1605 (2014). 24214992 10.1093/nar/gkt1090 PMC3919571

317. Guan Y A therapeutic strategy for preferential targeting of TET2 mutant and TET-dioxygenase deficient cells in myeloid neoplasms Blood Cancer Discov. 2021 2 146 161 10.1158/2643-3230.BCD-20-0173 33681816 PMC7935131 Guan, Y. et al. A therapeutic strategy for preferential targeting of TET2 mutant and TET-dioxygenase deficient cells in myeloid neoplasms. Blood Cancer Discov. 2 , 146–161 (2021). 33681816 10.1158/2643-3230.BCD-20-0173 PMC7935131

318. Lv H A small-molecule degrader of TET3 as treatment for anorexia nervosa in an animal model Proc. Natl Acad. Sci. USA 2023 120 e2300015120 10.1073/pnas.2300015120 37036983 PMC10120042 Lv, H. et al. A small-molecule degrader of TET3 as treatment for anorexia nervosa in an animal model. Proc. Natl Acad. Sci. USA 120 , e2300015120 (2023). 37036983 10.1073/pnas.2300015120 PMC10120042

319. Chen, F. et al. TET family members are integral to porcine oocyte maturation and parthenogenetic pre-implantation embryogenesis. Int. J. Mol. Sci . 24 , 12455 (2023). 10.3390/ijms241512455 PMC10419807 37569830

320. Jiang X Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia Nat. Commun. 2017 8 2099 10.1038/s41467-017-02290-w 29235481 PMC5727390 Jiang, X. et al. Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia. Nat. Commun. 8 , 2099 (2017). 29235481 10.1038/s41467-017-02290-w PMC5727390

321. Weirath NA Small molecule inhibitors of TET dioxygenases: Bobcat339 activity is mediated by contaminating copper(II) ACS Med. Chem. Lett. 2022 13 792 798 10.1021/acsmedchemlett.1c00677 35586434 PMC9109264 Weirath, N. A. et al. Small molecule inhibitors of TET dioxygenases: Bobcat339 activity is mediated by contaminating copper(II). ACS Med. Chem. Lett. 13 , 792–798 (2022). 35586434 10.1021/acsmedchemlett.1c00677 PMC9109264

322. Kim H Ten-eleven translocation protein 1 modulates medulloblastoma progression Genome. Biol. 2021 22 125 10.1186/s13059-021-02352-9 33926529 PMC8082834 Kim, H. et al. Ten-eleven translocation protein 1 modulates medulloblastoma progression. Genome. Biol. 22 , 125 (2021). 33926529 10.1186/s13059-021-02352-9 PMC8082834

323. Hore TA Retinol and ascorbate drive erasure of epigenetic memory and enhance reprogramming to naïve pluripotency by complementary mechanisms Proc. Natl. Acad. Sci. USA 2016 113 12202 12207 10.1073/pnas.1608679113 27729528 PMC5086989 Hore, T. A. et al. Retinol and ascorbate drive erasure of epigenetic memory and enhance reprogramming to naïve pluripotency by complementary mechanisms. Proc. Natl. Acad. Sci. USA 113 , 12202–12207 (2016). 27729528 10.1073/pnas.1608679113 PMC5086989

324. Zhao H Opioid receptor signaling suppresses leukemia through both catalytic and non-catalytic functions of TET2 Cell. Rep. 2022 38 110253 10.1016/j.celrep.2021.110253 35081358 Zhao, H. et al. Opioid receptor signaling suppresses leukemia through both catalytic and non-catalytic functions of TET2. Cell. Rep. 38 , 110253 (2022). 35081358 10.1016/j.celrep.2021.110253

325. Kim, H. et al. Development of novel epigenetic anti-cancer therapy targeting TET proteins. Int. J. Mol. Sci . 24 , 16375 (2023). 10.3390/ijms242216375 PMC10671484 38003566

326. Yin R Ascorbic acid enhances Tet-mediated 5-methylcytosine oxidation and promotes DNA demethylation in mammals J. Am. Chem. Soc. 2013 135 10396 10403 10.1021/ja4028346 23768208 Yin, R. et al. Ascorbic acid enhances Tet-mediated 5-methylcytosine oxidation and promotes DNA demethylation in mammals. J. Am. Chem. Soc. 135 , 10396–10403 (2013). 23768208 10.1021/ja4028346

327. Cimmino L Neel BG Aifantis I Vitamin C in stem cell reprogramming and cancer Trends Cell. Biol. 2018 28 698 708 10.1016/j.tcb.2018.04.001 29724526 PMC6102081 Cimmino, L., Neel, B. G. & Aifantis, I. Vitamin C in stem cell reprogramming and cancer. Trends Cell. Biol. 28 , 698–708 (2018). 29724526 10.1016/j.tcb.2018.04.001 PMC6102081

328. Shenoy N Ascorbic acid-induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma J. Clin. Investig. 2019 129 1612 1625 10.1172/JCI98747 30702441 PMC6436862 Shenoy, N. et al. Ascorbic acid-induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma. J. Clin. Investig. 129 , 1612–1625 (2019). 30702441 10.1172/JCI98747 PMC6436862

329. Röhr D Sodium-dependent Vitamin C transporter 2 deficiency impairs myelination and remyelination after injury: Roles of collagen and demethylation Glia 2017 65 1186 1200 10.1002/glia.23152 28456003 Röhr, D. et al. Sodium-dependent Vitamin C transporter 2 deficiency impairs myelination and remyelination after injury: Roles of collagen and demethylation. Glia 65 , 1186–1200 (2017). 28456003 10.1002/glia.23152

330. Yuan Y Vitamin C inhibits the metabolic changes induced by Tet1 insufficiency under high fat diet stress Mol. Nutr. Food Res. 2021 65 e2100417 10.1002/mnfr.202100417 34129274 Yuan, Y. et al. Vitamin C inhibits the metabolic changes induced by Tet1 insufficiency under high fat diet stress. Mol. Nutr. Food Res. 65 , e2100417 (2021). 34129274 10.1002/mnfr.202100417

331. Bensberg, M. et al. TET2 as a tumor suppressor and therapeutic target in T-cell acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA . 118 , e2110758118 (2021). 10.1073/pnas.2110758118 PMC8403940 34413196

332. Giansanti M Poly(ADP-Ribose) polymerase inhibitors for arsenic trioxide-resistant acute promyelocytic leukemia: synergistic in vitro antitumor effects with hypomethylating agents or high-dose vitamin C J. Pharmacol. Exp. Ther. 2021 377 385 397 10.1124/jpet.121.000537 33820831 Giansanti, M. et al. Poly(ADP-Ribose) polymerase inhibitors for arsenic trioxide-resistant acute promyelocytic leukemia: synergistic in vitro antitumor effects with hypomethylating agents or high-dose vitamin C. J. Pharmacol. Exp. Ther. 377 , 385–397 (2021). 33820831 10.1124/jpet.121.000537

333. Liu M Vitamin C increases viral mimicry induced by 5-aza-2’-deoxycytidine Proc. Natl. Acad. Sci. USA 2016 113 10238 10244 10.1073/pnas.1612262113 27573823 PMC5027469 Liu, M. et al. Vitamin C increases viral mimicry induced by 5-aza-2’-deoxycytidine. Proc. Natl. Acad. Sci. USA 113 , 10238–10244 (2016). 27573823 10.1073/pnas.1612262113 PMC5027469

334. Peng D Ascorbic acid induced TET2 enzyme activation enhances cancer immunotherapy efficacy in renal cell carcinoma Int. J. Biol. Sci. 2022 18 995 1007 10.7150/ijbs.67329 35173532 PMC8771844 Peng, D. et al. Ascorbic acid induced TET2 enzyme activation enhances cancer immunotherapy efficacy in renal cell carcinoma. Int. J. Biol. Sci. 18 , 995–1007 (2022). 35173532 10.7150/ijbs.67329 PMC8771844

335. Gillberg L Oral vitamin C supplementation to patients with myeloid cancer on azacitidine treatment: Normalization of plasma vitamin C induces epigenetic changes Clin. Epigenet. 2019 11 143 10.1186/s13148-019-0739-5 PMC6798470 31623675 Gillberg, L. et al. Oral vitamin C supplementation to patients with myeloid cancer on azacitidine treatment: Normalization of plasma vitamin C induces epigenetic changes. Clin. Epigenet. 11 , 143 (2019). 10.1186/s13148-019-0739-5 PMC6798470 31623675

336. Welch JS Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study Am. J. Hematol. 2011 86 796 800 10.1002/ajh.22092 21815182 Welch, J. S. et al. Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study. Am. J. Hematol. 86 , 796–800 (2011). 21815182 10.1002/ajh.22092

337. Carr AC Cook J Intravenous Vitamin C for cancer therapy—identifying the current gaps in our knowledge Front. Physiol. 2018 9 1182 10.3389/fphys.2018.01182 30190680 PMC6115501 Carr, A. C. & Cook, J. Intravenous Vitamin C for cancer therapy—identifying the current gaps in our knowledge. Front. Physiol. 9 , 1182 (2018). 30190680 10.3389/fphys.2018.01182 PMC6115501

338. McBrayer SK Transaminase Inhibition by 2-hydroxyglutarate impairs glutamate biosynthesis and redox homeostasis in glioma Cell 2018 175 101 116.e125 10.1016/j.cell.2018.08.038 30220459 PMC6219629 McBrayer, S. K. et al. Transaminase Inhibition by 2-hydroxyglutarate impairs glutamate biosynthesis and redox homeostasis in glioma. Cell 175 , 101–116.e125 (2018). 30220459 10.1016/j.cell.2018.08.038 PMC6219629

339. Li T D-2-hydroxyglutarate is necessary and sufficient for isocitrate dehydrogenase 1 mutant-induced MIR148A Promoter Methylation Mol. Cancer Res. 2018 16 947 960 10.1158/1541-7786.MCR-17-0367 29545476 PMC5984679 Li, T. et al. D-2-hydroxyglutarate is necessary and sufficient for isocitrate dehydrogenase 1 mutant-induced MIR148A Promoter Methylation. Mol. Cancer Res. 16 , 947–960 (2018). 29545476 10.1158/1541-7786.MCR-17-0367 PMC5984679

340. Yen K AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations Cancer Discov. 2017 7 478 493 10.1158/2159-8290.CD-16-1034 28193778 Yen, K. et al. AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations. Cancer Discov. 7 , 478–493 (2017). 28193778 10.1158/2159-8290.CD-16-1034

341. MacBeth KJ Combination of azacitidine and enasidenib enhances leukemic cell differentiation and cooperatively hypomethylates DNA Exp. Hematol. 2021 98 47 52.e46 10.1016/j.exphem.2021.03.003 33794295 MacBeth, K. J. et al. Combination of azacitidine and enasidenib enhances leukemic cell differentiation and cooperatively hypomethylates DNA. Exp. Hematol. 98 , 47–52.e46 (2021). 33794295 10.1016/j.exphem.2021.03.003

342. Yeung BHY Role of isocitrate dehydrogenase 2 on DNA hydroxymethylation in human airway smooth muscle cells Am. J. Respir. Cell. Mol. Biol. 2020 63 36 45 10.1165/rcmb.2019-0323OC 32150688 PMC7328249 Yeung, B. H. Y. et al. Role of isocitrate dehydrogenase 2 on DNA hydroxymethylation in human airway smooth muscle cells. Am. J. Respir. Cell. Mol. Biol. 63 , 36–45 (2020). 32150688 10.1165/rcmb.2019-0323OC PMC7328249

343. Fortin J Distinct and opposite effects of leukemogenic Idh and Tet2 mutations in hematopoietic stem and progenitor cells Proc. Natl. Acad. Sci. USA 2023 120 e2208176120 10.1073/pnas.2208176120 36652477 PMC9942850 Fortin, J. et al. Distinct and opposite effects of leukemogenic Idh and Tet2 mutations in hematopoietic stem and progenitor cells. Proc. Natl. Acad. Sci. USA 120 , e2208176120 (2023). 36652477 10.1073/pnas.2208176120 PMC9942850

344. Spallotta F Stable oxidative cytosine modifications accumulate in cardiac mesenchymal cells from type2 diabetes patients: rescue by α-ketoglutarate and TET-TDG functional reactivation Circ. Res. 2018 122 31 46 10.1161/CIRCRESAHA.117.311300 29158345 Spallotta, F. et al. Stable oxidative cytosine modifications accumulate in cardiac mesenchymal cells from type2 diabetes patients: rescue by α-ketoglutarate and TET-TDG functional reactivation. Circ. Res. 122 , 31–46 (2018). 29158345 10.1161/CIRCRESAHA.117.311300

345. Atlante S α-ketoglutarate dehydrogenase inhibition counteracts breast cancer-associated lung metastasis Cell. Death Dis. 2018 9 756 10.1038/s41419-018-0802-8 29988033 PMC6037705 Atlante, S. et al. α-ketoglutarate dehydrogenase inhibition counteracts breast cancer-associated lung metastasis. Cell. Death Dis. 9 , 756 (2018). 29988033 10.1038/s41419-018-0802-8 PMC6037705

346. Hu X Epigenetic drug screen identified IOX1 as an inhibitor of Th17-mediated inflammation through targeting TET2 EBioMedicine 2022 86 104333 10.1016/j.ebiom.2022.104333 36335665 PMC9646865 Hu, X. et al. Epigenetic drug screen identified IOX1 as an inhibitor of Th17-mediated inflammation through targeting TET2. EBioMedicine 86 , 104333 (2022). 36335665 10.1016/j.ebiom.2022.104333 PMC9646865

347. Ginder GD Williams DC Jr. Readers of DNA methylation, the MBD family as potential therapeutic targets Pharmacol. Ther. 2018 184 98 111 10.1016/j.pharmthera.2017.11.002 29128342 PMC6438182 Ginder, G. D. & Williams, D. C. Jr. Readers of DNA methylation, the MBD family as potential therapeutic targets. Pharmacol. Ther. 184 , 98–111 (2018). 29128342 10.1016/j.pharmthera.2017.11.002 PMC6438182

348. Mahmood N Arakelian A Szyf M Rabbani SA Methyl-CpG binding domain protein 2 (Mbd2) drives breast cancer progression through the modulation of epithelial-to-mesenchymal transition Exp. Mol. Med. 2024 56 959 974 10.1038/s12276-024-01205-2 38556549 PMC11058268 Mahmood, N., Arakelian, A., Szyf, M. & Rabbani, S. A. Methyl-CpG binding domain protein 2 (Mbd2) drives breast cancer progression through the modulation of epithelial-to-mesenchymal transition. Exp. Mol. Med. 56 , 959–974 (2024). 38556549 10.1038/s12276-024-01205-2 PMC11058268

349. Pan H CpG and methylation-dependent DNA binding and dynamics of the methylcytosine binding domain 2 protein at the single-molecule level Nucl. Acids Res. 2017 45 9164 9177 10.1093/nar/gkx548 28637186 PMC5587734 Pan, H. et al. CpG and methylation-dependent DNA binding and dynamics of the methylcytosine binding domain 2 protein at the single-molecule level. Nucl. Acids Res. 45 , 9164–9177 (2017). 28637186 10.1093/nar/gkx548 PMC5587734

350. Çalışkaner ZO Computational discovery of novel inhibitory candidates targeting versatile transcriptional repressor MBD2 J. Mol. Model 2022 28 296 10.1007/s00894-022-05297-3 36066769 Çalışkaner, Z. O. Computational discovery of novel inhibitory candidates targeting versatile transcriptional repressor MBD2. J. Mol. Model 28 , 296 (2022). 36066769 10.1007/s00894-022-05297-3

351. Gnanapragasam MN p66Alpha-MBD2 coiled-coil interaction and recruitment of Mi-2 are critical for globin gene silencing by the MBD2-NuRD complex Proc. Natl. Acad. Sci. USA 2011 108 7487 7492 10.1073/pnas.1015341108 21490301 PMC3088629 Gnanapragasam, M. N. et al. p66Alpha-MBD2 coiled-coil interaction and recruitment of Mi-2 are critical for globin gene silencing by the MBD2-NuRD complex. Proc. Natl. Acad. Sci. USA 108 , 7487–7492 (2011). 21490301 10.1073/pnas.1015341108 PMC3088629

352. Desai MA An intrinsically disordered region of methyl-CpG binding domain protein 2 (MBD2) recruits the histone deacetylase core of the NuRD complex Nucl. Acids Res. 2015 43 3100 3113 10.1093/nar/gkv168 25753662 PMC4381075 Desai, M. A. et al. An intrinsically disordered region of methyl-CpG binding domain protein 2 (MBD2) recruits the histone deacetylase core of the NuRD complex. Nucl. Acids Res. 43 , 3100–3113 (2015). 25753662 10.1093/nar/gkv168 PMC4381075

353. Leighton GO Analysis of the complex between MBD2 and the histone deacetylase core of NuRD reveals key interactions critical for gene silencing Proc. Natl. Acad. Sci. USA 2023 120 e2307287120 10.1073/pnas.2307287120 37552759 PMC10433457 Leighton, G. O. et al. Analysis of the complex between MBD2 and the histone deacetylase core of NuRD reveals key interactions critical for gene silencing. Proc. Natl. Acad. Sci. USA 120 , e2307287120 (2023). 37552759 10.1073/pnas.2307287120 PMC10433457

354. Kim MY Rational discovery of antimetastatic agents targeting the intrinsically disordered region of MBD2 Sci. Adv. 2019 5 eaav9810 10.1126/sciadv.aav9810 31799386 PMC6867884 Kim, M. Y. et al. Rational discovery of antimetastatic agents targeting the intrinsically disordered region of MBD2. Sci. Adv. 5 , eaav9810 (2019). 31799386 10.1126/sciadv.aav9810 PMC6867884

355. Na, I. et al. Drug discovery targeting the disorder-to-order transition regions through the conformational diversity mimicking and statistical analysis. Int. J. Mol. Sci . 21 , 5248 (2020). 10.3390/ijms21155248 PMC7432763 32722024

356. Sharif J The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA Nature 2007 450 908 912 10.1038/nature06397 17994007 Sharif, J. et al. The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA. Nature 450 , 908–912 (2007). 17994007 10.1038/nature06397

357. Kilin V Dynamics of methylated cytosine flipping by UHRF1 J. Am. Chem. Soc. 2017 139 2520 2528 10.1021/jacs.7b00154 28112929 PMC5335914 Kilin, V. et al. Dynamics of methylated cytosine flipping by UHRF1. J. Am. Chem. Soc. 139 , 2520–2528 (2017). 28112929 10.1021/jacs.7b00154 PMC5335914

358. Bostick M UHRF1 plays a role in maintaining DNA methylation in mammalian cells Science 2007 317 1760 1764 10.1126/science.1147939 17673620 Bostick, M. et al. UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science 317 , 1760–1764 (2007). 17673620 10.1126/science.1147939

359. Jiao D UHRF1 promotes renal cell carcinoma progression through epigenetic regulation of TXNIP Oncogene 2019 38 5686 5699 10.1038/s41388-019-0822-6 31043707 Jiao, D. et al. UHRF1 promotes renal cell carcinoma progression through epigenetic regulation of TXNIP. Oncogene 38 , 5686–5699 (2019). 31043707 10.1038/s41388-019-0822-6

360. Colyn L Dual targeting of G9a and DNA methyltransferase-1 for the treatment of experimental cholangiocarcinoma Hepatology 2021 73 2380 2396 10.1002/hep.31642 33222246 Colyn, L. et al. Dual targeting of G9a and DNA methyltransferase-1 for the treatment of experimental cholangiocarcinoma. Hepatology 73 , 2380–2396 (2021). 33222246 10.1002/hep.31642

361. Verdikt R Novel role of UHRF1 in the epigenetic repression of the latent HIV-1 EBioMedicine 2022 79 103985 10.1016/j.ebiom.2022.103985 35429693 PMC9038550 Verdikt, R. et al. Novel role of UHRF1 in the epigenetic repression of the latent HIV-1. EBioMedicine 79 , 103985 (2022). 35429693 10.1016/j.ebiom.2022.103985 PMC9038550

362. Myrianthopoulos V Tandem virtual screening targeting the SRA domain of UHRF1 identifies a novel chemical tool modulating DNA methylation Eur. J. Med. Chem. 2016 114 390 396 10.1016/j.ejmech.2016.02.043 27049577 Myrianthopoulos, V. et al. Tandem virtual screening targeting the SRA domain of UHRF1 identifies a novel chemical tool modulating DNA methylation. Eur. J. Med. Chem. 114 , 390–396 (2016). 27049577 10.1016/j.ejmech.2016.02.043

363. Zaayter L A molecular tool targeting the base-flipping activity of human UHRF1 Chemistry 2019 25 13363 13375 10.1002/chem.201902605 31322780 Zaayter, L. et al. A molecular tool targeting the base-flipping activity of human UHRF1. Chemistry 25 , 13363–13375 (2019). 31322780 10.1002/chem.201902605

364. Hu CL Targeting UHRF1-SAP30-MXD4 axis for leukemia initiating cell eradication in myeloid leukemia Cell. Res. 2022 32 1105 1123 10.1038/s41422-022-00735-6 36302855 PMC9715639 Hu, C. L. et al. Targeting UHRF1-SAP30-MXD4 axis for leukemia initiating cell eradication in myeloid leukemia. Cell. Res. 32 , 1105–1123 (2022). 36302855 10.1038/s41422-022-00735-6 PMC9715639

365. Awal MA Structural-guided identification of small molecule inhibitor of UHRF1 methyltransferase activity Front. Genet. 2022 13 928884 10.3389/fgene.2022.928884 35991572 PMC9382028 Awal, M. A. et al. Structural-guided identification of small molecule inhibitor of UHRF1 methyltransferase activity. Front. Genet. 13 , 928884 (2022). 35991572 10.3389/fgene.2022.928884 PMC9382028

366. Lou C Screening inhibitors for blocking UHRF1-methylated DNA interaction with capillary electrophoresis J. Chromatogr. A 2021 1636 461790 10.1016/j.chroma.2020.461790 33340746 Lou, C. et al. Screening inhibitors for blocking UHRF1-methylated DNA interaction with capillary electrophoresis. J. Chromatogr. A 1636 , 461790 (2021). 33340746 10.1016/j.chroma.2020.461790

367. Ciaco S Inhibitors of UHRF1 base flipping activity showing cytotoxicity against cancer cells Bioorg. Chem. 2023 137 106616 10.1016/j.bioorg.2023.106616 37247564 Ciaco, S. et al. Inhibitors of UHRF1 base flipping activity showing cytotoxicity against cancer cells. Bioorg. Chem. 137 , 106616 (2023). 37247564 10.1016/j.bioorg.2023.106616

368. Senisterra G Discovery of small-molecule antagonists of the H3K9me3 binding to UHRF1 tandem tudor domain SLAS Discov. 2018 23 930 940 10.1177/2472555218766278 29562800 Senisterra, G. et al. Discovery of small-molecule antagonists of the H3K9me3 binding to UHRF1 tandem tudor domain. SLAS Discov. 23 , 930–940 (2018). 29562800 10.1177/2472555218766278

369. Rajakumara E PHD finger recognition of unmodified histone H3R2 links UHRF1 to regulation of euchromatic gene expression Mol. Cell. 2011 43 275 284 10.1016/j.molcel.2011.07.006 21777816 PMC4691841 Rajakumara, E. et al. PHD finger recognition of unmodified histone H3R2 links UHRF1 to regulation of euchromatic gene expression. Mol. Cell. 43 , 275–284 (2011). 21777816 10.1016/j.molcel.2011.07.006 PMC4691841

370. Kori S Structure-based screening combined with computational and biochemical analyses identified the inhibitor targeting the binding of DNA Ligase 1 to UHRF1 Bioorg Med. Chem. 2021 52 116500 10.1016/j.bmc.2021.116500 34801826 Kori, S. et al. Structure-based screening combined with computational and biochemical analyses identified the inhibitor targeting the binding of DNA Ligase 1 to UHRF1. Bioorg Med. Chem. 52 , 116500 (2021). 34801826 10.1016/j.bmc.2021.116500

371. Chang L Discovery of small molecules targeting the tandem tudor domain of the epigenetic factor UHRF1 using fragment-based ligand discovery Sci. Rep. 2021 11 1121 10.1038/s41598-020-80588-4 33441849 PMC7806715 Chang, L. et al. Discovery of small molecules targeting the tandem tudor domain of the epigenetic factor UHRF1 using fragment-based ligand discovery. Sci. Rep. 11 , 1121 (2021). 33441849 10.1038/s41598-020-80588-4 PMC7806715

372. Liu WH Discovery and mechanism of small molecule inhibitors selective for the chromatin-binding domains of oncogenic UHRF1 Biochemistry 2022 61 354 366 10.1021/acs.biochem.1c00698 35143176 PMC9190237 Liu, W. H. et al. Discovery and mechanism of small molecule inhibitors selective for the chromatin-binding domains of oncogenic UHRF1. Biochemistry 61 , 354–366 (2022). 35143176 10.1021/acs.biochem.1c00698 PMC9190237

373. Niinuma T UHRF1 depletion and HDAC inhibition reactivate epigenetically silenced genes in colorectal cancer cells Clin. Epigenet. 2019 11 70 10.1186/s13148-019-0668-3 PMC6505222 31064417 Niinuma, T. et al. UHRF1 depletion and HDAC inhibition reactivate epigenetically silenced genes in colorectal cancer cells. Clin. Epigenet. 11 , 70 (2019). 10.1186/s13148-019-0668-3 PMC6505222 31064417

374. Kim JK UHRF1 downmodulation enhances antitumor effects of histone deacetylase inhibitors in retinoblastoma by augmenting oxidative stress-mediated apoptosis Mol. Oncol. 2020 14 329 346 10.1002/1878-0261.12607 31782885 PMC6998393 Kim, J. K. et al. UHRF1 downmodulation enhances antitumor effects of histone deacetylase inhibitors in retinoblastoma by augmenting oxidative stress-mediated apoptosis. Mol. Oncol. 14 , 329–346 (2020). 31782885 10.1002/1878-0261.12607 PMC6998393

375. Demir, S. et al. Targeting G9a/DNMT1 methyltransferase activity impedes IGF2-mediated survival in hepatoblastoma. Hepatol. Commun . 8 , e0378 (2024). 10.1097/HC9.0000000000000378 PMC10830081 38285887

376. Abdullah, O. et al. Thymoquinone is a multitarget single epidrug that inhibits the UHRF1 protein complex. Genes 12 , 622 (2021). 10.3390/genes12050622 PMC8143546 33922029

377. Fang T Lenvatinib inhibited HCC cell migration and invasion through regulating the transcription and ubiquitination of UHRF1 and DNMT1 Biochem. Pharmacol. 2023 210 115489 10.1016/j.bcp.2023.115489 36893815 Fang, T. et al. Lenvatinib inhibited HCC cell migration and invasion through regulating the transcription and ubiquitination of UHRF1 and DNMT1. Biochem. Pharmacol. 210 , 115489 (2023). 36893815 10.1016/j.bcp.2023.115489

378. Chow M Maintenance and pharmacologic targeting of ROR1 protein levels via UHRF1 in t(1;19) pre-B-ALL Oncogene 2018 37 5221 5232 10.1038/s41388-018-0299-8 29849118 PMC6150818 Chow, M. et al. Maintenance and pharmacologic targeting of ROR1 protein levels via UHRF1 in t(1;19) pre-B-ALL. Oncogene 37 , 5221–5232 (2018). 29849118 10.1038/s41388-018-0299-8 PMC6150818

379. Peng Y Diosgenin inhibits prostate cancer progression by inducing UHRF1 protein degradation Eur. J. Pharmacol. 2023 942 175522 10.1016/j.ejphar.2023.175522 36681316 Peng, Y. et al. Diosgenin inhibits prostate cancer progression by inducing UHRF1 protein degradation. Eur. J. Pharmacol. 942 , 175522 (2023). 36681316 10.1016/j.ejphar.2023.175522

380. Fu Y AKT1 regulates UHRF1 protein stability and promotes the resistance to abiraterone in prostate cancer Oncogenesis 2023 12 1 10.1038/s41389-022-00446-y 36593255 PMC9807647 Fu, Y. et al. AKT1 regulates UHRF1 protein stability and promotes the resistance to abiraterone in prostate cancer. Oncogenesis 12 , 1 (2023). 36593255 10.1038/s41389-022-00446-y PMC9807647

381. Wang Y UHRF1 inhibition epigenetically reprograms cancer stem cells to suppress the tumorigenic phenotype of hepatocellular carcinoma Cell. Death Dis. 2023 14 381 10.1038/s41419-023-05895-w 37380646 PMC10307895 Wang, Y. et al. UHRF1 inhibition epigenetically reprograms cancer stem cells to suppress the tumorigenic phenotype of hepatocellular carcinoma. Cell. Death Dis. 14 , 381 (2023). 37380646 10.1038/s41419-023-05895-w PMC10307895

382. Bousiges O Spatial memory consolidation is associated with induction of several lysine-acetyltransferase (histone acetyltransferase) expression levels and H2B/H4 acetylation-dependent transcriptional events in the rat hippocampus Neuropsychopharmacology 2010 35 2521 2537 10.1038/npp.2010.117 20811339 PMC3055563 Bousiges, O. et al. Spatial memory consolidation is associated with induction of several lysine-acetyltransferase (histone acetyltransferase) expression levels and H2B/H4 acetylation-dependent transcriptional events in the rat hippocampus. Neuropsychopharmacology 35 , 2521–2537 (2010). 20811339 10.1038/npp.2010.117 PMC3055563

383. Kawabe Y ACE2 exerts anti-obesity effect via stimulating brown adipose tissue and induction of browning in white adipose tissue Am. J. Physiol. Endocrinol. Metab. 2019 317 E1140 e1149 10.1152/ajpendo.00311.2019 31638856 Kawabe, Y. et al. ACE2 exerts anti-obesity effect via stimulating brown adipose tissue and induction of browning in white adipose tissue. Am. J. Physiol. Endocrinol. Metab. 317 , E1140–e1149 (2019). 31638856 10.1152/ajpendo.00311.2019

384. Malone CF The KAT module of the SAGA complex maintains the oncogenic gene expression program in MYCN-amplified neuroblastoma Sci. Adv. 2024 10 eadm9449 10.1126/sciadv.adm9449 38820154 PMC11141635 Malone, C. F. et al. The KAT module of the SAGA complex maintains the oncogenic gene expression program in MYCN-amplified neuroblastoma. Sci. Adv. 10 , eadm9449 (2024). 38820154 10.1126/sciadv.adm9449 PMC11141635

385. Sheikh BN Akhtar A The many lives of KATs - detectors, integrators and modulators of the cellular environment Nat. Rev. Genet. 2019 20 7 23 10.1038/s41576-018-0072-4 30390049 Sheikh, B. N. & Akhtar, A. The many lives of KATs - detectors, integrators and modulators of the cellular environment. Nat. Rev. Genet. 20 , 7–23 (2019). 30390049 10.1038/s41576-018-0072-4

386. Strachowska M Robaszkiewicz A Characteristics of anticancer activity of CBP/p300 inhibitors - Features of their classes, intracellular targets and future perspectives of their application in cancer treatment Pharmacol. Ther. 2024 257 108636 10.1016/j.pharmthera.2024.108636 38521246 Strachowska, M. & Robaszkiewicz, A. Characteristics of anticancer activity of CBP/p300 inhibitors - Features of their classes, intracellular targets and future perspectives of their application in cancer treatment. Pharmacol. Ther. 257 , 108636 (2024). 38521246 10.1016/j.pharmthera.2024.108636

387. Suryanarayanan V Rajavel T Devi KP Singh SK Structure based identification and biological evaluation of novel and potent inhibitors of PCAF catalytic domain Int. J. Biol. Macromol. 2018 120 823 834 10.1016/j.ijbiomac.2018.08.052 30118769 Suryanarayanan, V., Rajavel, T., Devi, K. P. & Singh, S. K. Structure based identification and biological evaluation of novel and potent inhibitors of PCAF catalytic domain. Int. J. Biol. Macromol. 120 , 823–834 (2018). 30118769 10.1016/j.ijbiomac.2018.08.052

388. Baell JB Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth Nature 2018 560 253 257 10.1038/s41586-018-0387-5 30069049 Baell, J. B. et al. Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth. Nature 560 , 253–257 (2018). 30069049 10.1038/s41586-018-0387-5

389. Vannam R Targeted degradation of the enhancer lysine acetyltransferases CBP and p300 Cell. Chem. Biol. 2021 28 503 514.e512 10.1016/j.chembiol.2020.12.004 33400925 Vannam, R. et al. Targeted degradation of the enhancer lysine acetyltransferases CBP and p300. Cell. Chem. Biol. 28 , 503–514.e512 (2021). 33400925 10.1016/j.chembiol.2020.12.004

390. Nicosia L Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies Cancer Cell. 2023 41 2136 2153.e2113 10.1016/j.ccell.2023.11.001 37995682 Nicosia, L. et al. Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies. Cancer Cell. 41 , 2136–2153.e2113 (2023). 37995682 10.1016/j.ccell.2023.11.001

391. Welti J Targeting the p300/CBP axis in lethal prostate cancer Cancer Discov. 2021 11 1118 1137 10.1158/2159-8290.CD-20-0751 33431496 PMC8102310 Welti, J. et al. Targeting the p300/CBP axis in lethal prostate cancer. Cancer Discov. 11 , 1118–1137 (2021). 33431496 10.1158/2159-8290.CD-20-0751 PMC8102310

392. Caligiuri M FT-6876, a potent and selective inhibitor of CBP/p300, is active in preclinical models of androgen receptor-positive breast cancer Target. Oncol. 2023 18 269 285 10.1007/s11523-023-00949-7 36826464 PMC10042772 Caligiuri, M. et al. FT-6876, a potent and selective inhibitor of CBP/p300, is active in preclinical models of androgen receptor-positive breast cancer. Target. Oncol. 18 , 269–285 (2023). 36826464 10.1007/s11523-023-00949-7 PMC10042772

393. Yan Y The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer EMBO Mol. Med. 2019 11 e10659 10.15252/emmm.201910659 31559706 PMC6835201 Yan, Y. et al. The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer. EMBO Mol. Med. 11 , e10659 (2019). 31559706 10.15252/emmm.201910659 PMC6835201

394. Morrison-Smith CD Combined targeting of the BRD4-NUT-p300 axis in NUT midline carcinoma by dual selective bromodomain inhibitor, NEO2734 Mol. Cancer Ther. 2020 19 1406 1414 10.1158/1535-7163.MCT-20-0087 32371576 PMC12108540 Morrison-Smith, C. D. et al. Combined targeting of the BRD4-NUT-p300 axis in NUT midline carcinoma by dual selective bromodomain inhibitor, NEO2734. Mol. Cancer Ther. 19 , 1406–1414 (2020). 32371576 10.1158/1535-7163.MCT-20-0087 PMC12108540

395. Yamaji K Molecular insights of a CBP/β-catenin-signaling inhibitor on nonalcoholic steatohepatitis-induced liver fibrosis and disorder Biomed. Pharmacother. 2023 166 115379 10.1016/j.biopha.2023.115379 37647690 Yamaji, K. et al. Molecular insights of a CBP/β-catenin-signaling inhibitor on nonalcoholic steatohepatitis-induced liver fibrosis and disorder. Biomed. Pharmacother. 166 , 115379 (2023). 37647690 10.1016/j.biopha.2023.115379

396. Kimura K Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: an investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study EBioMedicine 2022 80 104069 10.1016/j.ebiom.2022.104069 35605429 PMC9126795 Kimura, K. et al. Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: an investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study. EBioMedicine 80 , 104069 (2022). 35605429 10.1016/j.ebiom.2022.104069 PMC9126795

397. Kimura K Safety, tolerability, and preliminary efficacy of the anti-fibrotic small molecule PRI-724, a CBP/β-catenin inhibitor, in patients with hepatitis C virus-related cirrhosis: a single-center, open-label, dose escalation phase 1 trial EBioMedicine 2017 23 79 87 10.1016/j.ebiom.2017.08.016 28844410 PMC5605374 Kimura, K. et al. Safety, tolerability, and preliminary efficacy of the anti-fibrotic small molecule PRI-724, a CBP/β-catenin inhibitor, in patients with hepatitis C virus-related cirrhosis: a single-center, open-label, dose escalation phase 1 trial. EBioMedicine 23 , 79–87 (2017). 28844410 10.1016/j.ebiom.2017.08.016 PMC5605374

398. Liang T Targeting histone deacetylases for cancer therapy: trends and challenges Acta Pharmacol. Sin. B 2023 13 2425 2463 10.1016/j.apsb.2023.02.007 PMC10326266 37425042 Liang, T. et al. Targeting histone deacetylases for cancer therapy: trends and challenges. Acta Pharmacol. Sin. B 13 , 2425–2463 (2023). 10.1016/j.apsb.2023.02.007 PMC10326266 37425042

399. Jiang Y Sirtuin inhibition: strategies, inhibitors, and therapeutic potential Trends Pharmacol. Sci. 2017 38 459 472 10.1016/j.tips.2017.01.009 28389129 Jiang, Y. et al. Sirtuin inhibition: strategies, inhibitors, and therapeutic potential. Trends Pharmacol. Sci. 38 , 459–472 (2017). 28389129 10.1016/j.tips.2017.01.009

400. Li Y Zinc-dependent deacetylase (HDAC) inhibitors with different zinc binding groups Curr. Top. Med. Chem. 2019 19 223 241 10.2174/1568026619666190122144949 30674261 Li, Y. et al. Zinc-dependent deacetylase (HDAC) inhibitors with different zinc binding groups. Curr. Top. Med. Chem. 19 , 223–241 (2019). 30674261 10.2174/1568026619666190122144949

401. Jo JH A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma Int. J. Cancer 2022 151 1565 1577 10.1002/ijc.34144 35657348 PMC9545559 Jo, J. H. et al. A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma. Int. J. Cancer 151 , 1565–1577 (2022). 35657348 10.1002/ijc.34144 PMC9545559

402. Collier KA A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies Cancer Chemother. Pharmacol. 2021 87 599 611 10.1007/s00280-020-04229-3 33492438 PMC8162746 Collier, K. A. et al. A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies. Cancer Chemother. Pharmacol. 87 , 599–611 (2021). 33492438 10.1007/s00280-020-04229-3 PMC8162746

403. Welling DB Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas Laryngosc. Investig. Otolaryngol. 2021 6 1008 1019 10.1002/lio2.643 PMC8513424 34667843 Welling, D. B. et al. Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas. Laryngosc. Investig. Otolaryngol. 6 , 1008–1019 (2021). 10.1002/lio2.643 PMC8513424 34667843

404. Aggarwal R Inhibiting histone deacetylase as a means to reverse resistance to angiogenesis inhibitors: phase I study of abexinostat plus pazopanib in advanced solid tumor malignancies J. Clin. Oncol. 2017 35 1231 1239 10.1200/JCO.2016.70.5350 28221861 PMC5791833 Aggarwal, R. et al. Inhibiting histone deacetylase as a means to reverse resistance to angiogenesis inhibitors: phase I study of abexinostat plus pazopanib in advanced solid tumor malignancies. J. Clin. Oncol. 35 , 1231–1239 (2017). 28221861 10.1200/JCO.2016.70.5350 PMC5791833

405. Ribrag V Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study Haematologica 2017 102 903 909 10.3324/haematol.2016.154377 28126962 PMC5477609 Ribrag, V. et al. Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study. Haematologica 102 , 903–909 (2017). 28126962 10.3324/haematol.2016.154377 PMC5477609

406. Evens AM A phase I/II multicenter, open-label study of the oral histone deacetylase inhibitor abexinostat in relapsed/refractory lymphoma Clin. Cancer Res. 2016 22 1059 1066 10.1158/1078-0432.CCR-15-0624 26482040 Evens, A. M. et al. A phase I/II multicenter, open-label study of the oral histone deacetylase inhibitor abexinostat in relapsed/refractory lymphoma. Clin. Cancer Res. 22 , 1059–1066 (2016). 26482040 10.1158/1078-0432.CCR-15-0624

407. Zhou YB Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma Acta Pharmacol. Sin. 2022 43 1091 1099 10.1038/s41401-021-00728-y 34341512 PMC8976035 Zhou, Y. B. et al. Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma. Acta Pharmacol. Sin. 43 , 1091–1099 (2022). 34341512 10.1038/s41401-021-00728-y PMC8976035

408. Shah RR Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology Drug. Saf. 2019 42 235 245 10.1007/s40264-018-0773-9 30649740 Shah, R. R. Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology. Drug. Saf. 42 , 235–245 (2019). 30649740 10.1007/s40264-018-0773-9

409. Ho TCS Chan AHY Ganesan A Thirty years of HDAC inhibitors: 2020 insight and hindsight J. Med. Chem. 2020 63 12460 12484 10.1021/acs.jmedchem.0c00830 32608981 Ho, T. C. S., Chan, A. H. Y. & Ganesan, A. Thirty years of HDAC inhibitors: 2020 insight and hindsight. J. Med. Chem. 63 , 12460–12484 (2020). 32608981 10.1021/acs.jmedchem.0c00830

410. Roche J Bertrand P Inside HDACs with more selective HDAC inhibitors Eur. J. Med. Chem. 2016 121 451 483 10.1016/j.ejmech.2016.05.047 27318122 Roche, J. & Bertrand, P. Inside HDACs with more selective HDAC inhibitors. Eur. J. Med. Chem. 121 , 451–483 (2016). 27318122 10.1016/j.ejmech.2016.05.047

411. Adhikari N Jha T Ghosh B Dissecting histone deacetylase 3 in multiple disease conditions: selective inhibition as a promising therapeutic strategy J. Med. Chem. 2021 64 8827 8869 10.1021/acs.jmedchem.0c01676 34161101 Adhikari, N., Jha, T. & Ghosh, B. Dissecting histone deacetylase 3 in multiple disease conditions: selective inhibition as a promising therapeutic strategy. J. Med. Chem. 64 , 8827–8869 (2021). 34161101 10.1021/acs.jmedchem.0c01676

412. Xu B Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for chinese patients with hormone receptor-positive advanced breast cancer: a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial Acta Pharmacol. Sin. B 2023 13 2250 2258 10.1016/j.apsb.2023.02.001 PMC10213795 37250148 Xu, B. et al. Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for chinese patients with hormone receptor-positive advanced breast cancer: a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial. Acta Pharmacol. Sin. B 13 , 2250–2258 (2023). 10.1016/j.apsb.2023.02.001 PMC10213795 37250148

413. Karasic TB Phase I trial of regorafenib, hydroxychloroquine, and entinostat in metastatic colorectal cancer Oncologist 2022 27 716 e689 10.1093/oncolo/oyac078 35552447 PMC9438902 Karasic, T. B. et al. Phase I trial of regorafenib, hydroxychloroquine, and entinostat in metastatic colorectal cancer. Oncologist 27 , 716–e689 (2022). 35552447 10.1093/oncolo/oyac078 PMC9438902

414. Gentzler RD Phase I study of entinostat, atezolizumab, carboplatin, and etoposide in previously untreated extensive-stage small cell lung cancer, ETCTN 10399 Oncologist 2023 28 1007 e1107 10.1093/oncolo/oyad221 37555284 PMC10628589 Gentzler, R. D. et al. Phase I study of entinostat, atezolizumab, carboplatin, and etoposide in previously untreated extensive-stage small cell lung cancer, ETCTN 10399. Oncologist 28 , 1007–e1107 (2023). 37555284 10.1093/oncolo/oyad221 PMC10628589

415. Duska LR A surgical window trial evaluating medroxyprogesterone acetate with or without entinostat in patients with endometrial cancer and validation of biomarkers of cellular response Clin. Cancer Res. 2021 27 2734 2741 10.1158/1078-0432.CCR-20-4618 33766814 PMC8127359 Duska, L. R. et al. A surgical window trial evaluating medroxyprogesterone acetate with or without entinostat in patients with endometrial cancer and validation of biomarkers of cellular response. Clin. Cancer Res. 27 , 2734–2741 (2021). 33766814 10.1158/1078-0432.CCR-20-4618 PMC8127359

416. Carraway HE Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia Leuk. Res. 2021 110 106707 10.1016/j.leukres.2021.106707 34563945 PMC8915247 Carraway, H. E. et al. Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia. Leuk. Res. 110 , 106707 (2021). 34563945 10.1016/j.leukres.2021.106707 PMC8915247

417. Lai CJ CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity Cancer Res. 2010 70 3647 3656 10.1158/0008-5472.CAN-09-3360 20388807 Lai, C. J. et al. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res. 70 , 3647–3656 (2010). 20388807 10.1158/0008-5472.CAN-09-3360

418. Yu CC A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I Biochem. Pharmacol. 2014 90 320 330 10.1016/j.bcp.2014.06.001 24915421 Yu, C. C. et al. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I. Biochem. Pharmacol. 90 , 320–330 (2014). 24915421 10.1016/j.bcp.2014.06.001

419. Moertl, S. et al. Comparison of radiosensitization by HDAC inhibitors CUDC-101 and SAHA in pancreatic cancer cells. Int. J. Mol. Sci . 20 , 3259 (2019). 10.3390/ijms20133259 PMC6651299 31269745

420. Galloway TJ A phase I study Of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma Clin. Cancer Res. 2015 21 1566 1573 10.1158/1078-0432.CCR-14-2820 25573383 PMC6607903 Galloway, T. J. et al. A phase I study Of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma. Clin. Cancer Res. 21 , 1566–1573 (2015). 25573383 10.1158/1078-0432.CCR-14-2820 PMC6607903

421. Shimizu T Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors Clin. Cancer Res. 2014 20 5032 5040 10.1158/1078-0432.CCR-14-0570 25107918 Shimizu, T. et al. Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors. Clin. Cancer Res. 20 , 5032–5040 (2014). 25107918 10.1158/1078-0432.CCR-14-0570

422. Oki Y CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial Haematologica 2017 102 1923 1930 10.3324/haematol.2017.172882 28860342 PMC5664396 Oki, Y. et al. CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial. Haematologica 102 , 1923–1930 (2017). 28860342 10.3324/haematol.2017.172882 PMC5664396

423. Landsburg DJ Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses Br. J. Haematol. 2021 195 201 209 10.1111/bjh.17730 34341990 Landsburg, D. J. et al. Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses. Br. J. Haematol. 195 , 201–209 (2021). 34341990 10.1111/bjh.17730

424. Reijers ILM IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma J Exp Med. 2023 220 e20221952 10.1084/jem.20221952 36920329 PMC10037109 Reijers, I. L. M. et al. IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma. J Exp Med. 220 , e20221952 (2023). 36920329 10.1084/jem.20221952 PMC10037109

425. Ito K A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression Proc. Natl. Acad. Sci. USA 2002 99 8921 8926 10.1073/pnas.132556899 12070353 PMC124399 Ito, K. et al. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc. Natl. Acad. Sci. USA 99 , 8921–8926 (2002). 12070353 10.1073/pnas.132556899 PMC124399

426. Cosío BG Oral low-dose theophylline on top of inhaled fluticasone-salmeterol does not reduce exacerbations in patients with severe COPD: a pilot clinical trial Chest 2016 150 123 130 10.1016/j.chest.2016.04.011 27107490 Cosío, B. G. et al. Oral low-dose theophylline on top of inhaled fluticasone-salmeterol does not reduce exacerbations in patients with severe COPD: a pilot clinical trial. Chest 150 , 123–130 (2016). 27107490 10.1016/j.chest.2016.04.011

427. Vaquero A SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis Genes. Dev. 2006 20 1256 1261 10.1101/gad.1412706 16648462 PMC1472900 Vaquero, A. et al. SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. Genes. Dev. 20 , 1256–1261 (2006). 16648462 10.1101/gad.1412706 PMC1472900

428. Gomes P Fleming Outeiro T Cavadas C Emerging role of sirtuin 2 in the regulation of mammalian metabolism Trends Pharmacol. Sci. 2015 36 756 768 10.1016/j.tips.2015.08.001 26538315 Gomes, P., Fleming Outeiro, T. & Cavadas, C. Emerging role of sirtuin 2 in the regulation of mammalian metabolism. Trends Pharmacol. Sci. 36 , 756–768 (2015). 26538315 10.1016/j.tips.2015.08.001

429. Shen H Mitochondrial sirtuins in cancer: a revisited review from molecular mechanisms to therapeutic strategies Theranostics 2024 14 2993 3013 10.7150/thno.97320 38773972 PMC11103492 Shen, H. et al. Mitochondrial sirtuins in cancer: a revisited review from molecular mechanisms to therapeutic strategies. Theranostics 14 , 2993–3013 (2024). 38773972 10.7150/thno.97320 PMC11103492

430. Ianni A SIRT7: a novel molecular target for personalized cancer treatment? Oncogene 2024 43 993 1006 10.1038/s41388-024-02976-8 38383727 PMC10978493 Ianni, A. et al. SIRT7: a novel molecular target for personalized cancer treatment? Oncogene 43 , 993–1006 (2024). 38383727 10.1038/s41388-024-02976-8 PMC10978493

431. Bedalov A Identification of a small molecule inhibitor of Sir2p Proc. Natl. Acad. Sci. USA 2001 98 15113 15118 10.1073/pnas.261574398 11752457 PMC64992 Bedalov, A. et al. Identification of a small molecule inhibitor of Sir2p. Proc. Natl. Acad. Sci. USA 98 , 15113–15118 (2001). 11752457 10.1073/pnas.261574398 PMC64992

432. Grozinger CM Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening J. Biol. Chem. 2001 276 38837 38843 10.1074/jbc.M106779200 11483616 Grozinger, C. M. et al. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J. Biol. Chem. 276 , 38837–38843 (2001). 11483616 10.1074/jbc.M106779200

433. Broussy S Laaroussi H Vidal M Biochemical mechanism and biological effects of the inhibition of silent information regulator 1 (SIRT1) by EX-527 (SEN0014196 or selisistat) J. Enzym. Inhib. Med. Chem. 2020 35 1124 1136 10.1080/14756366.2020.1758691 PMC7241506 32366137 Broussy, S., Laaroussi, H. & Vidal, M. Biochemical mechanism and biological effects of the inhibition of silent information regulator 1 (SIRT1) by EX-527 (SEN0014196 or selisistat). J. Enzym. Inhib. Med. Chem. 35 , 1124–1136 (2020). 10.1080/14756366.2020.1758691 PMC7241506 32366137

434. Peck B SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2 Mol. Cancer Ther. 2010 9 844 855 10.1158/1535-7163.MCT-09-0971 20371709 Peck, B. et al. SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol. Cancer Ther. 9 , 844–855 (2010). 20371709 10.1158/1535-7163.MCT-09-0971

435. Spinck M Discovery of dihydro-1,4-benzoxazine carboxamides as potent and highly selective inhibitors of sirtuin-1 J. Med. Chem. 2021 64 5838 5849 10.1021/acs.jmedchem.1c00017 33876629 Spinck, M. et al. Discovery of dihydro-1,4-benzoxazine carboxamides as potent and highly selective inhibitors of sirtuin-1. J. Med. Chem. 64 , 5838–5849 (2021). 33876629 10.1021/acs.jmedchem.1c00017

436. Trapp J Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition J. Med. Chem. 2006 49 7307 7316 10.1021/jm060118b 17149860 Trapp, J. et al. Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition. J. Med. Chem. 49 , 7307–7316 (2006). 17149860 10.1021/jm060118b

437. Shim KH Small-molecule drug screening identifies drug Ro 31-8220 that reduces toxic phosphorylated tau in Drosophila melanogaster Neurobiol. Dis. 2019 130 104519 10.1016/j.nbd.2019.104519 31233882 Shim, K. H. et al. Small-molecule drug screening identifies drug Ro 31-8220 that reduces toxic phosphorylated tau in Drosophila melanogaster. Neurobiol. Dis. 130 , 104519 (2019). 31233882 10.1016/j.nbd.2019.104519

438. Disch JS Discovery of thieno[3,2-d]pyrimidine-6-carboxamides as potent inhibitors of SIRT1, SIRT2, and SIRT3 J. Med. Chem. 2013 56 3666 3679 10.1021/jm400204k 23570514 Disch, J. S. et al. Discovery of thieno[3,2-d]pyrimidine-6-carboxamides as potent inhibitors of SIRT1, SIRT2, and SIRT3. J. Med. Chem. 56 , 3666–3679 (2013). 23570514 10.1021/jm400204k

439. Lain S Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator Cancer Cell. 2008 13 454 463 10.1016/j.ccr.2008.03.004 18455128 PMC2742717 Lain, S. et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell. 13 , 454–463 (2008).l 18455128 10.1016/j.ccr.2008.03.004 PMC2742717

440. Moreno-Yruela C Hydroxamic acid-modified peptide microarrays for profiling isozyme-selective interactions and inhibition of histone deacetylases Nat. Commun. 2021 12 62 10.1038/s41467-020-20250-9 33397936 PMC7782793 Moreno-Yruela, C. et al. Hydroxamic acid-modified peptide microarrays for profiling isozyme-selective interactions and inhibition of histone deacetylases. Nat. Commun. 12 , 62 (2021). 33397936 10.1038/s41467-020-20250-9 PMC7782793

441. Asaba T Inhibition of human sirtuins by in situ generation of an acetylated lysine-ADP-ribose conjugate J. Am. Chem. Soc. 2009 131 6989 6996 10.1021/ja807083y 19413317 Asaba, T. et al. Inhibition of human sirtuins by in situ generation of an acetylated lysine-ADP-ribose conjugate. J. Am. Chem. Soc. 131 , 6989–6996 (2009). 19413317 10.1021/ja807083y

442. Shin DH Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer Exp. Mol. Med. 2023 55 2220 2237 10.1038/s12276-023-01091-0 37779142 PMC10618295 Shin, D. H. et al. Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer. Exp. Mol. Med. 55 , 2220–2237 (2023). 37779142 10.1038/s12276-023-01091-0 PMC10618295

443. Smith MR A potent and selective sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington’s disease Hum. Mol. Genet. 2014 23 2995 3007 10.1093/hmg/ddu010 24436303 PMC4031626 Smith, M. R. et al. A potent and selective sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington’s disease. Hum. Mol. Genet. 23 , 2995–3007 (2014). 24436303 10.1093/hmg/ddu010 PMC4031626

444. Süssmuth SD An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington’s disease Br. J. Clin. Pharmacol. 2015 79 465 476 10.1111/bcp.12512 25223731 PMC4345957 Süssmuth, S. D. et al. An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington’s disease. Br. J. Clin. Pharmacol. 79 , 465–476 (2015). 25223731 10.1111/bcp.12512 PMC4345957

445. Huang J The SIRT1 inhibitor EX-527 suppresses mTOR activation and alleviates acute lung injury in mice with endotoxiemia Innate Immun. 2017 23 678 686 10.1177/1753425917733531 28952835 Huang, J. et al. The SIRT1 inhibitor EX-527 suppresses mTOR activation and alleviates acute lung injury in mice with endotoxiemia. Innate Immun. 23 , 678–686 (2017). 28952835 10.1177/1753425917733531

446. Kundu A Protective effect of EX-527 against high-fat diet-induced diabetic nephropathy in Zucker rats Toxicol. Appl. Pharmacol. 2020 390 114899 10.1016/j.taap.2020.114899 31981641 Kundu, A. et al. Protective effect of EX-527 against high-fat diet-induced diabetic nephropathy in Zucker rats. Toxicol. Appl. Pharmacol. 390 , 114899 (2020). 31981641 10.1016/j.taap.2020.114899

447. Zhang Q Targeting a cryptic allosteric site of SIRT6 with small-molecule inhibitors that inhibit the migration of pancreatic cancer cells Acta Pharmacol. Sin. B 2022 12 876 889 10.1016/j.apsb.2021.06.015 PMC8897208 35256952 Zhang, Q. et al. Targeting a cryptic allosteric site of SIRT6 with small-molecule inhibitors that inhibit the migration of pancreatic cancer cells. Acta Pharmacol. Sin. B 12 , 876–889 (2022). 10.1016/j.apsb.2021.06.015 PMC8897208 35256952

448. Xu X Discovery of a potent and highly selective inhibitor of SIRT6 against pancreatic cancer metastasis in vivo Acta Pharmacol. Sin. B 2024 14 1302 1316 10.1016/j.apsb.2023.11.014 PMC10935062 38487000 Xu, X. et al. Discovery of a potent and highly selective inhibitor of SIRT6 against pancreatic cancer metastasis in vivo. Acta Pharmacol. Sin. B 14 , 1302–1316 (2024). 10.1016/j.apsb.2023.11.014 PMC10935062 38487000

449. Song N Discovery of a pyrrole-pyridinimidazole derivative as novel SIRT6 inhibitor for sensitizing pancreatic cancer to gemcitabine Cell. Death Dis. 2023 14 499 10.1038/s41419-023-06018-1 37542062 PMC10403574 Song, N. et al. Discovery of a pyrrole-pyridinimidazole derivative as novel SIRT6 inhibitor for sensitizing pancreatic cancer to gemcitabine. Cell. Death Dis. 14 , 499 (2023). 37542062 10.1038/s41419-023-06018-1 PMC10403574

450. Song, N. et al. A SIRT6 inhibitor, marine-derived pyrrole-pyridinimidazole derivative 8a, suppresses angiogenesis. Mar. Drugs . 21 , 517 (2023). 10.3390/md21100517 PMC10608785 37888452

451. Wang ZA Structural basis of sirtuin 6-catalyzed nucleosome deacetylation J. Am. Chem. Soc. 2023 145 6811 6822 10.1021/jacs.2c13512 36930461 PMC10071992 Wang, Z. A. et al. Structural basis of sirtuin 6-catalyzed nucleosome deacetylation. J. Am. Chem. Soc. 145 , 6811–6822 (2023). 36930461 10.1021/jacs.2c13512 PMC10071992

452. Deng Q Smooth muscle liver kinase B1 inhibits foam cell formation and atherosclerosis via direct phosphorylation and activation of SIRT6 Cell. Death Dis. 2023 14 542 10.1038/s41419-023-06054-x 37607939 PMC10444762 Deng, Q. et al. Smooth muscle liver kinase B1 inhibits foam cell formation and atherosclerosis via direct phosphorylation and activation of SIRT6. Cell. Death Dis. 14 , 542 (2023). 37607939 10.1038/s41419-023-06054-x PMC10444762

453. Howitz KT Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan Nature 2003 425 191 196 10.1038/nature01960 12939617 Howitz, K. T. et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425 , 191–196 (2003). 12939617 10.1038/nature01960

454. Wang Z Diosgenin protects against podocyte injury in early phase of diabetic nephropathy through regulating SIRT6 Phytomedicine 2022 104 154276 10.1016/j.phymed.2022.154276 35728388 Wang, Z. et al. Diosgenin protects against podocyte injury in early phase of diabetic nephropathy through regulating SIRT6. Phytomedicine 104 , 154276 (2022). 35728388 10.1016/j.phymed.2022.154276

455. Luo D Capsaicin attenuates arterial calcification through promoting SIRT6-mediated deacetylation and degradation of Hif1α (hypoxic-inducible factor-1 alpha) Hypertension 2022 79 906 917 10.1161/HYPERTENSIONAHA.121.18778 35232219 Luo, D. et al. Capsaicin attenuates arterial calcification through promoting SIRT6-mediated deacetylation and degradation of Hif1α (hypoxic-inducible factor-1 alpha). Hypertension 79 , 906–917 (2022). 35232219 10.1161/HYPERTENSIONAHA.121.18778

456. Xu K Apigenin alleviates oxidative stress-induced myocardial injury by regulating SIRT1 signaling pathway Eur. J. Pharmacol. 2023 944 175584 10.1016/j.ejphar.2023.175584 36781043 Xu, K. et al. Apigenin alleviates oxidative stress-induced myocardial injury by regulating SIRT1 signaling pathway. Eur. J. Pharmacol. 944 , 175584 (2023). 36781043 10.1016/j.ejphar.2023.175584

457. Xue C Pachymic acid protects hepatic cells against oxygen-glucose deprivation/reperfusion injury by activating sirtuin 1 to inhibit HMGB1 acetylation and inflammatory signaling Chin. J. Physiol. 2023 66 239 247 10.4103/cjop.CJOP-D-22-00118 37635483 Xue, C. et al. Pachymic acid protects hepatic cells against oxygen-glucose deprivation/reperfusion injury by activating sirtuin 1 to inhibit HMGB1 acetylation and inflammatory signaling. Chin. J. Physiol. 66 , 239–247 (2023). 37635483 10.4103/cjop.CJOP-D-22-00118

458. Sun, Y. et al. GB1a activates SIRT6 to regulate lipid metabolism in mouse primary hepatocytes. Int. J. Mol. Sci . 24 , 9540 (2023). 10.3390/ijms24119540 PMC10253419 37298491

459. Tu Q Andrographolide improves the dysfunction of endothelial progenitor cells from angiotensin II-induced hypertensive mice through SIRT1 signaling Biochem. Biophys. Res. Commun. 2023 642 11 20 10.1016/j.bbrc.2022.12.035 36543019 Tu, Q. et al. Andrographolide improves the dysfunction of endothelial progenitor cells from angiotensin II-induced hypertensive mice through SIRT1 signaling. Biochem. Biophys. Res. Commun. 642 , 11–20 (2023). 36543019 10.1016/j.bbrc.2022.12.035

460. Wu QJ The sirtuin family in health and disease Signal. Transduct. Target. Ther. 2022 7 402 10.1038/s41392-022-01257-8 36581622 PMC9797940 Wu, Q. J. et al. The sirtuin family in health and disease. Signal. Transduct. Target. Ther. 7 , 402 (2022). 36581622 10.1038/s41392-022-01257-8 PMC9797940

461. Yu X DDIT3/CHOP mediates the inhibitory effect of ER stress on chondrocyte differentiation by AMPKα-SIRT1 pathway Biochim. Biophys. Acta Mol. Cell. Res. 2022 1869 119265 10.1016/j.bbamcr.2022.119265 35381294 Yu, X. et al. DDIT3/CHOP mediates the inhibitory effect of ER stress on chondrocyte differentiation by AMPKα-SIRT1 pathway. Biochim. Biophys. Acta Mol. Cell. Res. 1869 , 119265 (2022). 35381294 10.1016/j.bbamcr.2022.119265

462. Han L Phloretin attenuation of hepatic steatosis via an improvement of mitochondrial dysfunction by activating AMPK-dependent signaling pathways in C57BL/6J mice and HepG2 cells Food Funct. 2021 12 12421 12433 10.1039/D1FO02577E 34788781 Han, L. et al. Phloretin attenuation of hepatic steatosis via an improvement of mitochondrial dysfunction by activating AMPK-dependent signaling pathways in C57BL/6J mice and HepG2 cells. Food Funct. 12 , 12421–12433 (2021). 34788781 10.1039/d1fo02577e

463. Pham TH Puerarin attenuates hepatic steatosis via G-protein-coupled estrogen receptor-mediated calcium and SIRT1 signaling pathways Phytother. Res. 2022 36 3601 3618 10.1002/ptr.7526 35871535 Pham, T. H. et al. Puerarin attenuates hepatic steatosis via G-protein-coupled estrogen receptor-mediated calcium and SIRT1 signaling pathways. Phytother. Res. 36 , 3601–3618 (2022). 35871535 10.1002/ptr.7526

464. Liu X Atractylenolide III from atractylodes macrocephala Koidz promotes the activation of brown and white adipose tissue through SIRT1/PGC-1α signaling pathway Phytomedicine 2022 104 154289 10.1016/j.phymed.2022.154289 35785561 Liu, X. et al. Atractylenolide III from atractylodes macrocephala Koidz promotes the activation of brown and white adipose tissue through SIRT1/PGC-1α signaling pathway. Phytomedicine 104 , 154289 (2022). 35785561 10.1016/j.phymed.2022.154289

465. Tang X Li X Zhang D Han W Astragaloside-IV alleviates high glucose-induced ferroptosis in retinal pigment epithelial cells by disrupting the expression of miR-138-5p/Sirt1/Nrf2 Bioengineered 2022 13 8240 8254 10.1080/21655979.2022.2049471 35302431 PMC9162003 Tang, X., Li, X., Zhang, D. & Han, W. Astragaloside-IV alleviates high glucose-induced ferroptosis in retinal pigment epithelial cells by disrupting the expression of miR-138-5p/Sirt1/Nrf2. Bioengineered 13 , 8240–8254 (2022). 35302431 10.1080/21655979.2022.2049471 PMC9162003

466. Chen H Low-dose deoxynivalenol exposure inhibits hepatic mitophagy and hesperidin reverses this phenomenon by activating SIRT1 J. Hazard. Mater. 2024 468 133854 10.1016/j.jhazmat.2024.133854 38401214 Chen, H. et al. Low-dose deoxynivalenol exposure inhibits hepatic mitophagy and hesperidin reverses this phenomenon by activating SIRT1. J. Hazard. Mater. 468 , 133854 (2024). 38401214 10.1016/j.jhazmat.2024.133854

467. Zhang Y Caffeic acid phenethyl ester inhibits neuro-inflammation and oxidative stress following spinal cord injury by mitigating mitochondrial dysfunction via the SIRT1/PGC1α/DRP1 signaling pathway J. Transl. Med. 2024 22 304 10.1186/s12967-024-05089-8 38528569 PMC10962082 Zhang, Y. et al. Caffeic acid phenethyl ester inhibits neuro-inflammation and oxidative stress following spinal cord injury by mitigating mitochondrial dysfunction via the SIRT1/PGC1α/DRP1 signaling pathway. J. Transl. Med. 22 , 304 (2024). 38528569 10.1186/s12967-024-05089-8 PMC10962082

468. Hafez HM Waz S El-Tahawy NFG Mohamed MZ Agomelatine ameliorates cadmium-induced toxicity through the modification of HMGB-1/TLR-4/NFκB pathway Toxicol. Appl. Pharmacol. 2022 457 116313 10.1016/j.taap.2022.116313 36356678 Hafez, H. M., Waz, S., El-Tahawy, N. F. G. & Mohamed, M. Z. Agomelatine ameliorates cadmium-induced toxicity through the modification of HMGB-1/TLR-4/NFκB pathway. Toxicol. Appl. Pharmacol. 457 , 116313 (2022). 36356678 10.1016/j.taap.2022.116313

469. Li G Hu C Liu Y Lin H Ligustilide, a novel SIRT1 agonist, alleviates lipopolysaccharide-induced acute lung injury through deacetylation of NICD Int. Immunopharmacol. 2023 121 110486 10.1016/j.intimp.2023.110486 37327514 Li, G., Hu, C., Liu, Y. & Lin, H. Ligustilide, a novel SIRT1 agonist, alleviates lipopolysaccharide-induced acute lung injury through deacetylation of NICD. Int. Immunopharmacol. 121 , 110486 (2023). 37327514 10.1016/j.intimp.2023.110486

470. Wu S Tanshinone IIA ameliorates experimental diabetic cardiomyopathy by inhibiting endoplasmic reticulum stress in cardiomyocytes via SIRT1 Phytother. Res. 2023 37 3543 3558 10.1002/ptr.7831 37128721 Wu, S. et al. Tanshinone IIA ameliorates experimental diabetic cardiomyopathy by inhibiting endoplasmic reticulum stress in cardiomyocytes via SIRT1. Phytother. Res. 37 , 3543–3558 (2023). 37128721 10.1002/ptr.7831

471. Li Y Farnesol exerts protective effects against chronic sleep deprivation-induced cognitive impairment via activation SIRT1/Nrf2 pathway in the hippocampi of adult mice Mol. Nutr. Food Res. 2023 67 e2200735 10.1002/mnfr.202200735 36989169 Li, Y. et al. Farnesol exerts protective effects against chronic sleep deprivation-induced cognitive impairment via activation SIRT1/Nrf2 pathway in the hippocampi of adult mice. Mol. Nutr. Food Res. 67 , e2200735 (2023). 36989169 10.1002/mnfr.202200735

472. Peng F 2-APQC, a small-molecule activator of Sirtuin-3 (SIRT3), alleviates myocardial hypertrophy and fibrosis by regulating mitochondrial homeostasis Signal. Transduct. Target. Ther. 2024 9 133 10.1038/s41392-024-01816-1 38744811 PMC11094072 Peng, F. et al. 2-APQC, a small-molecule activator of Sirtuin-3 (SIRT3), alleviates myocardial hypertrophy and fibrosis by regulating mitochondrial homeostasis. Signal. Transduct. Target. Ther. 9 , 133 (2024). 38744811 10.1038/s41392-024-01816-1 PMC11094072

473. Feng L Dual-target inhibitors of bromodomain and extra-terminal proteins in cancer: a review from medicinal chemistry perspectives Med. Res. Rev. 2022 42 710 743 10.1002/med.21859 34633088 PMC8837683 Feng, L. et al. Dual-target inhibitors of bromodomain and extra-terminal proteins in cancer: a review from medicinal chemistry perspectives. Med. Res. Rev. 42 , 710–743 (2022). 34633088 10.1002/med.21859 PMC8837683

474. Viviano M Successes and challenges in the development of BD1-selective BET inhibitors: a patent review Expert Opin. Ther. Pat. 2024 34 529 545 10.1080/13543776.2024.2327300 38465537 Viviano, M. et al. Successes and challenges in the development of BD1-selective BET inhibitors: a patent review. Expert Opin. Ther. Pat. 34 , 529–545 (2024). 38465537 10.1080/13543776.2024.2327300

475. Wang Z Discovery of a bromodomain and extra terminal domain (BET) inhibitor with the selectivity for the second bromodomain (BD2) and the capacity for the treatment of inflammatory diseases J. Med. Chem. 2023 66 10824 10848 10.1021/acs.jmedchem.3c01028 37478496 Wang, Z. et al. Discovery of a bromodomain and extra terminal domain (BET) inhibitor with the selectivity for the second bromodomain (BD2) and the capacity for the treatment of inflammatory diseases. J. Med. Chem. 66 , 10824–10848 (2023). 37478496 10.1021/acs.jmedchem.3c01028

476. Dhulkifle H Apabetalone (RVX-208): a potential epigenetic therapy for the treatment of cardiovascular, renal, neurological, viral, and cancer disorders ACS Pharmacol. Transl. Sci. 2024 7 546 559 10.1021/acsptsci.3c00219 38481679 PMC10928887 Dhulkifle, H. et al. Apabetalone (RVX-208): a potential epigenetic therapy for the treatment of cardiovascular, renal, neurological, viral, and cancer disorders. ACS Pharmacol. Transl. Sci. 7 , 546–559 (2024). 38481679 10.1021/acsptsci.3c00219 PMC10928887

477. Ray KK Effect of apabetalone added to standard therapy on major adverse cardiovascular events in patients with recent acute coronary syndrome and type 2 diabetes: a randomized clinical trial Jama 2020 323 1565 1573 10.1001/jama.2020.3308 32219359 PMC7101505 Ray, K. K. et al. Effect of apabetalone added to standard therapy on major adverse cardiovascular events in patients with recent acute coronary syndrome and type 2 diabetes: a randomized clinical trial. Jama 323 , 1565–1573 (2020). 32219359 10.1001/jama.2020.3308 PMC7101505

478. Picaud S RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain Proc. Natl. Acad. Sci. USA 2013 110 19754 19759 10.1073/pnas.1310658110 24248379 PMC3856850 Picaud, S. et al. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc. Natl. Acad. Sci. USA 110 , 19754–19759 (2013). 24248379 10.1073/pnas.1310658110 PMC3856850

479. Wasiak S The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activation in vitro and in a mouse model of systemic inflammation Transl. Neurosci. 2023 14 20220332 10.1515/tnsci-2022-0332 38222824 PMC10787226 Wasiak, S. et al. The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activation in vitro and in a mouse model of systemic inflammation. Transl. Neurosci. 14 , 20220332 (2023). 38222824 10.1515/tnsci-2022-0332 PMC10787226

480. Sun M Selective BET inhibitor RVX-208 ameliorates periodontal inflammation and bone loss J. Clin. Periodontol. 2023 50 1658 1669 10.1111/jcpe.13887 37855275 Sun, M. et al. Selective BET inhibitor RVX-208 ameliorates periodontal inflammation and bone loss. J. Clin. Periodontol. 50 , 1658–1669 (2023). 37855275 10.1111/jcpe.13887

481. Fu L Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy Pharmacol. Res. Perspect. 2022 10 e00949 10.1002/prp2.949 35417091 PMC9007222 Fu, L. et al. Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy. Pharmacol. Res. Perspect. 10 , e00949 (2022). 35417091 10.1002/prp2.949 PMC9007222

482. Gangat N Tefferi A New drugs in myelofibrosis: critical assessment of additional value to monotherapy with JAK inhibitors Am. J. Hematol. 2024 99 978 981 10.1002/ajh.27248 38332640 Gangat, N. & Tefferi, A. New drugs in myelofibrosis: critical assessment of additional value to monotherapy with JAK inhibitors. Am. J. Hematol. 99 , 978–981 (2024). 38332640 10.1002/ajh.27248

483. Gupta V Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis Blood Adv. 2023 7 5421 5432 10.1182/bloodadvances.2023010628 37530627 PMC10509667 Gupta, V. et al. Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis. Blood Adv. 7 , 5421–5432 (2023). 37530627 10.1182/bloodadvances.2023010628 PMC10509667

484. Mascarenhas J MANIFEST: pelabresib in combination with ruxolitinib for janus kinase inhibitor treatment-naïve myelofibrosis J. Clin. Oncol. 2023 41 4993 5004 10.1200/JCO.22.01972 36881782 PMC10642902 Mascarenhas, J. et al. MANIFEST: pelabresib in combination with ruxolitinib for janus kinase inhibitor treatment-naïve myelofibrosis. J. Clin. Oncol. 41 , 4993–5004 (2023). 36881782 10.1200/JCO.22.01972 PMC10642902

485. Kharenko OA Patel RG Calosing C van der Horst EH Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer Cancer Gene Ther. 2022 29 859 869 10.1038/s41417-021-00375-9 34385584 Kharenko, O. A., Patel, R. G., Calosing, C. & van der Horst, E. H. Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer. Cancer Gene Ther. 29 , 859–869 (2022). 34385584 10.1038/s41417-021-00375-9

486. Aggarwal RR A phase Ib/IIa study of the pan-BET inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer Clin. Cancer Res. 2020 26 5338 5347 10.1158/1078-0432.CCR-20-1707 32694156 PMC7572827 Aggarwal, R. R. et al. A phase Ib/IIa study of the pan-BET inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer. Clin. Cancer Res. 26 , 5338–5347 (2020). 32694156 10.1158/1078-0432.CCR-20-1707 PMC7572827

487. Marr AR The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling Exp. Hematol. Oncol. 2024 13 27 10.1186/s40164-024-00483-w 38438856 PMC10913666 Marr, A. R. et al. The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling. Exp. Hematol. Oncol. 13 , 27 (2024). 38438856 10.1186/s40164-024-00483-w PMC10913666

488. Stathis A Bertoni F BET proteins as targets for anticancer treatment Cancer Discov. 2018 8 24 36 10.1158/2159-8290.CD-17-0605 29263030 Stathis, A. & Bertoni, F. BET proteins as targets for anticancer treatment. Cancer Discov. 8 , 24–36 (2018). 29263030 10.1158/2159-8290.CD-17-0605

489. Smith, A. L. et al. BET inhibition reforms the immune microenvironment and alleviates T cell dysfunction in chronic lymphocytic leukemia. JCI Insight 9 , e177054 (2024). 10.1172/jci.insight.177054 PMC11141939 38775157

490. Li Y Structure-guided design and synthesis of pyridinone-based selective bromodomain and extra-terminal domain (BET)-first bromodomain (BD1) inhibitors J. Med. Chem. 2024 67 2712 2731 10.1021/acs.jmedchem.3c01837 38295759 Li, Y. et al. Structure-guided design and synthesis of pyridinone-based selective bromodomain and extra-terminal domain (BET)-first bromodomain (BD1) inhibitors. J. Med. Chem. 67 , 2712–2731 (2024). 38295759 10.1021/acs.jmedchem.3c01837

491. Ali I DW71177: A novel [1,2,4]triazolo[4,3-a]quinoxaline-based potent and BD1-Selective BET inhibitor for the treatment of acute myeloid leukemia Eur. J. Med. Chem. 2024 265 116052 10.1016/j.ejmech.2023.116052 38134745 Ali, I. et al. DW71177: A novel [1,2,4]triazolo[4,3-a]quinoxaline-based potent and BD1-Selective BET inhibitor for the treatment of acute myeloid leukemia. Eur. J. Med. Chem. 265 , 116052 (2024). 38134745 10.1016/j.ejmech.2023.116052

492. Chen X Discovery of a brain-permeable bromodomain and extra terminal domain (BET) inhibitor with selectivity for BD1 for the treatment of multiple sclerosis Eur. J. Med. Chem. 2024 265 116080 10.1016/j.ejmech.2023.116080 38142510 Chen, X. et al. Discovery of a brain-permeable bromodomain and extra terminal domain (BET) inhibitor with selectivity for BD1 for the treatment of multiple sclerosis. Eur. J. Med. Chem. 265 , 116080 (2024). 38142510 10.1016/j.ejmech.2023.116080

493. Bauer N Development of potent dual BET/HDAC inhibitors via pharmacophore merging and structure-guided optimization ACS Chem. Biol. 2024 19 266 279 10.1021/acschembio.3c00427 38291964 PMC10878397 Bauer, N. et al. Development of potent dual BET/HDAC inhibitors via pharmacophore merging and structure-guided optimization. ACS Chem. Biol. 19 , 266–279 (2024). 38291964 10.1021/acschembio.3c00427 PMC10878397

494. Jiang W Discovery of novel phenoxyaryl pyridones as bromodomain and extra-terminal domain (BET) inhibitors with high selectivity for the second bromodomain (BD2) to potentially treat acute myeloid leukemia J. Med. Chem. 2024 67 1513 1532 10.1021/acs.jmedchem.3c02104 38175809 Jiang, W. et al. Discovery of novel phenoxyaryl pyridones as bromodomain and extra-terminal domain (BET) inhibitors with high selectivity for the second bromodomain (BD2) to potentially treat acute myeloid leukemia. J. Med. Chem. 67 , 1513–1532 (2024). 38175809 10.1021/acs.jmedchem.3c02104

495. Pandey K SRX3177, a CDK4/6-PI3K-BET inhibitor, in combination with an RdRp inhibitor, molnupiravir, or an entry inhibitor MU-UNMC-2, has potent antiviral activity against the omicron variant of SARS-CoV-2 Antivir. Res. 2024 227 105904 10.1016/j.antiviral.2024.105904 38729306 PMC11922097 Pandey, K. et al. SRX3177, a CDK4/6-PI3K-BET inhibitor, in combination with an RdRp inhibitor, molnupiravir, or an entry inhibitor MU-UNMC-2, has potent antiviral activity against the omicron variant of SARS-CoV-2. Antivir. Res. 227 , 105904 (2024). 38729306 10.1016/j.antiviral.2024.105904 PMC11922097

496. Li Y AF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79 methylation Cell 2014 159 558 571 10.1016/j.cell.2014.09.049 25417107 PMC4344132 Li, Y. et al. AF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79 methylation. Cell 159 , 558–571 (2014). 25417107 10.1016/j.cell.2014.09.049 PMC4344132

497. Li Y Molecular coupling of histone crotonylation and active transcription by AF9 YEATS domain Mol. Cell. 2016 62 181 193 10.1016/j.molcel.2016.03.028 27105114 PMC4841940 Li, Y. et al. Molecular coupling of histone crotonylation and active transcription by AF9 YEATS domain. Mol. Cell. 62 , 181–193 (2016). 27105114 10.1016/j.molcel.2016.03.028 PMC4841940

498. Ren X Histone benzoylation serves as an epigenetic mark for DPF and YEATS family proteins Nucl. Acids Res. 2021 49 114 126 10.1093/nar/gkaa1130 33290558 PMC7797077 Ren, X. et al. Histone benzoylation serves as an epigenetic mark for DPF and YEATS family proteins. Nucl. Acids Res. 49 , 114–126 (2021). 33290558 10.1093/nar/gkaa1130 PMC7797077

499. Wan L ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia Nature 2017 543 265 269 10.1038/nature21687 28241141 PMC5372383 Wan, L. et al. ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia. Nature 543 , 265–269 (2017). 28241141 10.1038/nature21687 PMC5372383

500. Mi W YEATS2 links histone acetylation to tumorigenesis of non-small cell lung cancer Nat. Commun. 2017 8 1088 10.1038/s41467-017-01173-4 29057918 PMC5651844 Mi, W. et al. YEATS2 links histone acetylation to tumorigenesis of non-small cell lung cancer. Nat. Commun. 8 , 1088 (2017). 29057918 10.1038/s41467-017-01173-4 PMC5651844

501. Ji K Unveiling the role of GAS41 in cancer progression Cancer Cell. Int. 2023 23 245 10.1186/s12935-023-03098-z 37853482 PMC10583379 Ji, K. et al. Unveiling the role of GAS41 in cancer progression. Cancer Cell. Int. 23 , 245 (2023). 37853482 10.1186/s12935-023-03098-z PMC10583379

502. Bilgin N Reading and erasing of histone crotonyllysine mimics by the AF9 YEATS domain and SIRT2 deacylase Bioorg. Med. Chem. 2023 95 117500 10.1016/j.bmc.2023.117500 37839329 Bilgin, N. et al. Reading and erasing of histone crotonyllysine mimics by the AF9 YEATS domain and SIRT2 deacylase. Bioorg. Med. Chem. 95 , 117500 (2023). 37839329 10.1016/j.bmc.2023.117500

503. Li X Structure-guided development of YEATS domain inhibitors by targeting π-π-π stacking Nat. Chem. Biol. 2018 14 1140 1149 10.1038/s41589-018-0144-y 30374167 PMC6503841 Li, X. et al. Structure-guided development of YEATS domain inhibitors by targeting π-π-π stacking. Nat. Chem. Biol. 14 , 1140–1149 (2018). 30374167 10.1038/s41589-018-0144-y PMC6503841

504. Moustakim M Discovery of an MLLT1/3 YEATS domain chemical probe Angew. Chem. Int. Ed. Engl. 2018 57 16302 16307 10.1002/anie.201810617 30288907 PMC6348381 Moustakim, M. et al. Discovery of an MLLT1/3 YEATS domain chemical probe. Angew. Chem. Int. Ed. Engl. 57 , 16302–16307 (2018). 30288907 10.1002/anie.201810617 PMC6348381

505. Yang Y Structural studies of intrinsically disordered MLL-fusion protein AF9 in complex with peptidomimetic inhibitors Protein Sci. 2024 33 e5019 10.1002/pro.5019 38747396 PMC11094776 Yang, Y. et al. Structural studies of intrinsically disordered MLL-fusion protein AF9 in complex with peptidomimetic inhibitors. Protein Sci. 33 , e5019 (2024). 38747396 10.1002/pro.5019 PMC11094776

506. Yuan Y Design, synthesis, and biological evaluations of DOT1L peptide mimetics targeting the protein-protein interactions between DOT1L and MLL-AF9/MLL-ENL J. Med. Chem. 2022 65 7770 7785 10.1021/acs.jmedchem.2c00083 35612819 Yuan, Y. et al. Design, synthesis, and biological evaluations of DOT1L peptide mimetics targeting the protein-protein interactions between DOT1L and MLL-AF9/MLL-ENL. J. Med. Chem. 65 , 7770–7785 (2022). 35612819 10.1021/acs.jmedchem.2c00083

507. Liu Y Small-molecule inhibition of the acyl-lysine reader ENL as a strategy against acute myeloid leukemia Cancer Discov. 2022 12 2684 2709 10.1158/2159-8290.CD-21-1307 36053276 PMC9627135 Liu, Y. et al. Small-molecule inhibition of the acyl-lysine reader ENL as a strategy against acute myeloid leukemia. Cancer Discov. 12 , 2684–2709 (2022). 36053276 10.1158/2159-8290.CD-21-1307 PMC9627135

508. Yan F KAT6A and ENL form an epigenetic transcriptional control module to drive critical leukemogenic gene-expression programs Cancer Discov. 2022 12 792 811 10.1158/2159-8290.CD-20-1459 34853079 PMC8916037 Yan, F. et al. KAT6A and ENL form an epigenetic transcriptional control module to drive critical leukemogenic gene-expression programs. Cancer Discov. 12 , 792–811 (2022). 34853079 10.1158/2159-8290.CD-20-1459 PMC8916037

509. Chen Y Targeting the epigenetic reader ENL inhibits super-enhancer-driven oncogenic transcription and synergizes with BET inhibition to suppress tumor progression Cancer Res. 2024 84 1237 1251 10.1158/0008-5472.CAN-23-1836 38241700 Chen, Y. et al. Targeting the epigenetic reader ENL inhibits super-enhancer-driven oncogenic transcription and synergizes with BET inhibition to suppress tumor progression. Cancer Res. 84 , 1237–1251 (2024). 38241700 10.1158/0008-5472.CAN-23-1836

510. Jiang Y Selective targeting of AF9 YEATS domain by cyclopeptide inhibitors with preorganized conformation J. Am. Chem. Soc. 2020 142 21450 21459 10.1021/jacs.0c10324 33306911 Jiang, Y. et al. Selective targeting of AF9 YEATS domain by cyclopeptide inhibitors with preorganized conformation. J. Am. Chem. Soc. 142 , 21450–21459 (2020). 33306911 10.1021/jacs.0c10324

511. Travis CR Francis DY Williams DC Jr. Waters ML Evaluation of acyllysine isostere interactions with the aromatic pocket of the AF9 YEATS domain Protein Sci. 2023 32 e4533 10.1002/pro.4533 36482045 PMC9793969 Travis, C. R., Francis, D. Y., Williams, D. C. Jr. & Waters, M. L. Evaluation of acyllysine isostere interactions with the aromatic pocket of the AF9 YEATS domain. Protein Sci. 32 , e4533 (2023). 36482045 10.1002/pro.4533 PMC9793969

512. Liu, Y. et al. Fragment-based discovery of AF9 YEATS domain inhibitors. Int. J. Mol. Sci . 23 , 3893 (2022). 10.3390/ijms23073893 PMC8998803 35409252

513. Listunov D Development of potent dimeric inhibitors of GAS41 YEATS domain Cell. Chem. Biol. 2021 28 1716 1727.e1716 10.1016/j.chembiol.2021.06.010 34289376 PMC8923076 Listunov, D. et al. Development of potent dimeric inhibitors of GAS41 YEATS domain. Cell. Chem. Biol. 28 , 1716–1727.e1716 (2021). 34289376 10.1016/j.chembiol.2021.06.010 PMC8923076

514. Cheng CL Bromodomain-containing protein BRPF1 is a therapeutic target for liver cancer Commun. Biol. 2021 4 888 10.1038/s42003-021-02405-6 34285329 PMC8292510 Cheng, C. L. et al. Bromodomain-containing protein BRPF1 is a therapeutic target for liver cancer. Commun. Biol. 4 , 888 (2021). 34285329 10.1038/s42003-021-02405-6 PMC8292510

515. Bitler BG Targeting BRPF3 moderately reverses olaparib resistance in high grade serous ovarian carcinoma Mol. Carcinog. 2023 62 1717 1730 10.1002/mc.23610 37493106 PMC10592327 Bitler, B. G. et al. Targeting BRPF3 moderately reverses olaparib resistance in high grade serous ovarian carcinoma. Mol. Carcinog. 62 , 1717–1730 (2023). 37493106 10.1002/mc.23610 PMC10592327

516. Li F BPTF drives gastric cancer resistance to EGFR inhibitor by epigenetically regulating the C-MYC/PLCG1/Perk Axis Adv. Sci. 2023 10 e2303091 10.1002/advs.202303091 PMC10700682 37863665 Li, F. et al. BPTF drives gastric cancer resistance to EGFR inhibitor by epigenetically regulating the C-MYC/PLCG1/Perk Axis. Adv. Sci. 10 , e2303091 (2023). 10.1002/advs.202303091 PMC10700682 37863665

517. Zhang W Development of 3-acetylindole derivatives that selectively target BRPF1 as new inhibitors of receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis Bioorg. Med. Chem. 2023 96 117440 10.1016/j.bmc.2023.117440 37951134 Zhang, W. et al. Development of 3-acetylindole derivatives that selectively target BRPF1 as new inhibitors of receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis. Bioorg. Med. Chem. 96 , 117440 (2023). 37951134 10.1016/j.bmc.2023.117440

518. Ghazy E Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6/8 and bromodomain BRPF1 Eur. J. Med. Chem. 2020 200 112338 10.1016/j.ejmech.2020.112338 32497960 Ghazy, E. et al. Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6/8 and bromodomain BRPF1. Eur. J. Med. Chem. 200 , 112338 (2020). 32497960 10.1016/j.ejmech.2020.112338

519. Palmer WS Structure-guided design of IACS-9571, a selective high-affinity dual TRIM24-BRPF1 bromodomain inhibitor J. Med. Chem. 2016 59 1440 1454 10.1021/acs.jmedchem.5b00405 26061247 PMC4755933 Palmer, W. S. et al. Structure-guided design of IACS-9571, a selective high-affinity dual TRIM24-BRPF1 bromodomain inhibitor. J. Med. Chem. 59 , 1440–1454 (2016). 26061247 10.1021/acs.jmedchem.5b00405 PMC4755933

520. Xiang Q Discovery, optimization and evaluation of 1-(indolin-1-yl)ethan-1-ones as novel selective TRIM24/BRPF1 bromodomain inhibitors Eur. J. Med. Chem. 2022 236 114311 10.1016/j.ejmech.2022.114311 35385803 Xiang, Q. et al. Discovery, optimization and evaluation of 1-(indolin-1-yl)ethan-1-ones as novel selective TRIM24/BRPF1 bromodomain inhibitors. Eur. J. Med. Chem. 236 , 114311 (2022). 35385803 10.1016/j.ejmech.2022.114311

521. Igoe N Design of a biased potent small molecule inhibitor of the bromodomain and PHD finger-containing (BRPF) proteins suitable for cellular and in vivo studies J. Med. Chem. 2017 60 668 680 10.1021/acs.jmedchem.6b01583 28068087 Igoe, N. et al. Design of a biased potent small molecule inhibitor of the bromodomain and PHD finger-containing (BRPF) proteins suitable for cellular and in vivo studies. J. Med. Chem. 60 , 668–680 (2017). 28068087 10.1021/acs.jmedchem.6b01583

522. Zhu J Zhou C Caflisch A Structure-based discovery of selective BRPF1 bromodomain inhibitors Eur. J. Med. Chem. 2018 155 337 352 10.1016/j.ejmech.2018.05.037 29902720 Zhu, J., Zhou, C. & Caflisch, A. Structure-based discovery of selective BRPF1 bromodomain inhibitors. Eur. J. Med. Chem. 155 , 337–352 (2018). 29902720 10.1016/j.ejmech.2018.05.037

523. Urick AK Dual screening of BPTF and Brd4 using protein-observed fluorine NMR uncovers new bromodomain probe molecules ACS Chem. Biol. 2015 10 2246 2256 10.1021/acschembio.5b00483 26158404 PMC4858447 Urick, A. K. et al. Dual screening of BPTF and Brd4 using protein-observed fluorine NMR uncovers new bromodomain probe molecules. ACS Chem. Biol. 10 , 2246–2256 (2015). 26158404 10.1021/acschembio.5b00483 PMC4858447

524. Jiang C BPTF in bone marrow provides a potential progression biomarker regulated by TFAP4 through the PI3K/AKT pathway in neuroblastoma Biol. Proced. Online 2023 25 11 10.1186/s12575-023-00200-7 37170211 PMC10176855 Jiang, C. et al. BPTF in bone marrow provides a potential progression biomarker regulated by TFAP4 through the PI3K/AKT pathway in neuroblastoma. Biol. Proced. Online 25 , 11 (2023). 37170211 10.1186/s12575-023-00200-7 PMC10176855

525. Bezrookove V BPTF promotes the progression of distinct subtypes of breast cancer and is a therapeutic target Front Oncol. 2022 12 1011173 10.3389/fonc.2022.1011173 36530982 PMC9748419 Bezrookove, V. et al. BPTF promotes the progression of distinct subtypes of breast cancer and is a therapeutic target. Front Oncol. 12 , 1011173 (2022). 36530982 10.3389/fonc.2022.1011173 PMC9748419

526. Khan, I. & Kashani-Sabet, M. Bromodomain inhibition targeting BPTF in the treatment of melanoma and other solid tumors. Clin. Exp. Metastasis 509—515 (2024). 10.1007/s10585-024-10265-7 38683257

527. Xu J Compound C620-0696, a new potent inhibitor targeting BPTF, the chromatin-remodeling factor in non-small-cell lung cancer Front Med. 2020 14 60 67 10.1007/s11684-019-0694-8 31104301 Xu, J. et al. Compound C620-0696, a new potent inhibitor targeting BPTF, the chromatin-remodeling factor in non-small-cell lung cancer. Front Med. 14 , 60–67 (2020). 31104301 10.1007/s11684-019-0694-8

528. Zhu Y Promising role of protein arginine methyltransferases in overcoming anti-cancer drug resistance Drug Resist Updat. 2024 72 101016 10.1016/j.drup.2023.101016 37980859 Zhu, Y. et al. Promising role of protein arginine methyltransferases in overcoming anti-cancer drug resistance. Drug Resist Updat. 72 , 101016 (2024). 37980859 10.1016/j.drup.2023.101016

529. Tong C Overview of the development of protein arginine methyltransferase modulators: achievements and future directions Eur. J. Med. Chem. 2024 267 116212 10.1016/j.ejmech.2024.116212 38359536 Tong, C. et al. Overview of the development of protein arginine methyltransferase modulators: achievements and future directions. Eur. J. Med. Chem. 267 , 116212 (2024). 38359536 10.1016/j.ejmech.2024.116212

530. Li D Small molecules targeting selected histone methyltransferases (HMTs) for cancer treatment: current progress and novel strategies Eur. J. Med. Chem. 2024 264 115982 10.1016/j.ejmech.2023.115982 38056296 Li, D. et al. Small molecules targeting selected histone methyltransferases (HMTs) for cancer treatment: current progress and novel strategies. Eur. J. Med. Chem. 264 , 115982 (2024). 38056296 10.1016/j.ejmech.2023.115982

531. Rea S Regulation of chromatin structure by site-specific histone H3 methyltransferases Nature 2000 406 593 599 10.1038/35020506 10949293 Rea, S. et al. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 406 , 593–599 (2000). 10949293 10.1038/35020506

532. Haebe JR Bergin CJ Sandouka T Benoit YD Emerging role of G9a in cancer stemness and promises as a therapeutic target Oncogenesis 2021 10 76 10.1038/s41389-021-00370-7 34775469 PMC8590690 Haebe, J. R., Bergin, C. J., Sandouka, T. & Benoit, Y. D. Emerging role of G9a in cancer stemness and promises as a therapeutic target. Oncogenesis 10 , 76 (2021). 34775469 10.1038/s41389-021-00370-7 PMC8590690

533. Husmann D Gozani O Histone lysine methyltransferases in biology and disease Nat. Struct. Mol. Biol. 2019 26 880 889 10.1038/s41594-019-0298-7 31582846 PMC6951022 Husmann, D. & Gozani, O. Histone lysine methyltransferases in biology and disease. Nat. Struct. Mol. Biol. 26 , 880–889 (2019). 31582846 10.1038/s41594-019-0298-7 PMC6951022

534. Yang C Role of NSD1 as potential therapeutic target in tumor Pharmacol. Res. 2021 173 105888 10.1016/j.phrs.2021.105888 34536546 Yang, C. et al. Role of NSD1 as potential therapeutic target in tumor. Pharmacol. Res. 173 , 105888 (2021). 34536546 10.1016/j.phrs.2021.105888

535. Saha N Muntean AG Insight into the multi-faceted role of the SUV family of H3K9 methyltransferases in carcinogenesis and cancer progression Biochim. Biophys. Acta Rev. Cancer 2021 1875 188498 10.1016/j.bbcan.2020.188498 33373647 PMC7856268 Saha, N. & Muntean, A. G. Insight into the multi-faceted role of the SUV family of H3K9 methyltransferases in carcinogenesis and cancer progression. Biochim. Biophys. Acta Rev. Cancer 1875 , 188498 (2021). 33373647 10.1016/j.bbcan.2020.188498 PMC7856268

536. Ma T SETDB1: progress and prospects in cancer treatment potential and inhibitor research Bioorg. Chem. 2024 145 107219 10.1016/j.bioorg.2024.107219 38377821 Ma, T. et al. SETDB1: progress and prospects in cancer treatment potential and inhibitor research. Bioorg. Chem. 145 , 107219 (2024). 38377821 10.1016/j.bioorg.2024.107219

537. Ma Z Bolinger AA Chen H Zhou J Drug discovery targeting nuclear receptor binding SET domain protein 2 (NSD2) J. Med. Chem. 2023 66 10991 11026 10.1021/acs.jmedchem.3c00948 37578463 PMC11092389 Ma, Z., Bolinger, A. A., Chen, H. & Zhou, J. Drug discovery targeting nuclear receptor binding SET domain protein 2 (NSD2). J. Med. Chem. 66 , 10991–11026 (2023). 37578463 10.1021/acs.jmedchem.3c00948 PMC11092389

538. Fioravanti R Six years (2012-2018) of researches on catalytic EZH2 inhibitors: the boom of the 2-pyridone compounds Chem. Rec. 2018 18 1818 1832 10.1002/tcr.201800091 30338896 PMC7410397 Fioravanti, R. et al. Six years (2012-2018) of researches on catalytic EZH2 inhibitors: the boom of the 2-pyridone compounds. Chem. Rec. 18 , 1818–1832 (2018). 30338896 10.1002/tcr.201800091 PMC7410397

539. Wang, X. et al. The synergistic anti-tumor activity of EZH2 inhibitor SHR2554 and HDAC inhibitor chidamide through ORC1 reduction of DNA replication process in diffuse large B cell lymphoma. Cancers 13 , 4249 (2021). 10.3390/cancers13174249 PMC8428225 34503063

540. Song Y SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial Lancet Haematol. 2022 9 e493 e503 10.1016/S2352-3026(22)00134-X 35772429 Song, Y. et al. SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial. Lancet Haematol. 9 , e493–e503 (2022). 35772429 10.1016/S2352-3026(22)00134-X

541. Song Y Enhancer of zeste homolog 2 inhibitor SHR2554 in relapsed or refractory peripheral T-cell lymphoma: data from the first-in-human phase I study Clin. Cancer Res. 2024 30 1248 1255 10.1158/1078-0432.CCR-23-2582 38190117 Song, Y. et al. Enhancer of zeste homolog 2 inhibitor SHR2554 in relapsed or refractory peripheral T-cell lymphoma: data from the first-in-human phase I study. Clin. Cancer Res. 30 , 1248–1255 (2024). 38190117 10.1158/1078-0432.CCR-23-2582

542. Deng K Study on pharmacokinetic interactions between SHR2554 and itraconazole in healthy subjects: a single-center, open-label phase I trial Cancer Med. 2023 12 1431 1440 10.1002/cam4.5028 35841331 PMC9883540 Deng, K. et al. Study on pharmacokinetic interactions between SHR2554 and itraconazole in healthy subjects: a single-center, open-label phase I trial. Cancer Med. 12 , 1431–1440 (2023). 35841331 10.1002/cam4.5028 PMC9883540

543. Kung PP Optimization of orally bioavailable enhancer of zeste homolog 2 (EZH2) inhibitors using ligand and property-based design strategies: identification of development candidate (R)-5,8-dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497) J. Med. Chem. 2018 61 650 665 10.1021/acs.jmedchem.7b01375 29211475 Kung, P. P. et al. Optimization of orally bioavailable enhancer of zeste homolog 2 (EZH2) inhibitors using ligand and property-based design strategies: identification of development candidate (R)-5,8-dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497). J. Med. Chem. 61 , 650–665 (2018). 29211475 10.1021/acs.jmedchem.7b01375

544. Zhang Y EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG Neoplasia 2021 23 792 810 10.1016/j.neo.2021.06.007 34246076 PMC8274300 Zhang, Y. et al. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG. Neoplasia 23 , 792–810 (2021). 34246076 10.1016/j.neo.2021.06.007 PMC8274300

545. Al-Hasani K Inhibition of pancreatic EZH2 restores progenitor insulin in T1D donor Signal. Transduct. Target. Ther. 2022 7 248 10.1038/s41392-022-01034-7 35864094 PMC9304326 Al-Hasani, K. et al. Inhibition of pancreatic EZH2 restores progenitor insulin in T1D donor. Signal. Transduct. Target. Ther. 7 , 248 (2022). 35864094 10.1038/s41392-022-01034-7 PMC9304326

546. Yap TA Phase I study of the novel enhancer of zeste homolog 2 (EZH2) inhibitor GSK2816126 in patients with advanced hematologic and solid tumors Clin. Cancer Res. 2019 25 7331 7339 10.1158/1078-0432.CCR-18-4121 31471312 PMC7377921 Yap, T. A. et al. Phase I study of the novel enhancer of zeste homolog 2 (EZH2) inhibitor GSK2816126 in patients with advanced hematologic and solid tumors. Clin. Cancer Res. 25 , 7331–7339 (2019). 31471312 10.1158/1078-0432.CCR-18-4121 PMC7377921

547. Du D Structure-guided development of small-molecule PRC2 inhibitors targeting EZH2-EED interaction J. Med. Chem. 2021 64 8194 8207 10.1021/acs.jmedchem.0c02261 34077206 Du, D. et al. Structure-guided development of small-molecule PRC2 inhibitors targeting EZH2-EED interaction. J. Med. Chem. 64 , 8194–8207 (2021). 34077206 10.1021/acs.jmedchem.0c02261

548. Yu W Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors Nat. Commun. 2012 3 1288 10.1038/ncomms2304 23250418 Yu, W. et al. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat. Commun. 3 , 1288 (2012). 23250418 10.1038/ncomms2304

549. Daigle SR Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor Cancer Cell. 2011 20 53 65 10.1016/j.ccr.2011.06.009 21741596 PMC4046888 Daigle, S. R. et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 20 , 53–65 (2011). 21741596 10.1016/j.ccr.2011.06.009 PMC4046888

550. Rau RE DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia Blood 2016 128 971 981 10.1182/blood-2015-11-684225 27335278 PMC4990856 Rau, R. E. et al. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood 128 , 971–981 (2016). 27335278 10.1182/blood-2015-11-684225 PMC4990856

551. Godfrey L DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation Nat. Commun. 2019 10 2803 10.1038/s41467-019-10844-3 31243293 PMC6594956 Godfrey, L. et al. DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation. Nat. Commun. 10 , 2803 (2019). 31243293 10.1038/s41467-019-10844-3 PMC6594956

552. Perner F Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts Blood 2020 136 1983 1988 10.1182/blood.2020006113 32575123 PMC8209563 Perner, F. et al. Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts. Blood 136 , 1983–1988 (2020). 32575123 10.1182/blood.2020006113 PMC8209563

553. Klaus CR DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells J. Pharmacol. Exp. Ther. 2014 350 646 656 10.1124/jpet.114.214577 24993360 Klaus, C. R. et al. DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells. J. Pharmacol. Exp. Ther. 350 , 646–656 (2014). 24993360 10.1124/jpet.114.214577

554. Wong M The histone methyltransferase DOT1L promotes neuroblastoma by regulating gene transcription Cancer Res. 2017 77 2522 2533 10.1158/0008-5472.CAN-16-1663 28209620 Wong, M. et al. The histone methyltransferase DOT1L promotes neuroblastoma by regulating gene transcription. Cancer Res. 77 , 2522–2533 (2017). 28209620 10.1158/0008-5472.CAN-16-1663

555. Evanno E Tri-methylation of H3K79 is decreased in TGF-β1-induced epithelial-to-mesenchymal transition in lung cancer Clin. Epigenet. 2017 9 80 10.1186/s13148-017-0380-0 PMC5549304 28804523 Evanno, E. et al. Tri-methylation of H3K79 is decreased in TGF-β1-induced epithelial-to-mesenchymal transition in lung cancer. Clin. Epigenet. 9 , 80 (2017). 10.1186/s13148-017-0380-0 PMC5549304 28804523

556. Zhang J Gain-of-function mutations in the catalytic domain of DOT1L promote lung cancer malignant phenotypes via the MAPK/ERK signaling pathway Sci. Adv. 2023 9 eadc9273 10.1126/sciadv.adc9273 37256945 PMC10413674 Zhang, J. et al. Gain-of-function mutations in the catalytic domain of DOT1L promote lung cancer malignant phenotypes via the MAPK/ERK signaling pathway. Sci. Adv. 9 , eadc9273 (2023). 37256945 10.1126/sciadv.adc9273 PMC10413674

557. Alford JS Conformational-design-driven discovery of EZM0414: a Selective, potent SETD2 inhibitor for clinical studies ACS Med. Chem. Lett. 2022 13 1137 1143 10.1021/acsmedchemlett.2c00167 35859865 PMC9290024 Alford, J. S. et al. Conformational-design-driven discovery of EZM0414: a Selective, potent SETD2 inhibitor for clinical studies. ACS Med. Chem. Lett. 13 , 1137–1143 (2022). 35859865 10.1021/acsmedchemlett.2c00167 PMC9290024

558. Fedoriw A Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss Cancer Cell. 2019 36 100 114.e125 10.1016/j.ccell.2019.05.014 31257072 Fedoriw, A. et al. Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss. Cancer Cell. 36 , 100–114.e125 (2019). 31257072 10.1016/j.ccell.2019.05.014

559. Fedoriw A Inhibiting type I arginine methyltransferase activity promotes T cell-mediated antitumor immune responses Cancer Immunol. Res. 2022 10 420 436 10.1158/2326-6066.CIR-21-0614 35181787 PMC8976792 Fedoriw, A. et al. Inhibiting type I arginine methyltransferase activity promotes T cell-mediated antitumor immune responses. Cancer Immunol. Res. 10 , 420–436 (2022). 35181787 10.1158/2326-6066.CIR-21-0614 PMC8976792

560. Zhou S Targeting type I PRMTs as promising targets for the treatment of pulmonary disorders: asthma, COPD, lung cancer, PF, and PH Life Sci. 2024 342 122538 10.1016/j.lfs.2024.122538 38428571 Zhou, S. et al. Targeting type I PRMTs as promising targets for the treatment of pulmonary disorders: asthma, COPD, lung cancer, PF, and PH. Life Sci. 342 , 122538 (2024). 38428571 10.1016/j.lfs.2024.122538

561. El-Khoueiry AB Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors Br. J. Cancer 2023 129 309 317 10.1038/s41416-023-02276-0 37237172 PMC10338470 El-Khoueiry, A. B. et al. Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors. Br. J. Cancer 129 , 309–317 (2023). 37237172 10.1038/s41416-023-02276-0 PMC10338470

562. Martin, P. L. et al. towards the targeted protein degradation of PRMT1. ChemMedChem , e202400269 (2024). 10.1002/cmdc.202400269 PMC13494812 38724444

563. Li X Wang C Jiang H Luo C A patent review of arginine methyltransferase inhibitors (2010-2018) Expert Opin. Ther. Pat. 2019 29 97 114 10.1080/13543776.2019.1567711 30640571 Li, X., Wang, C., Jiang, H. & Luo, C. A patent review of arginine methyltransferase inhibitors (2010-2018). Expert Opin. Ther. Pat. 29 , 97–114 (2019). 30640571 10.1080/13543776.2019.1567711

564. Brehmer D Discovery and pharmacological characterization of JNJ-64619178, a novel small-molecule inhibitor of PRMT5 with potent antitumor activity Mol. Cancer Ther. 2021 20 2317 2328 10.1158/1535-7163.MCT-21-0367 34583982 PMC9398174 Brehmer, D. et al. Discovery and pharmacological characterization of JNJ-64619178, a novel small-molecule inhibitor of PRMT5 with potent antitumor activity. Mol. Cancer Ther. 20 , 2317–2328 (2021). 34583982 10.1158/1535-7163.MCT-21-0367 PMC9398174

565. Jensen-Pergakes K SAM-competitive PRMT5 inhibitor PF-06939999 demonstrates antitumor activity in splicing dysregulated NSCLC with decreased liability of drug resistance Mol. Cancer Ther. 2022 21 3 15 10.1158/1535-7163.MCT-21-0620 34737197 Jensen-Pergakes, K. et al. SAM-competitive PRMT5 inhibitor PF-06939999 demonstrates antitumor activity in splicing dysregulated NSCLC with decreased liability of drug resistance. Mol. Cancer Ther. 21 , 3–15 (2022). 34737197 10.1158/1535-7163.MCT-21-0620

566. O’Brien S Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer BMC Cancer 2023 23 775 10.1186/s12885-023-11260-z 37596538 PMC10436459 O’Brien, S. et al. Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer. BMC Cancer 23 , 775 (2023). 37596538 10.1186/s12885-023-11260-z PMC10436459

567. Zhang Y Verwilligen RAF Van Eck M Hoekstra M PRMT5 inhibition induces pro-inflammatory macrophage polarization and increased hepatic triglyceride levels without affecting atherosclerosis in mice J. Cell. Mol. Med. 2023 27 1056 1068 10.1111/jcmm.17676 36946061 PMC10098290 Zhang, Y., Verwilligen, R. A. F., Van Eck, M. & Hoekstra, M. PRMT5 inhibition induces pro-inflammatory macrophage polarization and increased hepatic triglyceride levels without affecting atherosclerosis in mice. J. Cell. Mol. Med. 27 , 1056–1068 (2023). 36946061 10.1111/jcmm.17676 PMC10098290

568. Haque T Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes Leuk. Res. 2023 134 107390 10.1016/j.leukres.2023.107390 37776843 Haque, T. et al. Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes. Leuk. Res. 134 , 107390 (2023). 37776843 10.1016/j.leukres.2023.107390

569. Rodon J A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations ESMO Open 2024 9 102961 10.1016/j.esmoop.2024.102961 38640748 PMC11047177 Rodon, J. et al. A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations. ESMO Open 9 , 102961 (2024). 38640748 10.1016/j.esmoop.2024.102961 PMC11047177

570. Cottrell KM Discovery of TNG908: a selective, brain penetrant, MTA-cooperative PRMT5 inhibitor that is synthetically lethal with MTAP-deleted cancers J. Med. Chem. 2024 67 6064 6080 10.1021/acs.jmedchem.4c00133 38595098 PMC11056935 Cottrell, K. M. et al. Discovery of TNG908: a selective, brain penetrant, MTA-cooperative PRMT5 inhibitor that is synthetically lethal with MTAP-deleted cancers. J. Med. Chem. 67 , 6064–6080 (2024). 38595098 10.1021/acs.jmedchem.4c00133 PMC11056935

571. Engstrom LD MRTX1719 Is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer Cancer Discov. 2023 13 2412 2431 10.1158/2159-8290.CD-23-0669 37552839 PMC10618744 Engstrom, L. D. et al. MRTX1719 Is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer. Cancer Discov. 13 , 2412–2431 (2023). 37552839 10.1158/2159-8290.CD-23-0669 PMC10618744

572. Ferrarotto R PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: an open-label, phase I dose-expansion study Oral. Oncol. 2024 149 106634 10.1016/j.oraloncology.2023.106634 38118249 Ferrarotto, R. et al. PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: an open-label, phase I dose-expansion study. Oral. Oncol. 149 , 106634 (2024). 38118249 10.1016/j.oraloncology.2023.106634

573. Tong D Tang Y Zhong P The emerging roles of histone demethylases in cancers Cancer Metastasis Rev. 2024 43 795 821 10.1007/s10555-023-10160-9 38227150 Tong, D., Tang, Y. & Zhong, P. The emerging roles of histone demethylases in cancers. Cancer Metastasis Rev. 43 , 795–821 (2024). 38227150 10.1007/s10555-023-10160-9

574. Arifuzzaman S Khatun MR Khatun R Emerging of lysine demethylases (KDMs): from pathophysiological insights to novel therapeutic opportunities Biomed. Pharmacother. 2020 129 110392 10.1016/j.biopha.2020.110392 32574968 Arifuzzaman, S., Khatun, M. R. & Khatun, R. Emerging of lysine demethylases (KDMs): from pathophysiological insights to novel therapeutic opportunities. Biomed. Pharmacother. 129 , 110392 (2020). 32574968 10.1016/j.biopha.2020.110392

575. Onuora S Targeting KDM2/7 histone demethylases could protect against OA Nat. Rev. Rheumatol. 2023 19 326 10.1038/s41584-023-00978-6 37165088 Onuora, S. Targeting KDM2/7 histone demethylases could protect against OA. Nat. Rev. Rheumatol. 19 , 326 (2023). 37165088 10.1038/s41584-023-00978-6

576. Suzuki T Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity J. Med. Chem. 2013 56 7222 7231 10.1021/jm400624b 23964788 PMC3929130 Suzuki, T. et al. Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity. J. Med. Chem. 56 , 7222–7231 (2013). 23964788 10.1021/jm400624b PMC3929130

577. Gerken PA Discovery of a highly selective cell-active inhibitor of the histone lysine demethylases KDM2/7 Angew. Chem. Int. Ed. Engl. 2017 56 15555 15559 10.1002/anie.201706788 28976073 PMC5725665 Gerken, P. A. et al. Discovery of a highly selective cell-active inhibitor of the histone lysine demethylases KDM2/7. Angew. Chem. Int. Ed. Engl. 56 , 15555–15559 (2017). 28976073 10.1002/anie.201706788 PMC5725665

578. Coleman OD Cyclic peptides target the aromatic cage of a PHD-finger reader domain to modulate epigenetic protein function Chem. Sci. 2023 14 7136 7146 10.1039/D2SC05944D 37416723 PMC10321576 Coleman, O. D. et al. Cyclic peptides target the aromatic cage of a PHD-finger reader domain to modulate epigenetic protein function. Chem. Sci. 14 , 7136–7146 (2023). 37416723 10.1039/d2sc05944d PMC10321576

579. Rose NR Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases J. Med. Chem. 2012 55 6639 6643 10.1021/jm300677j 22724510 PMC4673902 Rose, N. R. et al. Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases. J. Med. Chem. 55 , 6639–6643 (2012). 22724510 10.1021/jm300677j PMC4673902

580. Assi R Inhibition of KDM7A/B histone demethylases restores H3K79 methylation and protects against osteoarthritis Ann. Rheum. Dis. 2023 82 963 973 10.1136/ard-2022-223789 36927643 Assi, R. et al. Inhibition of KDM7A/B histone demethylases restores H3K79 methylation and protects against osteoarthritis. Ann. Rheum. Dis. 82 , 963–973 (2023). 36927643 10.1136/ard-2022-223789

581. Xu X Small molecular modulators of JMJD1C preferentially inhibit growth of leukemia cells Int. J. Cancer 2020 146 400 412 10.1002/ijc.32552 31271662 Xu, X. et al. Small molecular modulators of JMJD1C preferentially inhibit growth of leukemia cells. Int. J. Cancer 146 , 400–412 (2020). 31271662 10.1002/ijc.32552

582. Yang Y Modulators of histone demethylase JMJD1C selectively target leukemic stem cells FEBS Open. Bio. 2021 11 265 277 10.1002/2211-5463.13054 33289299 PMC7780120 Yang, Y. et al. Modulators of histone demethylase JMJD1C selectively target leukemic stem cells. FEBS Open. Bio. 11 , 265–277 (2021). 33289299 10.1002/2211-5463.13054 PMC7780120

583. Zhang W Epigenetic regulation of wnt signaling by carboxamide-substituted benzhydryl amines that function as histone demethylase inhibitors iScience 2020 23 101795 10.1016/j.isci.2020.101795 33305174 PMC7718485 Zhang, W. et al. Epigenetic regulation of wnt signaling by carboxamide-substituted benzhydryl amines that function as histone demethylase inhibitors. iScience 23 , 101795 (2020). 33305174 10.1016/j.isci.2020.101795 PMC7718485

584. Lee DH Advances in histone demethylase KDM4 as cancer therapeutic targets FASEB J. 2020 34 3461 3484 10.1096/fj.201902584R 31961018 Lee, D. H. et al. Advances in histone demethylase KDM4 as cancer therapeutic targets. FASEB J. 34 , 3461–3484 (2020). 31961018 10.1096/fj.201902584R

585. Wu Q Recent advances with KDM4 inhibitors and potential applications J. Med. Chem. 2022 65 9564 9579 10.1021/acs.jmedchem.2c00680 35838529 PMC9531573 Wu, Q. et al. Recent advances with KDM4 inhibitors and potential applications. J. Med. Chem. 65 , 9564–9579 (2022). 35838529 10.1021/acs.jmedchem.2c00680 PMC9531573

586. Chandhasin C TACH101, a first-in-class pan-inhibitor of KDM4 histone demethylase Anticancer Drugs 2023 34 1122 1131 37067993 10.1097/CAD.0000000000001514 PMC10569680 Chandhasin, C. et al. TACH101, a first-in-class pan-inhibitor of KDM4 histone demethylase. Anticancer Drugs 34 , 1122–1131 (2023). 37067993 10.1097/CAD.0000000000001514 PMC10569680

587. Li Y KDM4 inhibitor SD49-7 attenuates leukemia stem cell via KDM4A/MDM2/p21(CIP1) axis Theranostics 2022 12 4922 4934 10.7150/thno.71460 35836814 PMC9274755 Li, Y. et al. KDM4 inhibitor SD49-7 attenuates leukemia stem cell via KDM4A/MDM2/p21(CIP1) axis. Theranostics 12 , 4922–4934 (2022). 35836814 10.7150/thno.71460 PMC9274755

588. Lombino J In-silico guided chemical exploration of KDM4A fragments hits Clin. Epigenet. 2023 15 197 10.1186/s13148-023-01613-7 PMC10740270 38129913 Lombino, J. et al. In-silico guided chemical exploration of KDM4A fragments hits. Clin. Epigenet. 15 , 197 (2023). 10.1186/s13148-023-01613-7 PMC10740270 38129913

589. Del Moral-Morales A Transcriptomic and drug discovery analyses reveal natural compounds targeting the KDM4 subfamily as promising adjuvant treatments in cancer Front Genet. 2022 13 860924 10.3389/fgene.2022.860924 35480330 PMC9036480 Del Moral-Morales, A. et al. Transcriptomic and drug discovery analyses reveal natural compounds targeting the KDM4 subfamily as promising adjuvant treatments in cancer. Front Genet. 13 , 860924 (2022). 35480330 10.3389/fgene.2022.860924 PMC9036480

590. Tarhonskaya H Studies on the interaction of the histone demethylase KDM5B with tricarboxylic acid cycle intermediates J. Mol. Biol. 2017 429 2895 2906 10.1016/j.jmb.2017.08.007 28827149 PMC5636616 Tarhonskaya, H. et al. Studies on the interaction of the histone demethylase KDM5B with tricarboxylic acid cycle intermediates. J. Mol. Biol. 429 , 2895–2906 (2017). 28827149 10.1016/j.jmb.2017.08.007 PMC5636616

591. Tumber A Potent and selective KDM5 inhibitor stops cellular demethylation of H3K4me3 at transcription start sites and proliferation of MM1S myeloma cells Cell. Chem. Biol. 2017 24 371 380 10.1016/j.chembiol.2017.02.006 28262558 PMC5361737 Tumber, A. et al. Potent and selective KDM5 inhibitor stops cellular demethylation of H3K4me3 at transcription start sites and proliferation of MM1S myeloma cells. Cell. Chem. Biol. 24 , 371–380 (2017). 28262558 10.1016/j.chembiol.2017.02.006 PMC5361737

592. Pippa, S. et al. Small molecule inhibitors of KDM5 histone demethylases increase the radiosensitivity of breast cancer cells overexpressing JARID1B. Molecules 24 , 1739 (2019). 10.3390/molecules24091739 PMC6540222 31060229

593. Johansson C Structural analysis of human KDM5B guides histone demethylase inhibitor development Nat. Chem. Biol. 2016 12 539 545 10.1038/nchembio.2087 27214403 Johansson, C. et al. Structural analysis of human KDM5B guides histone demethylase inhibitor development. Nat. Chem. Biol. 12 , 539–545 (2016). 27214403 10.1038/nchembio.2087

594. Liang J Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies Bioorg. Med. Chem. Lett. 2016 26 4036 4041 10.1016/j.bmcl.2016.06.078 27406798 Liang, J. et al. Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies. Bioorg. Med. Chem. Lett. 26 , 4036–4041 (2016). 27406798 10.1016/j.bmcl.2016.06.078

595. Terao M Structural optimization of a lysine demethylase 5 inhibitor for improvement of its cellular activity Bioorg. Med. Chem. 2024 98 117579 10.1016/j.bmc.2023.117579 38168630 Terao, M. et al. Structural optimization of a lysine demethylase 5 inhibitor for improvement of its cellular activity. Bioorg. Med. Chem. 98 , 117579 (2024). 38168630 10.1016/j.bmc.2023.117579

596. Yang, G. J. et al. Structure-based discovery of a selective KDM5A inhibitor that exhibits anti-cancer activity via inducing cell cycle arrest and senescence in breast cancer cell lines. Cancers 11 , 92 (2019). 10.3390/cancers11010092 PMC6360022 30650517

597. Horton JR Structure-based engineering of irreversible inhibitors against histone lysine demethylase KDM5A J. Med. Chem. 2018 61 10588 10601 10.1021/acs.jmedchem.8b01219 30392349 PMC6467790 Horton, J. R. et al. Structure-based engineering of irreversible inhibitors against histone lysine demethylase KDM5A. J. Med. Chem. 61 , 10588–10601 (2018). 30392349 10.1021/acs.jmedchem.8b01219 PMC6467790

598. Miyake Y Identification of novel lysine demethylase 5-selective inhibitors by inhibitor-based fragment merging strategy Bioorg. Med. Chem. 2019 27 1119 1129 10.1016/j.bmc.2019.02.006 30745098 Miyake, Y. et al. Identification of novel lysine demethylase 5-selective inhibitors by inhibitor-based fragment merging strategy. Bioorg. Med. Chem. 27 , 1119–1129 (2019). 30745098 10.1016/j.bmc.2019.02.006

599. Liang J From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors Bioorg. Med. Chem. Lett. 2017 27 2974 2981 10.1016/j.bmcl.2017.05.016 28512031 Liang, J. et al. From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors. Bioorg. Med. Chem. Lett. 27 , 2974–2981 (2017). 28512031 10.1016/j.bmcl.2017.05.016

600. Paroni G HER2-positive breast-cancer cell lines are sensitive to KDM5 inhibition: definition of a gene-expression model for the selection of sensitive cases Oncogene 2019 38 2675 2689 10.1038/s41388-018-0620-6 30538297 Paroni, G. et al. HER2-positive breast-cancer cell lines are sensitive to KDM5 inhibition: definition of a gene-expression model for the selection of sensitive cases. Oncogene 38 , 2675–2689 (2019). 30538297 10.1038/s41388-018-0620-6

601. Leadem BR A KDM5 inhibitor increases global H3K4 trimethylation occupancy and enhances the biological efficacy of 5-aza-2 ' -deoxycytidine Cancer Res. 2018 78 1127 1139 10.1158/0008-5472.CAN-17-1453 29282222 PMC5935520 Leadem, B. R. et al. A KDM5 inhibitor increases global H3K4 trimethylation occupancy and enhances the biological efficacy of 5-aza-2 ' -deoxycytidine. Cancer Res. 78 , 1127–1139 (2018). 29282222 10.1158/0008-5472.CAN-17-1453 PMC5935520

602. Gilmore SA Characterization of a KDM5 small molecule inhibitor with antiviral activity against hepatitis B virus PLoS One 2022 17 e0271145 10.1371/journal.pone.0271145 36477212 PMC9728921 Gilmore, S. A. et al. Characterization of a KDM5 small molecule inhibitor with antiviral activity against hepatitis B virus. PLoS One 17 , e0271145 (2022). 36477212 10.1371/journal.pone.0271145 PMC9728921

603. Mitsui E Identification of ryuvidine as a KDM5A inhibitor Sci. Rep. 2019 9 9952 10.1038/s41598-019-46346-x 31289306 PMC6616564 Mitsui, E. et al. Identification of ryuvidine as a KDM5A inhibitor. Sci. Rep. 9 , 9952 (2019). 31289306 10.1038/s41598-019-46346-x PMC6616564

604. Liu Y Yu Y Zhang J Wang C The therapeutic effect of dexmedetomidine on protection from renal failure via inhibiting KDM5A in lipopolysaccharide-induced sepsis of mice Life Sci. 2019 239 116868 10.1016/j.lfs.2019.116868 31682847 Liu, Y., Yu, Y., Zhang, J. & Wang, C. The therapeutic effect of dexmedetomidine on protection from renal failure via inhibiting KDM5A in lipopolysaccharide-induced sepsis of mice. Life Sci. 239 , 116868 (2019). 31682847 10.1016/j.lfs.2019.116868

605. Yang GJ Selective inhibition of lysine-specific demethylase 5A (KDM5A) using a rhodium(III) complex for triple-negative breast cancer therapy Angew. Chem. Int. Ed. Engl. 2018 57 13091 13095 10.1002/anie.201807305 29968419 Yang, G. J. et al. Selective inhibition of lysine-specific demethylase 5A (KDM5A) using a rhodium(III) complex for triple-negative breast cancer therapy. Angew. Chem. Int. Ed. Engl. 57 , 13091–13095 (2018). 29968419 10.1002/anie.201807305

606. Dabiri Y Imidazopyridines as potent KDM5 demethylase inhibitors promoting reprogramming efficiency of human iPSCs iScience 2019 12 168 181 10.1016/j.isci.2019.01.012 30685712 PMC6354736 Dabiri, Y. et al. Imidazopyridines as potent KDM5 demethylase inhibitors promoting reprogramming efficiency of human iPSCs. iScience 12 , 168–181 (2019). 30685712 10.1016/j.isci.2019.01.012 PMC6354736

607. Tang K Discovery of novel pyrazole-based KDM5B inhibitor TK-129 and its protective effects on myocardial remodeling and fibrosis J. Med. Chem. 2022 65 12979 13000 10.1021/acs.jmedchem.2c00797 36112701 Tang, K. et al. Discovery of novel pyrazole-based KDM5B inhibitor TK-129 and its protective effects on myocardial remodeling and fibrosis. J. Med. Chem. 65 , 12979–13000 (2022). 36112701 10.1021/acs.jmedchem.2c00797

608. Sayegh J Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen J. Biol. Chem. 2013 288 9408 9417 10.1074/jbc.M112.419861 23408432 PMC3611010 Sayegh, J. et al. Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen. J. Biol. Chem. 288 , 9408–9417 (2013). 23408432 10.1074/jbc.M112.419861 PMC3611010

609. Zhao B Discovery of pyrazole derivatives as cellular active inhibitors of histone lysine-specific demethylase 5B (KDM5B/JARID1B) Eur. J. Med. Chem. 2020 192 112161 10.1016/j.ejmech.2020.112161 32155529 Zhao, B. et al. Discovery of pyrazole derivatives as cellular active inhibitors of histone lysine-specific demethylase 5B (KDM5B/JARID1B). Eur. J. Med. Chem. 192 , 112161 (2020). 32155529 10.1016/j.ejmech.2020.112161

610. Iida T Design, synthesis, and biological evaluation of lysine demethylase 5 C degraders ChemMedChem 2021 16 1609 1618 10.1002/cmdc.202000933 33470543 Iida, T. et al. Design, synthesis, and biological evaluation of lysine demethylase 5 C degraders. ChemMedChem 16 , 1609–1618 (2021). 33470543 10.1002/cmdc.202000933

611. Kruidenier L A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response Nature 2012 488 404 408 10.1038/nature11262 22842901 PMC4691848 Kruidenier, L. et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 488 , 404–408 (2012). 22842901 10.1038/nature11262 PMC4691848

612. Montano EN α-Ketoglutarate-dependent KDM6 histone demethylases and interferon-stimulated gene expression in lupus Arthritis Rheumatol. 2024 76 396 410 10.1002/art.42724 37800478 PMC10922114 Montano, E. N. et al. α-Ketoglutarate-dependent KDM6 histone demethylases and interferon-stimulated gene expression in lupus. Arthritis Rheumatol. 76 , 396–410 (2024). 37800478 10.1002/art.42724 PMC10922114

613. Hung, P. H. et al. The histone demethylase inhibitor GSK-J4 is a therapeutic target for the kidney fibrosis of diabetic kidney disease via DKK1 modulation. Int. J. Mol. Sci . 23 , 9407 (2022). 10.3390/ijms23169407 PMC9409090 36012674

614. Zhang W Therapeutically targeting head and neck squamous cell carcinoma through synergistic inhibition of LSD1 and JMJD3 by TCP and GSK-J1 Br. J. Cancer 2020 122 528 538 10.1038/s41416-019-0680-6 31848446 PMC7028736 Zhang, W. et al. Therapeutically targeting head and neck squamous cell carcinoma through synergistic inhibition of LSD1 and JMJD3 by TCP and GSK-J1. Br. J. Cancer 122 , 528–538 (2020). 31848446 10.1038/s41416-019-0680-6 PMC7028736

615. Wang JJ The JMJD3 histone demethylase inhibitor GSK-J1 ameliorates lipopolysaccharide-induced inflammation in a mastitis model J. Biol. Chem. 2022 298 102017 10.1016/j.jbc.2022.102017 35526564 PMC9168612 Wang, J. J. et al. The JMJD3 histone demethylase inhibitor GSK-J1 ameliorates lipopolysaccharide-induced inflammation in a mastitis model. J. Biol. Chem. 298 , 102017 (2022). 35526564 10.1016/j.jbc.2022.102017 PMC9168612

616. Cottone L Inhibition of histone H3K27 demethylases inactivates brachyury (TBXT) and promotes chordoma cell death Cancer Res. 2020 80 4540 4551 10.1158/0008-5472.CAN-20-1387 32855205 PMC7616956 Cottone, L. et al. Inhibition of histone H3K27 demethylases inactivates brachyury (TBXT) and promotes chordoma cell death. Cancer Res. 80 , 4540–4551 (2020). 32855205 10.1158/0008-5472.CAN-20-1387 PMC7616956

617. Giordano A Identification of the 2-benzoxazol-2-yl-phenol scaffold as new hit for JMJD3 inhibition ACS Med. Chem. Lett. 2019 10 601 605 10.1021/acsmedchemlett.8b00589 30996803 PMC6466828 Giordano, A. et al. Identification of the 2-benzoxazol-2-yl-phenol scaffold as new hit for JMJD3 inhibition. ACS Med. Chem. Lett. 10 , 601–605 (2019). 30996803 10.1021/acsmedchemlett.8b00589 PMC6466828

618. Zhang Y Screening of inhibitors against histone demethylation jumonji domain-containing protein 3 by capillary electrophoresis J. Chromatogr. A 2020 1613 460625 10.1016/j.chroma.2019.460625 31668999 Zhang, Y. et al. Screening of inhibitors against histone demethylation jumonji domain-containing protein 3 by capillary electrophoresis. J. Chromatogr. A 1613 , 460625 (2020). 31668999 10.1016/j.chroma.2019.460625

619. Jones SE Peptides derived from histone 3 and modified at position 18 inhibit histone demethylase KDM6 enzymes Chembiochem 2018 19 1817 1822 10.1002/cbic.201800185 29878441 Jones, S. E. et al. Peptides derived from histone 3 and modified at position 18 inhibit histone demethylase KDM6 enzymes. Chembiochem 19 , 1817–1822 (2018). 29878441 10.1002/cbic.201800185

620. Shen L Combination therapy and dual-target inhibitors based on LSD1: new emerging tools in cancer therapy J. Med. Chem. 2024 67 922 951 10.1021/acs.jmedchem.3c02133 38214982 Shen, L. et al. Combination therapy and dual-target inhibitors based on LSD1: new emerging tools in cancer therapy. J. Med. Chem. 67 , 922–951 (2024). 38214982 10.1021/acs.jmedchem.3c02133

621. Wass M A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy Leukemia 2021 35 701 711 10.1038/s41375-020-0892-z 32561840 PMC7303943 Wass, M. et al. A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy. Leukemia 35 , 701–711 (2021). 32561840 10.1038/s41375-020-0892-z PMC7303943

622. Tayari MM Clinical responsiveness to all-trans retinoic acid is potentiated by LSD1 inhibition and associated with a quiescent transcriptome in myeloid malignancies Clin. Cancer Res. 2021 27 1893 1903 10.1158/1078-0432.CCR-20-4054 33495312 PMC8026558 Tayari, M. M. et al. Clinical responsiveness to all-trans retinoic acid is potentiated by LSD1 inhibition and associated with a quiescent transcriptome in myeloid malignancies. Clin. Cancer Res. 27 , 1893–1903 (2021). 33495312 10.1158/1078-0432.CCR-20-4054 PMC8026558

623. Dai XJ Tranylcypromine based lysine-specific demethylase 1 inhibitor: summary and perspective J. Med. Chem. 2020 63 14197 14215 10.1021/acs.jmedchem.0c00919 32931269 Dai, X. J. et al. Tranylcypromine based lysine-specific demethylase 1 inhibitor: summary and perspective. J. Med. Chem. 63 , 14197–14215 (2020). 32931269 10.1021/acs.jmedchem.0c00919

624. Salamero O First-in-human phase I study of Iadademstat (ORY-1001): a first-in-class lysine-specific histone demethylase 1A inhibitor, in relapsed or refractory acute myeloid leukemia J. Clin. Oncol. 2020 38 4260 4273 10.1200/JCO.19.03250 33052756 PMC7768337 Salamero, O. et al. First-in-human phase I study of Iadademstat (ORY-1001): a first-in-class lysine-specific histone demethylase 1A inhibitor, in relapsed or refractory acute myeloid leukemia. J. Clin. Oncol. 38 , 4260–4273 (2020). 33052756 10.1200/JCO.19.03250 PMC7768337

625. Maes T ORY-1001, a potent and selective covalent KDM1A inhibitor, for the treatment of acute leukemia Cancer Cell. 2018 33 495 511.e412 10.1016/j.ccell.2018.02.002 29502954 Maes, T. et al. ORY-1001, a potent and selective covalent KDM1A inhibitor, for the treatment of acute leukemia. Cancer Cell. 33 , 495–511.e412 (2018). 29502954 10.1016/j.ccell.2018.02.002

626. Cuyàs E The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes Aging 2020 12 4794 4814 10.18632/aging.102887 32191225 PMC7138538 Cuyàs, E. et al. The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes. Aging 12 , 4794–4814 (2020). 32191225 10.18632/aging.102887 PMC7138538

627. Antonijoan RM First-in-human randomized trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of the KDM1A inhibitor vafidemstat CNS Drugs 2021 35 331 344 10.1007/s40263-021-00797-x 33755924 PMC7985749 Antonijoan, R. M. et al. First-in-human randomized trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of the KDM1A inhibitor vafidemstat. CNS Drugs 35 , 331–344 (2021). 33755924 10.1007/s40263-021-00797-x PMC7985749

628. Maes T Modulation of KDM1A with vafidemstat rescues memory deficit and behavioral alterations PLoS One 2020 15 e0233468 10.1371/journal.pone.0233468 32469975 PMC7259601 Maes, T. et al. Modulation of KDM1A with vafidemstat rescues memory deficit and behavioral alterations. PLoS One 15 , e0233468 (2020). 32469975 10.1371/journal.pone.0233468 PMC7259601

629. Benyoucef A Haigh K Cuddihy A Haigh JJ JAK/BCL2 inhibition acts synergistically with LSD1 inhibitors to selectively target ETP-ALL Leukemia 2022 36 2802 2816 10.1038/s41375-022-01716-9 36229595 PMC9712096 Benyoucef, A., Haigh, K., Cuddihy, A. & Haigh, J. J. JAK/BCL2 inhibition acts synergistically with LSD1 inhibitors to selectively target ETP-ALL. Leukemia 36 , 2802–2816 (2022). 36229595 10.1038/s41375-022-01716-9 PMC9712096

630. Bauer TM Phase I, open-label, dose-escalation study of the safety, pharmacokinetics, pharmacodynamics, and efficacy of GSK2879552 in relapsed/refractory SCLC J. Thorac. Oncol. 2019 14 1828 1838 10.1016/j.jtho.2019.06.021 31260835 Bauer, T. M. et al. Phase I, open-label, dose-escalation study of the safety, pharmacokinetics, pharmacodynamics, and efficacy of GSK2879552 in relapsed/refractory SCLC. J. Thorac. Oncol. 14 , 1828–1838 (2019). 31260835 10.1016/j.jtho.2019.06.021

631. Roboz GJ Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes Leuk. Lymphoma 2022 63 463 467 10.1080/10428194.2021.2012667 34927529 Roboz, G. J. et al. Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes. Leuk. Lymphoma 63 , 463–467 (2022). 34927529 10.1080/10428194.2021.2012667

632. Dai XJ Reversible lysine specific demethylase 1 (LSD1) inhibitors: a promising wrench to impair LSD1 J. Med. Chem. 2021 64 2466 2488 10.1021/acs.jmedchem.0c02176 33619958 Dai, X. J. et al. Reversible lysine specific demethylase 1 (LSD1) inhibitors: a promising wrench to impair LSD1. J. Med. Chem. 64 , 2466–2488 (2021). 33619958 10.1021/acs.jmedchem.0c02176

633. Kanouni T Discovery of CC-90011: a potent and selective reversible inhibitor of lysine specific demethylase 1 (LSD1) J. Med. Chem. 2020 63 14522 14529 10.1021/acs.jmedchem.0c00978 33034194 Kanouni, T. et al. Discovery of CC-90011: a potent and selective reversible inhibitor of lysine specific demethylase 1 (LSD1). J. Med. Chem. 63 , 14522–14529 (2020). 33034194 10.1021/acs.jmedchem.0c00978

634. Soldi R The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer PLoS One 2020 15 e0235705 10.1371/journal.pone.0235705 32649682 PMC7351179 Soldi, R. et al. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer. PLoS One 15 , e0235705 (2020). 32649682 10.1371/journal.pone.0235705 PMC7351179

635. Granieri L Targeting the USP7/RRM2 axis drives senescence and sensitizes melanoma cells to HDAC/LSD1 inhibitors Cell. Rep. 2022 40 111396 10.1016/j.celrep.2022.111396 36130505 Granieri, L. et al. Targeting the USP7/RRM2 axis drives senescence and sensitizes melanoma cells to HDAC/LSD1 inhibitors. Cell. Rep. 40 , 111396 (2022). 36130505 10.1016/j.celrep.2022.111396

636. Baba, R. et al. LSD1 enzyme inhibitor TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models. Sci Adv . 7 , eaba1187 (2021). 10.1126/sciadv.aba1187 PMC7954450 33712455

637. Baba R Investigating the therapeutic potential of LSD1 enzyme activity-specific inhibition by TAK-418 for social and memory deficits in Rodent Disease Models ACS Chem. Neurosci. 2022 13 313 321 10.1021/acschemneuro.1c00713 35061371 Baba, R. et al. Investigating the therapeutic potential of LSD1 enzyme activity-specific inhibition by TAK-418 for social and memory deficits in Rodent Disease Models. ACS Chem. Neurosci. 13 , 313–321 (2022). 35061371 10.1021/acschemneuro.1c00713

638. Yin W Safety, pharmacokinetics and pharmacodynamics of TAK-418, a novel inhibitor of the epigenetic modulator lysine-specific demethylase 1A Br. J. Clin. Pharmacol. 2021 87 4756 4768 10.1111/bcp.14912 33990969 PMC9290503 Yin, W. et al. Safety, pharmacokinetics and pharmacodynamics of TAK-418, a novel inhibitor of the epigenetic modulator lysine-specific demethylase 1A. Br. J. Clin. Pharmacol. 87 , 4756–4768 (2021). 33990969 10.1111/bcp.14912 PMC9290503

639. Huang X Chemical inhibitors targeting histone methylation readers Pharmacol. Ther. 2024 256 108614 10.1016/j.pharmthera.2024.108614 38401773 Huang, X. et al. Chemical inhibitors targeting histone methylation readers. Pharmacol. Ther. 256 , 108614 (2024). 38401773 10.1016/j.pharmthera.2024.108614

640. Musselman CA Lalonde ME Côté J Kutateladze TG Perceiving the epigenetic landscape through histone readers Nat. Struct. Mol. Biol. 2012 19 1218 1227 10.1038/nsmb.2436 23211769 PMC3645987 Musselman, C. A., Lalonde, M. E., Côté, J. & Kutateladze, T. G. Perceiving the epigenetic landscape through histone readers. Nat. Struct. Mol. Biol. 19 , 1218–1227 (2012). 23211769 10.1038/nsmb.2436 PMC3645987

641. Liu S Li X Li X Li XD Recent advances in the development of peptide-based inhibitors targeting epigenetic readers of histone lysine acetylation and methylation marks Curr. Opin. Chem. Biol. 2023 75 102334 10.1016/j.cbpa.2023.102334 37263048 Liu, S., Li, X., Li, X. & Li, X. D. Recent advances in the development of peptide-based inhibitors targeting epigenetic readers of histone lysine acetylation and methylation marks. Curr. Opin. Chem. Biol. 75 , 102334 (2023). 37263048 10.1016/j.cbpa.2023.102334

642. Huang Y Discovery of the clinical candidate MAK683: an EED-directed, allosteric, and selective PRC2 inhibitor for the treatment of advanced malignancies J. Med. Chem. 2022 65 5317 5333 10.1021/acs.jmedchem.1c02148 35352560 Huang, Y. et al. Discovery of the clinical candidate MAK683: an EED-directed, allosteric, and selective PRC2 inhibitor for the treatment of advanced malignancies. J. Med. Chem. 65 , 5317–5333 (2022). 35352560 10.1021/acs.jmedchem.1c02148

643. Jiang X The role of m6A modification in the biological functions and diseases Signal. Transduct. Target. Ther. 2021 6 74 10.1038/s41392-020-00450-x 33611339 PMC7897327 Jiang, X. et al. The role of m6A modification in the biological functions and diseases. Signal. Transduct. Target. Ther. 6 , 74 (2021). 33611339 10.1038/s41392-020-00450-x PMC7897327

644. Qi YN Methyltransferase-like proteins in cancer biology and potential therapeutic targeting J. Hematol. Oncol. 2023 16 89 10.1186/s13045-023-01477-7 37533128 PMC10394802 Qi, Y. N. et al. Methyltransferase-like proteins in cancer biology and potential therapeutic targeting. J. Hematol. Oncol. 16 , 89 (2023). 37533128 10.1186/s13045-023-01477-7 PMC10394802

645. Bedi RK Small-molecule inhibitors of METTL3, the major human epitranscriptomic writer ChemMedChem 2020 15 744 748 10.1002/cmdc.202000011 32159918 Bedi, R. K. et al. Small-molecule inhibitors of METTL3, the major human epitranscriptomic writer. ChemMedChem 15 , 744–748 (2020). 32159918 10.1002/cmdc.202000011

646. Moroz-Omori EV METTL3 inhibitors for epitranscriptomic modulation of cellular processes ChemMedChem 2021 16 3035 3043 10.1002/cmdc.202100291 34237194 PMC8518639 Moroz-Omori, E. V. et al. METTL3 inhibitors for epitranscriptomic modulation of cellular processes. ChemMedChem 16 , 3035–3043 (2021). 34237194 10.1002/cmdc.202100291 PMC8518639

647. Dolbois A 1,4,9-Triazaspiro[5.5]undecan-2-one derivatives as potent and selective METTL3 inhibitors J. Med. Chem. 2021 64 12738 12760 10.1021/acs.jmedchem.1c00773 34431664 Dolbois, A. et al. 1,4,9-Triazaspiro[5.5]undecan-2-one derivatives as potent and selective METTL3 inhibitors. J. Med. Chem. 64 , 12738–12760 (2021). 34431664 10.1021/acs.jmedchem.1c00773

648. Wang JN Inhibition of METTL3 attenuates renal injury and inflammation by alleviating TAB3 m6A modifications via IGF2BP2-dependent mechanisms Sci. Transl. Med. 2022 14 eabk2709 10.1126/scitranslmed.abk2709 35417191 Wang, J. N. et al. Inhibition of METTL3 attenuates renal injury and inflammation by alleviating TAB3 m6A modifications via IGF2BP2-dependent mechanisms. Sci. Transl. Med. 14 , eabk2709 (2022). 35417191 10.1126/scitranslmed.abk2709

649. Zhou X Inhibition of METTL3 alleviates NLRP3 inflammasome activation via increasing ubiquitination of NEK7 Adv. Sci. 2024 11 e2308786 10.1002/advs.202308786 PMC11234428 38696610 Zhou, X. et al. Inhibition of METTL3 alleviates NLRP3 inflammasome activation via increasing ubiquitination of NEK7. Adv. Sci. 11 , e2308786 (2024). 10.1002/advs.202308786 PMC11234428 38696610

650. Yankova E Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia Nature 2021 593 597 601 10.1038/s41586-021-03536-w 33902106 PMC7613134 Yankova, E. et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature 593 , 597–601 (2021). 33902106 10.1038/s41586-021-03536-w PMC7613134

651. Guirguis AA Inhibition of METTL3 results in a cell-intrinsic interferon response that enhances antitumor immunity Cancer Discov. 2023 13 2228 2247 10.1158/2159-8290.CD-23-0007 37548590 Guirguis, A. A. et al. Inhibition of METTL3 results in a cell-intrinsic interferon response that enhances antitumor immunity. Cancer Discov. 13 , 2228–2247 (2023). 37548590 10.1158/2159-8290.CD-23-0007

652. Pomaville M Small-molecule inhibition of the METTL3/METTL14 complex suppresses neuroblastoma tumor growth and promotes differentiation Cell. Rep. 2024 43 114165 10.1016/j.celrep.2024.114165 38691450 PMC11181463 Pomaville, M. et al. Small-molecule inhibition of the METTL3/METTL14 complex suppresses neuroblastoma tumor growth and promotes differentiation. Cell. Rep. 43 , 114165 (2024). 38691450 10.1016/j.celrep.2024.114165 PMC11181463

653. Sun Y METTL3 promotes chemoresistance in small cell lung cancer by inducing mitophagy J. Exp. Clin. Cancer Res. 2023 42 65 10.1186/s13046-023-02638-9 36932427 PMC10022264 Sun, Y. et al. METTL3 promotes chemoresistance in small cell lung cancer by inducing mitophagy. J. Exp. Clin. Cancer Res. 42 , 65 (2023). 36932427 10.1186/s13046-023-02638-9 PMC10022264

654. Xuan YF The combination of methionine adenosyltransferase 2A inhibitor and methyltransferase like 3 inhibitor promotes apoptosis of non-small cell lung cancer cells and produces synergistic anti-tumor activity Biochem. Biophys. Res. Commun. 2024 716 150011 10.1016/j.bbrc.2024.150011 38704890 Xuan, Y. F. et al. The combination of methionine adenosyltransferase 2A inhibitor and methyltransferase like 3 inhibitor promotes apoptosis of non-small cell lung cancer cells and produces synergistic anti-tumor activity. Biochem. Biophys. Res. Commun. 716 , 150011 (2024). 38704890 10.1016/j.bbrc.2024.150011

655. Ganguly, M., Gupta, R., Roychowdhury, A. & Hazra, D. De novo drug designing coupled with brute force screening and structure guided lead optimization gives highly specific inhibitor of METTL3: a potential cure for Acute Myeloid Leukaemia. J. Biomol. Struct. Dyn. , 1–14 (2023). 10.1080/07391102.2023.2291162 38069613

656. Du Y Discovery of METTL3 small molecule inhibitors by virtual screening of natural products Front Pharmacol. 2022 13 878135 10.3389/fphar.2022.878135 35571106 PMC9093036 Du, Y. et al. Discovery of METTL3 small molecule inhibitors by virtual screening of natural products. Front Pharmacol. 13 , 878135 (2022). 35571106 10.3389/fphar.2022.878135 PMC9093036

657. Jiao Y Williams A Wei N Quercetin ameliorated insulin resistance via regulating METTL3-mediated N6-methyladenosine modification of PRKD2 mRNA in skeletal muscle and C2C12 myocyte cell line Nutr. Metab. Cardiovasc Dis. 2022 32 2655 2668 10.1016/j.numecd.2022.06.019 36058761 Jiao, Y., Williams, A. & Wei, N. Quercetin ameliorated insulin resistance via regulating METTL3-mediated N6-methyladenosine modification of PRKD2 mRNA in skeletal muscle and C2C12 myocyte cell line. Nutr. Metab. Cardiovasc Dis. 32 , 2655–2668 (2022). 36058761 10.1016/j.numecd.2022.06.019

658. Hu J METTL3-dependent N6-methyladenosine modification is involved in berberine-mediated neuroprotection in ischemic stroke by enhancing the stability of NEAT1 in astrocytes Aging 2024 16 299 321 38180752 10.18632/aging.205369 PMC10817396 Hu, J. et al. METTL3-dependent N6-methyladenosine modification is involved in berberine-mediated neuroprotection in ischemic stroke by enhancing the stability of NEAT1 in astrocytes. Aging 16 , 299–321 (2024). 38180752 10.18632/aging.205369 PMC10817396

659. Cui J Wang X Dong L Wang Q Curcumin reduces myocardial ischemia-reperfusion injury, by increasing endogenous H(2)S levels and further modulating m(6)A Mol. Biol. Rep. 2024 51 558 10.1007/s11033-024-09478-6 38643323 Cui, J., Wang, X., Dong, L. & Wang, Q. Curcumin reduces myocardial ischemia-reperfusion injury, by increasing endogenous H(2)S levels and further modulating m(6)A. Mol. Biol. Rep. 51 , 558 (2024). 38643323 10.1007/s11033-024-09478-6

660. Yin H Inhibition of METTL3 in macrophages provides protection against intestinal inflammation Cell. Mol. Immunol. 2024 21 589 603 10.1038/s41423-024-01156-8 38649449 PMC11143309 Yin, H. et al. Inhibition of METTL3 in macrophages provides protection against intestinal inflammation. Cell. Mol. Immunol. 21 , 589–603 (2024). 38649449 10.1038/s41423-024-01156-8 PMC11143309

661. Issahaku AR Multi-dimensional structural footprint identification for the design of potential scaffolds targeting METTL3 in cancer treatment from natural compounds J. Mol. Model 2023 29 122 10.1007/s00894-023-05516-5 36995499 Issahaku, A. R. et al. Multi-dimensional structural footprint identification for the design of potential scaffolds targeting METTL3 in cancer treatment from natural compounds. J. Mol. Model 29 , 122 (2023). 36995499 10.1007/s00894-023-05516-5

662. Li Z A stapled peptide inhibitor targeting the binding interface of N6-adenosine-methyltransferase subunits METTL3 and METTL14 for cancer therapy Angew. Chem. Int. Ed. Engl. 2024 63 e202402611 10.1002/anie.202402611 38607929 Li, Z. et al. A stapled peptide inhibitor targeting the binding interface of N6-adenosine-methyltransferase subunits METTL3 and METTL14 for cancer therapy. Angew. Chem. Int. Ed. Engl. 63 , e202402611 (2024). 38607929 10.1002/anie.202402611

663. Lee JH Kim S Jin MS Kim YC Discovery of substituted indole derivatives as allosteric inhibitors of m(6) A-RNA methyltransferase, METTL3-14 complex Drug. Dev. Res. 2022 83 783 799 35040501 10.1002/ddr.21910 Lee, J. H., Kim, S., Jin, M. S. & Kim, Y. C. Discovery of substituted indole derivatives as allosteric inhibitors of m(6) A-RNA methyltransferase, METTL3-14 complex. Drug. Dev. Res. 83 , 783–799 (2022). 35040501 10.1002/ddr.21910

664. Lee, J. H. et al. Eltrombopag as an allosteric inhibitor of the METTL3-14 complex affecting the m(6)A methylation of RNA in acute myeloid leukemia cells. Pharmaceuticals . 15, 440 (2022). 10.3390/ph15040440 PMC9032718 35455436

665. Chen CJ Metformin attenuates multiple myeloma cell proliferation and encourages apoptosis by suppressing METTL3-mediated m6A methylation of THRAP3, RBM25, and USP4 Cell. Cycle 2023 22 986 1004 10.1080/15384101.2023.2170521 36762777 PMC10054227 Chen, C. J. et al. Metformin attenuates multiple myeloma cell proliferation and encourages apoptosis by suppressing METTL3-mediated m6A methylation of THRAP3, RBM25, and USP4. Cell. Cycle 22 , 986–1004 (2023). 36762777 10.1080/15384101.2023.2170521 PMC10054227

666. Cheng L Metformin exhibits antiproliferation activity in breast cancer via miR-483-3p/METTL3/m(6)A/p21 pathway Oncogenesis 2021 10 7 10.1038/s41389-020-00290-y 33431790 PMC7801402 Cheng, L. et al. Metformin exhibits antiproliferation activity in breast cancer via miR-483-3p/METTL3/m(6)A/p21 pathway. Oncogenesis 10 , 7 (2021). 33431790 10.1038/s41389-020-00290-y PMC7801402

667. Li K Stimulation of let-7 maturation by metformin improved the response to tyrosine kinase inhibitor therapy in an m6A dependent manner Front. Oncol. 2021 11 731561 10.3389/fonc.2021.731561 35070958 PMC8770959 Li, K. et al. Stimulation of let-7 maturation by metformin improved the response to tyrosine kinase inhibitor therapy in an m6A dependent manner. Front. Oncol. 11 , 731561 (2021). 35070958 10.3389/fonc.2021.731561 PMC8770959

668. Zhang Q Hypoxia-responsive PPARGC1A/BAMBI/ACSL5 axis promotes progression and resistance to lenvatinib in hepatocellular carcinoma Oncogene 2023 42 1509 1523 10.1038/s41388-023-02665-y 36932115 Zhang, Q. et al. Hypoxia-responsive PPARGC1A/BAMBI/ACSL5 axis promotes progression and resistance to lenvatinib in hepatocellular carcinoma. Oncogene 42 , 1509–1523 (2023). 36932115 10.1038/s41388-023-02665-y

669. Xiang Y RNA m(6)A methylation regulates the ultraviolet-induced DNA damage response Nature 2017 543 573 576 10.1038/nature21671 28297716 PMC5490984 Xiang, Y. et al. RNA m(6)A methylation regulates the ultraviolet-induced DNA damage response. Nature 543 , 573–576 (2017). 28297716 10.1038/nature21671 PMC5490984

670. Meng M mTOR signaling promotes rapid m6A mRNA methylation to regulate NK-cell activation and effector functions Immunol. Res. 2024 12 1039 1057 10.1158/2326-6066.CIR-23-0339 38640466 Meng, M. et al. mTOR signaling promotes rapid m6A mRNA methylation to regulate NK-cell activation and effector functions. Immunol. Res. 12 , 1039–1057 (2024). 10.1158/2326-6066.CIR-23-0339 38640466

671. Yang X METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST Mol. Cancer 2020 19 46 10.1186/s12943-020-1146-4 32111213 PMC7047419 Yang, X. et al. METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST. Mol. Cancer 19 , 46 (2020). 32111213 10.1186/s12943-020-1146-4 PMC7047419

672. Gao L Lee H Goodman JH Ding L Hematopoietic stem cell niche generation and maintenance are distinguishable by an epitranscriptomic program Cell 2024 187 2801 2816.e2817 10.1016/j.cell.2024.03.032 38657601 PMC11148849 Gao, L., Lee, H., Goodman, J. H. & Ding, L. Hematopoietic stem cell niche generation and maintenance are distinguishable by an epitranscriptomic program. Cell 187 , 2801–2816.e2817 (2024). 38657601 10.1016/j.cell.2024.03.032 PMC11148849

673. Selberg S Discovery of small molecules that activate RNA methylation through cooperative binding to the METTL3-14-WTAP complex active site Cell. Rep. 2019 26 3762 3771.e3765 10.1016/j.celrep.2019.02.100 30917327 Selberg, S. et al. Discovery of small molecules that activate RNA methylation through cooperative binding to the METTL3-14-WTAP complex active site. Cell. Rep. 26 , 3762–3771.e3765 (2019). 30917327 10.1016/j.celrep.2019.02.100

674. Lv Y Melatonin attenuates chromium (VI)-induced spermatogonial stem cell/progenitor mitophagy by restoration of METTL3-mediated RNA N(6)-methyladenosine modification Front Cell. Dev. Biol. 2021 9 684398 10.3389/fcell.2021.684398 34150779 PMC8212693 Lv, Y. et al. Melatonin attenuates chromium (VI)-induced spermatogonial stem cell/progenitor mitophagy by restoration of METTL3-mediated RNA N(6)-methyladenosine modification. Front Cell. Dev. Biol. 9 , 684398 (2021). 34150779 10.3389/fcell.2021.684398 PMC8212693

675. Li Y The effect mechanism of N6-adenosine methylation (m6A) in melatonin regulated LPS-induced colon inflammation Int. J. Biol. Sci. 2024 20 2491 2506 10.7150/ijbs.95316 38725850 PMC11077364 Li, Y. et al. The effect mechanism of N6-adenosine methylation (m6A) in melatonin regulated LPS-induced colon inflammation. Int. J. Biol. Sci. 20 , 2491–2506 (2024). 38725850 10.7150/ijbs.95316 PMC11077364

676. Li Y FTO in cancer: functions, molecular mechanisms, and therapeutic implications Trends Cancer 2022 8 598 614 10.1016/j.trecan.2022.02.010 35346615 Li, Y. et al. FTO in cancer: functions, molecular mechanisms, and therapeutic implications. Trends Cancer 8 , 598–614 (2022). 35346615 10.1016/j.trecan.2022.02.010

677. Qu J RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential J. Hematol. Oncol. 2022 15 8 10.1186/s13045-022-01224-4 35063010 PMC8780705 Qu, J. et al. RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential. J. Hematol. Oncol. 15 , 8 (2022). 35063010 10.1186/s13045-022-01224-4 PMC8780705

678. Chou, F. J., Liu, Y., Lang, F. & Yang, C. D-2-hydroxyglutarate in glioma biology. Cells. 10 , 2345 (2021). 10.3390/cells10092345 PMC8464856 34571995

679. Sun K Saikosaponin D exhibits anti-leukemic activity by targeting FTO/m(6)A signaling Theranostics 2021 11 5831 5846 10.7150/thno.55574 33897884 PMC8058711 Sun, K. et al. Saikosaponin D exhibits anti-leukemic activity by targeting FTO/m(6)A signaling. Theranostics 11 , 5831–5846 (2021). 33897884 10.7150/thno.55574 PMC8058711

680. Chen B Development of cell-active N6-methyladenosine RNA demethylase FTO inhibitor J. Am. Chem. Soc. 2012 134 17963 17971 10.1021/ja3064149 23045983 Chen, B. et al. Development of cell-active N6-methyladenosine RNA demethylase FTO inhibitor. J. Am. Chem. Soc. 134 , 17963–17971 (2012). 23045983 10.1021/ja3064149

681. Huang Y Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5 Nucl. Acids Res. 2015 43 373 384 10.1093/nar/gku1276 25452335 PMC4288171 Huang, Y. et al. Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5. Nucl. Acids Res. 43 , 373–384 (2015). 25452335 10.1093/nar/gku1276 PMC4288171

682. Chen H Jia B Zhang Q Zhang Y Meclofenamic acid restores gefinitib sensitivity by downregulating breast cancer resistance protein and multidrug resistance protein 7 via FTO/m6A-demethylation/c-myc in non-small cell lung cancer Front. Oncol. 2022 12 870636 10.3389/fonc.2022.870636 35530301 PMC9069108 Chen, H., Jia, B., Zhang, Q. & Zhang, Y. Meclofenamic acid restores gefinitib sensitivity by downregulating breast cancer resistance protein and multidrug resistance protein 7 via FTO/m6A-demethylation/c-myc in non-small cell lung cancer. Front. Oncol. 12 , 870636 (2022). 35530301 10.3389/fonc.2022.870636 PMC9069108

683. Wang T Fluorescein derivatives as bifunctional molecules for the simultaneous inhibiting and labeling of FTO protein J. Am. Chem. Soc. 2015 137 13736 13739 10.1021/jacs.5b06690 26457839 Wang, T. et al. Fluorescein derivatives as bifunctional molecules for the simultaneous inhibiting and labeling of FTO protein. J. Am. Chem. Soc. 137 , 13736–13739 (2015). 26457839 10.1021/jacs.5b06690

684. Cao K Glutathione-bioimprinted nanoparticles targeting of n6-methyladenosine FTO demethylase as a strategy against leukemic stem cells Small 2022 18 e2106558 10.1002/smll.202106558 35119204 Cao, K. et al. Glutathione-bioimprinted nanoparticles targeting of n6-methyladenosine FTO demethylase as a strategy against leukemic stem cells. Small 18 , e2106558 (2022). 35119204 10.1002/smll.202106558

685. Liu Z Structure-activity relationships and antileukemia effects of the tricyclic benzoic acid FTO inhibitors J. Med. Chem. 2022 65 10638 10654 10.1021/acs.jmedchem.2c00848 35793358 Liu, Z. et al. Structure-activity relationships and antileukemia effects of the tricyclic benzoic acid FTO inhibitors. J. Med. Chem. 65 , 10638–10654 (2022). 35793358 10.1021/acs.jmedchem.2c00848

686. Huang Y Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia Cancer Cell. 2019 35 677 691.e610 10.1016/j.ccell.2019.03.006 30991027 PMC6812656 Huang, Y. et al. Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia. Cancer Cell. 35 , 677–691.e610 (2019). 30991027 10.1016/j.ccell.2019.03.006 PMC6812656

687. Liu Y Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance Cell. Metab. 2021 33 1221 1233.e1211 10.1016/j.cmet.2021.04.001 33910046 Liu, Y. et al. Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance. Cell. Metab. 33 , 1221–1233.e1211 (2021). 33910046 10.1016/j.cmet.2021.04.001

688. Xiao P Rational design of RNA demethylase FTO inhibitors with enhanced antileukemia drug-like properties J. Med. Chem. 2023 66 9731 9752 10.1021/acs.jmedchem.3c00543 37418628 Xiao, P. et al. Rational design of RNA demethylase FTO inhibitors with enhanced antileukemia drug-like properties. J. Med. Chem. 66 , 9731–9752 (2023). 37418628 10.1021/acs.jmedchem.3c00543

689. Huff S m(6)A-RNA demethylase FTO inhibitors impair self-renewal in glioblastoma stem cells ACS Chem. Biol. 2021 16 324 333 10.1021/acschembio.0c00841 33412003 PMC7901021 Huff, S. et al. m(6)A-RNA demethylase FTO inhibitors impair self-renewal in glioblastoma stem cells. ACS Chem. Biol. 16 , 324–333 (2021). 33412003 10.1021/acschembio.0c00841 PMC7901021

690. Huff S Rational design and optimization of m(6)A-RNA demethylase FTO inhibitors as anticancer agents J. Med. Chem. 2022 65 10920 10937 10.1021/acs.jmedchem.1c02075 35939803 PMC9421652 Huff, S. et al. Rational design and optimization of m(6)A-RNA demethylase FTO inhibitors as anticancer agents. J. Med. Chem. 65 , 10920–10937 (2022). 35939803 10.1021/acs.jmedchem.1c02075 PMC9421652

691. Zhang Y Identification of specific N(6)-methyladenosine RNA demethylase FTO inhibitors by single-quantum-dot-based FRET nanosensors Anal. Chem. 2020 92 13936 13944 10.1021/acs.analchem.0c02828 32972135 Zhang, Y. et al. Identification of specific N(6)-methyladenosine RNA demethylase FTO inhibitors by single-quantum-dot-based FRET nanosensors. Anal. Chem. 92 , 13936–13944 (2020). 32972135 10.1021/acs.analchem.0c02828

692. Toh JDW A strategy based on nucleotide specificity leads to a subfamily-selective and cell-active inhibitor of N(6)-methyladenosine demethylase FTO Chem. Sci. 2015 6 112 122 10.1039/C4SC02554G 28553460 PMC5424463 Toh, J. D. W. et al. A strategy based on nucleotide specificity leads to a subfamily-selective and cell-active inhibitor of N(6)-methyladenosine demethylase FTO. Chem. Sci. 6 , 112–122 (2015). 28553460 10.1039/c4sc02554g PMC5424463

693. Zheng G Synthesis of a FTO inhibitor with anticonvulsant activity ACS Chem. Neurosci. 2014 5 658 665 10.1021/cn500042t 24834807 PMC4140589 Zheng, G. et al. Synthesis of a FTO inhibitor with anticonvulsant activity. ACS Chem. Neurosci. 5 , 658–665 (2014). 24834807 10.1021/cn500042t PMC4140589

694. He W Identification of a novel small-molecule binding site of the fat mass and obesity-associated protein (FTO) J. Med. Chem. 2015 58 7341 7348 10.1021/acs.jmedchem.5b00702 26314339 He, W. et al. Identification of a novel small-molecule binding site of the fat mass and obesity-associated protein (FTO). J. Med. Chem. 58 , 7341–7348 (2015). 26314339 10.1021/acs.jmedchem.5b00702

695. Qiao Y A novel inhibitor of the obesity-related protein FTO Biochemistry 2016 55 1516 1522 10.1021/acs.biochem.6b00023 26915401 Qiao, Y. et al. A novel inhibitor of the obesity-related protein FTO. Biochemistry 55 , 1516–1522 (2016). 26915401 10.1021/acs.biochem.6b00023

696. Wang R Identification of natural compound radicicol as a potent FTO inhibitor Mol. Pharm. 2018 15 4092 4098 10.1021/acs.molpharmaceut.8b00522 30063141 Wang, R. et al. Identification of natural compound radicicol as a potent FTO inhibitor. Mol. Pharm. 15 , 4092–4098 (2018). 30063141 10.1021/acs.molpharmaceut.8b00522

697. Su R Targeting FTO suppresses cancer stem cell maintenance and immune evasion Cancer Cell. 2020 38 79 96.e11 10.1016/j.ccell.2020.04.017 32531268 PMC7363590 Su, R. et al. Targeting FTO suppresses cancer stem cell maintenance and immune evasion. Cancer Cell. 38 , 79–96.e11 (2020). 32531268 10.1016/j.ccell.2020.04.017 PMC7363590

698. Wang Y Identification of clausine E as an inhibitor of fat mass and obesity-associated protein (FTO) demethylase activity J. Mol. Recognit. 2019 32 e2800 10.1002/jmr.2800 31321808 Wang, Y. et al. Identification of clausine E as an inhibitor of fat mass and obesity-associated protein (FTO) demethylase activity. J. Mol. Recognit. 32 , e2800 (2019). 31321808 10.1002/jmr.2800

699. Qiao Y Targeting FTO induces colorectal cancer ferroptotic cell death by decreasing SLC7A11/GPX4 expression J. Exp. Clin. Cancer Res. 2024 43 108 10.1186/s13046-024-03032-9 38600610 PMC11005233 Qiao, Y. et al. Targeting FTO induces colorectal cancer ferroptotic cell death by decreasing SLC7A11/GPX4 expression. J. Exp. Clin. Cancer Res. 43 , 108 (2024). 38600610 10.1186/s13046-024-03032-9 PMC11005233

700. Peng, S. et al. Identification of entacapone as a chemical inhibitor of FTO mediating metabolic regulation through FOXO1. Sci. Transl. Med . 11 , eaau7116 (2019). 10.1126/scitranslmed.aau7116 30996080

701. Xie G A novel inhibitor of N (6)-methyladenosine demethylase FTO induces mRNA methylation and shows anti-cancer activities Acta Pharmacol. Sin. B 2022 12 853 866 10.1016/j.apsb.2021.08.028 PMC8897214 35256950 Xie, G. et al. A novel inhibitor of N (6)-methyladenosine demethylase FTO induces mRNA methylation and shows anti-cancer activities. Acta Pharmacol. Sin. B 12 , 853–866 (2022). 10.1016/j.apsb.2021.08.028 PMC8897214 35256950

702. Selberg, S. et al. Small-molecule inhibitors of the RNA M6A demethylases FTO potently support the survival of dopamine neurons. Int. J. Mol. Sci . 22 , 4537 (2021). 10.3390/ijms22094537 PMC8123663 33926120

703. Qin B Discovery of novel mRNA demethylase FTO inhibitors against esophageal cancer J. Enzym. Inhib. Med. Chem. 2022 37 1995 2003 10.1080/14756366.2022.2098954 PMC9291647 35833378 Qin, B. et al. Discovery of novel mRNA demethylase FTO inhibitors against esophageal cancer. J. Enzym. Inhib. Med. Chem. 37 , 1995–2003 (2022). 10.1080/14756366.2022.2098954 PMC9291647 35833378

704. Wu PF Erasing m(6)A-dependent transcription signature of stress-sensitive genes triggers antidepressant actions Neurobiol. Stress 2021 15 100390 10.1016/j.ynstr.2021.100390 34527794 PMC8430387 Wu, P. F. et al. Erasing m(6)A-dependent transcription signature of stress-sensitive genes triggers antidepressant actions. Neurobiol. Stress 15 , 100390 (2021). 34527794 10.1016/j.ynstr.2021.100390 PMC8430387

705. Chen J Inhibition of ALKBH5 attenuates I/R-induced renal injury in male mice by promoting Ccl28 m6A modification and increasing Treg recruitment Nat. Commun. 2023 14 1161 10.1038/s41467-023-36747-y 36859428 PMC9977869 Chen, J. et al. Inhibition of ALKBH5 attenuates I/R-induced renal injury in male mice by promoting Ccl28 m6A modification and increasing Treg recruitment. Nat. Commun. 14 , 1161 (2023). 36859428 10.1038/s41467-023-36747-y PMC9977869

706. Malacrida A 3D proteome-wide scale screening and activity evaluation of a new ALKBH5 inhibitor in U87 glioblastoma cell line Bioorg. Med. Chem. 2020 28 115300 10.1016/j.bmc.2019.115300 31937477 Malacrida, A. et al. 3D proteome-wide scale screening and activity evaluation of a new ALKBH5 inhibitor in U87 glioblastoma cell line. Bioorg. Med. Chem. 28 , 115300 (2020). 31937477 10.1016/j.bmc.2019.115300

707. Takahashi H Discovery of two novel ALKBH5 selective inhibitors that exhibit uncompetitive or competitive type and suppress the growth activity of glioblastoma multiforme Chem. Biol. Drug. Des. 2022 100 1 12 10.1111/cbdd.14051 35384315 Takahashi, H. et al. Discovery of two novel ALKBH5 selective inhibitors that exhibit uncompetitive or competitive type and suppress the growth activity of glioblastoma multiforme. Chem. Biol. Drug. Des. 100 , 1–12 (2022). 35384315 10.1111/cbdd.14051

708. Wang YZ Discovery of pyrazolo[1,5-a]pyrimidine derivative as a novel and selective ALKBH5 inhibitor for the treatment of AML J. Med. Chem. 2023 66 15944 15959 10.1021/acs.jmedchem.3c01374 37983486 Wang, Y. Z. et al. Discovery of pyrazolo[1,5-a]pyrimidine derivative as a novel and selective ALKBH5 inhibitor for the treatment of AML. J. Med. Chem. 66 , 15944–15959 (2023). 37983486 10.1021/acs.jmedchem.3c01374

709. Selberg S Seli N Kankuri E Karelson M Rational design of novel anticancer small-molecule RNA m6A demethylase ALKBH5 inhibitors ACS Omega 2021 6 13310 13320 10.1021/acsomega.1c01289 34056479 PMC8158789 Selberg, S., Seli, N., Kankuri, E. & Karelson, M. Rational design of novel anticancer small-molecule RNA m6A demethylase ALKBH5 inhibitors. ACS Omega 6 , 13310–13320 (2021). 34056479 10.1021/acsomega.1c01289 PMC8158789

710. Fang Z Discovery of a potent, selective and cell active inhibitor of m(6)A demethylase ALKBH5 Eur. J. Med. Chem. 2022 238 114446 10.1016/j.ejmech.2022.114446 35597008 Fang, Z. et al. Discovery of a potent, selective and cell active inhibitor of m(6)A demethylase ALKBH5. Eur. J. Med. Chem. 238 , 114446 (2022). 35597008 10.1016/j.ejmech.2022.114446

711. Lai GQ A covalent compound selectively inhibits RNA demethylase ALKBH5 rather than FTO RSC Chem. Biol. 2024 5 335 343 10.1039/D3CB00230F 38576724 PMC10989504 Lai, G. Q. et al. A covalent compound selectively inhibits RNA demethylase ALKBH5 rather than FTO. RSC Chem. Biol. 5 , 335–343 (2024). 38576724 10.1039/d3cb00230f PMC10989504

712. Li N ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment Proc. Natl. Acad. Sci. USA 2020 117 20159 20170 10.1073/pnas.1918986117 32747553 PMC7443867 Li, N. et al. ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment. Proc. Natl. Acad. Sci. USA 117 , 20159–20170 (2020). 32747553 10.1073/pnas.1918986117 PMC7443867

713. Komal S ALKBH5 inhibitors as a potential treatment strategy in heart failure-inferences from gene expression profiling Front Cardiovasc. Med. 2023 10 1194311 10.3389/fcvm.2023.1194311 37583580 PMC10425272 Komal, S. et al. ALKBH5 inhibitors as a potential treatment strategy in heart failure-inferences from gene expression profiling. Front Cardiovasc. Med. 10 , 1194311 (2023). 37583580 10.3389/fcvm.2023.1194311 PMC10425272

714. Huang H Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation Nat. Cell. Biol. 2018 20 285 295 10.1038/s41556-018-0045-z 29476152 PMC5826585 Huang, H. et al. Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat. Cell. Biol. 20 , 285–295 (2018). 29476152 10.1038/s41556-018-0045-z PMC5826585

715. Ramesh-Kumar D Guil S The IGF2BP family of RNA binding proteins links epitranscriptomics to cancer Semin Cancer Biol. 2022 86 18 31 10.1016/j.semcancer.2022.05.009 35643219 Ramesh-Kumar, D. & Guil, S. The IGF2BP family of RNA binding proteins links epitranscriptomics to cancer. Semin Cancer Biol. 86 , 18–31 (2022). 35643219 10.1016/j.semcancer.2022.05.009

716. Mahapatra L A Novel IMP1 inhibitor, BTYNB, targets c-Myc and inhibits melanoma and ovarian cancer cell proliferation Transl. Oncol. 2017 10 818 827 10.1016/j.tranon.2017.07.008 28846937 PMC5576976 Mahapatra, L. et al. A Novel IMP1 inhibitor, BTYNB, targets c-Myc and inhibits melanoma and ovarian cancer cell proliferation. Transl. Oncol. 10 , 818–827 (2017). 28846937 10.1016/j.tranon.2017.07.008 PMC5576976

717. Wang JJ Elevated expression of the RNA-binding protein IGF2BP1 enhances the mRNA stability of INHBA to promote the invasion and migration of esophageal squamous cancer cells Exp. Hematol. Oncol. 2023 12 75 10.1186/s40164-023-00429-8 37644505 PMC10466848 Wang, J. J. et al. Elevated expression of the RNA-binding protein IGF2BP1 enhances the mRNA stability of INHBA to promote the invasion and migration of esophageal squamous cancer cells. Exp. Hematol. Oncol. 12 , 75 (2023). 37644505 10.1186/s40164-023-00429-8 PMC10466848

718. Hagemann S IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression Mol. Cancer 2023 22 88 10.1186/s12943-023-01792-0 37246217 PMC10226260 Hagemann, S. et al. IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression. Mol. Cancer 22 , 88 (2023). 37246217 10.1186/s12943-023-01792-0 PMC10226260

719. Xiao P IGF2BP1-mediated N6-methyladenosine modification promotes intrahepatic cholangiocarcinoma progression Cancer Lett. 2023 557 216075 10.1016/j.canlet.2023.216075 36736530 Xiao, P. et al. IGF2BP1-mediated N6-methyladenosine modification promotes intrahepatic cholangiocarcinoma progression. Cancer Lett. 557 , 216075 (2023). 36736530 10.1016/j.canlet.2023.216075

720. Weng H The m(6)A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia Cancer Cell. 2022 40 1566 1582.e1510 10.1016/j.ccell.2022.10.004 36306790 PMC9772162 Weng, H. et al. The m(6)A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. Cancer Cell. 40 , 1566–1582.e1510 (2022). 36306790 10.1016/j.ccell.2022.10.004 PMC9772162

721. Feng P Inhibition of the m(6)A reader IGF2BP2 as a strategy against T-cell acute lymphoblastic leukemia Leukemia 2022 36 2180 2188 10.1038/s41375-022-01651-9 35915142 PMC9417996 Feng, P. et al. Inhibition of the m(6)A reader IGF2BP2 as a strategy against T-cell acute lymphoblastic leukemia. Leukemia 36 , 2180–2188 (2022). 35915142 10.1038/s41375-022-01651-9 PMC9417996

722. Liu Y Allosteric Regulation of IGF2BP1 as a novel strategy for the activation of tumor immune microenvironment ACS Cent. Sci. 2022 8 1102 1115 10.1021/acscentsci.2c00107 36032766 PMC9413439 Liu, Y. et al. Allosteric Regulation of IGF2BP1 as a novel strategy for the activation of tumor immune microenvironment. ACS Cent. Sci. 8 , 1102–1115 (2022). 36032766 10.1021/acscentsci.2c00107 PMC9413439

723. Wallis N Small molecule inhibitor of Igf2bp1 represses Kras and a pro-oncogenic phenotype in cancer cells RNA Biol. 2022 19 26 43 10.1080/15476286.2021.2010983 34895045 PMC8794255 Wallis, N. et al. Small molecule inhibitor of Igf2bp1 represses Kras and a pro-oncogenic phenotype in cancer cells. RNA Biol. 19 , 26–43 (2022). 34895045 10.1080/15476286.2021.2010983 PMC8794255

724. Cui Y Isoliquiritigenin inhibits non-small cell lung cancer progression via m(6)A/IGF2BP3-dependent TWIST1 mRNA stabilization Phytomedicine 2022 104 154299 10.1016/j.phymed.2022.154299 35816995 Cui, Y. et al. Isoliquiritigenin inhibits non-small cell lung cancer progression via m(6)A/IGF2BP3-dependent TWIST1 mRNA stabilization. Phytomedicine 104 , 154299 (2022). 35816995 10.1016/j.phymed.2022.154299

725. Wang X N6-methyladenosine-dependent regulation of messenger RNA stability Nature 2014 505 117 120 10.1038/nature12730 24284625 PMC3877715 Wang, X. et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature 505 , 117–120 (2014). 24284625 10.1038/nature12730 PMC3877715

726. Liao J Insight into the structure, physiological function, and role in cancer of m6A readers-YTH domain-containing proteins Cell. Death Discov. 2022 8 137 10.1038/s41420-022-00947-0 35351856 PMC8964710 Liao, J. et al. Insight into the structure, physiological function, and role in cancer of m6A readers-YTH domain-containing proteins. Cell. Death Discov. 8 , 137 (2022). 35351856 10.1038/s41420-022-00947-0 PMC8964710

727. Wang L YTHDF2 inhibition potentiates radiotherapy antitumor efficacy Cancer Cell. 2023 41 1294 1308.e1298 10.1016/j.ccell.2023.04.019 37236197 PMC10524856 Wang, L. et al. YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. Cancer Cell. 41 , 1294–1308.e1298 (2023). 37236197 10.1016/j.ccell.2023.04.019 PMC10524856

728. Bao Y Targeting m(6)A reader YTHDF1 augments antitumour immunity and boosts anti-PD-1 efficacy in colorectal cancer Gut 2023 72 1497 1509 10.1136/gutjnl-2022-328845 36717220 PMC10359538 Bao, Y. et al. Targeting m(6)A reader YTHDF1 augments antitumour immunity and boosts anti-PD-1 efficacy in colorectal cancer. Gut 72 , 1497–1509 (2023). 36717220 10.1136/gutjnl-2022-328845 PMC10359538

729. Zhou L Hypoxia-induced lncRNA STEAP3-AS1 activates Wnt/β-catenin signaling to promote colorectal cancer progression by preventing m(6)A-mediated degradation of STEAP3 mRNA Mol. Cancer 2022 21 168 10.1186/s12943-022-01638-1 35986274 PMC9392287 Zhou, L. et al. Hypoxia-induced lncRNA STEAP3-AS1 activates Wnt/β-catenin signaling to promote colorectal cancer progression by preventing m(6)A-mediated degradation of STEAP3 mRNA. Mol. Cancer 21 , 168 (2022). 35986274 10.1186/s12943-022-01638-1 PMC9392287

730. Cazzanelli G Pliability in the m(6)A-binding region extends druggability of YTH domains J. Chem. Inf. Model 2024 64 1682 1690 10.1021/acs.jcim.4c00051 38417111 Cazzanelli, G. et al. Pliability in the m(6)A-binding region extends druggability of YTH domains. J. Chem. Inf. Model 64 , 1682–1690 (2024). 38417111 10.1021/acs.jcim.4c00051

731. Micaelli M Small-molecule ebselen binds to YTHDF proteins interfering with the recognition of N (6)-methyladenosine-modified RNAs ACS Pharmacol. Transl. Sci. 2022 5 872 891 10.1021/acsptsci.2c00008 36268123 PMC9578143 Micaelli, M. et al. Small-molecule ebselen binds to YTHDF proteins interfering with the recognition of N (6)-methyladenosine-modified RNAs. ACS Pharmacol. Transl. Sci. 5 , 872–891 (2022). 36268123 10.1021/acsptsci.2c00008 PMC9578143

732. Chen Y O-GlcNAcylation determines the translational regulation and phase separation of YTHDF proteins Nat. Cell. Biol. 2023 25 1676 1690 10.1038/s41556-023-01258-x 37945829 PMC12060179 Chen, Y. et al. O-GlcNAcylation determines the translational regulation and phase separation of YTHDF proteins. Nat. Cell. Biol. 25 , 1676–1690 (2023). 37945829 10.1038/s41556-023-01258-x PMC12060179

733. Yang Y O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an N(6)-methyladenosine-dependent manner Signal. Transduct. Target. Ther. 2023 8 63 10.1038/s41392-023-01316-8 36765030 PMC9918532 Yang, Y. et al. O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an N(6)-methyladenosine-dependent manner. Signal. Transduct. Target. Ther. 8 , 63 (2023). 36765030 10.1038/s41392-023-01316-8 PMC9918532

734. Dutta P Global epigenetic changes induced by SWI2/SNF2 inhibitors characterize neomycin-resistant mammalian cells PLoS One 2012 7 e49822 10.1371/journal.pone.0049822 23209606 PMC3509132 Dutta, P. et al. Global epigenetic changes induced by SWI2/SNF2 inhibitors characterize neomycin-resistant mammalian cells. PLoS One 7 , e49822 (2012). 23209606 10.1371/journal.pone.0049822 PMC3509132

735. Dreier MR Walia J de la Serna IL Targeting SWI/SNF complexes in cancer: pharmacological approaches and implications Epigenome 2024 8 7 10.3390/epigenomes8010007 PMC10885108 38390898 Dreier, M. R., Walia, J. & de la Serna, I. L. Targeting SWI/SNF complexes in cancer: pharmacological approaches and implications. Epigenome 8 , 7 (2024). 10.3390/epigenomes8010007 PMC10885108 38390898

736. Xue Y SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer Nat. Commun. 2019 10 557 10.1038/s41467-019-08380-1 30718506 PMC6362083 Xue, Y. et al. SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer. Nat. Commun. 10 , 557 (2019). 30718506 10.1038/s41467-019-08380-1 PMC6362083

737. Xue Y SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca(2+) flux to mitochondria Nat. Commun. 2021 12 5404 10.1038/s41467-021-25260-9 34518526 PMC8438089 Xue, Y. et al. SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca(2+) flux to mitochondria. Nat. Commun. 12 , 5404 (2021). 34518526 10.1038/s41467-021-25260-9 PMC8438089

738. Papillon JPN Discovery of orally active inhibitors of brahma homolog (BRM)/SMARCA2 ATPase activity for the treatment of brahma related gene 1 (BRG1)/SMARCA4-mutant cancers J. Med. Chem. 2018 61 10155 10172 10.1021/acs.jmedchem.8b01318 30339381 Papillon, J. P. N. et al. Discovery of orally active inhibitors of brahma homolog (BRM)/SMARCA2 ATPase activity for the treatment of brahma related gene 1 (BRG1)/SMARCA4-mutant cancers. J. Med. Chem. 61 , 10155–10172 (2018). 30339381 10.1021/acs.jmedchem.8b01318

739. Rago F Exquisite sensitivity to dual BRG1/BRM ATPase inhibitors reveals broad SWI/SNF dependencies in acute myeloid leukemia Mol. Cancer Res. 2022 20 361 372 10.1158/1541-7786.MCR-21-0390 34799403 Rago, F. et al. Exquisite sensitivity to dual BRG1/BRM ATPase inhibitors reveals broad SWI/SNF dependencies in acute myeloid leukemia. Mol. Cancer Res. 20 , 361–372 (2022). 34799403 10.1158/1541-7786.MCR-21-0390

740. Panditharatna E BAF complex maintains glioma stem cells in pediatric H3K27M glioma Cancer Discov. 2022 12 2880 2905 36305736 10.1158/2159-8290.CD-21-1491 PMC9716260 Panditharatna, E. et al. BAF complex maintains glioma stem cells in pediatric H3K27M glioma. Cancer Discov. 12 , 2880–2905 (2022). 36305736 10.1158/2159-8290.CD-21-1491 PMC9716260

741. Fiskus W BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor Blood 2024 143 2059 2072 10.1182/blood.2023022832 38437498 Fiskus, W. et al. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor. Blood 143 , 2059–2072 (2024). 38437498 10.1182/blood.2023022832

742. Charlop-Powers Z Zeng L Zhang Q Zhou MM Structural insights into selective histone H3 recognition by the human polybromo bromodomain 2 Cell. Res. 2010 20 529 538 10.1038/cr.2010.43 20368734 PMC2921579 Charlop-Powers, Z., Zeng, L., Zhang, Q. & Zhou, M. M. Structural insights into selective histone H3 recognition by the human polybromo bromodomain 2. Cell. Res. 20 , 529–538 (2010). 20368734 10.1038/cr.2010.43 PMC2921579

743. Gerstenberger BS Identification of a chemical probe for family VIII bromodomains through optimization of a fragment hit J. Med. Chem. 2016 59 4800 4811 10.1021/acs.jmedchem.6b00012 27115555 PMC5034155 Gerstenberger, B. S. et al. Identification of a chemical probe for family VIII bromodomains through optimization of a fragment hit. J. Med. Chem. 59 , 4800–4811 (2016). 27115555 10.1021/acs.jmedchem.6b00012 PMC5034155

744. Fedorov O Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cell maintenance Sci. Adv. 2015 1 e1500723 10.1126/sciadv.1500723 26702435 PMC4681344 Fedorov, O. et al. Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cell maintenance. Sci. Adv. 1 , e1500723 (2015). 26702435 10.1126/sciadv.1500723 PMC4681344

745. He Y Novel structural-related analogs of PFI-3 (SRAPs) that target the BRG1 catalytic subunit of the SWI/SNF complex increase the activity of temozolomide in glioblastoma cells Bioorg Med. Chem. 2022 53 116533 10.1016/j.bmc.2021.116533 34863065 He, Y. et al. Novel structural-related analogs of PFI-3 (SRAPs) that target the BRG1 catalytic subunit of the SWI/SNF complex increase the activity of temozolomide in glioblastoma cells. Bioorg Med. Chem. 53 , 116533 (2022). 34863065 10.1016/j.bmc.2021.116533

746. Taylor AM GNE-064: a potent, selective, and orally bioavailable chemical probe for the bromodomains of SMARCA2 and SMARCA4 and the fifth bromodomain of PBRM1 J. Med. Chem. 2022 65 11177 11186 10.1021/acs.jmedchem.2c00662 35930799 Taylor, A. M. et al. GNE-064: a potent, selective, and orally bioavailable chemical probe for the bromodomains of SMARCA2 and SMARCA4 and the fifth bromodomain of PBRM1. J. Med. Chem. 65 , 11177–11186 (2022). 35930799 10.1021/acs.jmedchem.2c00662

747. Sutherell CL Identification and development of 2,3-dihydropyrrolo[1,2-a]quinazolin-5(1H)-one inhibitors targeting bromodomains within the switch/sucrose nonfermenting complex J. Med. Chem. 2016 59 5095 5101 10.1021/acs.jmedchem.5b01997 27119626 PMC4920105 Sutherell, C. L. et al. Identification and development of 2,3-dihydropyrrolo[1,2-a]quinazolin-5(1H)-one inhibitors targeting bromodomains within the switch/sucrose nonfermenting complex. J. Med. Chem. 59 , 5095–5101 (2016). 27119626 10.1021/acs.jmedchem.5b01997 PMC4920105

748. Mélin L Design and synthesis of LM146, a potent inhibitor of PB1 with an improved selectivity profile over SMARCA2 ACS Omega 2021 6 21327 21338 10.1021/acsomega.1c01555 34471737 PMC8387997 Mélin, L. et al. Design and synthesis of LM146, a potent inhibitor of PB1 with an improved selectivity profile over SMARCA2. ACS Omega 6 , 21327–21338 (2021). 34471737 10.1021/acsomega.1c01555 PMC8387997

749. Shishodia S Selective and cell-active PBRM1 bromodomain inhibitors discovered through NMR fragment screening J. Med. Chem. 2022 65 13714 13735 10.1021/acs.jmedchem.2c00864 36227159 PMC9630929 Shishodia, S. et al. Selective and cell-active PBRM1 bromodomain inhibitors discovered through NMR fragment screening. J. Med. Chem. 65 , 13714–13735 (2022). 36227159 10.1021/acs.jmedchem.2c00864 PMC9630929

750. Cochran AG Flynn M GNE-235: a lead compound selective for the second bromodomain of PBRM1 J. Med. Chem. 2023 66 13116 13134 10.1021/acs.jmedchem.3c01149 37702400 Cochran, A. G. & Flynn, M. GNE-235: a lead compound selective for the second bromodomain of PBRM1. J. Med. Chem. 66 , 13116–13134 (2023). 37702400 10.1021/acs.jmedchem.3c01149

751. Wu X Ablation of Brg1 in fibroblast/myofibroblast lineages attenuates renal fibrosis in mice with diabetic nephropathy Life Sci. 2024 344 122578 10.1016/j.lfs.2024.122578 38537899 Wu, X. et al. Ablation of Brg1 in fibroblast/myofibroblast lineages attenuates renal fibrosis in mice with diabetic nephropathy. Life Sci. 344 , 122578 (2024). 38537899 10.1016/j.lfs.2024.122578

752. Hong W The chromatin remodeling protein BRG1 mediates Ang II induced pro-fibrogenic response in renal fibroblasts Life Sci. 2024 340 122320 10.1016/j.lfs.2023.122320 38272440 Hong, W. et al. The chromatin remodeling protein BRG1 mediates Ang II induced pro-fibrogenic response in renal fibroblasts. Life Sci. 340 , 122320 (2024). 38272440 10.1016/j.lfs.2023.122320

753. Li N The chromatin remodeling protein BRG1 contributes to liver ischemia-reperfusion injury by regulating NOXA expression Life Sci. 2023 334 122235 10.1016/j.lfs.2023.122235 37926300 Li, N. et al. The chromatin remodeling protein BRG1 contributes to liver ischemia-reperfusion injury by regulating NOXA expression. Life Sci. 334 , 122235 (2023). 37926300 10.1016/j.lfs.2023.122235

754. Jolly, A. J. et al. Redistribution of the chromatin remodeler Brg1 directs smooth muscle-derived adventitial progenitor-to-myofibroblast differentiation and vascular fibrosis. JCI Insight 8 , e164862 (2023). 10.1172/jci.insight.164862 PMC10243795 36976650

755. Li N Targetable Brg1-CXCL14 axis contributes to alcoholic liver injury by driving neutrophil trafficking EMBO Mol. Med. 2023 15 e16592 10.15252/emmm.202216592 36722664 PMC9994483 Li, N. et al. Targetable Brg1-CXCL14 axis contributes to alcoholic liver injury by driving neutrophil trafficking. EMBO Mol. Med. 15 , e16592 (2023). 36722664 10.15252/emmm.202216592 PMC9994483

756. Martin LJ Structure-based design of an in vivo active selective BRD9 inhibitor J. Med. Chem. 2016 59 4462 4475 10.1021/acs.jmedchem.5b01865 26914985 PMC4885110 Martin, L. J. et al. Structure-based design of an in vivo active selective BRD9 inhibitor. J. Med. Chem. 59 , 4462–4475 (2016). 26914985 10.1021/acs.jmedchem.5b01865 PMC4885110

757. Theodoulou NH Discovery of I-BRD9, a selective cell active chemical probe for bromodomain containing protein 9 inhibition J. Med. Chem. 2016 59 1425 1439 10.1021/acs.jmedchem.5b00256 25856009 PMC7354103 Theodoulou, N. H. et al. Discovery of I-BRD9, a selective cell active chemical probe for bromodomain containing protein 9 inhibition. J. Med. Chem. 59 , 1425–1439 (2016). 25856009 10.1021/acs.jmedchem.5b00256 PMC7354103

758. Basuroy T Epigenetic and pharmacological control of pigmentation via bromodomain protein 9 (BRD9) Pigment Cell. Melanoma Res. 2023 36 19 32 10.1111/pcmr.13068 36112085 PMC10091956 Basuroy, T. et al. Epigenetic and pharmacological control of pigmentation via bromodomain protein 9 (BRD9). Pigment Cell. Melanoma Res. 36 , 19–32 (2023). 36112085 10.1111/pcmr.13068 PMC10091956

759. Crawford TD Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistance Bioorg. Med. Chem. Lett. 2017 27 3534 3541 10.1016/j.bmcl.2017.05.063 28606761 Crawford, T. D. et al. Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistance. Bioorg. Med. Chem. Lett. 27 , 3534–3541 (2017). 28606761 10.1016/j.bmcl.2017.05.063

760. Ali, M. M. et al. Identification of selective BRD9 inhibitor via integrated computational approach. Int. J. Mol. Sci . 23 , 13513 (2022). 10.3390/ijms232113513 PMC9655433 36362300

761. Ordonez-Rubiano SC Rational design and development of selective BRD7 bromodomain inhibitors and their activity in prostate cancer J. Med. Chem. 2023 66 11250 11270 10.1021/acs.jmedchem.3c00671 37552884 PMC10641717 Ordonez-Rubiano, S. C. et al. Rational design and development of selective BRD7 bromodomain inhibitors and their activity in prostate cancer. J. Med. Chem. 66 , 11250–11270 (2023). 37552884 10.1021/acs.jmedchem.3c00671 PMC10641717

762. Clark PG LP99: discovery and synthesis of the first selective BRD7/9 bromodomain inhibitor Angew. Chem. Int. Ed. Engl. 2015 54 6217 6221 10.1002/anie.201501394 25864491 PMC4449114 Clark, P. G. et al. LP99: discovery and synthesis of the first selective BRD7/9 bromodomain inhibitor. Angew. Chem. Int. Ed. Engl. 54 , 6217–6221 (2015). 25864491 10.1002/anie.201501394 PMC4449114

763. Mason, L. D., Chava, S., Reddi, K. K. & Gupta, R. The BRD9/7 inhibitor TP-472 blocks melanoma tumor growth by suppressing ECM-mediated oncogenic signaling and inducing apoptosis. Cancers 13 , 5516 (2021). 10.3390/cancers13215516 PMC8582741 34771678

764. Hügle M 4-acyl pyrroles as dual BET-BRD7/9 bromodomain inhibitors address BETi insensitive human cancer cell lines J. Med. Chem. 2020 63 15603 15620 10.1021/acs.jmedchem.0c00478 33275431 Hügle, M. et al. 4-acyl pyrroles as dual BET-BRD7/9 bromodomain inhibitors address BETi insensitive human cancer cell lines. J. Med. Chem. 63 , 15603–15620 (2020). 33275431 10.1021/acs.jmedchem.0c00478

765. Clegg MA Application of atypical acetyl-lysine methyl mimetics in the development of selective inhibitors of the bromodomain-containing protein 7 (BRD7)/bromodomain-containing protein 9 (BRD9) bromodomains J. Med. Chem. 2020 63 5816 5840 10.1021/acs.jmedchem.0c00075 32410449 Clegg, M. A. et al. Application of atypical acetyl-lysine methyl mimetics in the development of selective inhibitors of the bromodomain-containing protein 7 (BRD7)/bromodomain-containing protein 9 (BRD9) bromodomains. J. Med. Chem. 63 , 5816–5840 (2020). 32410449 10.1021/acs.jmedchem.0c00075

766. He T Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer Proc. Natl. Acad. Sci. USA 2024 121 e2322563121 10.1073/pnas.2322563121 38557192 PMC11009648 He, T. et al. Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer. Proc. Natl. Acad. Sci. USA 121 , e2322563121 (2024). 38557192 10.1073/pnas.2322563121 PMC11009648

767. Xiao L Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer Nature 2022 601 434 439 10.1038/s41586-021-04246-z 34937944 PMC8770127 Xiao, L. et al. Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer. Nature 601 , 434–439 (2022). 34937944 10.1038/s41586-021-04246-z PMC8770127

768. Remillard D Degradation of the BAF complex factor BRD9 by heterobifunctional ligands Angew. Chem. Int. Ed. Engl. 2017 56 5738 5743 10.1002/anie.201611281 28418626 PMC5967236 Remillard, D. et al. Degradation of the BAF complex factor BRD9 by heterobifunctional ligands. Angew. Chem. Int. Ed. Engl. 56 , 5738–5743 (2017). 28418626 10.1002/anie.201611281 PMC5967236

769. Bouguenina H A degron blocking strategy towards improved CRL4(CRBN) recruiting PROTAC selectivity Chembiochem 2023 24 e202300351 10.1002/cbic.202300351 37418539 Bouguenina, H. et al. A degron blocking strategy towards improved CRL4(CRBN) recruiting PROTAC selectivity. Chembiochem 24 , e202300351 (2023). 37418539 10.1002/cbic.202300351

770. Kurata K BRD9 degradation disrupts ribosome biogenesis in multiple myeloma Clin. Cancer Res. 2023 29 1807 1821 10.1158/1078-0432.CCR-22-3668 36780189 PMC10150249 Kurata, K. et al. BRD9 degradation disrupts ribosome biogenesis in multiple myeloma. Clin. Cancer Res. 29 , 1807–1821 (2023). 36780189 10.1158/1078-0432.CCR-22-3668 PMC10150249

771. Ahmed, N. S. et al. BRD9 regulates interferon-stimulated genes during macrophage activation via cooperation with BET protein BRD4. Proc. Natl. Acad. Sci. USA 119 , e2110812119 (2022). 10.1073/pnas.2110812119 PMC8740701 34983841

772. Cantley J Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers Nat. Commun. 2022 13 6814 10.1038/s41467-022-34562-5 36357397 PMC9649729 Cantley, J. et al. Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers. Nat. Commun. 13 , 6814 (2022). 36357397 10.1038/s41467-022-34562-5 PMC9649729

773. Zoppi V Iterative design and optimization of initially inactive proteolysis targeting chimeras (PROTACs) identify VZ185 as a potent, fast, and selective von Hippel-lindau (VHL) based dual degrader probe of BRD9 and BRD7 J. Med. Chem. 2019 62 699 726 10.1021/acs.jmedchem.8b01413 30540463 PMC6348446 Zoppi, V. et al. Iterative design and optimization of initially inactive proteolysis targeting chimeras (PROTACs) identify VZ185 as a potent, fast, and selective von Hippel-lindau (VHL) based dual degrader probe of BRD9 and BRD7. J. Med. Chem. 62 , 699–726 (2019). 30540463 10.1021/acs.jmedchem.8b01413 PMC6348446

774. Hescheler, D. A. et al. Targeted therapy for adrenocortical carcinoma: a genomic-based search for available and emerging options. Cancers 14 , 2721 (2022). 10.3390/cancers14112721 PMC9179357 35681700

775. Alahdal M Elkord E Non-coding RNAs in cancer immunotherapy: predictive biomarkers and targets Clin. Transl. Med. 2023 13 e1425 10.1002/ctm2.1425 37735815 PMC10514379 Alahdal, M. & Elkord, E. Non-coding RNAs in cancer immunotherapy: predictive biomarkers and targets. Clin. Transl. Med. 13 , e1425 (2023). 37735815 10.1002/ctm2.1425 PMC10514379

776. Jadhav V Vaishnaw A Fitzgerald K Maier MA RNA interference in the era of nucleic acid therapeutics Nat. Biotechnol. 2024 42 394 405 10.1038/s41587-023-02105-y 38409587 Jadhav, V., Vaishnaw, A., Fitzgerald, K. & Maier, M. A. RNA interference in the era of nucleic acid therapeutics. Nat. Biotechnol. 42 , 394–405 (2024). 38409587 10.1038/s41587-023-02105-y

777. Adams BD Targeting noncoding RNAs in disease J. Clin. Investig. 2017 127 761 771 10.1172/JCI84424 28248199 PMC5330746 Adams, B. D. et al. Targeting noncoding RNAs in disease. J. Clin. Investig. 127 , 761–771 (2017). 28248199 10.1172/JCI84424 PMC5330746

778. Mahato RK Targeting long non-coding RNAs in cancer therapy using CRISPR-Cas9 technology: a novel paradigm for precision oncology J. Biotechnol. 2024 379 98 119 10.1016/j.jbiotec.2023.12.003 38065367 Mahato, R. K. et al. Targeting long non-coding RNAs in cancer therapy using CRISPR-Cas9 technology: a novel paradigm for precision oncology. J. Biotechnol. 379 , 98–119 (2024). 38065367 10.1016/j.jbiotec.2023.12.003

779. Wei C Role of long non-coding RNAs in cancer: from subcellular localization to nanoparticle-mediated targeted regulation Mol. Ther. Nucl. Acids 2023 33 774 793 10.1016/j.omtn.2023.07.009 PMC10466435 37655045 Wei, C. et al. Role of long non-coding RNAs in cancer: from subcellular localization to nanoparticle-mediated targeted regulation. Mol. Ther. Nucl. Acids 33 , 774–793 (2023). 10.1016/j.omtn.2023.07.009 PMC10466435 37655045

780. Crooke ST Vickers TA Liang XH Phosphorothioate modified oligonucleotide-protein interactions Nucl. Acids Res. 2020 48 5235 5253 10.1093/nar/gkaa299 32356888 PMC7261153 Crooke, S. T., Vickers, T. A. & Liang, X. H. Phosphorothioate modified oligonucleotide-protein interactions. Nucl. Acids Res. 48 , 5235–5253 (2020). 32356888 10.1093/nar/gkaa299 PMC7261153

781. Sergeeva O Structure-activity relationship study of mesyl and busyl phosphoramidate antisense oligonucleotides for unaided and PSMA-mediated uptake into prostate cancer cells Front. Chem. 2024 12 1342178 10.3389/fchem.2024.1342178 38501046 PMC10944894 Sergeeva, O. et al. Structure-activity relationship study of mesyl and busyl phosphoramidate antisense oligonucleotides for unaided and PSMA-mediated uptake into prostate cancer cells. Front. Chem. 12 , 1342178 (2024). 38501046 10.3389/fchem.2024.1342178 PMC10944894

782. Egli M Manoharan M Chemistry, structure and function of approved oligonucleotide therapeutics Nucleic Acids Res. 2023 51 2529 2573 10.1093/nar/gkad067 36881759 PMC10085713 Egli, M. & Manoharan, M. Chemistry, structure and function of approved oligonucleotide therapeutics. Nucleic Acids Res. 51 , 2529–2573 (2023). 36881759 10.1093/nar/gkad067 PMC10085713

783. Kamali MJ Locked nucleic acid (LNA): a modern approach to cancer diagnosis and treatment Exp. Cell. Res. 2023 423 113442 10.1016/j.yexcr.2022.113442 36521777 Kamali, M. J. et al. Locked nucleic acid (LNA): a modern approach to cancer diagnosis and treatment. Exp. Cell. Res. 423 , 113442 (2023). 36521777 10.1016/j.yexcr.2022.113442

784. Anastasiadou E Cobomarsen, an oligonucleotide inhibitor of miR-155, slows DLBCL tumor cell growth in vitro and in vivo Clin. Cancer Res. 2021 27 1139 1149 10.1158/1078-0432.CCR-20-3139 33208342 PMC8287597 Anastasiadou, E. et al. Cobomarsen, an oligonucleotide inhibitor of miR-155, slows DLBCL tumor cell growth in vitro and in vivo. Clin. Cancer Res. 27 , 1139–1149 (2021). 33208342 10.1158/1078-0432.CCR-20-3139 PMC8287597

785. Cheng M Zain J Rosen ST Querfeld C Emerging drugs for the treatment of cutaneous T-cell lymphoma Expert Opin. Emerg. Drugs 2022 27 45 54 10.1080/14728214.2022.2049233 35235473 PMC10320301 Cheng, M., Zain, J., Rosen, S. T. & Querfeld, C. Emerging drugs for the treatment of cutaneous T-cell lymphoma. Expert Opin. Emerg. Drugs 27 , 45–54 (2022). 35235473 10.1080/14728214.2022.2049233 PMC10320301

786. Seto AG Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma Br. J. Haematol. 2018 183 428 444 10.1111/bjh.15547 30125933 Seto, A. G. et al. Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. Br. J. Haematol. 183 , 428–444 (2018). 30125933 10.1111/bjh.15547

787. Witten L Slack FJ miR-155 as a novel clinical target for hematological malignancies Carcinogenesis 2020 41 2 7 10.1093/carcin/bgz183 31711135 Witten, L. & Slack, F. J. miR-155 as a novel clinical target for hematological malignancies. Carcinogenesis 41 , 2–7 (2020). 31711135 10.1093/carcin/bgz183

788. Kim S Targeted eicosanoids profiling reveals a prostaglandin reprogramming in breast Cancer by microRNA-155 J. Exp. Clin. Cancer Res. 2021 40 43 10.1186/s13046-021-01839-4 33494773 PMC7831268 Kim, S. et al. Targeted eicosanoids profiling reveals a prostaglandin reprogramming in breast Cancer by microRNA-155. J. Exp. Clin. Cancer Res. 40 , 43 (2021). 33494773 10.1186/s13046-021-01839-4 PMC7831268

789. Ozpolat B Sood AK Lopez-Berestein G Nanomedicine based approaches for the delivery of siRNA in cancer J. Intern. Med. 2010 267 44 53 10.1111/j.1365-2796.2009.02191.x 20059643 Ozpolat, B., Sood, A. K. & Lopez-Berestein, G. Nanomedicine based approaches for the delivery of siRNA in cancer. J. Intern. Med. 267 , 44–53 (2010). 20059643 10.1111/j.1365-2796.2009.02191.x

790. Chen LL Linking long noncoding RNA localization and function Trends Biochem. Sci. 2016 41 761 772 10.1016/j.tibs.2016.07.003 27499234 Chen, L. L. Linking long noncoding RNA localization and function. Trends Biochem. Sci. 41 , 761–772 (2016). 27499234 10.1016/j.tibs.2016.07.003

791. Guo CJ Xu G Chen LL Mechanisms of long noncoding RNA nuclear retention Trends Biochem. Sci. 2020 45 947 960 10.1016/j.tibs.2020.07.001 32800670 Guo, C. J., Xu, G. & Chen, L. L. Mechanisms of long noncoding RNA nuclear retention. Trends Biochem. Sci. 45 , 947–960 (2020). 32800670 10.1016/j.tibs.2020.07.001

792. Gong N Teng X Li J Liang XJ Antisense oligonucleotide-conjugated nanostructure-targeting lncRNA MALAT1 inhibits cancer metastasis ACS Appl. Mater. Interfaces 2019 11 37 42 10.1021/acsami.8b18288 30548064 Gong, N., Teng, X., Li, J. & Liang, X. J. Antisense oligonucleotide-conjugated nanostructure-targeting lncRNA MALAT1 inhibits cancer metastasis. ACS Appl. Mater. Interfaces 11 , 37–42 (2019). 30548064 10.1021/acsami.8b18288

793. Xu R Remodeling of mitochondrial metabolism by a mitochondria-targeted RNAi nanoplatform for effective cancer therapy Small 2024 20 e2305923 10.1002/smll.202305923 37919865 Xu, R. et al. Remodeling of mitochondrial metabolism by a mitochondria-targeted RNAi nanoplatform for effective cancer therapy. Small 20 , e2305923 (2024). 37919865 10.1002/smll.202305923

794. Shi Y Pharmaceutical strategies for endoplasmic reticulum-targeting and their prospects of application J. Control Release 2021 329 337 352 10.1016/j.jconrel.2020.11.054 33290795 Shi, Y. et al. Pharmaceutical strategies for endoplasmic reticulum-targeting and their prospects of application. J. Control Release 329 , 337–352 (2021). 33290795 10.1016/j.jconrel.2020.11.054

795. Zhang M Potential therapies and diagnosis based on Golgi-targeted nano drug delivery systems Pharmacol. Res. 2022 175 105861 10.1016/j.phrs.2021.105861 34464677 Zhang, M. et al. Potential therapies and diagnosis based on Golgi-targeted nano drug delivery systems. Pharmacol. Res. 175 , 105861 (2022). 34464677 10.1016/j.phrs.2021.105861

796. Van de Vyver T De Smedt SC Raemdonck K Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics Adv. Drug. Deliv. Rev. 2022 181 114041 10.1016/j.addr.2021.114041 34763002 Van de Vyver, T., De Smedt, S. C. & Raemdonck, K. Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics. Adv. Drug. Deliv. Rev. 181 , 114041 (2022). 34763002 10.1016/j.addr.2021.114041

797. Xun G Harnessing noncanonical crRNA for highly efficient genome editing Nat. Commun. 2024 15 3823 10.1038/s41467-024-48012-x 38714643 PMC11076584 Xun, G. et al. Harnessing noncanonical crRNA for highly efficient genome editing. Nat. Commun. 15 , 3823 (2024). 38714643 10.1038/s41467-024-48012-x PMC11076584

798. Wang L CRISPR-Cas13d screens identify KILR, a breast cancer risk-associated lncRNA that regulates DNA replication and repair Mol. Cancer 2024 23 101 10.1186/s12943-024-02021-y 38745269 PMC11094906 Wang, L. et al. CRISPR-Cas13d screens identify KILR, a breast cancer risk-associated lncRNA that regulates DNA replication and repair. Mol. Cancer 23 , 101 (2024). 38745269 10.1186/s12943-024-02021-y PMC11094906

799. Li S Wu H Chen LL Screening circular RNAs with functional potential using the RfxCas13d/BSJ-gRNA system Nat. Protoc. 2022 17 2085 2107 10.1038/s41596-022-00715-5 35831613 Li, S., Wu, H. & Chen, L. L. Screening circular RNAs with functional potential using the RfxCas13d/BSJ-gRNA system. Nat. Protoc. 17 , 2085–2107 (2022). 35831613 10.1038/s41596-022-00715-5

800. Hussen BM Targeting miRNA by CRISPR/Cas in cancer: advantages and challenges Mil. Med. Res. 2023 10 32 37460924 10.1186/s40779-023-00468-6 PMC10351202 Hussen, B. M. et al. Targeting miRNA by CRISPR/Cas in cancer: advantages and challenges. Mil. Med. Res. 10 , 32 (2023). 37460924 10.1186/s40779-023-00468-6 PMC10351202

801. Capelletti, S., García Soto, S. C. & Gonçalves, M. On RNA-programmable gene modulation as a versatile set of principles targeting muscular dystrophies. Mol. Ther . S1525–0016 (2024). 10.1016/j.ymthe.2024.08.016 PMC11573585 39169620

802. Narayanan A In vivo mutagenesis of miRNA gene families using a scalable multiplexed CRISPR/Cas9 nuclease system Sci. Rep. 2016 6 32386 10.1038/srep32386 27572667 PMC5004112 Narayanan, A. et al. In vivo mutagenesis of miRNA gene families using a scalable multiplexed CRISPR/Cas9 nuclease system. Sci. Rep. 6 , 32386 (2016). 27572667 10.1038/srep32386 PMC5004112

803. Prinz F MicroRNA mimics can distort physiological microRNA effects on immune checkpoints by triggering an antiviral interferon response RNA Biol. 2022 19 1305 1315 10.1080/15476286.2022.2152978 36469564 PMC9728468 Prinz, F. et al. MicroRNA mimics can distort physiological microRNA effects on immune checkpoints by triggering an antiviral interferon response. RNA Biol. 19 , 1305–1315 (2022). 36469564 10.1080/15476286.2022.2152978 PMC9728468

804. Hong DS Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours Br. J. Cancer 2020 122 1630 1637 10.1038/s41416-020-0802-1 32238921 PMC7251107 Hong, D. S. et al. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br. J. Cancer 122 , 1630–1637 (2020). 32238921 10.1038/s41416-020-0802-1 PMC7251107

805. Feng X He C Mammalian DNA N(6)-methyladenosine: challenges and new insights Mol. Cell. 2023 83 343 351 10.1016/j.molcel.2023.01.005 36736309 PMC10182828 Feng, X. & He, C. Mammalian DNA N(6)-methyladenosine: challenges and new insights. Mol. Cell. 83 , 343–351 (2023). 36736309 10.1016/j.molcel.2023.01.005 PMC10182828

806. Xie, L. et al. Emerging roles for DNA 6mA and RNA m6A methylation in mammalian genome. Int. J. Mol. Sci . 24 , 13897 (2023). 10.3390/ijms241813897 PMC10531503 37762200

807. Wiener D Schwartz S The epitranscriptome beyond m(6)A Nat. Rev. Genet. 2021 22 119 131 10.1038/s41576-020-00295-8 33188361 Wiener, D. & Schwartz, S. The epitranscriptome beyond m(6)A. Nat. Rev. Genet. 22 , 119–131 (2021). 33188361 10.1038/s41576-020-00295-8

808. Chen PC Leveraging a phage-encoded noncanonical amino acid: a novel pathway to potent and selective epigenetic reader protein inhibitors ACS Cent. Sci. 2024 10 782 792 38680566 10.1021/acscentsci.3c01419 PMC11046469 Chen, P. C. et al. Leveraging a phage-encoded noncanonical amino acid: a novel pathway to potent and selective epigenetic reader protein inhibitors. ACS Cent. Sci. 10 , 782–792 (2024). 38680566 10.1021/acscentsci.3c01419 PMC11046469

809. Tomassi S Polycomb repressive complex 2 modulation through the development of EZH2-EED interaction inhibitors and EED binders J. Med. Chem. 2021 64 11774 11797 10.1021/acs.jmedchem.1c00226 34351144 PMC8404197 Tomassi, S. et al. Polycomb repressive complex 2 modulation through the development of EZH2-EED interaction inhibitors and EED binders. J. Med. Chem. 64 , 11774–11797 (2021). 34351144 10.1021/acs.jmedchem.1c00226 PMC8404197

810. Li X Song Y Structure, function and inhibition of critical protein-protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins J. Hematol. Oncol. 2021 14 56 10.1186/s13045-021-01057-7 33823889 PMC8022399 Li, X. & Song, Y. Structure, function and inhibition of critical protein-protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins. J. Hematol. Oncol. 14 , 56 (2021). 33823889 10.1186/s13045-021-01057-7 PMC8022399

811. Dong G Structure-based design of the indole-substituted triazolopyrimidines as new EED-H3K27me3 inhibitors for the treatment of lymphoma J. Med. Chem. 2023 66 1063 1081 10.1021/acs.jmedchem.2c02028 36580346 Dong, G. et al. Structure-based design of the indole-substituted triazolopyrimidines as new EED-H3K27me3 inhibitors for the treatment of lymphoma. J. Med. Chem. 66 , 1063–1081 (2023). 36580346 10.1021/acs.jmedchem.2c02028

812. Perfetti MT Identification of a fragment-like small molecule ligand for the methyl-lysine binding protein, 53BP1 ACS Chem. Biol. 2015 10 1072 1081 10.1021/cb500956g 25590533 PMC4402254 Perfetti, M. T. et al. Identification of a fragment-like small molecule ligand for the methyl-lysine binding protein, 53BP1. ACS Chem. Biol. 10 , 1072–1081 (2015). 25590533 10.1021/cb500956g PMC4402254

813. Dang F Wei W Targeting the acetylation signaling pathway in cancer therapy Semin Cancer Biol. 2022 85 209 218 10.1016/j.semcancer.2021.03.001 33705871 PMC8423867 Dang, F. & Wei, W. Targeting the acetylation signaling pathway in cancer therapy. Semin Cancer Biol. 85 , 209–218 (2022). 33705871 10.1016/j.semcancer.2021.03.001 PMC8423867

814. Hanquier JN Identification of nonhistone substrates of the lysine methyltransferase PRDM9 J. Biol. Chem. 2023 299 104651 10.1016/j.jbc.2023.104651 36972790 PMC10164904 Hanquier, J. N. et al. Identification of nonhistone substrates of the lysine methyltransferase PRDM9. J. Biol. Chem. 299 , 104651 (2023). 36972790 10.1016/j.jbc.2023.104651 PMC10164904

815. Shu S Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer Nature 2016 529 413 417 10.1038/nature16508 26735014 PMC4854653 Shu, S. et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature 529 , 413–417 (2016). 26735014 10.1038/nature16508 PMC4854653

816. Zhang Y Elevating PLK1 overcomes BETi resistance in prostate cancer via triggering BRD4 phosphorylation-dependent degradation in mitosis Cell. Rep. 2024 43 114431 10.1016/j.celrep.2024.114431 38968071 PMC11334074 Zhang, Y. et al. Elevating PLK1 overcomes BETi resistance in prostate cancer via triggering BRD4 phosphorylation-dependent degradation in mitosis. Cell. Rep. 43 , 114431 (2024). 38968071 10.1016/j.celrep.2024.114431 PMC11334074

817. Paolini RL Souroullas GP The cell cycle: a key to unlock EZH2-targeted therapy resistance Cancer Discov. 2024 14 903 905 10.1158/2159-8290.CD-24-0186 38826100 Paolini, R. L. & Souroullas, G. P. The cell cycle: a key to unlock EZH2-targeted therapy resistance. Cancer Discov. 14 , 903–905 (2024). 38826100 10.1158/2159-8290.CD-24-0186

818. Fong CY BET inhibitor resistance emerges from leukaemia stem cells Nature 2015 525 538 542 10.1038/nature14888 26367796 PMC6069604 Fong, C. Y. et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature 525 , 538–542 (2015). 26367796 10.1038/nature14888 PMC6069604

819. Rathert P Transcriptional plasticity promotes primary and acquired resistance to BET inhibition Nature 2015 525 543 547 10.1038/nature14898 26367798 PMC4921058 Rathert, P. et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature 525 , 543–547 (2015). 26367798 10.1038/nature14898 PMC4921058

820. Zhang P Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation Nat. Med. 2017 23 1055 1062 10.1038/nm.4379 28805822 PMC5653288 Zhang, P. et al. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. Nat. Med. 23 , 1055–1062 (2017). 28805822 10.1038/nm.4379 PMC5653288

821. Hao BB Proteomics analysis of histone deacetylase inhibitor-resistant solid tumors reveals resistant signatures and potential drug combinations Acta Pharmacol. Sin. 2024 45 1305 1315 10.1038/s41401-024-01236-5 38383757 PMC11130134 Hao, B. B. et al. Proteomics analysis of histone deacetylase inhibitor-resistant solid tumors reveals resistant signatures and potential drug combinations. Acta Pharmacol. Sin. 45 , 1305–1315 (2024). 38383757 10.1038/s41401-024-01236-5 PMC11130134

822. Mills, G. B. & Labrie, M. Enhancing anticancer activity of macrophages through rational drug combinations. J. Clin. Investig . 134 , e180512 (2024). 10.1172/JCI180512 PMC11060729 38690738

823. Qiao J Macrophages confer resistance to BET inhibition in triple-negative breast cancer by upregulating IKBKE Biochem. Pharmacol. 2020 180 114126 10.1016/j.bcp.2020.114126 32603665 Qiao, J. et al. Macrophages confer resistance to BET inhibition in triple-negative breast cancer by upregulating IKBKE. Biochem. Pharmacol. 180 , 114126 (2020). 32603665 10.1016/j.bcp.2020.114126

824. Kazansky Y Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy Cancer Discov. 2024 14 965 981 10.1158/2159-8290.CD-23-0110 38315003 PMC11147720 Kazansky, Y. et al. Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy. Cancer Discov. 14 , 965–981 (2024). 38315003 10.1158/2159-8290.CD-23-0110 PMC11147720

825. Intlekofer AM Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations Nature 2018 559 125 129 10.1038/s41586-018-0251-7 29950729 PMC6121718 Intlekofer, A. M. et al. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. Nature 559 , 125–129 (2018). 29950729 10.1038/s41586-018-0251-7 PMC6121718

826. Wang F Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia Nat. Commun. 2021 12 2607 10.1038/s41467-021-22874-x 33972549 PMC8110775 Wang, F. et al. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nat. Commun. 12 , 2607 (2021). 33972549 10.1038/s41467-021-22874-x PMC8110775

827. Yuan Z Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors Eur. J. Med. Chem. 2017 134 281 292 10.1016/j.ejmech.2017.04.017 28419930 Yuan, Z. et al. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors. Eur. J. Med. Chem. 134 , 281–292 (2017). 28419930 10.1016/j.ejmech.2017.04.017

828. Ocaña-Paredes B The pharmacoepigenetic paradigm in cancer treatment Front. Pharmacol. 2024 15 1381168 10.3389/fphar.2024.1381168 38720770 PMC11076712 Ocaña-Paredes, B. et al. The pharmacoepigenetic paradigm in cancer treatment. Front. Pharmacol. 15 , 1381168 (2024). 38720770 10.3389/fphar.2024.1381168 PMC11076712

829. Peng X Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies Acta Pharmacol. Sin. B 2024 14 533 578 10.1016/j.apsb.2023.09.003 PMC10840439 38322348 Peng, X. et al. Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies. Acta Pharmacol. Sin. B 14 , 533–578 (2024). 10.1016/j.apsb.2023.09.003 PMC10840439 38322348

830. Hogg SJ Beavis PA Dawson MA Johnstone RW Targeting the epigenetic regulation of antitumour immunity Nat. Rev. Drug. Discov. 2020 19 776 800 10.1038/s41573-020-0077-5 32929243 Hogg, S. J., Beavis, P. A., Dawson, M. A. & Johnstone, R. W. Targeting the epigenetic regulation of antitumour immunity. Nat. Rev. Drug. Discov. 19 , 776–800 (2020). 32929243 10.1038/s41573-020-0077-5

831. Bonaventura P Cold tumors: a therapeutic challenge for immunotherapy Front. Immunol. 2019 10 168 10.3389/fimmu.2019.00168 30800125 PMC6376112 Bonaventura, P. et al. Cold tumors: a therapeutic challenge for immunotherapy. Front. Immunol. 10 , 168 (2019). 30800125 10.3389/fimmu.2019.00168 PMC6376112

832. Qian X Hu W Yan J Nano-chemotherapy synergize with immune checkpoint inhibitor- a better option? Front. Immunol. 2022 13 963533 10.3389/fimmu.2022.963533 36016946 PMC9395615 Qian, X., Hu, W. & Yan, J. Nano-chemotherapy synergize with immune checkpoint inhibitor- a better option? Front. Immunol. 13 , 963533 (2022). 36016946 10.3389/fimmu.2022.963533 PMC9395615

833. Kong Y Yu J Ge S Fan X Novel insight into RNA modifications in tumor immunity: promising targets to prevent tumor immune escape Innovation 2023 4 100452 37485079 10.1016/j.xinn.2023.100452 PMC10362524 Kong, Y., Yu, J., Ge, S. & Fan, X. Novel insight into RNA modifications in tumor immunity: promising targets to prevent tumor immune escape. Innovation 4 , 100452 (2023). 37485079 10.1016/j.xinn.2023.100452 PMC10362524

834. Wang DX Mutation status of the KMT2 family associated with immune checkpoint inhibitors (ICIs) therapy and implicating diverse tumor microenvironments Mol. Cancer 2024 23 15 10.1186/s12943-023-01930-8 38225603 PMC10789049 Wang, D. X. et al. Mutation status of the KMT2 family associated with immune checkpoint inhibitors (ICIs) therapy and implicating diverse tumor microenvironments. Mol. Cancer 23 , 15 (2024). 38225603 10.1186/s12943-023-01930-8 PMC10789049

835. Jiang Z A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune J. Nanobiotechnol. 2024 22 296 10.1186/s12951-024-02525-1 PMC11134718 38811964 Jiang, Z. et al. A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune. J. Nanobiotechnol. 22 , 296 (2024). 10.1186/s12951-024-02525-1 PMC11134718 38811964

836. Bauer, K. et al. BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALL. Am. J. Hematol. 99 , 1721-1731(2024). 10.1002/ajh.27385 38822666

837. Zhang J Research progress of long non-coding RNA in tumor drug resistance: a new paradigm Drug. Des. Dev. Ther. 2024 18 1385 1398 10.2147/DDDT.S448707 PMC11060174 38689609 Zhang, J. et al. Research progress of long non-coding RNA in tumor drug resistance: a new paradigm. Drug. Des. Dev. Ther. 18 , 1385–1398 (2024). 10.2147/DDDT.S448707 PMC11060174 38689609

838. Solta A Entinostat enhances the efficacy of chemotherapy in small cell lung cancer through s-phase arrest and decreased base excision repair Clin. Cancer Res. 2023 29 4644 4659 10.1158/1078-0432.CCR-23-1795 37725585 PMC10644001 Solta, A. et al. Entinostat enhances the efficacy of chemotherapy in small cell lung cancer through s-phase arrest and decreased base excision repair. Clin. Cancer Res. 29 , 4644–4659 (2023). 37725585 10.1158/1078-0432.CCR-23-1795 PMC10644001

839. Cervena, K. et al. Methylation-based therapies for colorectal cancer. Cells 9 , 1540 (2020). 10.3390/cells9061540 PMC7349319 32599894

840. Manengu, C. et al. HDAC inhibitors as a potential therapy for chemotherapy-induced neuropathic pain. Inflammopharmacology 32 , 2153–2175(2024). 10.1007/s10787-024-01488-x 38761314

841. He Y Inhibiting DNA methylation alleviates cisplatin-induced hearing loss by decreasing oxidative stress-induced mitochondria-dependent apoptosis via the LRP1-PI3K/AKT pathway Acta Pharmacol. Sin. B 2022 12 1305 1321 10.1016/j.apsb.2021.11.002 PMC9069410 35530135 He, Y. et al. Inhibiting DNA methylation alleviates cisplatin-induced hearing loss by decreasing oxidative stress-induced mitochondria-dependent apoptosis via the LRP1-PI3K/AKT pathway. Acta Pharmacol. Sin. B 12 , 1305–1321 (2022). 10.1016/j.apsb.2021.11.002 PMC9069410 35530135

842. Clozel T Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma Cancer Discov. 2013 3 1002 1019 10.1158/2159-8290.CD-13-0117 23955273 PMC3770813 Clozel, T. et al. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov. 3 , 1002–1019 (2013). 23955273 10.1158/2159-8290.CD-13-0117 PMC3770813

843. Zhong L Small molecules in targeted cancer therapy: advances, challenges, and future perspectives Signal. Transduct. Target. Ther. 2021 6 201 10.1038/s41392-021-00572-w 34054126 PMC8165101 Zhong, L. et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal. Transduct. Target. Ther. 6 , 201 (2021). 34054126 10.1038/s41392-021-00572-w PMC8165101

844. Parag-Sharma K Synergistic efficacy of combined EGFR and HDAC inhibitors overcomes tolerance to EGFR monotherapy in salivary mucoepidermoid carcinoma Oral. Oncol. 2021 115 105166 10.1016/j.oraloncology.2020.105166 33581505 PMC8026571 Parag-Sharma, K. et al. Synergistic efficacy of combined EGFR and HDAC inhibitors overcomes tolerance to EGFR monotherapy in salivary mucoepidermoid carcinoma. Oral. Oncol. 115 , 105166 (2021). 33581505 10.1016/j.oraloncology.2020.105166 PMC8026571

845. Wang JH A novel small-molecule antagonist enhances the sensitivity of osteosarcoma to cabozantinib in vitro and in vivo by targeting DNMT-1 correlated with disease severity in human patients Pharmacol. Res. 2021 173 105869 10.1016/j.phrs.2021.105869 34481973 Wang, J. H. et al. A novel small-molecule antagonist enhances the sensitivity of osteosarcoma to cabozantinib in vitro and in vivo by targeting DNMT-1 correlated with disease severity in human patients. Pharmacol. Res. 173 , 105869 (2021). 34481973 10.1016/j.phrs.2021.105869

846. Bass AKA Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors Eur. J. Med. Chem. 2021 209 112904 10.1016/j.ejmech.2020.112904 33077264 Bass, A. K. A. et al. Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors. Eur. J. Med. Chem. 209 , 112904 (2021). 33077264 10.1016/j.ejmech.2020.112904

847. Heath H Targeting systemic and gut microbial metabolism in ER(+) breast cancer Trends Endocrinol. Metab. 2024 35 321 330 10.1016/j.tem.2023.12.008 38220576 Heath, H. et al. Targeting systemic and gut microbial metabolism in ER(+) breast cancer. Trends Endocrinol. Metab. 35 , 321–330 (2024). 38220576 10.1016/j.tem.2023.12.008

848. Llinas-Bertran A Bellet-Ezquerra M Seoane JA Epigenetic control of cancer cell dormancy and awakening in endocrine therapy resistance Cancer Discov. 2024 14 704 706 10.1158/2159-8290.CD-24-0282 38690600 Llinas-Bertran, A., Bellet-Ezquerra, M. & Seoane, J. A. Epigenetic control of cancer cell dormancy and awakening in endocrine therapy resistance. Cancer Discov. 14 , 704–706 (2024). 38690600 10.1158/2159-8290.CD-24-0282

849. Culig Z Puhr M Androgen receptor-interacting proteins in prostate cancer development and therapy resistance Am. J. Pathol. 2024 194 324 334 10.1016/j.ajpath.2023.12.003 38104650 Culig, Z. & Puhr, M. Androgen receptor-interacting proteins in prostate cancer development and therapy resistance. Am. J. Pathol. 194 , 324–334 (2024). 38104650 10.1016/j.ajpath.2023.12.003

850. Fischetti I Combined therapy targeting AR and EZH2 curbs castration-resistant prostate cancer enhancing anti-tumor T-cell response Epigenomics 2024 16 653 670 10.2217/epi-2023-0374 38530086 PMC11160446 Fischetti, I. et al. Combined therapy targeting AR and EZH2 curbs castration-resistant prostate cancer enhancing anti-tumor T-cell response. Epigenomics 16 , 653–670 (2024). 38530086 10.2217/epi-2023-0374 PMC11160446

851. Manda S A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia Hematol. Oncol. 2024 42 e3274 10.1002/hon.3274 38711253 Manda, S. et al. A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia. Hematol. Oncol. 42 , e3274 (2024). 38711253 10.1002/hon.3274

852. Bazinet A Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study Lancet Haematol. 2024 11 e276 e286 10.1016/S2352-3026(24)00033-4 38452788 PMC12268998 Bazinet, A. et al. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study. Lancet Haematol. 11 , e276–e286 (2024). 38452788 10.1016/S2352-3026(24)00033-4 PMC12268998

853. Bataller A Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study Lancet Haematol. 2024 11 e186 e195 10.1016/S2352-3026(23)00367-8 38316133 Bataller, A. et al. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study. Lancet Haematol. 11 , e186–e195 (2024). 38316133 10.1016/S2352-3026(23)00367-8

854. Lachowiez CA A phase Ib/II study of ivosidenib with venetoclax ± azacitidine in IDH1-mutated myeloid malignancies Blood Cancer Discov. 2023 4 276 293 10.1158/2643-3230.BCD-22-0205 37102976 PMC10320628 Lachowiez, C. A. et al. A phase Ib/II study of ivosidenib with venetoclax ± azacitidine in IDH1-mutated myeloid malignancies. Blood Cancer Discov. 4 , 276–293 (2023). 37102976 10.1158/2643-3230.BCD-22-0205 PMC10320628

855. Pereira MP Herrity E Kim DDH TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches Ann. Hematol. 2024 103 1049 1067 10.1007/s00277-023-05462-5 37770618 Pereira, M. P., Herrity, E. & Kim, D. D. H. TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches. Ann. Hematol. 103 , 1049–1067 (2024). 37770618 10.1007/s00277-023-05462-5

856. DiNardo KW LeBlanc TW Chen H Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH annual meeting J. Hematol. Oncol. 2023 16 17 10.1186/s13045-023-01411-x 36869366 PMC9983204 DiNardo, K. W., LeBlanc, T. W. & Chen, H. Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH annual meeting. J. Hematol. Oncol. 16 , 17 (2023). 36869366 10.1186/s13045-023-01411-x PMC9983204

857. Pommert L Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium Am. J. Hematol. 2022 97 613 622 10.1002/ajh.26510 35180323 PMC8986610 Pommert, L. et al. Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. Am. J. Hematol. 97 , 613–622 (2022). 35180323 10.1002/ajh.26510 PMC8986610

858. Croucher PJP Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia Ann. Hematol. 2023 102 3049 3059 10.1007/s00277-023-05442-9 37702821 PMC10567832 Croucher, P. J. P. et al. Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia. Ann. Hematol. 102 , 3049–3059 (2023). 37702821 10.1007/s00277-023-05442-9 PMC10567832

859. Zeidan AM Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial Lancet Haematol. 2024 11 e38 e50 10.1016/S2352-3026(23)00333-2 38065203 Zeidan, A. M. et al. Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol. 11 , e38–e50 (2024). 38065203 10.1016/S2352-3026(23)00333-2

860. Saxena K A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia Cancer 2021 127 3761 3771 10.1002/cncr.33690 34171128 Saxena, K. et al. A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. Cancer 127 , 3761–3771 (2021). 34171128 10.1002/cncr.33690

861. Ruan J Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL Blood 2023 141 2194 2205 36796016 10.1182/blood.2022018254 PMC10356559 Ruan, J. et al. Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL. Blood 141 , 2194–2205 (2023). 36796016 10.1182/blood.2022018254 PMC10356559

862. Martin P Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL Blood 2022 139 1147 1159 10.1182/blood.2021011679 34428285 PMC9211445 Martin, P. et al. Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL. Blood 139 , 1147–1159 (2022). 34428285 10.1182/blood.2021011679 PMC9211445

863. Short NJ Kantarjian H Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: past discoveries and future directions Am. J. Hematol. 2022 97 1616 1626 10.1002/ajh.26667 35871436 Short, N. J. & Kantarjian, H. Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: past discoveries and future directions. Am. J. Hematol. 97 , 1616–1626 (2022). 35871436 10.1002/ajh.26667

864. Patnaik MM Tefferi A Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management Am. J. Hematol. 2024 99 1142 1165 10.1002/ajh.27271 38450850 PMC11096042 Patnaik, M. M. & Tefferi, A. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management. Am. J. Hematol. 99 , 1142–1165 (2024). 38450850 10.1002/ajh.27271 PMC11096042

865. Mayerhofer, C., Niemeyer, C. M. & Flotho, C. Current treatment of juvenile myelomonocytic leukemia. J. Clin. Med . 10 , 3084 (2021). 10.3390/jcm10143084 PMC8305558 34300250

866. Dai XJ Degraders in epigenetic therapy: PROTACs and beyond Theranostics 2024 14 1464 1499 10.7150/thno.92526 38389844 PMC10879860 Dai, X. J. et al. Degraders in epigenetic therapy: PROTACs and beyond. Theranostics 14 , 1464–1499 (2024). 38389844 10.7150/thno.92526 PMC10879860

867. Sakamoto KM Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation Proc. Natl. Acad. Sci. USA 2001 98 8554 8559 10.1073/pnas.141230798 11438690 PMC37474 Sakamoto, K. M. et al. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc. Natl. Acad. Sci. USA 98 , 8554–8559 (2001). 11438690 10.1073/pnas.141230798 PMC37474

868. Sinatra L Solid-phase synthesis of cereblon-recruiting selective histone deacetylase 6 degraders (HDAC6 PROTACs) with antileukemic activity J. Med. Chem. 2022 65 16860 16878 10.1021/acs.jmedchem.2c01659 36473103 Sinatra, L. et al. Solid-phase synthesis of cereblon-recruiting selective histone deacetylase 6 degraders (HDAC6 PROTACs) with antileukemic activity. J. Med. Chem. 65 , 16860–16878 (2022). 36473103 10.1021/acs.jmedchem.2c01659

869. Min J Phenyl-glutarimides: alternative cereblon binders for the design of PROTACs Angew. Chem. Int. Ed. Engl. 2021 60 26663 26670 10.1002/anie.202108848 34614283 PMC8648984 Min, J. et al. Phenyl-glutarimides: alternative cereblon binders for the design of PROTACs. Angew. Chem. Int. Ed. Engl. 60 , 26663–26670 (2021). 34614283 10.1002/anie.202108848 PMC8648984

870. Winter GE DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation Science 2015 348 1376 1381 10.1126/science.aab1433 25999370 PMC4937790 Winter, G. E. et al. DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348 , 1376–1381 (2015). 25999370 10.1126/science.aab1433 PMC4937790

871. Maneiro MA Antibody-PROTAC conjugates enable HER2-dependent targeted protein degradation of BRD4 ACS Chem. Biol. 2020 15 1306 1312 10.1021/acschembio.0c00285 32338867 PMC7309268 Maneiro, M. A. et al. Antibody-PROTAC conjugates enable HER2-dependent targeted protein degradation of BRD4. ACS Chem. Biol. 15 , 1306–1312 (2020). 32338867 10.1021/acschembio.0c00285 PMC7309268

872. Dragovich PS Antibody-mediated delivery of chimeric brd4 degraders. part 1: exploration of antibody linker, payload loading, and payload molecular properties J. Med. Chem. 2021 64 2534 2575 10.1021/acs.jmedchem.0c01845 33596065 Dragovich, P. S. et al. Antibody-mediated delivery of chimeric brd4 degraders. part 1: exploration of antibody linker, payload loading, and payload molecular properties. J. Med. Chem. 64 , 2534–2575 (2021). 33596065 10.1021/acs.jmedchem.0c01845

873. Pfaff P Samarasinghe KTG Crews CM Carreira EM Reversible spatiotemporal control of induced protein degradation by bistable photoPROTACs ACS Cent. Sci. 2019 5 1682 1690 10.1021/acscentsci.9b00713 31660436 PMC6813558 Pfaff, P., Samarasinghe, K. T. G., Crews, C. M. & Carreira, E. M. Reversible spatiotemporal control of induced protein degradation by bistable photoPROTACs. ACS Cent. Sci. 5 , 1682–1690 (2019). 31660436 10.1021/acscentsci.9b00713 PMC6813558

874. Xue G Light-induced protein degradation with photocaged PROTACs J. Am. Chem. Soc. 2019 141 18370 18374 10.1021/jacs.9b06422 31566962 Xue, G. et al. Light-induced protein degradation with photocaged PROTACs. J. Am. Chem. Soc. 141 , 18370–18374 (2019). 31566962 10.1021/jacs.9b06422

875. Li X Chemical proteomic profiling of bromodomains enables the wide-spectrum evaluation of bromodomain inhibitors in living cells J. Am. Chem. Soc. 2019 141 11497 11505 10.1021/jacs.9b02738 31246451 Li, X. et al. Chemical proteomic profiling of bromodomains enables the wide-spectrum evaluation of bromodomain inhibitors in living cells. J. Am. Chem. Soc. 141 , 11497–11505 (2019). 31246451 10.1021/jacs.9b02738

876. Yang C Radiotherapy-triggered proteolysis targeting chimera prodrug activation in tumors J. Am. Chem. Soc. 2023 145 385 391 10.1021/jacs.2c10177 36542856 Yang, C. et al. Radiotherapy-triggered proteolysis targeting chimera prodrug activation in tumors. J. Am. Chem. Soc. 145 , 385–391 (2023). 36542856 10.1021/jacs.2c10177

877. Takahashi D AUTACs: cargo-specific degraders using selective autophagy Mol. Cell. 2019 76 797 810.e710 10.1016/j.molcel.2019.09.009 31606272 Takahashi, D. et al. AUTACs: cargo-specific degraders using selective autophagy. Mol. Cell. 76 , 797–810.e710 (2019). 31606272 10.1016/j.molcel.2019.09.009

878. Ding Y Xing D Fei Y Lu B Emerging degrader technologies engaging lysosomal pathways Chem. Soc. Rev. 2022 51 8832 8876 10.1039/D2CS00624C 36218065 PMC9620493 Ding, Y., Xing, D., Fei, Y. & Lu, B. Emerging degrader technologies engaging lysosomal pathways. Chem. Soc. Rev. 51 , 8832–8876 (2022). 36218065 10.1039/d2cs00624c PMC9620493

879. Pei J Developing potent LC3-targeting AUTAC tools for protein degradation with selective autophagy Chem. Commun. 2021 57 13194 13197 10.1039/D1CC04661F 34816823 Pei, J. et al. Developing potent LC3-targeting AUTAC tools for protein degradation with selective autophagy. Chem. Commun. 57 , 13194–13197 (2021). 10.1039/d1cc04661f 34816823

880. Xie S Small-molecule hydrophobic tagging: a promising strategy of druglike technology for targeted protein degradation J. Med. Chem. 2023 66 10917 10933 10.1021/acs.jmedchem.3c00736 37535706 Xie, S. et al. Small-molecule hydrophobic tagging: a promising strategy of druglike technology for targeted protein degradation. J. Med. Chem. 66 , 10917–10933 (2023). 37535706 10.1021/acs.jmedchem.3c00736

881. Ma A Discovery of a first-in-class EZH2 selective degrader Nat. Chem. Biol. 2020 16 214 222 10.1038/s41589-019-0421-4 31819273 PMC6982609 Ma, A. et al. Discovery of a first-in-class EZH2 selective degrader. Nat. Chem. Biol. 16 , 214–222 (2020). 31819273 10.1038/s41589-019-0421-4 PMC6982609

882. Schiedel M Halotag-targeted sirtuin-rearranging ligand (sirreal) for the development of proteolysis-targeting chimeras (PROTACs) against the lysine deacetylase sirtuin 2 (Sirt2)* Chembiochem 2020 21 3371 3376 10.1002/cbic.202000351 32672888 PMC7754454 Schiedel, M. et al. Halotag-targeted sirtuin-rearranging ligand (sirreal) for the development of proteolysis-targeting chimeras (PROTACs) against the lysine deacetylase sirtuin 2 (Sirt2)*. Chembiochem 21 , 3371–3376 (2020). 32672888 10.1002/cbic.202000351 PMC7754454

883. Huang M A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects Eur. J. Med. Chem. 2020 188 111991 10.1016/j.ejmech.2019.111991 31883490 Huang, M. et al. A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects. Eur. J. Med. Chem. 188 , 111991 (2020). 31883490 10.1016/j.ejmech.2019.111991

884. Li X Yao Y Wu F Song Y A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth J. Hematol. Oncol. 2022 15 41 10.1186/s13045-022-01258-8 35395864 PMC8994274 Li, X., Yao, Y., Wu, F. & Song, Y. A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth. J. Hematol. Oncol. 15 , 41 (2022). 35395864 10.1186/s13045-022-01258-8 PMC8994274

885. Xie S Discovery of norbornene as a novel hydrophobic tag applied in protein degradation Angew. Chem. Int. Ed. Engl. 2023 62 e202217246 10.1002/anie.202217246 36670545 Xie, S. et al. Discovery of norbornene as a novel hydrophobic tag applied in protein degradation. Angew. Chem. Int. Ed. Engl. 62 , e202217246 (2023). 36670545 10.1002/anie.202217246

886. Domostegui A Nieto-Barrado L Perez-Lopez C Mayor-Ruiz C Chasing molecular glue degraders: screening approaches Chem. Soc. Rev. 2022 51 5498 5517 10.1039/D2CS00197G 35723413 Domostegui, A., Nieto-Barrado, L., Perez-Lopez, C. & Mayor-Ruiz, C. Chasing molecular glue degraders: screening approaches. Chem. Soc. Rev. 51 , 5498–5517 (2022). 35723413 10.1039/d2cs00197g

887. Kozicka Z Thomä NH Haven’t got a glue: protein surface variation for the design of molecular glue degraders Cell. Chem. Biol. 2021 28 1032 1047 10.1016/j.chembiol.2021.04.009 33930325 Kozicka, Z. & Thomä, N. H. Haven’t got a glue: protein surface variation for the design of molecular glue degraders. Cell. Chem. Biol. 28 , 1032–1047 (2021). 33930325 10.1016/j.chembiol.2021.04.009

888. Toriki ES Rational chemical design of molecular glue degraders ACS Cent. Sci. 2023 9 915 926 10.1021/acscentsci.2c01317 37252349 PMC10214506 Toriki, E. S. et al. Rational chemical design of molecular glue degraders. ACS Cent. Sci. 9 , 915–926 (2023). 37252349 10.1021/acscentsci.2c01317 PMC10214506

889. Cavalli G Heard E Advances in epigenetics link genetics to the environment and disease Nature 2019 571 489 499 10.1038/s41586-019-1411-0 31341302 Cavalli, G. & Heard, E. Advances in epigenetics link genetics to the environment and disease. Nature 571 , 489–499 (2019). 31341302 10.1038/s41586-019-1411-0

890. Schwartzman O Tanay A Single-cell epigenomics: techniques and emerging applications Nat. Rev. Genet. 2015 16 716 726, 10.1038/nrg3980 26460349 Schwartzman, O. & Tanay, A. Single-cell epigenomics: techniques and emerging applications. Nat. Rev. Genet. 16 , 716–726, (2015). 26460349 10.1038/nrg3980

891. Hawkins RD Hon GC Ren B Next-generation genomics: an integrative approach Nat. Rev. Genet. 2010 11 476 486, 10.1038/nrg2795 20531367 PMC3321268 Hawkins, R. D., Hon, G. C. & Ren, B. Next-generation genomics: an integrative approach. Nat. Rev. Genet. 11 , 476–486, (2010). 20531367 10.1038/nrg2795 PMC3321268

892. Cusanovich DA A single-cell atlas of in vivo mammalian chromatin accessibility Cell 2018 174 1309 1324.e1318 10.1016/j.cell.2018.06.052 30078704 PMC6158300 Cusanovich, D. A. et al. A single-cell atlas of in vivo mammalian chromatin accessibility. Cell 174 , 1309–1324.e1318 (2018). 30078704 10.1016/j.cell.2018.06.052 PMC6158300

893. Preissl S Gaulton KJ Ren B Characterizing cis-regulatory elements using single-cell epigenomics Nat. Rev. Genet 2023 24 21 43 10.1038/s41576-022-00509-1 35840754 PMC9771884 Preissl, S., Gaulton, K. J. & Ren, B. Characterizing cis-regulatory elements using single-cell epigenomics. Nat. Rev. Genet 24 , 21–43 (2023). 35840754 10.1038/s41576-022-00509-1 PMC9771884

894. Kelsey G Stegle O Reik W Single-cell epigenomics: recording the past and predicting the future Science 2017 358 69 75 10.1126/science.aan6826 28983045 Kelsey, G., Stegle, O. & Reik, W. Single-cell epigenomics: recording the past and predicting the future. Science 358 , 69–75 (2017). 28983045 10.1126/science.aan6826

895. Gaulton KJ Preissl S Ren B Interpreting non-coding disease-associated human variants using single-cell epigenomics Nat. Rev. Genet. 2023 24 516 534 10.1038/s41576-023-00598-6 37161089 PMC10629587 Gaulton, K. J., Preissl, S. & Ren, B. Interpreting non-coding disease-associated human variants using single-cell epigenomics. Nat. Rev. Genet. 24 , 516–534 (2023). 37161089 10.1038/s41576-023-00598-6 PMC10629587

896. Shapiro E Biezuner T Linnarsson S Single-cell sequencing-based technologies will revolutionize whole-organism science Nat. Rev. Genet. 2013 14 618 630 10.1038/nrg3542 23897237 Shapiro, E., Biezuner, T. & Linnarsson, S. Single-cell sequencing-based technologies will revolutionize whole-organism science. Nat. Rev. Genet. 14 , 618–630 (2013). 23897237 10.1038/nrg3542

897. Liu H Epigenomic and transcriptomic analyses define core cell types, genes and targetable mechanisms for kidney disease Nat. Genet. 2022 54 950 962 10.1038/s41588-022-01097-w 35710981 PMC11626562 Liu, H. et al. Epigenomic and transcriptomic analyses define core cell types, genes and targetable mechanisms for kidney disease. Nat. Genet. 54 , 950–962 (2022). 35710981 10.1038/s41588-022-01097-w PMC11626562

898. Ren B High-resolution Hi-C maps highlight multiscale 3D epigenome reprogramming during pancreatic cancer metastasis J. Hematol. Oncol. 2021 14 120 10.1186/s13045-021-01131-0 34348759 PMC8336101 Ren, B. et al. High-resolution Hi-C maps highlight multiscale 3D epigenome reprogramming during pancreatic cancer metastasis. J. Hematol. Oncol. 14 , 120 (2021). 34348759 10.1186/s13045-021-01131-0 PMC8336101

899. Stricker SH Köferle A Beck S From profiles to function in epigenomics Nat. Rev. Genet. 2017 18 51 66 10.1038/nrg.2016.138 27867193 Stricker, S. H., Köferle, A. & Beck, S. From profiles to function in epigenomics. Nat. Rev. Genet. 18 , 51–66 (2017). 27867193 10.1038/nrg.2016.138

900. Thakore PI Black JB Hilton IB Gersbach CA Editing the epigenome: technologies for programmable transcription and epigenetic modulation Nat. Methods 2016 13 127 137 10.1038/nmeth.3733 26820547 PMC4922638 Thakore, P. I., Black, J. B., Hilton, I. B. & Gersbach, C. A. Editing the epigenome: technologies for programmable transcription and epigenetic modulation. Nat. Methods 13 , 127–137 (2016). 26820547 10.1038/nmeth.3733 PMC4922638

901. Wright S Interrogating bromodomain inhibitor resistance in KMT2A-rearranged leukemia through combinatorial CRISPR screens Proc. Natl. Acad. Sci. USA 2023 120 e2220134120 10.1073/pnas.2220134120 37036970 PMC10120025 Wright, S. et al. Interrogating bromodomain inhibitor resistance in KMT2A-rearranged leukemia through combinatorial CRISPR screens. Proc. Natl. Acad. Sci. USA 120 , e2220134120 (2023). 37036970 10.1073/pnas.2220134120 PMC10120025

902. Ruan P NEpiC: a network-assisted algorithm for epigenetic studies using mean and variance combined signals Nucl. Acids Res. 2016 44 e134 10.1093/nar/gkw546 27302130 PMC5027497 Ruan, P. et al. NEpiC: a network-assisted algorithm for epigenetic studies using mean and variance combined signals. Nucl. Acids Res. 44 , e134 (2016). 27302130 10.1093/nar/gkw546 PMC5027497

903. Liu Q Detection of DNA base modifications by deep recurrent neural network on Oxford Nanopore sequencing data Nat. Commun. 2019 10 2449 10.1038/s41467-019-10168-2 31164644 PMC6547721 Liu, Q. et al. Detection of DNA base modifications by deep recurrent neural network on Oxford Nanopore sequencing data. Nat. Commun. 10 , 2449 (2019). 31164644 10.1038/s41467-019-10168-2 PMC6547721

904. Buenrostro JD Single-cell chromatin accessibility reveals principles of regulatory variation Nature 2015 523 486 490 10.1038/nature14590 26083756 PMC4685948 Buenrostro, J. D. et al. Single-cell chromatin accessibility reveals principles of regulatory variation. Nature 523 , 486–490 (2015). 26083756 10.1038/nature14590 PMC4685948

905. Nagano T Single-cell Hi-C reveals cell-to-cell variability in chromosome structure Nature 2013 502 59 64 10.1038/nature12593 24067610 PMC3869051 Nagano, T. et al. Single-cell Hi-C reveals cell-to-cell variability in chromosome structure. Nature 502 , 59–64 (2013). 24067610 10.1038/nature12593 PMC3869051

906. Shao D PEGR: a flexible management platform for reproducible epigenomic and genomic research Genome Biol. 2022 23 99 10.1186/s13059-022-02671-5 35440038 PMC9016988 Shao, D. et al. PEGR: a flexible management platform for reproducible epigenomic and genomic research. Genome Biol. 23 , 99 (2022). 35440038 10.1186/s13059-022-02671-5 PMC9016988

907. Du Q Wang Z Schramm VL Human DNMT1 transition state structure Proc. Natl. Acad. Sci. USA 2016 113 2916 2921 10.1073/pnas.1522491113 26929335 PMC4801242 Du, Q., Wang, Z. & Schramm, V. L. Human DNMT1 transition state structure. Proc. Natl. Acad. Sci. USA 113 , 2916–2921 (2016). 26929335 10.1073/pnas.1522491113 PMC4801242

908. Huang ZX Position 34 of tRNA is a discriminative element for m5C38 modification by human DNMT2 Nucl. Acids Res. 2021 49 13045 13061 10.1093/nar/gkab1148 34871455 PMC8682788 Huang, Z. X. et al. Position 34 of tRNA is a discriminative element for m5C38 modification by human DNMT2. Nucl. Acids Res. 49 , 13045–13061 (2021). 34871455 10.1093/nar/gkab1148 PMC8682788

909. Yang L Rau R Goodell MA DNMT3A in haematological malignancies Nat. Rev. Cancer 2015 15 152 165 10.1038/nrc3895 25693834 PMC5814392 Yang, L., Rau, R. & Goodell, M. A. DNMT3A in haematological malignancies. Nat. Rev. Cancer 15 , 152–165 (2015). 25693834 10.1038/nrc3895 PMC5814392

910. Yu J DNA methyltransferases: emerging targets for the discovery of inhibitors as potent anticancer drugs Drug. Discov. Today 2019 24 2323 2331 10.1016/j.drudis.2019.08.006 31494187 Yu, J. et al. DNA methyltransferases: emerging targets for the discovery of inhibitors as potent anticancer drugs. Drug. Discov. Today 24 , 2323–2331 (2019). 31494187 10.1016/j.drudis.2019.08.006

911. Xu TH Structure of nucleosome-bound DNA methyltransferases DNMT3A and DNMT3B Nature 2020 586 151 155 10.1038/s41586-020-2747-1 32968275 PMC7540737 Xu, T. H. et al. Structure of nucleosome-bound DNA methyltransferases DNMT3A and DNMT3B. Nature 586 , 151–155 (2020). 32968275 10.1038/s41586-020-2747-1 PMC7540737

912. Suetake I DNMT3L stimulates the DNA methylation activity of Dnmt3a and Dnmt3b through a direct interaction J. Biol. Chem. 2004 279 27816 27823 10.1074/jbc.M400181200 15105426 Suetake, I. et al. DNMT3L stimulates the DNA methylation activity of Dnmt3a and Dnmt3b through a direct interaction. J. Biol. Chem. 279 , 27816–27823 (2004). 15105426 10.1074/jbc.M400181200

913. Liu W Wu G Xiong F Chen Y Advances in the DNA methylation hydroxylase TET1 Biomark. Res. 2021 9 76 10.1186/s40364-021-00331-7 34656178 PMC8520278 Liu, W., Wu, G., Xiong, F. & Chen, Y. Advances in the DNA methylation hydroxylase TET1. Biomark. Res. 9 , 76 (2021). 34656178 10.1186/s40364-021-00331-7 PMC8520278

914. Ko M Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX Nature 2013 497 122 126 10.1038/nature12052 23563267 PMC3643997 Ko, M. et al. Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX. Nature 497 , 122–126 (2013). 23563267 10.1038/nature12052 PMC3643997

915. Gu TP The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes Nature 2011 477 606 610 10.1038/nature10443 21892189 Gu, T. P. et al. The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes. Nature 477 , 606–610 (2011). 21892189 10.1038/nature10443

916. Feng Q Zhang Y The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes Genes. Dev. 2001 15 827 832 11297506 10.1101/gad.876201 PMC312663 Feng, Q. & Zhang, Y. The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes. Genes. Dev. 15 , 827–832 (2001). 11297506 10.1101/gad.876201 PMC312663

917. Adkins NL Georgel PT MeCP2: structure and function Biochem. Cell. Biol. 2011 89 1 11 10.1139/O10-112 21326358 Adkins, N. L. & Georgel, P. T. MeCP2: structure and function. Biochem. Cell. Biol. 89 , 1–11 (2011). 21326358 10.1139/O10-112

918. Ichimura T Transcriptional repression and heterochromatin formation by MBD1 and MCAF/AM family proteins J. Biol. Chem. 2005 280 13928 13935 10.1074/jbc.M413654200 15691849 Ichimura, T. et al. Transcriptional repression and heterochromatin formation by MBD1 and MCAF/AM family proteins. J. Biol. Chem. 280 , 13928–13935 (2005). 15691849 10.1074/jbc.M413654200

919. Klose RJ Bird AP Genomic DNA methylation: the mark and its mediators Trends Biochem. Sci. 2006 31 89 97 10.1016/j.tibs.2005.12.008 16403636 Klose, R. J. & Bird, A. P. Genomic DNA methylation: the mark and its mediators. Trends Biochem. Sci. 31 , 89–97 (2006). 16403636 10.1016/j.tibs.2005.12.008

920. Ng HH MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex Nat. Genet. 1999 23 58 61 10.1038/12659 10471499 Ng, H. H. et al. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat. Genet. 23 , 58–61 (1999). 10471499 10.1038/12659

921. Yildirim O Mbd3/NURD complex regulates expression of 5-hydroxymethylcytosine marked genes in embryonic stem cells Cell 2011 147 1498 1510 10.1016/j.cell.2011.11.054 22196727 PMC3252821 Yildirim, O. et al. Mbd3/NURD complex regulates expression of 5-hydroxymethylcytosine marked genes in embryonic stem cells. Cell 147 , 1498–1510 (2011). 22196727 10.1016/j.cell.2011.11.054 PMC3252821

922. Le Guezennec X MBD2/NuRD and MBD3/NuRD, two distinct complexes with different biochemical and functional properties Mol. Cell. Biol. 2006 26 843 851 10.1128/MCB.26.3.843-851.2006 16428440 PMC1347035 Le Guezennec, X. et al. MBD2/NuRD and MBD3/NuRD, two distinct complexes with different biochemical and functional properties. Mol. Cell. Biol. 26 , 843–851 (2006). 16428440 10.1128/MCB.26.3.843-851.2006 PMC1347035

923. Busque L Godley LA MBD4: guardian of the epigenetic galaxy Blood 2018 132 1468 1469 10.1182/blood-2018-08-867044 30287469 Busque, L. & Godley, L. A. MBD4: guardian of the epigenetic galaxy. Blood 132 , 1468–1469 (2018). 30287469 10.1182/blood-2018-08-867044

924. Zhang J S phase-dependent interaction with DNMT1 dictates the role of UHRF1 but not UHRF2 in DNA methylation maintenance Cell. Res. 2011 21 1723 1739 10.1038/cr.2011.176 22064703 PMC3357991 Zhang, J. et al. S phase-dependent interaction with DNMT1 dictates the role of UHRF1 but not UHRF2 in DNA methylation maintenance. Cell. Res. 21 , 1723–1739 (2011). 22064703 10.1038/cr.2011.176 PMC3357991

925. Zhou T Structural basis for hydroxymethylcytosine recognition by the SRA domain of UHRF2 Mol. Cell. 2014 54 879 886 10.1016/j.molcel.2014.04.003 24813944 Zhou, T. et al. Structural basis for hydroxymethylcytosine recognition by the SRA domain of UHRF2. Mol. Cell. 54 , 879–886 (2014). 24813944 10.1016/j.molcel.2014.04.003

926. Liu X UHRF2 commissions the completion of DNA demethylation through allosteric activation by 5hmC and K33-linked ubiquitination of XRCC1 Mol. Cell. 2021 81 2960 2974.e2967 10.1016/j.molcel.2021.05.022 34111398 Liu, X. et al. UHRF2 commissions the completion of DNA demethylation through allosteric activation by 5hmC and K33-linked ubiquitination of XRCC1. Mol. Cell. 81 , 2960–2974.e2967 (2021). 34111398 10.1016/j.molcel.2021.05.022

927. Sterner DE Berger SL Acetylation of histones and transcription-related factors Microbiol. Mol. Biol. Rev. 2000 64 435 459 10.1128/MMBR.64.2.435-459.2000 10839822 PMC98999 Sterner, D. E. & Berger, S. L. Acetylation of histones and transcription-related factors. Microbiol. Mol. Biol. Rev. 64 , 435–459 (2000). 10839822 10.1128/mmbr.64.2.435-459.2000 PMC98999

928. Ortega, M. A. et al. Understanding HAT1: a comprehensive review of noncanonical roles and connection with disease. Genes . 14 , 915 (2023). 10.3390/genes14040915 PMC10137880 37107673

929. Poziello A Recent insights into Histone Acetyltransferase-1: biological function and involvement in pathogenesis Epigenetics 2021 16 838 850 10.1080/15592294.2020.1827723 33016232 PMC8330999 Poziello, A. et al. Recent insights into Histone Acetyltransferase-1: biological function and involvement in pathogenesis. Epigenetics 16 , 838–850 (2021). 33016232 10.1080/15592294.2020.1827723 PMC8330999

930. González-Medina A Hidalgo E Ayté J Gcn5-mediated acetylation at MBF-regulated promoters induces the G1/S transcriptional wave Nucl. Acids Res. 2019 47 8439 8451 10.1093/nar/gkz561 31260531 PMC6895280 González-Medina, A., Hidalgo, E. & Ayté, J. Gcn5-mediated acetylation at MBF-regulated promoters induces the G1/S transcriptional wave. Nucl. Acids Res. 47 , 8439–8451 (2019). 31260531 10.1093/nar/gkz561 PMC6895280

931. Ogryzko VV The transcriptional coactivators p300 and CBP are histone acetyltransferases Cell 1996 87 953 959 10.1016/S0092-8674(00)82001-2 8945521 Ogryzko, V. V. et al. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87 , 953–959 (1996). 8945521 10.1016/s0092-8674(00)82001-2

932. Jin Q Distinct roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation EMBO J. 2011 30 249 262 10.1038/emboj.2010.318 21131905 PMC3025463 Jin, Q. et al. Distinct roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation. EMBO J. 30 , 249–262 (2011). 21131905 10.1038/emboj.2010.318 PMC3025463

933. Hess L A toolbox for class I HDACs reveals isoform specific roles in gene regulation and protein acetylation PLoS Genet. 2022 18 e1010376 10.1371/journal.pgen.1010376 35994477 PMC9436093 Hess, L. et al. A toolbox for class I HDACs reveals isoform specific roles in gene regulation and protein acetylation. PLoS Genet. 18 , e1010376 (2022). 35994477 10.1371/journal.pgen.1010376 PMC9436093

934. Li J Nuclear accumulation of HDAC4 in ATM deficiency promotes neurodegeneration in ataxia telangiectasia Nat. Med. 2012 18 783 790 10.1038/nm.2709 22466704 PMC3378917 Li, J. et al. Nuclear accumulation of HDAC4 in ATM deficiency promotes neurodegeneration in ataxia telangiectasia. Nat. Med. 18 , 783–790 (2012). 22466704 10.1038/nm.2709 PMC3378917

935. Yang C Croteau S Hardy P Histone deacetylase (HDAC) 9: versatile biological functions and emerging roles in human cancer Cell. Oncol. 2021 44 997 1017 10.1007/s13402-021-00626-9 PMC8516780 34318404 Yang, C., Croteau, S. & Hardy, P. Histone deacetylase (HDAC) 9: versatile biological functions and emerging roles in human cancer. Cell. Oncol. 44 , 997–1017 (2021). 10.1007/s13402-021-00626-9 PMC8516780 34318404

936. Vaquero A Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin Mol. Cell. 2004 16 93 105 10.1016/j.molcel.2004.08.031 15469825 Vaquero, A. et al. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol. Cell. 16 , 93–105 (2004). 15469825 10.1016/j.molcel.2004.08.031

937. Bosch-Presegué L Stabilization of Suv39H1 by SirT1 is part of oxidative stress response and ensures genome protection Mol. Cell. 2011 42 210 223 10.1016/j.molcel.2011.02.034 21504832 Bosch-Presegué, L. et al. Stabilization of Suv39H1 by SirT1 is part of oxidative stress response and ensures genome protection. Mol. Cell. 42 , 210–223 (2011). 21504832 10.1016/j.molcel.2011.02.034

938. Serrano L The tumor suppressor SirT2 regulates cell cycle progression and genome stability by modulating the mitotic deposition of H4K20 methylation Genes. Dev. 2013 27 639 653 10.1101/gad.211342.112 23468428 PMC3613611 Serrano, L. et al. The tumor suppressor SirT2 regulates cell cycle progression and genome stability by modulating the mitotic deposition of H4K20 methylation. Genes. Dev. 27 , 639–653 (2013). 23468428 10.1101/gad.211342.112 PMC3613611

939. Vempati RK p300-mediated acetylation of histone H3 lysine 56 functions in DNA damage response in mammals J. Biol. Chem. 2010 285 28553 28564 10.1074/jbc.M110.149393 20587414 PMC2937881 Vempati, R. K. et al. p300-mediated acetylation of histone H3 lysine 56 functions in DNA damage response in mammals. J. Biol. Chem. 285 , 28553–28564 (2010). 20587414 10.1074/jbc.M110.149393 PMC2937881

940. Gil R Barth S Kanfi Y Cohen HY SIRT6 exhibits nucleosome-dependent deacetylase activity Nucl. Acids Res. 2013 41 8537 8545 10.1093/nar/gkt642 23892288 PMC3794599 Gil, R., Barth, S., Kanfi, Y. & Cohen, H. Y. SIRT6 exhibits nucleosome-dependent deacetylase activity. Nucl. Acids Res. 41 , 8537–8545 (2013). 23892288 10.1093/nar/gkt642 PMC3794599

941. Tasselli L SIRT6 deacetylates H3K18ac at pericentric chromatin to prevent mitotic errors and cellular senescence Nat. Struct. Mol. Biol. 2016 23 434 440 10.1038/nsmb.3202 27043296 PMC5826646 Tasselli, L. et al. SIRT6 deacetylates H3K18ac at pericentric chromatin to prevent mitotic errors and cellular senescence. Nat. Struct. Mol. Biol. 23 , 434–440 (2016). 27043296 10.1038/nsmb.3202 PMC5826646

942. Barber MF SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation Nature 2012 487 114 118 10.1038/nature11043 22722849 PMC3412143 Barber, M. F. et al. SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature 487 , 114–118 (2012). 22722849 10.1038/nature11043 PMC3412143

943. Umehara T Structural basis for acetylated histone H4 recognition by the human BRD2 bromodomain J. Biol. Chem. 2010 285 7610 7618 10.1074/jbc.M109.062422 20048151 PMC2844208 Umehara, T. et al. Structural basis for acetylated histone H4 recognition by the human BRD2 bromodomain. J. Biol. Chem. 285 , 7610–7618 (2010). 20048151 10.1074/jbc.M109.062422 PMC2844208

944. Lee JE Brd4 binds to active enhancers to control cell identity gene induction in adipogenesis and myogenesis Nat. Commun. 2017 8 2217 10.1038/s41467-017-02403-5 29263365 PMC5738375 Lee, J. E. et al. Brd4 binds to active enhancers to control cell identity gene induction in adipogenesis and myogenesis. Nat. Commun. 8 , 2217 (2017). 29263365 10.1038/s41467-017-02403-5 PMC5738375

945. Liu Y Chromatin looping shapes KLF5-dependent transcriptional programs in human epithelial cancers Cancer Res. 2020 80 5464 5477 10.1158/0008-5472.CAN-20-1287 33115806 PMC7787512 Liu, Y. et al. Chromatin looping shapes KLF5-dependent transcriptional programs in human epithelial cancers. Cancer Res. 80 , 5464–5477 (2020). 33115806 10.1158/0008-5472.CAN-20-1287 PMC7787512

946. Yokoyama A Leukemogenesis via aberrant self-renewal by the MLL/AEP-mediated transcriptional activation system Cancer Sci. 2021 112 3935 3944 10.1111/cas.15054 34251718 PMC8486200 Yokoyama, A. Leukemogenesis via aberrant self-renewal by the MLL/AEP-mediated transcriptional activation system. Cancer Sci. 112 , 3935–3944 (2021). 34251718 10.1111/cas.15054 PMC8486200

947. Andrews FH Shanle EK Strahl BD Kutateladze TG The essential role of acetyllysine binding by the YEATS domain in transcriptional regulation Transcription 2016 7 14 20 10.1080/21541264.2015.1125987 26934307 PMC4802754 Andrews, F. H., Shanle, E. K., Strahl, B. D. & Kutateladze, T. G. The essential role of acetyllysine binding by the YEATS domain in transcriptional regulation. Transcription 7 , 14–20 (2016). 26934307 10.1080/21541264.2015.1125987 PMC4802754

948. Zhao D YEATS2 is a selective histone crotonylation reader Cell. Res. 2016 26 629 632 10.1038/cr.2016.49 27103431 PMC4856769 Zhao, D. et al. YEATS2 is a selective histone crotonylation reader. Cell. Res. 26 , 629–632 (2016). 27103431 10.1038/cr.2016.49 PMC4856769

949. Cho HJ GAS41 recognizes diacetylated histone h3 through a bivalent binding mode ACS Chem. Biol. 2018 13 2739 2746 10.1021/acschembio.8b00674 30071723 PMC6611172 Cho, H. J. et al. GAS41 recognizes diacetylated histone h3 through a bivalent binding mode. ACS Chem. Biol. 13 , 2739–2746 (2018). 30071723 10.1021/acschembio.8b00674 PMC6611172

950. Kikuchi M GAS41 promotes H2A.Z deposition through recognition of the N terminus of histone H3 by the YEATS domain Proc. Natl. Acad. Sci. USA 2023 120 e2304103120 10.1073/pnas.2304103120 37844223 PMC10614846 Kikuchi, M. et al. GAS41 promotes H2A.Z deposition through recognition of the N terminus of histone H3 by the YEATS domain. Proc. Natl. Acad. Sci. USA 120 , e2304103120 (2023). 37844223 10.1073/pnas.2304103120 PMC10614846

951. Margueron R Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms Mol. Cell. 2008 32 503 518 10.1016/j.molcel.2008.11.004 19026781 PMC3641558 Margueron, R. et al. Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol. Cell. 32 , 503–518 (2008). 19026781 10.1016/j.molcel.2008.11.004 PMC3641558

952. Stulemeijer IJ Dot1 histone methyltransferases share a distributive mechanism but have highly diverged catalytic properties Sci. Rep. 2015 5 9824 10.1038/srep09824 25965993 PMC4650758 Stulemeijer, I. J. et al. Dot1 histone methyltransferases share a distributive mechanism but have highly diverged catalytic properties. Sci. Rep. 5 , 9824 (2015). 25965993 10.1038/srep09824 PMC4650758

953. Strepkos D Histone methyltransferase SETDB1: a common denominator of tumorigenesis with therapeutic potential Cancer Res. 2021 81 525 534 10.1158/0008-5472.CAN-20-2906 33115801 Strepkos, D. et al. Histone methyltransferase SETDB1: a common denominator of tumorigenesis with therapeutic potential. Cancer Res. 81 , 525–534 (2021). 33115801 10.1158/0008-5472.CAN-20-2906

954. Shinkai Y Tachibana M H3K9 methyltransferase G9a and the related molecule GLP Genes. Dev. 2011 25 781 788, 10.1101/gad.2027411 21498567 PMC3078703 Shinkai, Y. & Tachibana, M. H3K9 methyltransferase G9a and the related molecule GLP. Genes. Dev. 25 , 781–788, (2011). 21498567 10.1101/gad.2027411 PMC3078703

955. Huang J G9a and Glp methylate lysine 373 in the tumor suppressor p53 J. Biol. Chem. 2010 285 9636 9641 10.1074/jbc.M109.062588 20118233 PMC2843213 Huang, J. et al. G9a and Glp methylate lysine 373 in the tumor suppressor p53. J. Biol. Chem. 285 , 9636–9641 (2010). 20118233 10.1074/jbc.M109.062588 PMC2843213

956. Brown MA Sims RJ 3rd Gottlieb PD Tucker PW Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex Mol. Cancer 2006 5 26 10.1186/1476-4598-5-26 16805913 PMC1524980 Brown, M. A., Sims, R. J. 3rd, Gottlieb, P. D. & Tucker, P. W. Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex. Mol. Cancer 5 , 26 (2006). 16805913 10.1186/1476-4598-5-26 PMC1524980

957. Huang J Repression of p53 activity by Smyd2-mediated methylation Nature 2006 444 629 632 10.1038/nature05287 17108971 Huang, J. et al. Repression of p53 activity by Smyd2-mediated methylation. Nature 444 , 629–632 (2006). 17108971 10.1038/nature05287

958. Li W Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases Nature 2021 590 498 503 10.1038/s41586-020-03069-8 33361816 PMC7889650 Li, W. et al. Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases. Nature 590 , 498–503 (2021). 33361816 10.1038/s41586-020-03069-8 PMC7889650

959. Thiebaut, C., Eve, L., Poulard, C. & Le Romancer, M. Structure, activity, and function of PRMT1. Life 11 , 1147 (2021). 10.3390/life11111147 PMC8619983 34833023

960. Liu F PRMT5-mediated histone arginine methylation antagonizes transcriptional repression by polycomb complex PRC2 Nucl. Acids Res. 2020 48 2956 2968 10.1093/nar/gkaa065 32025719 PMC7102951 Liu, F. et al. PRMT5-mediated histone arginine methylation antagonizes transcriptional repression by polycomb complex PRC2. Nucl. Acids Res. 48 , 2956–2968 (2020). 32025719 10.1093/nar/gkaa065 PMC7102951

961. Liu R PHD finger protein 1 (PHF1) is a novel reader for histone H4R3 symmetric dimethylation and coordinates with PRMT5-WDR77/CRL4B complex to promote tumorigenesis Nucl. Acids Res. 2018 46 6608 6626 10.1093/nar/gky461 29846670 PMC6061854 Liu, R. et al. PHD finger protein 1 (PHF1) is a novel reader for histone H4R3 symmetric dimethylation and coordinates with PRMT5-WDR77/CRL4B complex to promote tumorigenesis. Nucl. Acids Res. 46 , 6608–6626 (2018). 29846670 10.1093/nar/gky461 PMC6061854

962. Whyte WA Enhancer decommissioning by LSD1 during embryonic stem cell differentiation Nature 2012 482 221 225 10.1038/nature10805 22297846 PMC4144424 Whyte, W. A. et al. Enhancer decommissioning by LSD1 during embryonic stem cell differentiation. Nature 482 , 221–225 (2012). 22297846 10.1038/nature10805 PMC4144424

963. Reischl S Kramer A Fbxl11 is a novel negative element of the mammalian circadian clock J. Biol. Rhythm. 2015 30 291 301 10.1177/0748730415587407 26037310 Reischl, S. & Kramer, A. Fbxl11 is a novel negative element of the mammalian circadian clock. J. Biol. Rhythm. 30 , 291–301 (2015). 10.1177/0748730415587407 26037310

964. Tsukada Y Ishitani T Nakayama KI KDM7 is a dual demethylase for histone H3 Lys 9 and Lys 27 and functions in brain development Genes. Dev. 2010 24 432 437 10.1101/gad.1864410 20194436 PMC2827838 Tsukada, Y., Ishitani, T. & Nakayama, K. I. KDM7 is a dual demethylase for histone H3 Lys 9 and Lys 27 and functions in brain development. Genes. Dev. 24 , 432–437 (2010). 20194436 10.1101/gad.1864410 PMC2827838

965. Hoyle RG IOX1 suppresses wnt target gene transcription and colorectal cancer tumorigenesis through inhibition of KDM3 histone demethylases Mol. Cancer Ther. 2021 20 191 202 10.1158/1535-7163.MCT-20-0328 33203729 PMC7790990 Hoyle, R. G. et al. IOX1 suppresses wnt target gene transcription and colorectal cancer tumorigenesis through inhibition of KDM3 histone demethylases. Mol. Cancer Ther. 20 , 191–202 (2021). 33203729 10.1158/1535-7163.MCT-20-0328 PMC7790990

966. Agger K The KDM4/JMJD2 histone demethylases are required for hematopoietic stem cell maintenance Blood 2019 134 1154 1158 10.1182/blood.2019000855 31434704 PMC6776794 Agger, K. et al. The KDM4/JMJD2 histone demethylases are required for hematopoietic stem cell maintenance. Blood 134 , 1154–1158 (2019). 31434704 10.1182/blood.2019000855 PMC6776794

967. Zhang Y The PHD1 finger of KDM5B recognizes unmodified H3K4 during the demethylation of histone H3K4me2/3 by KDM5B Protein Cell. 2014 5 837 850 10.1007/s13238-014-0078-4 24952722 PMC4225485 Zhang, Y. et al. The PHD1 finger of KDM5B recognizes unmodified H3K4 during the demethylation of histone H3K4me2/3 by KDM5B. Protein Cell. 5 , 837–850 (2014). 24952722 10.1007/s13238-014-0078-4 PMC4225485

968. Tran, N., Broun, A. & Ge, K. Lysine demethylase KDM6A in differentiation, development, and cancer. Mol. Cell Biol . 40 , e00341–e00320 (2020). 10.1128/MCB.00341-20 PMC7523656 32817139

969. Lagunas-Rangel FA KDM6B (JMJD3) and its dual role in cancer Biochimie 2021 184 63 71 10.1016/j.biochi.2021.02.005 33581195 Lagunas-Rangel, F. A. KDM6B (JMJD3) and its dual role in cancer. Biochimie 184 , 63–71 (2021). 33581195 10.1016/j.biochi.2021.02.005

970. Li H Structural basis for lower lysine methylation state-specific readout by MBT repeats of L3MBTL1 and an engineered PHD finger Mol. Cell. 2007 28 677 691 10.1016/j.molcel.2007.10.023 18042461 PMC4689580 Li, H. et al. Structural basis for lower lysine methylation state-specific readout by MBT repeats of L3MBTL1 and an engineered PHD finger. Mol. Cell. 28 , 677–691 (2007). 18042461 10.1016/j.molcel.2007.10.023 PMC4689580

971. Gonzalez-Sandoval A Perinuclear anchoring of H3K9-methylated chromatin stabilizes induced cell fate in C. elegans embryos Cell 2015 163 1333 1347 10.1016/j.cell.2015.10.066 26607792 Gonzalez-Sandoval, A. et al. Perinuclear anchoring of H3K9-methylated chromatin stabilizes induced cell fate in C. elegans embryos. Cell 163 , 1333–1347 (2015). 26607792 10.1016/j.cell.2015.10.066

972. Tavares L RYBP-PRC1 complexes mediate H2A ubiquitylation at polycomb target sites independently of PRC2 and H3K27me3 Cell 2012 148 664 678 10.1016/j.cell.2011.12.029 22325148 PMC3281992 Tavares, L. et al. RYBP-PRC1 complexes mediate H2A ubiquitylation at polycomb target sites independently of PRC2 and H3K27me3. Cell 148 , 664–678 (2012). 22325148 10.1016/j.cell.2011.12.029 PMC3281992

973. Lu R Wang GG Tudor: a versatile family of histone methylation ‘readers’ Trends Biochem Sci. 2013 38 546 555 10.1016/j.tibs.2013.08.002 24035451 PMC3830939 Lu, R. & Wang, G. G. Tudor: a versatile family of histone methylation ‘readers’. Trends Biochem Sci. 38 , 546–555 (2013). 24035451 10.1016/j.tibs.2013.08.002 PMC3830939

974. Vezzoli A Molecular basis of histone H3K36me3 recognition by the PWWP domain of Brpf1 Nat. Struct. Mol. Biol. 2010 17 617 619 10.1038/nsmb.1797 20400950 Vezzoli, A. et al. Molecular basis of histone H3K36me3 recognition by the PWWP domain of Brpf1. Nat. Struct. Mol. Biol. 17 , 617–619 (2010). 20400950 10.1038/nsmb.1797

975. Qiu Y Solution structure of the Pdp1 PWWP domain reveals its unique binding sites for methylated H4K20 and DNA Biochem. J. 2012 442 527 538 10.1042/BJ20111885 22150589 Qiu, Y. et al. Solution structure of the Pdp1 PWWP domain reveals its unique binding sites for methylated H4K20 and DNA. Biochem. J. 442 , 527–538 (2012). 22150589 10.1042/BJ20111885

976. Black JC Kutateladze TG Atypical histone targets of PHD fingers J. Biol. Chem. 2023 299 104601 10.1016/j.jbc.2023.104601 36907441 PMC10124903 Black, J. C. & Kutateladze, T. G. Atypical histone targets of PHD fingers. J. Biol. Chem. 299 , 104601 (2023). 36907441 10.1016/j.jbc.2023.104601 PMC10124903

977. Wysocka J WDR5 associates with histone H3 methylated at K4 and is essential for H3 K4 methylation and vertebrate development Cell 2005 121 859 872 10.1016/j.cell.2005.03.036 15960974 Wysocka, J. et al. WDR5 associates with histone H3 methylated at K4 and is essential for H3 K4 methylation and vertebrate development. Cell 121 , 859–872 (2005). 15960974 10.1016/j.cell.2005.03.036

978. Huang J Yin P Structural Insights into N(6)-methyladenosine (m(6)A) Modification in the transcriptome Genom. Proteom. Bioinforma. 2018 16 85 98 10.1016/j.gpb.2018.03.001 PMC6112310 29709557 Huang, J. & Yin, P. Structural Insights into N(6)-methyladenosine (m(6)A) Modification in the transcriptome. Genom. Proteom. Bioinforma. 16 , 85–98 (2018). 10.1016/j.gpb.2018.03.001 PMC6112310 29709557

979. Wang X Structural basis of N(6)-adenosine methylation by the METTL3-METTL14 complex Nature 2016 534 575 578 10.1038/nature18298 27281194 Wang, X. et al. Structural basis of N(6)-adenosine methylation by the METTL3-METTL14 complex. Nature 534 , 575–578 (2016). 27281194 10.1038/nature18298

980. Jia G N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO Nat. Chem. Biol. 2011 7 885 887 10.1038/nchembio.687 22002720 PMC3218240 Jia, G. et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat. Chem. Biol. 7 , 885–887 (2011). 22002720 10.1038/nchembio.687 PMC3218240

981. Bartosovic M N6-methyladenosine demethylase FTO targets pre-mRNAs and regulates alternative splicing and 3’-end processing Nucl. Acids Res. 2017 45 11356 11370 10.1093/nar/gkx778 28977517 PMC5737695 Bartosovic, M. et al. N6-methyladenosine demethylase FTO targets pre-mRNAs and regulates alternative splicing and 3’-end processing. Nucl. Acids Res. 45 , 11356–11370 (2017). 28977517 10.1093/nar/gkx778 PMC5737695

982. Zheng G ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility Mol. Cell. 2013 49 18 29 10.1016/j.molcel.2012.10.015 23177736 PMC3646334 Zheng, G. et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol. Cell. 49 , 18–29 (2013). 23177736 10.1016/j.molcel.2012.10.015 PMC3646334

983. Esteve-Puig R Epigenetic loss of m1A RNA demethylase ALKBH3 in Hodgkin lymphoma targets collagen, conferring poor clinical outcome Blood 2021 137 994 999 10.1182/blood.2020005823 32915956 PMC7918181 Esteve-Puig, R. et al. Epigenetic loss of m1A RNA demethylase ALKBH3 in Hodgkin lymphoma targets collagen, conferring poor clinical outcome. Blood 137 , 994–999 (2021). 32915956 10.1182/blood.2020005823 PMC7918181

984. Wang X N(6)-methyladenosine modulates messenger RNA translation efficiency Cell 2015 161 1388 1399 10.1016/j.cell.2015.05.014 26046440 PMC4825696 Wang, X. et al. N(6)-methyladenosine modulates messenger RNA translation efficiency. Cell 161 , 1388–1399 (2015). 26046440 10.1016/j.cell.2015.05.014 PMC4825696

985. Einstein JM Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer Mol. Cell. 2021 81 3048 3064.e3049 10.1016/j.molcel.2021.06.014 34216543 PMC8359670 Einstein, J. M. et al. Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer. Mol. Cell. 81 , 3048–3064.e3049 (2021). 34216543 10.1016/j.molcel.2021.06.014 PMC8359670

986. Buscarlet M Essential role of BRG, the ATPase subunit of BAF chromatin remodeling complexes, in leukemia maintenance Blood 2014 123 1720 1728 10.1182/blood-2013-02-483495 24478402 PMC3954053 Buscarlet, M. et al. Essential role of BRG, the ATPase subunit of BAF chromatin remodeling complexes, in leukemia maintenance. Blood 123 , 1720–1728 (2014). 24478402 10.1182/blood-2013-02-483495 PMC3954053

987. Singh M Popowicz GM Krajewski M Holak TA Structural ramification for acetyl-lysine recognition by the bromodomain of human BRG1 protein, a central ATPase of the SWI/SNF remodeling complex Chembiochem 2007 8 1308 1316, 10.1002/cbic.200600562 17582821 Singh, M., Popowicz, G. M., Krajewski, M. & Holak, T. A. Structural ramification for acetyl-lysine recognition by the bromodomain of human BRG1 protein, a central ATPase of the SWI/SNF remodeling complex. Chembiochem 8 , 1308–1316, (2007). 17582821 10.1002/cbic.200600562

988. Sanchez OF Williamson D Cai L Yuan C A sensitive protein-based sensor for quantifying histone acetylation levels Talanta 2015 140 212 218 10.1016/j.talanta.2015.03.046 26048844 Sanchez, O. F., Williamson, D., Cai, L. & Yuan, C. A sensitive protein-based sensor for quantifying histone acetylation levels. Talanta 140 , 212–218 (2015). 26048844 10.1016/j.talanta.2015.03.046

989. Peng C The transcriptional regulation role of BRD7 by binding to acetylated histone through bromodomain J. Cell. Biochem. 2006 97 882 892 10.1002/jcb.20645 16265664 Peng, C. et al. The transcriptional regulation role of BRD7 by binding to acetylated histone through bromodomain. J. Cell. Biochem. 97 , 882–892 (2006). 16265664 10.1002/jcb.20645

990. Li S LncRNA LENGA acts as a tumor suppressor in gastric cancer through BRD7/TP53 signaling Cell. Mol. Life Sci. 2022 80 5 10.1007/s00018-022-04642-2 36477655 PMC11071885 Li, S. et al. LncRNA LENGA acts as a tumor suppressor in gastric cancer through BRD7/TP53 signaling. Cell. Mol. Life Sci. 80 , 5 (2022). 36477655 10.1007/s00018-022-04642-2 PMC11071885

991. Flynn EM A subset of human bromodomains recognizes butyryllysine and crotonyllysine histone peptide modifications Structure 2015 23 1801 1814 10.1016/j.str.2015.08.004 26365797 Flynn, E. M. et al. A subset of human bromodomains recognizes butyryllysine and crotonyllysine histone peptide modifications. Structure 23 , 1801–1814 (2015). 26365797 10.1016/j.str.2015.08.004

992. Niemeyer CM Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial Blood Adv. 2021 5 2901 2908 10.1182/bloodadvances.2020004144 34297046 PMC8341358 Niemeyer, C. M. et al. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. Blood Adv. 5 , 2901–2908 (2021). 34297046 10.1182/bloodadvances.2020004144 PMC8341358

993. Adès L Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML Blood Adv. 2022 6 5132 5145 10.1182/bloodadvances.2022007334 35728048 PMC9631625 Adès, L. et al. Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML. Blood Adv. 6 , 5132–5145 (2022). 35728048 10.1182/bloodadvances.2022007334 PMC9631625

994. Sekeres MA Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML Leukemia 2021 35 2119 2124 10.1038/s41375-021-01125-4 33483617 PMC8257476 Sekeres, M. A. et al. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML. Leukemia 35 , 2119–2124 (2021). 33483617 10.1038/s41375-021-01125-4 PMC8257476

995. Ravandi F Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial J. Hematol. Oncol. 2021 14 133 10.1186/s13045-021-01142-x 34454540 PMC8401338 Ravandi, F. et al. Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial. J. Hematol. Oncol. 14 , 133 (2021). 34454540 10.1186/s13045-021-01142-x PMC8401338

996. Santini V A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia Leukemia 2018 32 413 418 10.1038/leu.2017.186 28607470 PMC5808077 Santini, V. et al. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. Leukemia 32 , 413–418 (2018). 28607470 10.1038/leu.2017.186 PMC5808077

997. Garcia-Manero G Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study Lancet Haematol. 2024 11 e15 e26 10.1016/S2352-3026(23)00338-1 38135371 Garcia-Manero, G. et al. Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. Lancet Haematol. 11 , e15–e26 (2024). 38135371 10.1016/S2352-3026(23)00338-1

998. Itzykson R Decitabine versus hydroxyurea for advanced proliferative chronic myelomonocytic leukemia: results of a randomized phase III trial within the EMSCO network J. Clin. Oncol. 2023 41 1888 1897 10.1200/JCO.22.00437 36455187 Itzykson, R. et al. Decitabine versus hydroxyurea for advanced proliferative chronic myelomonocytic leukemia: results of a randomized phase III trial within the EMSCO network. J. Clin. Oncol. 41 , 1888–1897 (2023). 36455187 10.1200/JCO.22.00437

999. Garcia-Manero G Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study Blood 2020 136 674 683 10.1182/blood.2019004143 32285126 PMC7414597 Garcia-Manero, G. et al. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. Blood 136 , 674–683 (2020). 32285126 10.1182/blood.2019004143 PMC7414597

1000. Kim YH Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial Lancet Oncol. 2018 19 1192 1204 10.1016/S1470-2045(18)30379-6 30100375 Kim, Y. H. et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 19 , 1192–1204 (2018). 30100375 10.1016/S1470-2045(18)30379-6

1001. Duvic M Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) Blood 2007 109 31 39 10.1182/blood-2006-06-025999 16960145 PMC1785068 Duvic, M. et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109 , 31–39 (2007). 16960145 10.1182/blood-2006-06-025999 PMC1785068

1002. Bates SE Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data Br. J. Haematol. 2015 170 96 109 10.1111/bjh.13400 25891346 PMC4675455 Bates, S. E. et al. Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data. Br. J. Haematol. 170 , 96–109 (2015). 25891346 10.1111/bjh.13400 PMC4675455

1003. Foss F Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial J. Hematol. Oncol. 2016 9 22 10.1186/s13045-016-0243-8 26965915 PMC4785666 Foss, F. et al. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. J. Hematol. Oncol. 9 , 22 (2016). 26965915 10.1186/s13045-016-0243-8 PMC4785666

1004. Brunvand MW Carson J Complete remission with romidepsin in a patient with T-cell acute lymphoblastic leukemia refractory to induction hyper-CVAD Hematol. Oncol. 2018 36 340 343 10.1002/hon.2421 28560733 PMC5836898 Brunvand, M. W. & Carson, J. Complete remission with romidepsin in a patient with T-cell acute lymphoblastic leukemia refractory to induction hyper-CVAD. Hematol. Oncol. 36 , 340–343 (2018). 28560733 10.1002/hon.2421 PMC5836898

1005. Gimsing P A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia Eur. J. Haematol. 2008 81 170 176 10.1111/j.1600-0609.2008.01102.x 18510700 Gimsing, P. et al. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur. J. Haematol. 81 , 170–176 (2008). 18510700 10.1111/j.1600-0609.2008.01102.x

1006. Foss F A phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma Br. J. Haematol. 2015 168 811 819 10.1111/bjh.13222 25404094 Foss, F. et al. A phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br. J. Haematol. 168 , 811–819 (2015). 25404094 10.1111/bjh.13222

1007. Dimicoli S Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome Am. J. Hematol. 2012 87 127 129 10.1002/ajh.22198 22072492 PMC4085038 Dimicoli, S. et al. Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. Am. J. Hematol. 87 , 127–129 (2012). 22072492 10.1002/ajh.22198 PMC4085038

1008. Garcia-Manero G A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts Leukemia 2017 31 2799 2806 10.1038/leu.2017.159 28546581 PMC5729337 Garcia-Manero, G. et al. A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts. Leukemia 31 , 2799–2806 (2017). 28546581 10.1038/leu.2017.159 PMC5729337

1009. Zhang MC Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma Clin. Epigenet. 2020 12 160 10.1186/s13148-020-00948-9 PMC7585299 33097085 Zhang, M. C. et al. Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma. Clin. Epigenet. 12 , 160 (2020). 10.1186/s13148-020-00948-9 PMC7585299 33097085

1010. Wang Y Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: a multicenter phase II trial Am. J. Hematol. 2022 97 623 629 10.1002/ajh.26499 35170082 PMC9314976 Wang, Y. et al. Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: a multicenter phase II trial. Am. J. Hematol. 97 , 623–629 (2022). 35170082 10.1002/ajh.26499 PMC9314976

1011. DiNardo CD Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML N. Engl. J. Med. 2018 378 2386 2398 10.1056/NEJMoa1716984 29860938 DiNardo, C. D. et al. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N. Engl. J. Med. 378 , 2386–2398 (2018). 29860938 10.1056/NEJMoa1716984

1012. Abou-Alfa GK Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study Lancet Oncol. 2020 21 796 807 10.1016/S1470-2045(20)30157-1 32416072 PMC7523268 Abou-Alfa, G. K. et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 21 , 796–807 (2020). 32416072 10.1016/S1470-2045(20)30157-1 PMC7523268

1013. Albany C A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer Cancer Med. 2021 10 156 163 10.1002/cam4.3583 33135391 PMC7826483 Albany, C. et al. A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer. Cancer Med. 10 , 156–163 (2021). 33135391 10.1002/cam4.3583 PMC7826483

1014. Papadatos-Pastos, D. et al. Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors. J. Immunother Cancer . 10 , e004495. (2022). 10.1136/jitc-2022-004495 PMC9240883 35717027

1015. Wei CX A brief report of a phase II trial evaluating efficacy and safety of hypomethylating agent guadecitabine in combination with carboplatin in extensive stage small cell lung cancer Clin. Lung Cancer 2023 24 347 352 10.1016/j.cllc.2023.03.003 37032265 Wei, C. X. et al. A brief report of a phase II trial evaluating efficacy and safety of hypomethylating agent guadecitabine in combination with carboplatin in extensive stage small cell lung cancer. Clin. Lung Cancer 24 , 347–352 (2023). 37032265 10.1016/j.cllc.2023.03.003

1016. Jang HJ A phase II trial of guadecitabine plus atezolizumab in metastatic urothelial carcinoma progressing after initial immune checkpoint inhibitor therapy Clin. Cancer Res. 2023 29 2052 2065 10.1158/1078-0432.CCR-22-3642 36928921 PMC10233355 Jang, H. J. et al. A phase II trial of guadecitabine plus atezolizumab in metastatic urothelial carcinoma progressing after initial immune checkpoint inhibitor therapy. Clin. Cancer Res. 29 , 2052–2065 (2023). 36928921 10.1158/1078-0432.CCR-22-3642 PMC10233355

1017. Chen, S. et al. Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer. J. Clin. Investig . 132 , e158800 (2022). 10.1172/JCI158800 PMC9282926 35671108

1018. Sébert M A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure Haematologica 2019 104 1565 1571 10.3324/haematol.2018.207118 30733271 PMC6669173 Sébert, M. et al. A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. Haematologica 104 , 1565–1571 (2019). 30733271 10.3324/haematol.2018.207118 PMC6669173

1019. Sheikh TN Growth inhibition and induction of innate immune signaling of chondrosarcomas with epigenetic inhibitors Mol. Cancer Ther. 2021 20 2362 2371 10.1158/1535-7163.MCT-21-0066 34552007 PMC8643315 Sheikh, T. N. et al. Growth inhibition and induction of innate immune signaling of chondrosarcomas with epigenetic inhibitors. Mol. Cancer Ther. 20 , 2362–2371 (2021). 34552007 10.1158/1535-7163.MCT-21-0066 PMC8643315

1020. Oza AM A randomized phase II trial of epigenetic priming with guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer Clin. Cancer Res. 2020 26 1009 1016 10.1158/1078-0432.CCR-19-1638 31831561 PMC7056559 Oza, A. M. et al. A randomized phase II trial of epigenetic priming with guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer. Clin. Cancer Res. 26 , 1009–1016 (2020). 31831561 10.1158/1078-0432.CCR-19-1638 PMC7056559

1021. Zakharia Y Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study BTCRC-GU16-043 Nat. Commun. 2024 15 972 10.1038/s41467-024-45216-z 38302476 PMC10834488 Zakharia, Y. et al. Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study BTCRC-GU16-043. Nat. Commun. 15 , 972 (2024). 38302476 10.1038/s41467-024-45216-z PMC10834488

1022. O’Connell CL Safety, outcomes, and T-cell characteristics in patients with relapsed or refractory MDS or CMML treated with atezolizumab in combination with guadecitabine Clin. Cancer Res. 2022 28 5306 5316 10.1158/1078-0432.CCR-22-1810 36222848 PMC9772102 O’Connell, C. L. et al. Safety, outcomes, and T-cell characteristics in patients with relapsed or refractory MDS or CMML treated with atezolizumab in combination with guadecitabine. Clin. Cancer Res. 28 , 5306–5316 (2022). 36222848 10.1158/1078-0432.CCR-22-1810 PMC9772102

1023. Garcia-Manero G Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial Lancet Haematol. 2019 6 e317 e327 10.1016/S2352-3026(19)30029-8 31060979 PMC9012213 Garcia-Manero, G. et al. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. Lancet Haematol. 6 , e317–e327 (2019). 31060979 10.1016/S2352-3026(19)30029-8 PMC9012213

1024. Chung W Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia Clin. Epigenet. 2019 11 106 10.1186/s13148-019-0704-3 PMC6647096 31331399 Chung, W. et al. Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia. Clin. Epigenet. 11 , 106 (2019). 10.1186/s13148-019-0704-3 PMC6647096 31331399

1025. Kantarjian HM Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial Lancet Oncol. 2017 18 1317 1326 10.1016/S1470-2045(17)30576-4 28844816 PMC5925750 Kantarjian, H. M. et al. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncol. 18 , 1317–1326 (2017). 28844816 10.1016/S1470-2045(17)30576-4 PMC5925750

1026. Issa JJ Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study Lancet Oncol. 2015 16 1099 1110 10.1016/S1470-2045(15)00038-8 26296954 PMC5557041 Issa, J. J. et al. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 16 , 1099–1110 (2015). 26296954 10.1016/S1470-2045(15)00038-8 PMC5557041

1027. Sharma A Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells PLoS ONE 2017 12 e0176139 10.1371/journal.pone.0176139 28445481 PMC5405959 Sharma, A. et al. Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells. PLoS ONE 12 , e0176139 (2017). 28445481 10.1371/journal.pone.0176139 PMC5405959

1028. Liu YC A clinical trial with valproic acid and hydralazine in combination with gemcitabine and cisplatin followed by doxorubicin and dacarbazine for advanced hepatocellular carcinoma Asia Pac. J. Clin. Oncol. 2022 18 19 27 10.1111/ajco.13443 32964588 Liu, Y. C. et al. A clinical trial with valproic acid and hydralazine in combination with gemcitabine and cisplatin followed by doxorubicin and dacarbazine for advanced hepatocellular carcinoma. Asia Pac. J. Clin. Oncol. 18 , 19–27 (2022). 32964588 10.1111/ajco.13443

1029. Kim B Huh KY Yu KS Lee S Pharmacokinetics, pharmacodynamics and safety of oral formulation (CG-750) of ivaltinostat, a histone deacetylase inhibitor, compared to IV formulation (CG-745) Br. J. Clin. Pharmacol. 2024 90 1103 1114 10.1111/bcp.15997 38263733 Kim, B., Huh, K. Y., Yu, K. S. & Lee, S. Pharmacokinetics, pharmacodynamics and safety of oral formulation (CG-750) of ivaltinostat, a histone deacetylase inhibitor, compared to IV formulation (CG-745). Br. J. Clin. Pharmacol. 90 , 1103–1114 (2024). 38263733 10.1111/bcp.15997

1030. Vey N Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia Leuk. Lymphoma 2017 58 1880 1886 10.1080/10428194.2016.1263843 27911138 Vey, N. et al. Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia. Leuk. Lymphoma 58 , 1880–1886 (2017). 27911138 10.1080/10428194.2016.1263843

1031. Choy E Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma Cancer 2015 121 1223 1230 10.1002/cncr.29175 25536954 PMC4393337 Choy, E. et al. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma. Cancer 121 , 1223–1230 (2015). 25536954 10.1002/cncr.29175 PMC4393337

1032. Morschhauser F Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia Investig. New. Drugs 2015 33 423 431 10.1007/s10637-015-0206-x 25600050 Morschhauser, F. et al. Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Investig. New. Drugs 33 , 423–431 (2015). 25600050 10.1007/s10637-015-0206-x

1033. Liva SG Phase I study of AR-42 and decitabine in acute myeloid leukemia Leuk. Lymphoma 2020 61 1484 1492 10.1080/10428194.2020.1719095 32037935 PMC7375689 Liva, S. G. et al. Phase I study of AR-42 and decitabine in acute myeloid leukemia. Leuk. Lymphoma 61 , 1484–1492 (2020). 32037935 10.1080/10428194.2020.1719095 PMC7375689

1034. Sborov DW A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas Leuk. Lymphoma 2017 58 2310 2318 10.1080/10428194.2017.1298751 28270022 PMC5489371 Sborov, D. W. et al. A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. Leuk. Lymphoma 58 , 2310–2318 (2017). 28270022 10.1080/10428194.2017.1298751 PMC5489371

1035. Abaza YM Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies Cancer 2017 123 4851 4859 10.1002/cncr.30949 28841236 PMC5901648 Abaza, Y. M. et al. Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. Cancer 123 , 4851–4859 (2017). 28841236 10.1002/cncr.30949 PMC5901648

1036. Yong WP Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies Ann. Oncol. 2011 22 2516 2522 10.1093/annonc/mdq784 21385886 Yong, W. P. et al. Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies. Ann. Oncol. 22 , 2516–2522 (2011). 21385886 10.1093/annonc/mdq784

1037. Razak AR Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours Br. J. Cancer 2011 104 756 762 10.1038/bjc.2011.13 21285985 PMC3048208 Razak, A. R. et al. Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. Br. J. Cancer 104 , 756–762 (2011). 21285985 10.1038/bjc.2011.13 PMC3048208

1038. Garcia-Manero G Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study Blood Adv. 2019 3 508 518 10.1182/bloodadvances.2018027409 30760466 PMC6391673 Garcia-Manero, G. et al. Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. Blood Adv. 3 , 508–518 (2019). 30760466 10.1182/bloodadvances.2018027409 PMC6391673

1039. Bose P A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis Leuk. Lymphoma 2019 60 1767 1774 10.1080/10428194.2018.1543876 30632841 PMC6594864 Bose, P. et al. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leuk. Lymphoma 60 , 1767–1774 (2019). 30632841 10.1080/10428194.2018.1543876 PMC6594864

1040. Yalniz FF A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy Br. J. Haematol. 2020 188 404 412 10.1111/bjh.16173 31468521 Yalniz, F. F. et al. A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy. Br. J. Haematol. 188 , 404–412 (2020). 31468521 10.1111/bjh.16173

1041. Eigl BJ A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195 Investig. New. Drugs 2015 33 969 976 10.1007/s10637-015-0252-4 25983041 Eigl, B. J. et al. A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195. Investig. New. Drugs 33 , 969–976 (2015). 25983041 10.1007/s10637-015-0252-4

1042. Garcia-Manero G Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes Cancer 2017 123 994 1002 10.1002/cncr.30533 28094841 PMC5432122 Garcia-Manero, G. et al. Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes. Cancer 123 , 994–1002 (2017). 28094841 10.1002/cncr.30533 PMC5432122

1043. Quintás-Cardama A Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis Leuk. Res. 2012 36 1124 1127 10.1016/j.leukres.2012.03.003 22475363 PMC4152772 Quintás-Cardama, A. et al. Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leuk. Res. 36 , 1124–1127 (2012). 22475363 10.1016/j.leukres.2012.03.003 PMC4152772

1044. Chu QS A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200 †. Ann. Oncol. 2015 26 973 981 10.1093/annonc/mdv033 25632070 Chu, Q. S. et al. A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200. †. Ann. Oncol. 26 , 973–981 (2015). 25632070 10.1093/annonc/mdv033

1045. Garcia-Manero G Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study Leuk. Res. 2024 140 107480 10.1016/j.leukres.2024.107480 38499457 Garcia-Manero, G. et al. Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study. Leuk. Res. 140 , 107480 (2024). 38499457 10.1016/j.leukres.2024.107480

1046. Ikeda M Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer Investig. New. Drugs 2019 37 109 117 10.1007/s10637-018-0634-5 29995287 Ikeda, M. et al. Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer. Investig. New. Drugs 37 , 109–117 (2019). 29995287 10.1007/s10637-018-0634-5

1047. Brunetto AT First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors Clin. Cancer Res. 2013 19 5494 5504 10.1158/1078-0432.CCR-13-0735 24065624 PMC3790647 Brunetto, A. T. et al. First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors. Clin. Cancer Res. 19 , 5494–5504 (2013). 24065624 10.1158/1078-0432.CCR-13-0735 PMC3790647

1048. Walewski J Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study Leuk. Lymphoma 2019 60 675 684 10.1080/10428194.2018.1492122 30160566 Walewski, J. et al. Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study. Leuk. Lymphoma 60 , 675–684 (2019). 30160566 10.1080/10428194.2018.1492122

1049. Bitzer M Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study J. Hepatol. 2016 65 280 288 10.1016/j.jhep.2016.02.043 26952006 Bitzer, M. et al. Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study. J. Hepatol. 65 , 280–288 (2016). 26952006 10.1016/j.jhep.2016.02.043

1050. Ueno M A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy Cancer Med. 2021 10 2088 2099 10.1002/cam4.3813 33635605 PMC7957161 Ueno, M. et al. A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy. Cancer Med. 10 , 2088–2099 (2021). 33635605 10.1002/cam4.3813 PMC7957161

1051. Tak WY Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients Investig. New. Drugs 2018 36 1072 1084 10.1007/s10637-018-0658-x 30198057 Tak, W. Y. et al. Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients. Investig. New. Drugs 36 , 1072–1084 (2018). 30198057 10.1007/s10637-018-0658-x

1052. Tambo Y Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy Investig. New. Drugs 2017 35 217 226 10.1007/s10637-017-0435-2 28138828 Tambo, Y. et al. Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy. Investig. New. Drugs 35 , 217–226 (2017). 28138828 10.1007/s10637-017-0435-2

1053. Pauer LR Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors Cancer Investig. 2004 22 886 896 10.1081/CNV-200039852 15641487 Pauer, L. R. et al. Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Cancer Investig. 22 , 886–896 (2004). 15641487 10.1081/cnv-200039852

1054. Undevia SD A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine Ann. Oncol. 2004 15 1705 1711 10.1093/annonc/mdh438 15520075 Undevia, S. D. et al. A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann. Oncol. 15 , 1705–1711 (2004). 15520075 10.1093/annonc/mdh438

1055. Nemunaitis JJ Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer Cancer J. 2003 9 58 66 10.1097/00130404-200301000-00010 12602769 Nemunaitis, J. J. et al. Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer. Cancer J. 9 , 58–66 (2003). 12602769 10.1097/00130404-200301000-00010

1056. Prakash S Chronic oral administration of CI-994: a phase 1 study Investig. New. Drugs 2001 19 1 11 10.1023/A:1006489328324 11291827 Prakash, S. et al. Chronic oral administration of CI-994: a phase 1 study. Investig. New. Drugs 19 , 1–11 (2001). 11291827 10.1023/a:1006489328324

1057. Richards DA Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study Ann. Oncol. 2006 17 1096 1102 10.1093/annonc/mdl081 16641168 Richards, D. A. et al. Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study. Ann. Oncol. 17 , 1096–1102 (2006). 16641168 10.1093/annonc/mdl081

1058. Ljubenkov PA Effect of the histone deacetylase inhibitor FRM-0334 on progranulin levels in patients with progranulin gene haploinsufficiency: a randomized clinical trial JAMA Netw. Open. 2021 4 e2125584 10.1001/jamanetworkopen.2021.25584 34559230 PMC8463943 Ljubenkov, P. A. et al. Effect of the histone deacetylase inhibitor FRM-0334 on progranulin levels in patients with progranulin gene haploinsufficiency: a randomized clinical trial. JAMA Netw. Open. 4 , e2125584 (2021). 34559230 10.1001/jamanetworkopen.2021.25584 PMC8463943

1059. Venugopal B A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors Clin. Cancer Res. 2013 19 4262 4272 10.1158/1078-0432.CCR-13-0312 23741066 Venugopal, B. et al. A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. Clin. Cancer Res. 19 , 4262–4272 (2013). 23741066 10.1158/1078-0432.CCR-13-0312

1060. Moreau P Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma Leuk. Lymphoma 2016 57 1546 1559 10.3109/10428194.2015.1117611 26758913 Moreau, P. et al. Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma. Leuk. Lymphoma 57 , 1546–1559 (2016). 26758913 10.3109/10428194.2015.1117611

1061. Child F Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome Br. J. Derm. 2016 175 80 88 10.1111/bjd.14427 26836950 Child, F. et al. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome. Br. J. Derm. 175 , 80–88 (2016). 10.1111/bjd.14427 26836950

1062. Booth SW A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma BMC Cancer 2021 21 851 10.1186/s12885-021-08595-w 34301221 PMC8306282 Booth, S. W. et al. A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma. BMC Cancer 21 , 851 (2021). 34301221 10.1186/s12885-021-08595-w PMC8306282

1063. Saunders MP CXD101 and nivolumab in patients with metastatic microsatellite-stable colorectal cancer (CAROSELL): a multicentre, open-label, single-arm, phase II trial ESMO Open. 2022 7 100594 10.1016/j.esmoop.2022.100594 36327756 PMC9808483 Saunders, M. P. et al. CXD101 and nivolumab in patients with metastatic microsatellite-stable colorectal cancer (CAROSELL): a multicentre, open-label, single-arm, phase II trial. ESMO Open. 7 , 100594 (2022). 36327756 10.1016/j.esmoop.2022.100594 PMC9808483

1064. Heath EI Phase Ia dose escalation study of OBP-801, a cyclic depsipeptide class I histone deacetylase inhibitor, in patients with advanced solid tumors Investig. New. Drugs 2022 40 300 307 10.1007/s10637-021-01180-9 34613570 Heath, E. I. et al. Phase Ia dose escalation study of OBP-801, a cyclic depsipeptide class I histone deacetylase inhibitor, in patients with advanced solid tumors. Investig. New. Drugs 40 , 300–307 (2022). 34613570 10.1007/s10637-021-01180-9

1065. Haverkos B Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study Blood Adv. 2023 7 6339 6350 10.1182/bloodadvances.2023010330 37530631 PMC10587711 Haverkos, B. et al. Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study. Blood Adv. 7 , 6339–6350 (2023). 37530631 10.1182/bloodadvances.2023010330 PMC10587711

1066. Lin J Phase I study of entinostat in combination with enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer Oncologist 2021 26 e2136 e2142 10.1002/onco.13957 34427023 PMC8649040 Lin, J. et al. Phase I study of entinostat in combination with enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer. Oncologist 26 , e2136–e2142 (2021). 34427023 10.1002/onco.13957 PMC8649040

1067. Wang J Phase I study and pilot efficacy analysis of entinostat, a novel histone deacetylase inhibitor, in chinese postmenopausal women with hormone receptor-positive metastatic breast cancer Target. Oncol. 2021 16 591 599 10.1007/s11523-021-00823-4 34196874 PMC8484140 Wang, J. et al. Phase I study and pilot efficacy analysis of entinostat, a novel histone deacetylase inhibitor, in chinese postmenopausal women with hormone receptor-positive metastatic breast cancer. Target. Oncol. 16 , 591–599 (2021). 34196874 10.1007/s11523-021-00823-4 PMC8484140

1068. Gojo I Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias Blood 2007 109 2781 2790 10.1182/blood-2006-05-021873 17179232 PMC1852211 Gojo, I. et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 109 , 2781–2790 (2007). 17179232 10.1182/blood-2006-05-021873 PMC1852211

1069. Kummar S Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies Clin. Cancer Res. 2007 13 5411 5417 10.1158/1078-0432.CCR-07-0791 17875771 Kummar, S. et al. Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin. Cancer Res. 13 , 5411–5417 (2007). 17875771 10.1158/1078-0432.CCR-07-0791

1070. Bewersdorf JP A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents Ann. Hematol. 2024 103 105 116 10.1007/s00277-023-05552-4 38036712 PMC11838822 Bewersdorf, J. P. et al. A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents. Ann. Hematol. 103 , 105–116 (2024). 38036712 10.1007/s00277-023-05552-4 PMC11838822

1071. Pili R Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours Br. J. Cancer 2012 106 77 84 10.1038/bjc.2011.527 22134508 PMC3251867 Pili, R. et al. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Br. J. Cancer 106 , 77–84 (2012). 22134508 10.1038/bjc.2011.527 PMC3251867

1072. Prebet T Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study Br. J. Haematol. 2016 172 384 391, 10.1111/bjh.13832 26577691 PMC4794257 Prebet, T. et al. Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. Br. J. Haematol. 172 , 384–391, (2016). 26577691 10.1111/bjh.13832 PMC4794257

1073. Figueroa ME MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation Blood 2009 114 3448 3458 10.1182/blood-2009-01-200519 19652201 PMC2765680 Figueroa, M. E. et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 114 , 3448–3458 (2009). 19652201 10.1182/blood-2009-01-200519 PMC2765680

1074. Fandy TE Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies Blood 2009 114 2764 2773 10.1182/blood-2009-02-203547 19546476 PMC2756131 Fandy, T. E. et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 114 , 2764–2773 (2009). 19546476 10.1182/blood-2009-02-203547 PMC2756131

1075. Masuda N Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer BMC Cancer 2021 21 1269 10.1186/s12885-021-08973-4 34819039 PMC8611843 Masuda, N. et al. Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer. BMC Cancer 21 , 1269 (2021). 34819039 10.1186/s12885-021-08973-4 PMC8611843

1076. Bukowinski A A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phase-Clinical Trial Network (PEP-CTN) Pediatr. Blood Cancer 2021 68 e28892 10.1002/pbc.28892 33438318 PMC9176707 Bukowinski, A. et al. A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phase-Clinical Trial Network (PEP-CTN). Pediatr. Blood Cancer 68 , e28892 (2021). 33438318 10.1002/pbc.28892 PMC9176707

1077. Lim B A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment Br. J. Cancer 2019 120 1105 1112 10.1038/s41416-019-0473-y 31097774 PMC6738035 Lim, B. et al. A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. Br. J. Cancer 120 , 1105–1112 (2019). 31097774 10.1038/s41416-019-0473-y PMC6738035

1078. Ngamphaiboon N A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors Investig. New. Drugs 2015 33 225 232 10.1007/s10637-014-0174-6 25371323 Ngamphaiboon, N. et al. A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors. Investig. New. Drugs 33 , 225–232 (2015). 25371323 10.1007/s10637-014-0174-6

1079. Torres Roussos Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial Nat. Cancer 2024 5 866 879 10.1038/s43018-024-00729-w 38355777 PMC11552660 Torres, Roussos et al. Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial. Nat. Cancer 5 , 866–879 (2024). 38355777 10.1038/s43018-024-00729-w PMC11552660

1080. Iwata H Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial Jpn J. Clin. Oncol. 2023 53 4 15 10.1093/jjco/hyac166 36398439 PMC9825728 Iwata, H. et al. Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial. Jpn J. Clin. Oncol. 53 , 4–15 (2023). 36398439 10.1093/jjco/hyac166 PMC9825728

1081. Jespersen H Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study BMC Cancer 2019 19 415 10.1186/s12885-019-5623-3 31046743 PMC6498539 Jespersen, H. et al. Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study. BMC Cancer 19 , 415 (2019). 31046743 10.1186/s12885-019-5623-3 PMC6498539

1082. Ny L The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma Nat. Commun. 2021 12 5155 10.1038/s41467-021-25332-w 34453044 PMC8397717 Ny, L. et al. The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma. Nat. Commun. 12 , 5155 (2021). 34453044 10.1038/s41467-021-25332-w PMC8397717

1083. Batlevi CL ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma Haematologica 2016 101 968 975 10.3324/haematol.2016.142406 27151994 PMC4967576 Batlevi, C. L. et al. ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma. Haematologica 101 , 968–975 (2016). 27151994 10.3324/haematol.2016.142406 PMC4967576

1084. Prebet T Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905 J. Clin. Oncol. 2014 32 1242 1248 10.1200/JCO.2013.50.3102 24663049 PMC3986386 Prebet, T. et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. J. Clin. Oncol. 32 , 1242–1248 (2014). 24663049 10.1200/JCO.2013.50.3102 PMC3986386

1085. Yardley DA Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor J. Clin. Oncol. 2013 31 2128 2135 10.1200/JCO.2012.43.7251 23650416 PMC4881332 Yardley, D. A. et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J. Clin. Oncol. 31 , 2128–2135 (2013). 23650416 10.1200/JCO.2012.43.7251 PMC4881332

1086. Hellmann MD Entinostat plus pembrolizumab in patients with metastatic NSCLC previously treated with anti-PD-(L)1 therapy Clin. Cancer Res. 2021 27 1019 1028 10.1158/1078-0432.CCR-20-3305 33203644 PMC7887114 Hellmann, M. D. et al. Entinostat plus pembrolizumab in patients with metastatic NSCLC previously treated with anti-PD-(L)1 therapy. Clin. Cancer Res. 27 , 1019–1028 (2021). 33203644 10.1158/1078-0432.CCR-20-3305 PMC7887114

1087. van Tilburg CM INFORM2 NivEnt: the first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies BMC Cancer 2020 20 523 10.1186/s12885-020-07008-8 32503469 PMC7275428 van Tilburg, C. M. et al. INFORM2 NivEnt: the first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies. BMC Cancer 20 , 523 (2020). 32503469 10.1186/s12885-020-07008-8 PMC7275428

1088. Pili R Immunomodulation by Entinostat in renal cell carcinoma patients receiving high-dose interleukin 2: a multicenter, single-arm, phase I/II trial (NCI-CTEP#7870) Clin. Cancer Res. 2017 23 7199 7208 10.1158/1078-0432.CCR-17-1178 28939740 PMC5712266 Pili, R. et al. Immunomodulation by Entinostat in renal cell carcinoma patients receiving high-dose interleukin 2: a multicenter, single-arm, phase I/II trial (NCI-CTEP#7870). Clin. Cancer Res. 23 , 7199–7208 (2017). 28939740 10.1158/1078-0432.CCR-17-1178 PMC5712266

1089. Juergens RA Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer Cancer Discov. 2011 1 598 607 10.1158/2159-8290.CD-11-0214 22586682 PMC3353724 Juergens, R. A. et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 1 , 598–607 (2011). 22586682 10.1158/2159-8290.CD-11-0214 PMC3353724

1090. Witta SE Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy J. Clin. Oncol. 2012 30 2248 2255 10.1200/JCO.2011.38.9411 22508830 PMC4798782 Witta, S. E. et al. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J. Clin. Oncol. 30 , 2248–2255 (2012). 22508830 10.1200/JCO.2011.38.9411 PMC4798782

1091. Connolly RM E2112: randomized phase III trial of endocrine therapy plus entinostat or placebo in hormone receptor-positive advanced breast cancer. a trial of the ecog-acrin cancer research group J. Clin. Oncol. 2021 39 3171 3181 10.1200/JCO.21.00944 34357781 PMC8478386 Connolly, R. M. et al. E2112: randomized phase III trial of endocrine therapy plus entinostat or placebo in hormone receptor-positive advanced breast cancer. a trial of the ecog-acrin cancer research group. J. Clin. Oncol. 39 , 3171–3181 (2021). 34357781 10.1200/JCO.21.00944 PMC8478386

1092. Ballinger TJ Impact of muscle measures on outcome in patients receiving endocrine therapy for metastatic breast cancer: analysis of ECOG-ACRIN E2112 J. Natl Compr. Cancer Netw. 2023 21 915 923.e911 10.6004/jnccn.2023.7045 PMC10594540 37673107 Ballinger, T. J. et al. Impact of muscle measures on outcome in patients receiving endocrine therapy for metastatic breast cancer: analysis of ECOG-ACRIN E2112. J. Natl Compr. Cancer Netw. 21 , 915–923.e911 (2023). 10.6004/jnccn.2023.7045 PMC10594540 37673107

1093. Garcia-Manero G Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia Blood 2008 112 981 989 10.1182/blood-2007-10-115873 18495956 PMC4081529 Garcia-Manero, G. et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 112 , 981–989 (2008). 18495956 10.1182/blood-2007-10-115873 PMC4081529

1094. Weber JS Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma Melanoma Res. 2022 32 324 333 10.1097/CMR.0000000000000818 35678233 PMC9444873 Weber, J. S. et al. Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma. Melanoma Res. 32 , 324–333 (2022). 35678233 10.1097/CMR.0000000000000818 PMC9444873

1095. Grivas P Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes Cancer 2019 125 533 540 10.1002/cncr.31817 30570744 PMC6590473 Grivas, P. et al. Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. Cancer 125 , 533–540 (2019). 30570744 10.1002/cncr.31817 PMC6590473

1096. Younes A Mocetinostat for relapsed classical Hodgkin’s lymphoma: an open-label, single-arm, phase 2 trial Lancet Oncol. 2011 12 1222 1228 10.1016/S1470-2045(11)70265-0 22033282 PMC5042214 Younes, A. et al. Mocetinostat for relapsed classical Hodgkin’s lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 12 , 1222–1228 (2011). 22033282 10.1016/S1470-2045(11)70265-0 PMC5042214

1097. Batlevi CL A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma Br. J. Haematol. 2017 178 434 441 10.1111/bjh.14698 28440559 PMC5576135 Batlevi, C. L. et al. A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma. Br. J. Haematol. 178 , 434–441 (2017). 28440559 10.1111/bjh.14698 PMC5576135

1098. Blum KA Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia Br. J. Haematol. 2009 147 507 514 10.1111/j.1365-2141.2009.07881.x 19747365 PMC2779118 Blum, K. A. et al. Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br. J. Haematol. 147 , 507–514 (2009). 19747365 10.1111/j.1365-2141.2009.07881.x PMC2779118

1099. Chan E Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors Cancer Chemother. Pharmacol. 2018 81 355 364 10.1007/s00280-017-3494-3 29238851 Chan, E. et al. Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors. Cancer Chemother. Pharmacol. 81 , 355–364 (2018). 29238851 10.1007/s00280-017-3494-3

1100. Qualls D Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study Leuk. Lymphoma 2023 64 738 741 10.1080/10428194.2022.2164194 36642966 PMC10841916 Qualls, D. et al. Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study. Leuk. Lymphoma 64 , 738–741 (2023). 36642966 10.1080/10428194.2022.2164194 PMC10841916

1101. Johnson ML Mocetinostat in combination with durvalumab for patients with advanced NSCLC: results from a phase I/II Study Clin. Lung Cancer 2023 24 218 227 10.1016/j.cllc.2023.01.013 36890020 Johnson, M. L. et al. Mocetinostat in combination with durvalumab for patients with advanced NSCLC: results from a phase I/II Study. Clin. Lung Cancer 24 , 218–227 (2023). 36890020 10.1016/j.cllc.2023.01.013

1102. von Tresckow B Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies Eur. J. Haematol. 2019 102 163 173 10.1111/ejh.13188 30347469 von Tresckow, B. et al. Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies. Eur. J. Haematol. 102 , 163–173 (2019). 30347469 10.1111/ejh.13188

1103. Cartwright E Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGE ESMO Open. 2024 9 102971 10.1016/j.esmoop.2024.102971 38518549 PMC10972804 Cartwright, E. et al. Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGE. ESMO Open. 9 , 102971 (2024). 38518549 10.1016/j.esmoop.2024.102971 PMC10972804

1104. Younes A Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial Lancet Oncol. 2016 17 622 631 10.1016/S1470-2045(15)00584-7 27049457 PMC5494693 Younes, A. et al. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. Lancet Oncol. 17 , 622–631 (2016). 27049457 10.1016/S1470-2045(15)00584-7 PMC5494693

1105. Ossenkoppele GJ A phase I first-in-human study with tefinostat—a monocyte/macrophage targeted histone deacetylase inhibitor—in patients with advanced haematological malignancies Br. J. Haematol. 2013 162 191 201 10.1111/bjh.12359 23647373 Ossenkoppele, G. J. et al. A phase I first-in-human study with tefinostat—a monocyte/macrophage targeted histone deacetylase inhibitor—in patients with advanced haematological malignancies. Br. J. Haematol. 162 , 191–201 (2013). 23647373 10.1111/bjh.12359

1106. Ford PA Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD Chest 2010 137 1338 1344 10.1378/chest.09-2363 20299628 Ford, P. A. et al. Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. Chest 137 , 1338–1344 (2010). 20299628 10.1378/chest.09-2363

1107. Cosio BG Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD Thorax 2009 64 424 429 10.1136/thx.2008.103432 19158122 Cosio, B. G. et al. Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD. Thorax 64 , 424–429 (2009). 19158122 10.1136/thx.2008.103432

1108. Bo S Impact of sirtuin-1 expression on H3K56 acetylation and oxidative stress: a double-blind randomized controlled trial with resveratrol supplementation Acta Diabetol. 2018 55 331 340 10.1007/s00592-017-1097-4 29330620 PMC5851693 Bo, S. et al. Impact of sirtuin-1 expression on H3K56 acetylation and oxidative stress: a double-blind randomized controlled trial with resveratrol supplementation. Acta Diabetol. 55 , 331–340 (2018). 29330620 10.1007/s00592-017-1097-4 PMC5851693

1109. Moreno V Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: a phase I, “window-of-opportunity” study Neuro Oncol. 2023 25 1113 1122 10.1093/neuonc/noac263 36455228 PMC10237409 Moreno, V. et al. Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: a phase I, “window-of-opportunity” study. Neuro Oncol. 25 , 1113–1122 (2023). 36455228 10.1093/neuonc/noac263 PMC10237409

1110. Moreno V BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas Nat. Commun. 2023 14 1359 10.1038/s41467-023-36976-1 36914652 PMC10011554 Moreno, V. et al. BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas. Nat. Commun. 14 , 1359 (2023). 36914652 10.1038/s41467-023-36976-1 PMC10011554

1111. Moreno V Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin’s lymphoma Ann. Oncol. 2020 31 780 788 10.1016/j.annonc.2020.03.294 32240793 Moreno, V. et al. Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin’s lymphoma. Ann. Oncol. 31 , 780–788 (2020). 32240793 10.1016/j.annonc.2020.03.294

1112. Brown JA A randomized study of the safety and pharmacokinetics of GSK3358699, a mononuclear myeloid-targeted bromodomain and extra-terminal domain inhibitor Br. J. Clin. Pharmacol. 2022 88 2140 2155 10.1111/bcp.15137 34773923 PMC9300116 Brown, J. A. et al. A randomized study of the safety and pharmacokinetics of GSK3358699, a mononuclear myeloid-targeted bromodomain and extra-terminal domain inhibitor. Br. J. Clin. Pharmacol. 88 , 2140–2155 (2022). 34773923 10.1111/bcp.15137 PMC9300116

1113. Roboz GJ A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome Leuk. Lymphoma 2021 62 1740 1748 10.1080/10428194.2021.1881509 33586590 Roboz, G. J. et al. A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome. Leuk. Lymphoma 62 , 1740–1748 (2021). 33586590 10.1080/10428194.2021.1881509

1114. Shapiro GI A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma Br. J. Cancer 2021 124 744 753 10.1038/s41416-020-01180-1 33311588 PMC7884382 Shapiro, G. I. et al. A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. Br. J. Cancer 124 , 744–753 (2021). 33311588 10.1038/s41416-020-01180-1 PMC7884382

1115. Ramasamy K A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma Blood Cancer J. 2021 11 149 10.1038/s41408-021-00545-w 34480019 PMC8417099 Ramasamy, K. et al. A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma. Blood Cancer J. 11 , 149 (2021). 34480019 10.1038/s41408-021-00545-w PMC8417099

1116. Dickinson M Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma Blood Adv. 2021 5 4762 4770 10.1182/bloodadvances.2021004619 34581757 PMC8759125 Dickinson, M. et al. Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma. Blood Adv. 5 , 4762–4770 (2021). 34581757 10.1182/bloodadvances.2021004619 PMC8759125

1117. Ameratunga M First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours Br. J. Cancer 2020 123 1730 1736 10.1038/s41416-020-01077-z 32989226 PMC7722752 Ameratunga, M. et al. First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours. Br. J. Cancer 123 , 1730–1736 (2020). 32989226 10.1038/s41416-020-01077-z PMC7722752

1118. Lewin J Phase Ib trial with birabresib, a small-molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors J. Clin. Oncol. 2018 36 3007 3014 10.1200/JCO.2018.78.2292 29733771 Lewin, J. et al. Phase Ib trial with birabresib, a small-molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors. J. Clin. Oncol. 36 , 3007–3014 (2018). 29733771 10.1200/JCO.2018.78.2292

1119. Amorim S Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study Lancet Haematol. 2016 3 e196 e204 10.1016/S2352-3026(16)00021-1 27063978 Amorim, S. et al. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. Lancet Haematol. 3 , e196–e204 (2016). 27063978 10.1016/S2352-3026(16)00021-1

1120. Berthon C Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study Lancet Haematol. 2016 3 e186 e195 10.1016/S2352-3026(15)00247-1 27063977 Berthon, C. et al. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. Lancet Haematol. 3 , e186–e195 (2016). 27063977 10.1016/S2352-3026(15)00247-1

1121. Cousin S Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: results of a Phase I/II open-label, dose escalation study Int. J. Cancer 2022 150 993 1006 10.1002/ijc.33861 34724226 Cousin, S. et al. Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: results of a Phase I/II open-label, dose escalation study. Int. J. Cancer 150 , 993–1006 (2022). 34724226 10.1002/ijc.33861

1122. Krishnatry AS Population pharmacokinetic modeling of molibresib and its active metabolites in patients with solid tumors: a semimechanistic autoinduction model CPT Pharmacomet. Syst. Pharmacol. 2021 10 709 722 10.1002/psp4.12639 PMC8302244 33955700 Krishnatry, A. S. et al. Population pharmacokinetic modeling of molibresib and its active metabolites in patients with solid tumors: a semimechanistic autoinduction model. CPT Pharmacomet. Syst. Pharmacol. 10 , 709–722 (2021). 10.1002/psp4.12639 PMC8302244 33955700

1123. Cescon DW A phase I/II Study of GSK525762 combined with fulvestrant in patients with hormone receptor-positive/HER2-negative advanced or metastatic breast cancer Clin. Cancer Res. 2024 30 334 343 10.1158/1078-0432.CCR-23-0133 37992310 PMC10792358 Cescon, D. W. et al. A phase I/II Study of GSK525762 combined with fulvestrant in patients with hormone receptor-positive/HER2-negative advanced or metastatic breast cancer. Clin. Cancer Res. 30 , 334–343 (2024). 37992310 10.1158/1078-0432.CCR-23-0133 PMC10792358

1124. Riddell K An adaptive physiologically based pharmacokinetic-driven design to investigate the effect of itraconazole and rifampicin on the pharmacokinetics of molibresib (GSK525762) in healthy female volunteers J. Clin. Pharmacol. 2021 61 125 137 10.1002/jcph.1711 32820548 PMC7754455 Riddell, K. et al. An adaptive physiologically based pharmacokinetic-driven design to investigate the effect of itraconazole and rifampicin on the pharmacokinetics of molibresib (GSK525762) in healthy female volunteers. J. Clin. Pharmacol. 61 , 125–137 (2021). 32820548 10.1002/jcph.1711 PMC7754455

1125. Dawson MA A phase I/II open-label study of molibresib for the treatment of relapsed/refractory hematologic malignancies Clin. Cancer Res. 2023 29 711 722 10.1158/1078-0432.CCR-22-1284 36350312 PMC9932578 Dawson, M. A. et al. A phase I/II open-label study of molibresib for the treatment of relapsed/refractory hematologic malignancies. Clin. Cancer Res. 29 , 711–722 (2023). 36350312 10.1158/1078-0432.CCR-22-1284 PMC9932578

1126. Borthakur G A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia Cancer 2021 127 2943 2953 10.1002/cncr.33590 33934351 PMC8360206 Borthakur, G. et al. A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia. Cancer 127 , 2943–2953 (2021). 33934351 10.1002/cncr.33590 PMC8360206

1127. Piha-Paul SA First-in-human study of mivebresib (ABBV-075), an oral pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed/refractory solid tumors Clin. Cancer Res. 2019 25 6309 6319 10.1158/1078-0432.CCR-19-0578 31420359 Piha-Paul, S. A. et al. First-in-human study of mivebresib (ABBV-075), an oral pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed/refractory solid tumors. Clin. Cancer Res. 25 , 6309–6319 (2019). 31420359 10.1158/1078-0432.CCR-19-0578

1128. Falchook G Development of 2 bromodomain and extraterminal inhibitors with distinct pharmacokinetic and pharmacodynamic profiles for the treatment of advanced malignancies Clin. Cancer Res. 2020 26 1247 1257 10.1158/1078-0432.CCR-18-4071 31527168 PMC7528620 Falchook, G. et al. Development of 2 bromodomain and extraterminal inhibitors with distinct pharmacokinetic and pharmacodynamic profiles for the treatment of advanced malignancies. Clin. Cancer Res. 26 , 1247–1257 (2020). 31527168 10.1158/1078-0432.CCR-18-4071 PMC7528620

1129. Hamilton EP First-in-human Study of AZD5153, a small-molecule inhibitor of bromodomain protein 4, in patients with relapsed/refractory malignant solid tumors and lymphoma Mol. Cancer Ther. 2023 22 1154 1165 10.1158/1535-7163.MCT-23-0065 37486983 PMC10544002 Hamilton, E. P. et al. First-in-human Study of AZD5153, a small-molecule inhibitor of bromodomain protein 4, in patients with relapsed/refractory malignant solid tumors and lymphoma. Mol. Cancer Ther. 22 , 1154–1165 (2023). 37486983 10.1158/1535-7163.MCT-23-0065 PMC10544002

1130. Schöffski P Phase Ia dose-escalation trial with the BET protein inhibitor BI 894999 in patients with advanced or metastatic solid tumours Eur. J. Cancer 2023 191 112987 10.1016/j.ejca.2023.112987 37556913 Schöffski, P. et al. Phase Ia dose-escalation trial with the BET protein inhibitor BI 894999 in patients with advanced or metastatic solid tumours. Eur. J. Cancer 191 , 112987 (2023). 37556913 10.1016/j.ejca.2023.112987

1131. Provencher S BET protein inhibition for pulmonary arterial hypertension: a pilot clinical trial Am. J. Respir. Crit. Care Med. 2022 205 1357 1360 10.1164/rccm.202109-2182LE 35289736 Provencher, S. et al. BET protein inhibition for pulmonary arterial hypertension: a pilot clinical trial. Am. J. Respir. Crit. Care Med. 205 , 1357–1360 (2022). 35289736 10.1164/rccm.202109-2182LE

1132. Nicholls SJ Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial J. Am. Coll. Cardiol. 2011 57 1111 1119 10.1016/j.jacc.2010.11.015 21255957 Nicholls, S. J. et al. Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. J. Am. Coll. Cardiol. 57 , 1111–1119 (2011). 21255957 10.1016/j.jacc.2010.11.015

1133. Siebel AL Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: a randomized controlled trial Metabolism 2016 65 904 914 10.1016/j.metabol.2016.03.002 27173469 Siebel, A. L. et al. Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: a randomized controlled trial. Metabolism 65 , 904–914 (2016). 27173469 10.1016/j.metabol.2016.03.002

1134. Nicholls SJ ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies Cardiovasc. Drugs Ther. 2012 26 181 187 10.1007/s10557-012-6373-5 22349989 Nicholls, S. J. et al. ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies. Cardiovasc. Drugs Ther. 26 , 181–187 (2012). 22349989 10.1007/s10557-012-6373-5

1135. Shishikura D The effect of bromodomain and extra-terminal inhibitor apabetalone on attenuated coronary atherosclerotic plaque: insights from the ASSURE trial Am. J. Cardiovasc. Drugs 2019 19 49 57 10.1007/s40256-018-0298-8 30155718 Shishikura, D. et al. The effect of bromodomain and extra-terminal inhibitor apabetalone on attenuated coronary atherosclerotic plaque: insights from the ASSURE trial. Am. J. Cardiovasc. Drugs 19 , 49–57 (2019). 30155718 10.1007/s40256-018-0298-8

1136. Nicholls SJ Effect of the BET protein inhibitor, RVX-208, on progression of coronary atherosclerosis: results of the phase 2b, randomized, double-blind, multicenter, ASSURE trial Am. J. Cardiovasc. Drugs 2016 16 55 65 10.1007/s40256-015-0146-z 26385396 Nicholls, S. J. et al. Effect of the BET protein inhibitor, RVX-208, on progression of coronary atherosclerosis: results of the phase 2b, randomized, double-blind, multicenter, ASSURE trial. Am. J. Cardiovasc. Drugs 16 , 55–65 (2016). 26385396 10.1007/s40256-015-0146-z

1137. Kulikowski E Apabetalone mediated epigenetic modulation is associated with favorable kidney function and alkaline phosphatase profile in patients with chronic kidney disease Kidney Blood Press Res. 2018 43 449 457 10.1159/000488257 29566379 Kulikowski, E. et al. Apabetalone mediated epigenetic modulation is associated with favorable kidney function and alkaline phosphatase profile in patients with chronic kidney disease. Kidney Blood Press Res. 43 , 449–457 (2018). 29566379 10.1159/000488257

1138. Schwartz GG Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial Cardiovasc. Diabetol. 2021 20 125 10.1186/s12933-021-01311-9 34158057 PMC8218391 Schwartz, G. G. et al. Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial. Cardiovasc. Diabetol. 20 , 125 (2021). 34158057 10.1186/s12933-021-01311-9 PMC8218391

1139. Ray KK Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: rationale, design, and baseline characteristics of the BETonMACE trial Am. Hear. J. 2019 217 72 83 10.1016/j.ahj.2019.08.001 31520897 Ray, K. K. et al. Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: rationale, design, and baseline characteristics of the BETonMACE trial. Am. Hear. J. 217 , 72–83 (2019). 10.1016/j.ahj.2019.08.001 31520897

1140. Cummings J Cognitive effects of the BET protein inhibitor apabetalone: a prespecified montreal cognitive assessment analysis nested in the BETonMACE randomized controlled trial J. Alzheimers Dis. 2021 83 1703 1715 10.3233/JAD-210570 34459400 PMC8609701 Cummings, J. et al. Cognitive effects of the BET protein inhibitor apabetalone: a prespecified montreal cognitive assessment analysis nested in the BETonMACE randomized controlled trial. J. Alzheimers Dis. 83 , 1703–1715 (2021). 34459400 10.3233/JAD-210570 PMC8609701

1141. Kalantar-Zadeh K Effect of apabetalone on cardiovascular events in diabetes, CKD, and recent acute coronary syndrome: results from the BETonMACE randomized controlled trial Clin. J. Am. Soc. Nephrol. 2021 16 705 716 10.2215/CJN.16751020 33906908 PMC8259488 Kalantar-Zadeh, K. et al. Effect of apabetalone on cardiovascular events in diabetes, CKD, and recent acute coronary syndrome: results from the BETonMACE randomized controlled trial. Clin. J. Am. Soc. Nephrol. 16 , 705–716 (2021). 33906908 10.2215/CJN.16751020 PMC8259488

1142. Nicholls SJ Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study Cardiovasc. Diabetol. 2021 20 13 10.1186/s12933-020-01199-x 33413345 PMC7791841 Nicholls, S. J. et al. Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study. Cardiovasc. Diabetol. 20 , 13 (2021). 33413345 10.1186/s12933-020-01199-x PMC7791841

1143. Blum KA A phase I study of pelabresib (CPI-0610), a small-molecule inhibitor of BET proteins, in patients with relapsed or refractory lymphoma Cancer Res. Commun. 2022 2 795 805 10.1158/2767-9764.CRC-22-0060 36923307 PMC10010313 Blum, K. A. et al. A phase I study of pelabresib (CPI-0610), a small-molecule inhibitor of BET proteins, in patients with relapsed or refractory lymphoma. Cancer Res. Commun. 2 , 795–805 (2022). 36923307 10.1158/2767-9764.CRC-22-0060 PMC10010313

1144. Stein EM Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies Leuk. Lymphoma 2024 65 503 510 10.1080/10428194.2023.2300710 38259250 Stein, E. M. et al. Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies. Leuk. Lymphoma 65 , 503–510 (2024). 38259250 10.1080/10428194.2023.2300710

1145. Eickhoff, N., Bergman, A. M. & Zwart, W. Homing in on a moving target: androgen receptor cistromic plasticity in prostate cancer. Endocrinology 163 , bqac153 (2022). 10.1210/endocr/bqac153 36125208

1146. Stein EM The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia Blood 2018 131 2661 2669 10.1182/blood-2017-12-818948 29724899 PMC6265654 Stein, E. M. et al. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood 131 , 2661–2669 (2018). 29724899 10.1182/blood-2017-12-818948 PMC6265654

1147. Vieito M Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in advanced solid tumors Clin. Cancer Res. 2023 29 3592 3602 10.1158/1078-0432.CCR-23-0092 37491846 Vieito, M. et al. Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in advanced solid tumors. Clin. Cancer Res. 29 , 3592–3602 (2023). 37491846 10.1158/1078-0432.CCR-23-0092

1148. Guo C PK/PD model-informed dose selection for oncology phase I expansion: case study based on PF-06939999, a PRMT5 inhibitor CPT Pharmacomet. Syst. Pharmacol. 2023 12 1619 1625 10.1002/psp4.12882 PMC10681508 36394153 Guo, C. et al. PK/PD model-informed dose selection for oncology phase I expansion: case study based on PF-06939999, a PRMT5 inhibitor. CPT Pharmacomet. Syst. Pharmacol. 12 , 1619–1625 (2023). 10.1002/psp4.12882 PMC10681508 36394153

1149. Hollebecque A Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies Cancer 2022 128 3185 3195 10.1002/cncr.34366 35737639 PMC9540525 Hollebecque, A. et al. Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies. Cancer 128 , 3185–3195 (2022). 35737639 10.1002/cncr.34366 PMC9540525

1150. Hollebecque A Phase I study of lysine-specific demethylase 1 inhibitor, CC-90011, in patients with advanced solid tumors and relapsed/refractory non-hodgkin lymphoma Clin. Cancer Res. 2021 27 438 446 10.1158/1078-0432.CCR-20-2380 33046517 Hollebecque, A. et al. Phase I study of lysine-specific demethylase 1 inhibitor, CC-90011, in patients with advanced solid tumors and relapsed/refractory non-hodgkin lymphoma. Clin. Cancer Res. 27 , 438–446 (2021). 33046517 10.1158/1078-0432.CCR-20-2380

1151. Abplanalp WT Efficiency and target derepression of anti-mir-92a: results of a first in human study Nucl. Acid. Ther. 2020 30 335 345 10.1089/nat.2020.0871 32707001 Abplanalp, W. T. et al. Efficiency and target derepression of anti-mir-92a: results of a first in human study. Nucl. Acid. Ther. 30 , 335–345 (2020). 10.1089/nat.2020.0871 32707001

1152. Beg MS Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors Investig. New. Drugs 2017 35 180 188 10.1007/s10637-016-0407-y 27917453 PMC5893501 Beg, M. S. et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Investig. New. Drugs 35 , 180–188 (2017). 27917453 10.1007/s10637-016-0407-y PMC5893501

1153. van Zandwijk N Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study Lancet Oncol. 2017 18 1386 1396 10.1016/S1470-2045(17)30621-6 28870611 van Zandwijk, N. et al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 18 , 1386–1396 (2017). 28870611 10.1016/S1470-2045(17)30621-6